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Cyclin-Dependent Kinase 11 (CDK11) is a serine/threonine kinase encoded 
at human locus 1p36.3 by two paralogous genes CDK11A and CDK11B. 
CDK11 has diverse roles in the regulation of transcription, splicing, 
apoptosis and mitosis. In proliferating cells, two predominant isoforms are 
expressed: CDK11p58 and CDK11p110. CDK11p110 is expressed throughout 
the cell cycle and regulates transcription and splicing. CDK11p58 is 
expressed at mitosis via IRES-dependent translation; it mediates mitotic 
progression and faithful chromosome segregation. 
Loss of Cdk11 in murine models causes early embryonic lethality, 
demonstrating that CDK11 is essential for normal development. 
Furthermore, dysregulated CDK11 expression is associated with numerous 
late-onset disease states, indicating its importance in adult life. In cancer, 
abnormal expression of CDK11 correlates with poor prognosis in a variety of 
tumours. Moreover, deletion of the chromosomal region 1p36.3, containing 
the CDK11 locus, is frequently observed in cancer and has recently been 
identified in a case of the development disorder, Cornelia de Lange 
Syndrome (CdLS). This thesis aimed to examine the functions of CDK11 and 
the impact of their dysregulation in cancer and developmental phenotypes.  
The initial aim was to investigate the novel role for CDK11 in regulating 
autophagy in cancer cells; CDK11 depletion causes a marked autophagy 
phenotype, with accumulation of autophagy protein LC3. I demonstrate that 
this CDK11-mediated autophagy occurs as a consequence of mitotic 
dysregulation. Subsequently, I examined the role of autophagy following 
aberrant mitosis and chromosome missegregation. I show that autophagy is 
important in the maintenance of aneuploid karyotypes, with loss of 
autophagy impairing the survival of aneuploid cell populations.  
I then investigated the effects of CDK11 in regulating cancer cell motility and 
determined that CDK11 depletion retards cancer cell migration. However, I 
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was unable to identify any failure in cell adhesion or cell polarization to 
explain this migration phenotype. Subsequently, I interrogated the CDK11 
interactome to further characterize the mechanisms through which CDK11 
regulates both novel and established functions. This work indicated the 
involvement of the distinct CDK11 isoforms in pathways that have not 
previously been reported. This included the interaction of CDK11p110 with 
ribosomal and spliceosomal proteins during mitosis and the interaction of 
CDK11p58 with spliceosomal and proteosomal constituents also during 
mitosis. These findings may provide the foundation for further study.    
Finally I describe work undertaken to sequence the CDK11 locus in a cohort 
of CdLS patients, with no known causative genetic mutation, to investigate 
CDK11A/CDK11B as candidate disease-associated genes. Although no 
causative mutation in CDK11A or CDK11B was identifying, sequencing of 
this region indicated NCBI and UCSC genome assemblies of this locus were 
inaccurate due to the genomic duplication. This has been confirmed by 





Cyclin Dependent Kinase 11 (CDK11) is a cell protein that performs many 
essential functions; these include regulating cell division and regulating 
processes that generate proteins from their DNA code. CDK11 is required 
both during embryonic development and for health in later life. Mice that 
lose CDK11 are predisposed to developing tumours and certain human 
cancers also appear to lose CDK11. Furthermore, abnormal levels of CDK11 
are linked to poor outcomes in various forms of cancer, while several recent 
studies have identified CDK11 as a potential target for cancer treatment. 
Therefore understanding how CDK11 functions in both cancer and 
development is important. 
This work set out to examine different effects that are observed in cancer 
cells, when CDK11 is depleted. Initially I examined the effects of CDK11 
depletion on a process called autophagy. Autophagy is a ‘self-eating’ process 
whereby a cell can engulf its unwanted or harmful components and break 
these down to provide an energy source; this enables it to survive in stressful 
conditions. Defective autophagy may contribute to cancer development. 
However the role of autophagy in cancer cells themselves is less clear. This 
appears to be due to the multiple different mechanisms by which autophagy 
is activated and regulated in these cells; consequently autophagy may have 
either positive or negative effects on cancer cells depending on the signal that 
activates it and the components it engulfs. Autophagy has also been 
identified as a potential target in the treatment of cancer but due to the 
different effects of autophagy, it is important to understand more about the 
pathways that regulate it in each circumstance. 
Depletion of CDK11 causes the accumulation of autophagy proteins in 
cancer cells. In this work, I have demonstrated that the changes in autophagy 
observed after CDK11 depletion occur due to abnormal cell division. This 
abnormal cell division leads to failure of cells to evenly divide their 
chromosomes between their ‘daughter’ cells resulting in an abnormal 
number of chromosomes within the divided cells. This abnormal number of 
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chromosomes is termed aneuploidy and is a common finding in cancer. 
Aneuploidy itself can harm cells and my work indicates that autophagy can 
aid cells to survive the damaging effects of aneuploidy.   
I have also demonstrated that CDK11 depletion affects the ability of cancer 
cells to migrate; migration is fundamental to the ability of cancer to spread. 
Partial loss of CDK11 impaired the movement of breast cancer cells. In order 
to better understand how CDK11 regulates this cell migration and its other 
functions, I examined the proteins that interact with CDK11. This work 
identified many proteins known to interact with CDK11 but also many 
proteins with which CDK11 was not known to interact. These novel CDK11 
interacting proteins indicate new mechanism through which CDK11 may 
perform its functions. Further work is required to confirm these interactions 
and to determine their significance.  




aCGH	   	   	   Array	  Comparative	  Genomic	  Hybridisation	  
ATG5	   	   	   Autophagy-­‐related	  Protein	  5	   	   	   	  
ATG7	   	   	   Autophagy-­‐related	  Protein	  7	  
APC/C	  	   	   Anaphase	  Promoting	  Complex/Cyclosome	  
β-­‐1,4-­‐GT	  1	   	   Beta-­‐1,4-­‐galactosyltransferase	  1	  
BSA	   	   	   Bovine	  Serum	  Albumin	  
bp	   	   	   Base	  Pairs	  
BrdU	   	   	   Bromodeoxyuridine	   	  
cDNA	   	   	   Single	  Stranded	  Complimentary	  Deoxyribonucleic	  Acid	   	  
CdLS	   	   	   Cornelia	  de	  Lange	  Syndrome	   	  
CDK	   	   	   Cyclin	  Dependent	  Kinase	  
CK2	   	   	   Casein	  Kinase	  2	   	   	   	  
CSK	   	   	   C-­‐terminal	  Src	  Kinase	  
DAPI	   	   	   6-­‐diamidino-­‐2-­‐phenylindole	  dihydrochloride	   	  
DMSO	   	   	   Dimethyl	  Sulphoxide	  
DMEM	  	   	   Dulbecco	  Modified	  Eagle	  Medium	  
DNA	   	   	   Deoxyribonucleic	  Acid	  
dNTP	   	   	   Deoxynucleotide	  Triphosphate	  
EDTA	   	   	   Ethylenediaminetetraacetic	  Acid	  
EIF3F	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Eukaryotic	  Initiation	  Factor	  3	  Subunit	  F	  
FAK	   	   	   Focal	  Adhesion	  Kinase	  
FCS	   	   	   Foetal	  Calf	  Serum	  
FISH	   	   	   Fluorescence	  in	  situ	  hybridisation	  
GST	   	   	   Glutathione	  S-­‐transferase	  
GFP	   	   	   Green	  fluorescent	  protein	  
HDAC	   	   	   Histone	  Deacetylase	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HIV	   	   	   Human	  Immunodeficiency	  Virus	  
HSP70	  	   	   Heat	  Shock	  Protein	  70	   	   	   	  
HSP90	  	   	   Heat	  Shock	  Protein	  90	  
IPTG	   	   	   Isopropyl	  β-­‐D-­‐thiogalactopyranoside	  
Ig	   	   	   Immunoglobulin	  
IRES	   	   	   Internal	  Ribosomal	  Entry	  Site	  
Kb	   	   	   Kilobases	  
KD	   	   	   Kilodalton	  
mg	   	   	   Milligrams	  
ml	   	   	   Millilitres	  
mM	  	   	   	   Millimolar	  
MMP	   	   	   Metalloproteinase	  
MTOR	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Mammalian	  Target	  of	  Rapamycin	  protein	  kinase	  
NCBI	   	   	   National	  Centre	  for	  Biotechnology	  Information	  
NGS	   	   	   Next	  Generation	  Sequencing	  
NIPBL	  	   	   Nipped-­‐B-­‐like	  Protein	  
NP40	   	   	   Nonidet	  P-­‐40	  Detergent	  
PAK1	   	   	   p21	  Activated	  Kinase	  1	  
PBS	   	   	   Phosphate	  Buffered	  Saline	  
PBS-­‐T	   	   	   Phosphate	  Buffered	  Saline-­‐Tween-­‐20	  
PCR	   	   	   Polymerase	  Chain	  Reaction	  
PFA	   	   	   Paraformaldehyde	  
PLK1	   	   	   Polo-­‐Like	  Kinase	  1	  
pTEFB	  	   	   Positive	  Transcription	  Elongation	  Factor	  B	  
RIPA	   	   	   Radioimmunoprecipitation	  Assay	  Buffer	  
RNA	   	   	   Ribonucleic	  Acid	  
RNA	  Pol	  II	   	   RNA	  Polymerase	  II	  
ROS	   	   	   Reactive	  Oxygen	  Species	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SAC	   	   	   Spindle	  Assembly	  Checkpoint	  
SDS	  PAGE	   Sodium	  Dodecyl	  Sulfate-­‐Polyacrylamide	  Gel	  
Electrophoresis	  
SH2	  Domain	   	   Src	  Homology	  2	  Domain	  
SH3	  Domain	   	   Src	  Homology	  3	  Domain	  
SMC	  Proteins	  	   Structural	  Maintenance	  of	  Chromosomes	  Proteins	  
snRNP	  	   	   Small	  Nuclear	  Ribonucleoproteins	  
SNP	   	   	   Single	  Nucleotide	  Polymorphisms	  
SRSF1-­‐10	   	   SR	  (Serine/Arginine)	  Splicing	  Factors	  1-­‐10	  
TFIIA-­‐H	   	   Transcription	  Factor	  II	  A-­‐H	  
TBE	   	   	   Tris/Borate/EDTA	  
TBS	   	   	   Tris	  Buffered	  Saline	  
TBST	  	   	   	   Tris	  Buffered	  Saline-­‐Tween-­‐20	  
UCSC	   	   	   University	  of	  California,	  Santa	  Cruz	  
μl	   	   	   Microlitres	  
μM	   	   	   Micromolar	  
μg	   	   	   Micrograms	  
UTR	   	   	   Untranslated	  Region	  
WES	   	   	   Whole	  Exome	  Sequencing	  
WGS	   	   	   Whole	  Genome	  Sequencing	  
WT	   	   	   Wild	  Type	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1.1	  The	  Human	  Kinome	  
The evolution of increasingly sophisticated regulatory mechanisms to govern 
the panoply of cellular processes permits increased cellular and organismal 
complexity.  Phosphorylation is a ubiquitous regulatory mechanism that has 
major roles in virtually every aspect of cellular physiology [1].  The 
phosphorylation of substrates by protein kinases regulates diverse processes 
including growth, differentiation, metabolism, cell cycle progression and cell 
death.  Protein kinases share a conserved catalytic domain, which catalyses 
the transfer of the gamma-phosphate of ATP to a serine, threonine, or 
tyrosine residue in the protein substrate [1].  On account of the integral role 
phosphorylation plays, it is unsurprising that the protein kinase super family 
is one of the largest of eukaryotic proteins.  The human kinome comprises 
518 protein kinases that represent 1.7% of human genes [2].  Eukaryotic 
protein kinases may be assigned to 1 of 7 major groups on the basis of 
characteristic sequence identification features; the CMGC (CDK, MAPK, 
GSK, CDK-like related) group comprises 61 members [3].  The Cyclin-
Dependent Kinase (CDK) family is classified within this group and 
comprises 20 human CDKs [4]. 
1.2	  Cyclin-­‐Dependent	  Kinases	  (CDKs)	  
CDKs are the catalytic subunits of heterodimeric serine/threonine protein 
kinases, generated by the association of each CDK with its regulatory cyclin 
partner [4].  CDKs are characterised by the presence of a kinase domain, the 
activity of which is modulated by cyclin binding. This conserved catalytic 
core comprises an ATP-binding pocket, a cyclin-binding domain and an 
activating T-loop motif [5].  This family of proteins participates in many 
cellular signaling pathways. The original member of the CDK family, 
designated CDK1, was identified through genetic screens of yeast species 
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examining for mutants unable to complete the cell division cycle [6].  CDKs 
play a major role in the regulation of the cell cycle but other important 
functions such as the regulation of gene expression, through mediation of co-
transcriptional events, are well established [7].  The unifying CDK 
nomenclature was adopted in 1991 but prior to this members were often 
designated on the basis of the amino acid sequence within the conserved 
cyclin-binding domain of the kinase [4].  On account of this, CDK11 was 
previously termed PITSLRE.  To be formally designated a CDK requires the 
identification of the activating cyclin subunit.  The cyclins represent a diverse 
group of proteins characterised by a domain, termed the cyclin box, that 
mediates binding to the CDK [5].  Expression of cyclins often follows an 
oscillatory pattern through the cell cycle, to enable temporal CDK regulation.  
However, this is less frequently observed among the more recently identified 
members of the cyclin family, with their expression frequently regulated 
through signaling pathways activated by external stimuli [5].  The activity of 
these CDK/cyclin complexes is not only regulated by their co-expression but 
also by numerous CDK inhibitors (CKIs) [8].  CKIs are subdivided into two 
classes based on structure and CDK specificity; these constitute the INK4 
family members, such as p16INK4A (CDKN2A) and p19INK4D (CDKN2D), 
and the CIP/KIP family, comprising p21CIP1 (CDKN1A), p27KIP1 
(CDKN1B) and p57KIP2 (CDKN1C) [8].  The INK4 family members 
primarily target CDK4 and CDK6 while the CIP/KIP family members are 
more promiscuous and restrict the activities of a greater range of cyclin-
dependent complexes [8]. In addition, there is evidence to suggest individual 
CDK, CKI or cyclin subunits may perform certain functions in isolation [5]. 
1.3	  Cyclin-­‐Dependent	  Kinase	  11	  (CDK11)	  
CDK11, a member of the CDK family, is a serine/threonine kinase encoded 
at human locus 1p36.3.  This locus on human Chromosome 1 encodes two 
duplicate and tandemly linked CDK11 genes; these are CDK11A (CDC2L2) 
and CDK11B (CDC2L1) [9].  Both genes are transcribed and both are 
ubiquitously expressed in all human cells, although their level of expression 
is reported to differ in certain tissues [10, 11].  The genes together span 
approximately 100kb on Chromosome 1, with each individual gene 
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comprising 20 exons and spanning approximately 30kb.  In conjunction with 
the CDK11 genes, the metalloprotease (MMP) genes, MMP21 and MMP22 are 
also duplicated [11].  This duplication is present in humans but absent in 
chimpanzees and other vertebrates, indicating this event has occurred late in 
evolution [12]. 
1.3.1 CDK11A and CDK11B Homology 
The two CDK11 genes encode proteins with a high degree of similarity and 
only a total of 15 amino acids of the 773-786 residues in the CDK11 protein 
are unique to either CDK11A or CDK11B [9].  The majority of these 15 amino 
acid alterations are located within the amino-terminal domain, with only 
four located in the protein kinase catalytic and carboxy-terminal domains [9].  
This high degree of homology between the two gene products has made the 
study of each protein challenging; indeed, in all published work 
interrogating protein function, there is no differentiation of CDK11A and 
CDK11B, with the proteins considered to have indistinguishable functions.  
Although this has not been definitely established, given the homology and 
co-expression, a degree of functional redundancy is highly probable.  It is 
reported that functional redundancy between duplicate genes can be actively 
maintained through evolution and speciation, over a period of more than 80 
million years [13].  The duplication at the CDK11 locus is a comparatively 
recent event in evolution and therefore some redundancy is expected.  The 
CDK11 sequence is highly conserved across vertebrates, with CDK11B most 
closely resembling these homologues [9].  This may indicate that CDK11A is 
either subject to positive selection or is potentially degenerating into a 
pseudogene.   
1.3.2 CDK11 Gene Promoters  
Although the expression of both genes is ubiquitous within human tissues, 
characterisation of the gene promoters reveals not only similarities but 
differences.  The promoter regions of both genes are found to be GC-rich but 
lack both TATA and CAAT boxes [14, 15].  CDK11A and CDK11B contain 
ETS-1 binding motifs; ETS-1 is a member of the ETS (E26 Transforming-
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by the binding of both ETS-1 and SKN-1, with both transcription factors 
obligate for basal transcription of the gene [15].  In contrast, the CDK11A 
promoter lacks the SKN-1 binding motif but contains CREB and 
TCF11/NRF2 sites.  CREB and ETS-1 are required to sustain transcriptional 
activity of the CDK11A gene [16].  This demonstrates discrete mechanisms of 
transcriptional regulation, which may enable differential transcription of the 
genes. 
1.3.3 CDK11 Isoforms 
Transcription of the CDK11 genes was initially reported to generate more 
than 20 distinct mRNA isoforms and this was assumed secondary to 
extensive alternate splicing [10, 17].  It is now established that a number of 
these supposed transcript isoforms undergo non-sense mediated decay.  In 
total, 8 alternate CDK11 transcripts are now described [18].  These transcripts 
encode two predominant cellular protein isoforms, termed CDK11p110 and 
CDK11p58 on account of their molecular weights.  CDK11p58 was the first 
isoform to be described. It was identified through purification of β -1,4 
Galactosyltransferase 1, with which it was found to associate [19] [20]. The 
CDK11p110 isoform was subsequently identified from alternate CDK11 
transcripts.  Originally, translation of the two isoforms was reported to occur 
from distinct transcripts but it is now established that this is not the case [21].  
The CDK11p110 isoform is expressed constitutively throughout the cell 
cycle, without significant fluctuation in protein levels.  In contrast, the 
CDK11p58 protein is expressed predominantly, if not exclusively, at mitosis 
[21].  This observation led to the identification of an internal ribosomal entry 
site (IRES) within the CDK11 transcript [21].  This IRES sequence mediates 
the expression of the shorter p58 isoform at mitosis. 
CDK11p110 regulates both transcription and splicing [22, 23].  In contrast, 
consistent with its mitotic expression, CDK11p58 regulates mitotic events 
[24, 25].  A third CDK11 isoform is also described, with CDK11p46 generated 
through cleavage of the longer isoforms on induction of apoptosis [26].  This 
chapter aims to provide an appraisal of published literature on CDK11, its 
roles in cellular processes and its contribution to health and disease. This will 
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provide a basis for the discussion of functions and interactions of CDK11 in 
later chapters. 
1.4	  CDK11,	  Transcription	  and	  Splicing	  
The regulation of gene expression is fundamental to the normal growth, 
development and survival of all organisms.  Within eukaryotes, gene 
expression is highly complex and tightly controlled [27]. The transcription of 
DNA template to RNA, and associated RNA processing, represents the 
predominant stage regulating gene expression [28].  The major steps in 
mRNA biogenesis constitute transcription, 5’ capping, splicing, and 
cleavage/polyadenylation [28]. Although all can be reconstituted 
independently in vitro, in vivo they occur synchronously and are termed co-
transcriptional [29].  The regulation of these processes is mediated by 
analogous events [29, 30]. 
1.4.1 Transcription 
Transcription is established to occur in three principal phases, termed 
initiation, elongation and termination [28].  At initiation, binding of 
activators to enhancer DNA elements, located upstream or downstream of 
the target gene promoter, causes sequential recruitment of general 
transcription factors and RNA polymerase II (RNA Pol II) to the promoter 
elements [31].  Proteins such as cohesin are reported to facilitate chromatin 
looping and thereby contact between enhancers and promoters [32]. The 
assembly of the pre-initiation complex (PIC), comprising general 
transcription factors TFIIA, TFIIB, TFIID, TFIIE, TFIIF, and TFIIH in 
association with the Mediator complex and RNA polymerase, is necessary 
for initiation to occur [33].  Within eukaryotes, all mRNA is synthesised by 
RNA Pol II. RNA Pol II is distinguished from other polymerases by the 
presence of the C-terminal domain (CTD) of its largest polypeptide 
constituent RPB1 [34].  The CTD comprises tandem heptad repeats that 
undergo extensive post-translational modifications, most notably 
phosphorylation, which regulate co-transcriptional events.  On recruitment 
to the pre-initiation complex, serine 2 and serine 5 of the RNA Pol II CTD are 
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describes the phosphorylation of serine 5 by CDK7 near the transcription 
start site. On elongation, serine 2 is phosphorylated by Positive Transcription 
Elongation Factor b (P-TEFb), comprising CDK9 and one of its cyclin 
partners [31]. 
Previously, transcription was thought to be regulated predominantly by the 
recruitment of RNA polymerase to the promoter at transcription initiation 
[28].  It is now evident, however, that transcription elongation also plays a 
significant role in the regulation of gene expression. Transcriptional 
elongation by RNA Pol II is categorised into three distinct stages; these are 
promoter escape, promoter-proximal pausing and productive elongation.  
During promoter escape, RNA Pol II undergoes maturation and breaks 
contact with the promoter element [28]. Promoter-proximal pausing, or 
transcriptional stalling, occurs when the immature transcriptional complex 
pauses, approximately 20 to 40 bases from the transcriptional start site.  This 
pausing plays an important regulatory role in vivo, with escape enabling 
productive elongation [28].  Numerous heat shock inducible genes and genes 
that modulate response to cellular stress are regulated through this 
mechanism, enabling more rapid induction of transcription [35].  Numerous 
elements mediate proximal pausing including DRB Sensitivity-Inducing 
Factor (DSIF) and Negative Elongation Factor (NELF) [28].  Proteins, 
including P-TEFb, TFIIS, and Elongator, allow transition to productive 
elongation.  Other proteins have been implicated in this process, with the 
cohesin complex found to selectively bind and regulate genes with paused 
RNA polymerase in Drosophila [36].  Following progression to productive 
elongation, proteins such as Elongin and TFIIF are described to mediate 
elongation rate.  In addition, epigenomic modifications to the chromatin 
structure such as histone acetylation or methylation are able to influence 
transcription rate [28].  The rate of transcription is noted to affect co-
transcriptional processes including splicing, with it reported to determine 
alternative splicing decisions [37]. 
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1.4.2 Splicing 
RNA splicing is one of three major processing events in the production of 
mature messenger RNA, the two other processes being RNA capping and 
polyadenylation [29]. The removal of introns and congression of exons 
through the splicing of pre-mRNA is integral to eukaryotic gene expression.  
The splicing process is catalysed primarily by the spliceosome, which 
constitutes a large multimodular, highly dynamic complex [38]. It comprises 
five small nuclear ribonucleoproteins (snRNPs). Each snRNP is composed of 
a small nuclear RNA (U1, U2, U4, U5 or U6) in addition to a group of seven 
proteins termed the Sm ribonucleoproteins [38]. In addition to this snRNP, 
the spliceosome contains multiple non-snRNP protein components. Many 
RNA binding proteins mediate splicing regulation but the two predominant 
families of regulators are the SR proteins and heterogeneous nuclear 
ribonuleoproteins (hnRNPs) [39]. Classically, the SR proteins promote 
splicing, whilst the hnRNPs have the opposite effect [39].  The SR proteins 
are named on account of the RS protein domain, present within all family 
members, which comprises long repeats of serine and arginine residues [40].  
This domain enables bindings with other members of the spliceosome 
complex.  In addition, SR proteins contain an RNA recognition motif (RRM) 
domain, which facilitates binding to RNA [40]. 
The co-transcriptional regulation of transcription and RNA biogenesis is both 
dynamic and complex, with a large cohort of proteins required to mediate 
precise gene expression [29].  The modulation of proteins by phosphorylation 
is fundamental to this process and phosphorylation of the RNA Pol II CTD 
represents an influential and well-established mechanism of control [34]. 
Several CDKs and their respective cyclin partners are involved in the 
regulation of this intricate network [34].   
1.4.3 CDK11 Interacts with Splicing Components 
The involvement of CDK11p110 in splicing was first proposed on account of 
the RD (arginine and aspartate) and RE (arginine and glutamate) motifs 
within its N-terminal domain [41].  These motifs are important in the 
localisation of splicing components to nuclear speckles, also termed 
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interchromatin granules (ICGs), which contain numerous pre-mRNA 
splicing factors [42].  CDK11p110 co-localises with SR protein and splicing 
component SC35, also termed SR Splicing Factor 2 (SRSF2), at these ICGs 
[41]. In addition, RNA binding proteins RNPS1 and SS-A/Ro were identified 
as novel CDK11 binding partners using a yeast two-hybrid assay [41].  The 
interaction with RNPS1 is specific to the longer CDK11p110 isoform.  
Overexpression of RNPS1 causes the aggregation of nuclear speckles into 
fewer but larger clusters, with altered localisation of both CDK11p110 and 
SC35.  Similar results are obtained on subjecting cells to transcriptional 
inhibition with H8 inhibitor [41].  The localisation of CDK11p110 with 
splicing components and its altered localisation on transcriptional inhibition 
were considered the first evidence of the involvement of CDK11 in 
transcription or splicing [41]. 
1.4.4 CDK11, Cyclin L and RNA Polymerase II 
1.4.4.1 CDK11p110 and Transcriptional Elongation 
CDK11p110 co-purifies with transcription elongation complexes, using fast 
protein liquid chromatography [23]. CDK11p110 co-elutes with both 
hypophosphorylated and hyperphosphorylated forms of RNA Pol II; 
proteins SPT16 and SSRP1, members of the FAcilitates Chromatin 
Transcription (FACT) heterodimeric complex, along with RAP30 and RAP74, 
constituents of TFIIF, also co-purify [23].  In addition, a yeast two-hybrid 
assay and subsequent co-immunoprecipitation assay identified transcription 
elongation factor ELL2 and TFIIS as novel binding partners of CDK11p110 
[23]. Transcription elongation complexes have been classified into three 
distinct classes, based on their roles [43].  The first class comprises those that 
inhibit RNA polymerase arrest and includes TFIIS.  The second class 
prevents transient pausing of RNA Pol II and comprises proteins such as 
ELL, ELL2 and TFIIF.  The third class promotes transcription elongation 
through modification of chromatin structure and includes the FACT 
complex. CDK11p110 therefore interacts with members of all three classes of 
elongation complexes [23].  Consistent with these observations, inhibition of 
CDK11p110 kinase activity by addition of CDK11 monoclonal antibody, 
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vitro transcription assays. Re-addition of purified CDK11p110 to the reaction 
restores transcriptional activity [23].  This demonstrates the association of 
CDK11 with transcription elongation complexes and its ability to regulate 
transcription. 
1.4.4.2 CDK11 and RNA Pol II CTD 
Dickson et al. (2002) subsequently reported a possible role for CDK11 in the 
phosphorylation of RNA Pol II CTD [44].  The authors found that Cyclin L 
co-immunoprecipitate was able to phosphorylate both the RNA Pol II CTD 
and splicing factor SC35. CDK11p110 was assumed to be responsible on 
account of its interaction with Cyclin L and this was supported by the 
observation that addition of CDK inhibitor p21 ablated both phosphorylation 
events.  The study subsequently interrogated the consequence of Cyclin L 
inhibition, utilising anti-Cyclin L antibody, on in vitro splicing.  This found 
inhibition of splicing with the accumulation of intermediate products [44]. 
Again, CDK11p110 was considered the partner catalytic domain responsible 
for splicing regulation in this assay.   
Although subsequent work has confirmed the importance of CDK11 to 
splicing, Trembley et al. (2003) demonstrated that CDK11p110 was not 
responsible for RNA Pol II CTD phosphorylation [45].  Instead, Casein 
Kinase-2 (CK2) was responsible for the CTD phosphorylation, with CK2 
found to co-immunoprecipitate with both Cyclin L and CDK11.  In addition, 
CK2 is found to phosphorylate CDK11p110, with the RE domain of CDK11 
required for this phosphorylation [45].   
The identification of CK2 as the kinase responsible for both RNA Pol II and 
CDK11p110 phosphorylation was corroborated in a subsequent paper by 
Sachs et al. (2003) [46]. This work confirmed that purified CDK11p110 was 
unable to phosphorylate the CTD in the absence of CK2.  In addition, it 
reported phosphorylation of CDK11p110 by CK2 at serine 227. Serine 227 lies 
within the SH2 binding domain contained in the N-terminus of CDK11p110. 
The significance of this phosphorylation was not explored but the original 
paper that identified the SH2 binding domain within CDK11 reported 
enhanced SH2 binding with adjacent phosphorylation [47].  Although at that 
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time the precise site of phosphorylation was not identified, CK2 was again 
implicated in CDK11p110 phosphorylation [47]. 
1.4.4.3 CDK11 and 9G8 
CDK11p110 interacts with splicing factor and SR protein 9G8 (SRSF7) [22].  
9G8 is a general splicing factor that is involved not only in splicing but also 
in mediating the nucleocytoplasmic export of mRNA.  The interaction with 
CDK11p110 is dependent on the RE motif within the p110 isoform, but not 
the poly(E) domain or the CK2 phosphorylation site [22]. CDK11p110 
phosphorylates 9G8 both in vitro and in vivo, with the phosphorylation of 
9G8 required for both its splicing and export functions [48]. 9G8 contains a 
long RS domain similar to that found both in SC35 and Cyclin L; the RS 
domain has been implicated in determining the specificity of protein-protein 
interactions and these similarities may explain their common interactors [44].  
Hu et al. (2003) directly interrogated the role of both CDK11p110 and 9G8 in 
splicing, with the use of standard in vitro splicing assays. As expected, 9G8 
promoted in vitro splicing activity, while immunodepletion of CDK11p110 
caused abrogation of splicing in this assay; this was reversed by the re-
addition of immunoprecipitated CDK11p110 complexes [22]. 
1.4.4.4 CDK11 and HIV  
This CDK11-9G8 interaction has also been reported to regulate the 3’ end 
processing of HIV-1 mRNA [49].  9G8 is observed to bind upstream of the 
HIV-1 poly(A) site and promotes its cleavage in a sequence-specific manner 
[49].  Eukaryotic initiation factor 3f (eIF3f) is a component of the multi-
subunit eIF3 translation factor that facilitates the formation of the ribosomal 
43S preinitiation complex and has previously been identified as a substrate of 
the apoptosis-associated CDK11p46 isoform [50].  Interaction of eIF3f and 
CDK11p110 with 9G8 disrupts its mediation of 3’ end processing of the HIV-
1 pre-mRNA, with the resulting degradation of unprocessed RNA in the 
nucleus [49].  Consistent with this, overexpression of either eIF3f or CDK11 
reduced susceptibility to VSV-HIV viral transduction [49].  This work 
indicates a role for CDK11 not only in regulating HIV-1 infectivity but also in 
the 3’ end processing of pre-mRNA.    
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Yu et al. (2008) also suggested a role for CDK11 in HIV-1 replication [51].  
HIV-1 infection targets both T-cells and macrophages, with T-cell activation 
necessary to enable high viral replication.  Cyclin T1, a constituent of P-TEFb, 
is directly targeted by the viral Tat protein to activate proviral transcription.  
Yu et al. (2008) examined genes dependent on Cyclin T1 for expression 
following T-cell activation, to identify putative HIV-1 cofactors.  CDK11 was 
identified in this assay and CDK11 knockdown was observed to inhibit HIV-
1 luciferase reporter expression.  This is paradoxical to the reduction in HIV-
1 expression observed on CDK11 overexpression [49].  The reason for this 
remains unclear but may result from the different assays employed.  In 
addition, Yu et al. (2008) reported reduction in CDK9 and HEXIM1 
expression on CDK11 knockdown but with no effect on CDK8 [51].  Again, 
this indicates a role for CDK11 in the regulation of proteins integral to 
transcriptional elongation.   
1.4.5 CDK11 and Cyclin L Regulatory Partners 
Cyclin L1, previously termed Ania-6, was identified in murine cells as the 
first regulatory cyclin to associate with CDK11 [52]. Cyclin L1 co-localises 
with CDK11 to nuclear speckles and is able to co-immunoprecipitate both 
hyperphosphorylated RNA Pol II and CDK11p110, consistent with the p110 
isoforms roles in transcription and splicing [52]. Two studies, published 
simultaneously, identified a distinct novel RNA Pol II-associated cyclin, 
which in similarity to Cyclin L1, contained an RS repeat domain [53, 54].  
This novel cyclin, designated as Cyclin L2, was also observed to associate 
with CDK11p110, SC35, 9G8, and RNA Pol II [53, 54].  Cyclin L2 co-localises 
with splicing factors to nuclear speckles, indicating a role in splicing 
regulation.  Corroborating this, recombinant Cyclin L2 stimulates in vitro 
mRNA splicing [54].   
It is established that both Cyclin L1 and Cyclin L2 engage CDK11 as alternate 
cyclin regulatory partners.  Both Cyclin L members contain similar domains, 
including both the cyclin box and RS domain.  In addition, both Cyclin L 
genes generate numerous alternative transcripts that give rise to two 
predominant protein isoforms from each gene [55].  These constitute a long 
and short isoform, with both isoforms comprising equivalent N-terminal 
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sequences containing the cyclin box domain.  The sequences diverge at their 
C-termini, with the longer or alpha isoforms containing the RS dipeptide 
repeat sequence.  The significance of the similarity in protein biology 
between Cyclin L and CDK11 remains uncertain. 
1.4.5.1 CDK11 and Cyclin L1 and L2 Interaction 
Both Cyclin L genes are expressed ubiquitously, although their relative 
abundance differs in discrete tissues [54]. All the major Cyclin L isoforms 
bind all major CDK11 isoforms, including CDK11p46, although the observed 
binding affinity varies between isoforms.  In addition, all major Cyclin L1 
and L2 isoforms are reported to enhance splicing activity as assessed by both 
in vivo and in vitro splicing assays [55].  Loyer et al. (2008) also demonstrated 
that wild-type CDK11p110 enhanced splicing, whilst the kinase-dead 
CDK11p110 and CDK11p110, lacking the RE domain, inhibit splicing 
activity. Furthermore, constitutive expression of both CDK11p58 and 
CDK11p46 inhibited splicing in this assay [55]. 
Although the similarities between Cyclin L1 and Cyclin L2 are noted, it has 
been demonstrated that their cellular distribution and mobility differ [53].  
Under physiological conditions both localise to nuclear speckles, however, 
GFP.Cyclin L1 is found to be immobile compared to GFP.Cyclin L2, using 
photo-bleaching techniques [56]. The relevance of the difference in the 
mobility remains unclear but Herrman et al. (2007) proposed it may indicate 
that Cyclin L1 is not directly involved in transcriptional regulation [56]. 
1.4.5.2 Cyclin L2 and DYRK1A 
De Graff et al. (2004) identified interaction of Cyclin L2 with nuclear protein 
kinase DYRK1A [53].  DYRK1A is located on chromosome 21 in a locus 
termed the ‘Down syndrome-critical region’. Overexpression of the protein 
in transgenic mice causes learning deficits and altered neurodevelopment 
[57]. The contribution of DYRK1A to human development has been 
confirmed with the recent description of DYRK1A gene mutations causing a 
syndromic intellectual disability with severe microcephaly and epilepsy [58].  
DYRK1A was found to phosphorylate Cyclin L2, suggesting a putative role 
in splicing regulation. 
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1.4.5.3 Cyclin L Proteins and Alternate Splicing 
In addition to the global effects on splicing activity mediated by Cyclin L 
proteins, enforced Cyclin L expression alone or in combination with 
CDK11p110 strongly mediates alternative splicing in vivo [55].  This was 
demonstrated using an E1A minigene reporter construct, with Cyclin L 
proteins influencing alternate splicing selection and the protein synthesised 
[55].  Published studies therefore demonstrate the influential role of CDK11 
and its Cyclin L regulatory partners in both splicing activity and alternative 
splicing [55] [54].   
The novel CDK11 binding protein RNA binding motif protein 15B (RBM15B) 
has been shown to regulate the CDK11p110-Cyclin L2 complex in its 
mediation of splicing [59]. RBM15B is an established cofactor of the nuclear 
export receptor NXF1 and is engaged in mRNA export but Loyer et al. (2011) 
established RBM15B is also a functional competitor of specific SR proteins 
[59]. This antagonism of SR proteins by RBM15B inhibits the formation of 
functional spliceosomal complexes and suppresses the stimulatory effect of 
the CDK11p110-Cyclin L2 complex on splicing both in vitro and in vivo.  The 
authors confirmed that this was not due to the protein’s influence on mRNA 
export, with this therefore providing insight into the mechanisms regulating 
CDK11 splicing activity [59]. 
1.4.6 CDK11 and Chk2 
The recent identification of Checkpoint Kinase 2 (Chk2) as a novel 
CDK11p110 interacting protein further characterizes the mechanisms 
regulating CDK11 and splicing [60, 61]. Chk2 phosphorylates CDK11p110 at 
serine 737, with phosphorylation of this residue indispensible for 
homodimerisation of CDK11p110. While homodimerisation of CDK11p58 
had been previously described [57], this represented the first report of it 
occurring with CDK11p110 [60, 61]. Phosphorylation of CDK11p110 at serine 
737 had no influence on kinase activity but ablation of phosphorylation at 
this site, via introduction of a phospho-refractory mutant, abrogated 
CDK11p110 mediated splicing.  This regulation of pre-mRNA splicing by 
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Chk2 was found to be constitutive and not associated with the DNA damage 
response, which regulates other Chk2 functions [60, 61]. 
1.4.7 CDK11 and Mediator Complex Assembly 
This chapter provides a synopsis of the evidence establishing a role for 
CDK11 in splicing and transcription. Whilst these functions are evident, the 
mechanisms by which CDK11 regulates these processes require 
characterisation.  As discussed, CDK11 interacts with RNA Pol II and 
proteins involved in transcriptional elongation, with its influence in 
transcription demonstrated by in vitro transcription assays [23].  A recent 
study identified a putative mechanism through which CDK11-cyclin L may 
mediate transcription [62].  This demonstrated that the fission yeast 
homologues of CDK11 and Cyclin L phosphorylate yeast mediator subunits, 
Med27 and Med4.  This phosphorylation regulates the association of the 
CDK8 kinase module with the S-mediator complex [62].  Consistent with its 
role in regulating the association of a kinase-competent mediator complex, 
CDK11 depletion altered gene expression in a similar manner to CDK8 
knockout [62].  Furthermore, CDK11 was observed in ChIP assays to 
distribute throughout the genome with bimodal enhancement at the 5’ and 3’ 
end of genes.  Although the fission yeast CDK11 homologue differs 
substantially from metazoan CDK11p110, it does resemble the CDK11p58 
isoform more closely.  Drogat et al. (2012) therefore describe a novel 
mechanism through which CDK11 may regulate transcription [62]. However, 
no interaction with the mediator complex has been reported with human 
CDK11.   
The report of a novel interaction between CDK11p58 and the histone 
acetyltransferase HBO1, a MYST family protein, demonstrates additional 
mechanisms through which CDK11 may regulate eukaryotic transcription 
[63].  Histone modification is established to influence transcription, with 
acetylation characteristically linked to euchromatin and transcriptional 
activation [28].  This may be due to both the reduction in the affinity of 
histones to DNA and the generation of binding sites that recruit proteins to 
facilitate gene expression.  CDK11p58 enhances the histone acetyltransferase 
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activity of HBO1, however, CDK11p58 is primarily expressed at mitosis and 
this study did not examine interaction with the CDK11p110 [63]. Therefore, 
the relevance of this finding to interphase transcription remains unclear. 
1.4.8 CDK11 and Steroid Hormone Receptors  
In addition to its roles in transcription and splicing, CDK11 mediates 
transcriptional activation associated with the nuclear steroid receptor family 
[64-66].  In three papers by Gu and coworkers, CDK11p58 represses 
transcriptional activation associated with oestrogen receptor alpha, androgen 
receptor and vitamin D receptor [64-66].  This did not occur through 
modulation of translation or transcription of the receptors, as there was no 
associated repression of androgen receptor protein expression or oestrogen 
receptor / vitamin D receptor transcript levels.  The repression of 
transcription mediated by both oestrogen receptor alpha and vitamin D 
receptor occurred through their ubiquitin-proteasome degradation, 
promoted by CDK11p58 [64, 65].  Both the interaction with CDK11p58 and 
its kinase activity are required for the receptors’ polyubiquitination and 
subsequent degradation.  In contrast, CDK11p110 enhances oestrogen 
receptor alpha-mediated transcriptional activation.  Paradoxically, although 
CDK11p110 is the predominant constitutive isoform, CDK11 depletion also 
enhances oestrogen-driven transcription [65].  This dichotomy has not 
satisfactorily been explained.   
In contrast, repression of the androgen receptor transcriptional activity 
required phosphorylation of its transcriptional activation unit 1 (TAU1) 
motif by CDK11p58 and a kinase-dead CDK11p58 mutant was unable to 
repress androgen receptor activity [66]. These papers therefore describe 
mechanisms through which CDK11 may modulate the transcriptional 
activity of nuclear receptors. These interactions and their effects were 
observed using constitutively expressed CDK11p58 but no interaction with 
these signaling pathways has been demonstrated with endogenous 
CDK11p58, expressed primarily during mitosis. 
1.5	  CDK11	  and	  Mitosis	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1.5.1 Mitosis 
The faithful replication and subsequent accurate division of the genome is 
integral to the maintenance of orthodox cellular physiology.  Aberrations in 
these processes have deleterious consequences and are frequently associated 
with cancer [67].  Mitosis describes the segregation of the replicated genome 
into two daughter cells. It comprises the stages prophase, prometaphase, 
metaphase, anaphase and telophase [68].  At prophase, chromatin within the 
nucleus condenses, with the loss of nucleoli.  The centrosome comprising 
two centrioles, duplicated during S phase divides and the centrioles migrate 
to opposing cell poles [68].  Dissolution of the nuclear membrane marks the 
onset of prometaphase.  During this period, kinetochore complexes form at 
the chromosome centromeres.  Microtubules extending from the opposing 
centrosomes attach at kinetochores to form the mitotic spindle.  The spindle 
fibres align the chromosomes at the cellular equator to form the metaphase 
plate that designates metaphase [68].  The separation of sister chromatids is 
delayed until the accurate alignment and attachment of bi-orientated sister 
kinetochore has occurred.  The prevention of precocious sister chromatic 
dissociation is mediated by the mitotic checkpoint, termed the Spindle 
Assembly Checkpoint (SAC) [69].  Conserved across eukaryotes, the SAC 
comprises serine/threonine kinases Monopolar Spindle (MPS1) and Budding 
Uninhibited by Benomyl 1 (BUB1) in addition to non-kinase components 
Mitotic Arrest Deficient 1 (MAD1), MAD2, BUB3 and BUB1-related 1 
(BUBR1) [69].  This protein complex inactivates Cell Division Cycle 20 
(CDC20), a co-factor of the E3 ubiquitin ligase Anaphase Promoting 
Complex/Cyclosome (APC/C).  APC/C enables sister chromatid 
segregation and mitotic exit via the ubiquitylation and subsequent 
proteasome-dependent destruction of both Cyclin B, a regulator of mitotic 
progression, and Securin, an inhibitor of Separase, to promote cleavage of the 
Cohesin complex [69].  Unattached kinetochores activate SAC signaling, 
causing inhibition of CDC20 and therefore APC/C, which delays mitotic 
exit. On kinetochore attachment and fulfillment of this mitotic checkpoint, 
sister chromatids separate, marking the onset of anaphase, and move to 
opposing poles [69].  At telophase, chromosomes disperse and novel nuclear 
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membranes are assembled around the daughter nuclei [68].  Cytokinesis 
describes the division of the residual single cytoplasm to form two daughter 
cells [70].  Following sister chromatid separation, a contractile ring 
comprising actin filaments assembles equatorially at the cell cortex [70].  This 
constricts the cell membrane to form a cleavage furrow, with ingression 
progressing until a midbody structure is formed.  Abscission cleaves this 
midbody to enable completion of cytokinesis and separation of daughter 
cells [70].  Numerous proteins are reported to mediate cytokinesis and 
abscission, including RhoA [71].  
1.5.2 CDK11p58 and Mitotic IRES Translation 
The influence of CDK11 on mitotic regulation is well established.  One of the 
first papers interrogating CDK11 function found that apposite levels of the 
kinase were required for successful completion of mitosis [24].  This study 
found that expression of CDK11p58 in Chinese Hamster Ovary (CHO) cells, 
with resultant overexpression of the kinase, resulted in mitotic aberrations 
[24].  These abnormalities comprised mitotic delay with prolonged telophase, 
an aberrant increase in tubulin midbodies and increased aneuploidy within 
the cells.  It was subsequently determined that overexpression of CDK11p58 
resulted in reduced growth rates in the same CHO cell line, with this 
reduction reported to occur secondary to apoptosis [72].  The mitotic role of 
CDK11 was further characterised by the identification of a novel cell cycle-
regulated internal ribosome entry site (IRES) [21].  This work was predicated 
by the identification of the strong cell cycle regulation of the p58 isoform, 
which was predominantly expressed during mitosis, in contrast to the 
constitutively expressed p110 isoform. Cornelis et al. (2000) undertook the 
study using Ba/F3 cells, which represent interleukin 3-dependent pre-B-cells 
[21]. These cells show marked upregulation of CDK11p58 at mitosis; 
although this finding was subsequently confirmed in other cell types, the 
upregulation of CDK11p58 in Ba/F3 cells appears proportionately greater at 
mitosis [21, 25]. Cornelis et al. (2000) demonstrated the presence of an IRES 
sequence, which unusually was contained within the coding mRNA [21].  In 
contrast, the majority of described IRES sequences lie within the 5'UTR of the 
mRNA transcript.  This study demonstrated that translation could be 
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initiated from the IRES sequence through an internal AUG codon, despite the 
introduction of frameshift mutations within the 5' sequence of the p110 
coding mRNA [21].  This finding excluded the generation of CDK11p58 
through the proteolytic cleavage of CDK11p110. In addition, no evidence of 
the alternative splicing was identified on analysis of mRNA transcripts.  
Translation at this IRES region was found to be exceptionally cell cycle 
dependent [21].  The mechanism of this mitotic regulation of the CDK11 IRES 
was subsequently characterized, with work demonstrating the importance of 
Upstream of N-ras (Unr) and hnRNP C1/C2 proteins [73, 74].  Unr itself is 
translated through IRES-mediated mechanisms at G2/M under strict 
regulation by hnRNP C1/C2 [73, 74]. hnRNP C1/C2 stimulates Unr 
translation, while polypyrimidine tract-binding protein (PTB) and Unr 
together suppress Unr translation[73, 75]. Subsequently, Unr regulates 
translation at the CDK11 IRES in this mitotic IRES-dependent cascade [73, 
74].  Interestingly, subsequent work in embryonic stem cells demonstrates 
the importance of PTB in regulating CDK11 IRES activity [76] independent of 
Unr in stem cells, with PTB inhibiting CDK11 IRES activity.  PTB depletion 
resulted in significant mitotic delay and aberrant chromosome segregation, 
considered a consequence of CDK11p58 overexpression and proposed to 
explain the embryonic lethality of PTB-deficient mice [76]. 
1.5.3 Mitotic Suppression of Cap-Dependent Translation 
The importance of translation through IRES-mediated mechanisms has 
become evident [77].  This mechanism of translation is integral to 
maintaining cellular regulation during periods of physiological and 
pathological stress in eukaryote cells, when cap-dependent translation is 
compromised [77].  Protein biosynthesis consists of three principal stages, 
constituting initiation, elongation and termination.  In canonical 
cap-dependent translation, initiation occurs with the binding of the cap-
binding complex (eIF4F) 5' m7G cap-structure of mRNA [78].  This binding 
of eIF4F to the mRNA leads to the subsequent recruitment of the 40S 
ribosomal subunit and its associated initiation factors to form the 43S 
initiation complex.  The 43S complex, when assembled on the 5'UTR, moves 
3' in search of the initiation codon [78].  On recognition of the initiation AUG 
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codon, the 40S subunit is joined by the 60S subunit to form an elongation-
competent 80S ribosome.  This was once considered to be the only mode of 
translation initiation in eukaryote. However, study of viral RNA genomes 
identified alternative mechanisms that subjugated the requirement for cap-
dependent scanning and resulted in the direct recruitment of the 40S 
ribosome to the initiating codon [78], with subsequent work identifying 
cellular transcripts that also undergo IRES-mediated translation.  IRES-
mediated translation enables continued translation during periods of cellular 
stress, when cap-dependent mechanisms are suppressed; many of the 
cellular mRNAs that contain IRES elements encode proteins mediating 
responses to cellular stress [77]. The importance of cap-independent 
translation in mitosis has been established, with 14-3-3σ found to regulate of 
mitotic translation [79, 80]. 14-3-3σ binds numerous translation initiation 
factors including eukaryotic initiation factor 4B in mitosis [80], enabling the 
suppression of cap-dependent translation and resultant stimulation of 
cap-independent mechanisms.  Depletion of 14-3-3σ causes mitotic 
dysregulation, which is ascribed to the inability to inhibit cap-dependent 
translation and consequential reduction in CDK11p58 [80]. Forced expression 
of CDK11p58 rescues the mitotic phenotype caused by 14-3-3σ depletion 
[80].  Subsequently, Barna et al. (2008) attributed the mitotic dysregulation 
caused by hyperactivation of the oncogene Myc on the failure to undergo the 
translational switch to cap-independent mechanisms and the subsequent 
mitotic dysregulation of CDK11 expression [79].  Again, rescue of the mitotic 
phenotype by CDK11p58 expression was demonstrated [79].  These works 
demonstrate both the importance of cap-independent translation in mitosis 
and the consequential translational control of CDK11p58 expression. 
1.5.4 CDK11, the Mitotic Centrosome and Spindle  
The importance of CDK11 in the faithful regulation of mitosis has been 
demonstrated in vivo [81].  Li et al. (2004) generated a CDK11-null mouse 
model through targeted disruption of the gene using homologous 
recombination [81].  In this model, heterozygous CDK11+/- mice demonstrate 
normal development but loss of both alleles results in early embryonic 
lethality, with apoptosis of blastocyst cells at four days post-coitus.  These 
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cells exhibit both proliferative defects and mitotic arrest, consistent with the 
role of CDK11 in mitosis [81].  Subsequent work has confirmed that it is the 
shorter p58 isoform that mediates mitotic regulation, as is expected given its 
primarily mitotic expression [25].  It was demonstrated that expression of 
GFP-tagged CDK11p58 could rescue the mitotic dysregulation caused by 
CDK11 depletion in HeLa cells [25]. However, expression of GFP-tagged 
CDK11p110, with mutation of the IRES region to prevent translation of the 
shorter isoform, failed to rescue the aberrant mitotic phenotype [25].  Petretti 
et al. (2006) were the first to demonstrate localisation of either CDK11 
isoform to the centrosome; CDK11 was found to localise to the centrosome 
throughout the cell cycle, with enhanced signal at mitosis [25]. CDK11 
knockdown resulted in the aberrant localisation of Aurora A and Plk1, with 
abrogation of Aurora A recruitment to the centrosome. Furthermore, there 
was also a reduction in Plk1 recruitment to both the centrosome and 
kinetochore [25].  The centrosomal localisation of gamma tubulin at was also 
decreased, with microtubule regrowth assays demonstrating a diminished 
capacity for microtubule nucleation following CDK11 depletion.  Moreover, 
using an in vitro H1 histone kinase assay, Petretti et al. (2006) demonstrated 
enhanced kinase activity of CDK11p58 following precipitation from mitotic 
cells, whilst the mitotic activity of CDK11p110 was diminished compared to 
interphase [25].  This work established that GFP.CDK11p58, but not 
GFP.CDK11p110, localised to the centrosome consistent with its role in 
mitosis.  However, if it is the p58 isoform that localises to the centrosome, 
then the reported CDK11 centrosomal localisation at interphase is discrepant 
as there is little CDK11p58 expression during interphase [25]. In addition, 
although this paper was fundamental in determining the differential roles of 
CDK11 isoforms at mitosis, the p110 isoform used in these rescue 
experiments lacked the 14-3-3 binding site [25], with binding of 14-3-3 
proteins to CDK11p110 maximal at mitosis [82].  It remains unclear whether 
this may have influenced the findings observed. 
1.5.5 CDK11 and Centrosome Duplication 
The role of CDK11 at the mitotic centrosome was further characterised in a 
subsequent paper by Hotchin et al. (2011) [83].  This demonstrated CDK11 
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depletion caused defective centrosomal recruitment of proteins essential to 
centriole biogenesis, with reduction of both Plk4 and centrosomal protein 
CEP192.  The mislocalisation of these proteins was considered to cause the 
failure of centriole amplification after CDK11 knockdown [83].  CDK11p58 
and Plk4 were found to interact both in vitro and in vivo, using tagged 
expression constructs of both proteins. However, there was no evidence of 
CDK11 phosphorylation by Plk4 and the reverse kinase assay to determine 
whether Plk4 was a substrate of CDK11 could not be undertaken due to 
inactivity of precipitated recombinant CDK11p58 [83].  Interestingly, in this 
work, there was no localisation of CDK11 to the centrosome but instead it 
located to the mitotic spindle, although this was only observed on initial 
expression of the TET-regulated CDK11 fusion protein [83].  
CDK11 recruitment to the mitotic spindle had been previously reported in 
work, which established a role for the CDK11 in mediating microtubule 
stabilization [84].  This study by Yokoyama et al. (2008) was based on the 
discovery that RanGTP supported local nucleation and plus-end stabilisation 
of microtubules at chromosomes during mitosis. Nuclear protein TPX2 was 
requisite for this nucleation and in order to identify other proteins integral to 
microtubule stabilisation, a complex affinity purification protocol was 
devised [84].  This identified both CDK11 and Cyclin L1 within the active 
fraction and an assay using mitotic Xenopus egg extracts established that 
CDK11 mediated this microtubule stabilisation.  Paradoxically, this work 
suggested that it was CDK11p110 isoform and not the p58 isoform that was 
responsible for stabilization [84]. This was determined by the production of 
specific antibodies that distinguished the two isoforms; however, it is unclear 
how the antibody specific to the p58 isoform was derived given the identical 
peptide sequence of the proteins [84]. This work again demonstrated 
localisation of CDK11 (although CDK11p110 on this assay) to the mitotic 
centrosome and spindle.  Following immunodepletion of CDK11, restitution 
of normal spindle assembly was observed following re-addition of 
recombinant, full-length CDK11p110 [84].  If these findings are valid, it 
indicates that both isoforms of CDK11 may engage in the regulation of 
mitosis, although this is not the accepted paradigm. 
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1.5.6 CDK11 and Sister Chromatid Cohesion 
The cohesion of sister chromatids is integral to the accurate segregation of 
chromosomes at mitosis [85].  Sister chromatid cohesion is mediated by the 
Cohesin complex, a ring-shaped protein complex that is believed to encircle 
the DNA helices of sister chromatids following DNA replication and hold 
them adjacent [85]. In vertebrates, cohesin is loaded onto chromatin from late 
telophase, with the reformation of the nuclear envelope [86].  It is maintained 
on the chromatin through interphase and DNA replication, to be removed in 
distinct stages at mitosis [85].  During prophase, the majority of cohesin is 
removed from the chromosome arms, while cohesin remains bound at the 
centromeres. This process is regulated by Plk1, which is activated in early 
mitosis and translocates from the cytoplasm into the nucleus.  Plk1 
phosphorylates the cohesin SA2 subunit, which in combination with 
phosphorylation of pro-cohesion factor Sororin by CDK1 and Aurora B, 
leads to displacement of cohesin and loss of chromosome arm cohesion [86].  
Cohesion at the centromere is maintained until the metaphase-anaphase 
transition, at which time all kinetochores are attached to spindle 
microtubules and the Spindle Assembly Checkpoint (SAC) is satisfied.  The 
SAC then promotes release of activated separase, a proteolytic enzyme that 
cleaves the cohesin subunit Rad21, causing dissociation of the remaining 
centromeric cohesin [86].  For this to occur, the centromeric cohesin must be 
protected through the early mitosis until the metaphase-anaphase transition.  
Shugoshin 1 (Sgo1) mediates the protection of the centromeric cohesion.  
Sgo1 is recruited to the inner centromere at early mitosis following Bub1-
mediated phosphorylation of histone H2A [86].  Sgo1 acts in conjunction 
with protein phosphatase 2A to oppose phosphorylation of SA2 and Sororin.  
The premature loss of sister chromatid cohesion engenders aberrant mitotic 
progression, with a propensity for chromosome mis-segregation.  CDK11p58 
is requisite for the maintenance of sister chromatid cohesion [87, 88].  CDK11 
depletion impairs the recruitment of both BUB1 and Sgo1 to the inner 
centromere during prophase [88].  This causes a failure in the protection of 
centromeric cohesin and the subsequent premature sister chromatid 
separation.  The precise mechanisms mediating this function remain unclear 
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but the kinase function of CDK11p58 is necessary for this role [88]. Following 
CDK11 knockdown, no aberrant cohesion is noted prior to prophase to 
indicate anomalous loading of cohesin [87].  In addition, Hu et al. (2007) 
confirmed that sister chromatid separation was not merely a consequence of 
precocious mitotic exit via staining for phosphorylated Histone H3 and 
Cyclin B1, which are both lost on transition to anaphase [87].  These studies 
characterize the mechanisms through which CDK11 depletion causes mitotic 
dysregulation and chromosome mis-segregation. 
1.5.7 CDK11p58 and Pak1 
CDK11p58 is reported to bind p21-activated kinase 1 (Pak1) during mitosis 
[89].  In the original study by Chen et al. (2003), the CDK11–Pak1 interaction 
was described only with CDK11p46 during apoptosis and no interaction 
with either CDK11p58 or CDK11p110 was detected [90]. However, 
subsequent work by Kong et al. (2009) found interaction of Pak1 with 
CDK11p58 during mitosis, using tagged fusion proteins [89]. The authors 
established that CDK11p58 phosphorylated Pak1 at Ser174; Pak1 
representing the only described substrate of CDK11p58 [90].  
Phosphorylation of Pak1 enabled its recruitment to the myosin V motor 
complex, through binding to dynein light chain 2 (DLC2), and this 
interaction was reported to be fundamental to mitosis [89]. Pak1 mutants that 
mimicked the phosphorylated and dephosphorylated protein were 
generated, with the phospho-mimetic Pak1 enabling mitotic progression 
following nocodazole block while the phospho-refractory mutant exhibited 
mitotic arrest [89].  Kong et al. (2009) therefore proposed Pak1 to be the 
predominant downstream effector of CDK11p58 during mitosis. 
1.5.8 CDK11p58 and Cyclin D3 
Although CDK11 is established to interact with Cyclin L1 and Cyclin L2, 
Zhang et al. (2002) demonstrated that CDK11p58 also interacts with Cyclin 
D3 [91].  This interaction was identified in the yeast two-hybrid system but 
was subsequently confirmed in human hepatocellular carcinoma cells. This 
interaction was exclusive to the G2/M phase of the cell cycle, with Cyclin D3 
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This interaction was specific to both the p58 isoform and the D3 Cyclin, with 
no Cyclin D1 or Cyclin D2 interaction demonstrated [91].  This work 
therefore identified an alternative cyclin regulator of CDK11p58 in mitosis. 
1.5.9 CDK11 and Meiosis 
The role of CDK11 in mitotic regulation is established, although the precise 
mechanisms require further characterisation.  A recent study by Zeng et al. 
(2014) indicates a role for the Arabidopsis CDK11 homolog, CDKG1, in the 
regulation of synapsis and recombination during male meiosis [92].  
Insertion of a mutation within the cdkg1 gene leads to temperature-sensitive 
failure of meiosis in the late Pachytene and this is associated with defective 
formation of the synaptonemal complex, reduced bivalent formation and 
crossing over with resultant aneuploid gametes [92]. Disruption of the 
Cyclin L gene homologue strongly enhances the phenotype of these cdkg1 
mutants. Although no interrogation of members of the cohesin complex was 
undertaken in this study, the phenotype of cdkg1 mutants, with partial 
asynapsis, is similar to that reported in other species on loss of cohesin 
complex proteins [93, 94]. The possible engagement of CDK11 in mediating 
meiosis is interesting and CDK11 may mediate this phenotype though 
mediation of Cohesin, as observed in mitosis [87]. Furthermore, the putative 
requirement for CDK11 at meiosis may explain the observation of discrete 
CDK11 testis-specific transcripts [95, 96].  Several studies have identified the 
presence of these alternate CDK11 transcripts, with one transcript generated 
via a trans-splicing event with non-coding RNA originating on the Y 
chromosome [97].  This non-coding RNA was spliced to the 5'UTR of 
CDK11A mRNA and Jehan et al. (2007) proposed that this alteration in the 
UTR may differentially regulate the expression of CDK11 within the testis 
[97].  In addition, work has demonstrated the expression of CDK11 within 
proliferating germ cells of the developing testis [98].  Furthermore, the 
protein is expressed in Pachytene primary spermatocytes during stage 7 to 
stage 11 of spermatogenesis, which is when synaptonemal complex 
formation and homologous chromosome crossover occurs [95, 96]. 
1.6	  CDK11	  and	  Apoptosis	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Programmed cell death or apoptosis is a highly regulated process that plays 
a fundamental role in development and homeostasis [99].  Dysregulation of 
apoptotic signaling pathways is proposed to promote tumourigenesis by 
preventing the elimination of cells through normal checkpoint controls [100].  
Apoptosis is characterised morphologically by chromatin condensation and 
formation of apoptotic bodies; biochemically, DNA fragments into 
oligonucleosome-size fractions.  Similarities between early events of mitosis 
and apoptosis, such as nuclear envelope dissolution, have been recognized 
and moreover, there are evident links between cell cycle checkpoint control 
and apoptosis [72].  The engagement of cell cycle regulators in the mediation 
of apoptosis is therefore apposite.  The role of CDK11 in apoptotic signaling 
pathways was one of the earliest established functions of the protein [72].  
The initial study demonstrating the influence of CDK11 in apoptosis 
reported that ectopic expression of the CDK11p58 isoform resulted in the 
induction of apoptosis in Chinese hamster ovary cells [72].  Subsequent 
studies and work described in this thesis do not clearly demonstrate 
induction of apoptosis on ectopic expression of the p58 isoform in human cell 
lines [25], particularly the MDA-231 and HCT-116 lines used in my work. 
Lahti et al. (1995) demonstrated that on induction of apoptosis by Fas ligand, 
transcription of CDK11 mRNA was enhanced [72].  In addition, elevated 
levels of a novel CDK11 protein of approximately 50kDa were observed, later 
identified as CDK11p46.  CDK11p46 comprises the C-terminal domain of the 
longer CDK11 isoforms and Lahti et al. (1995) demonstrated that addition of 
protease inhibitors after application of Fas ligand reversed both the 
accumulation of CDK11p46 and the apoptotic phenotype [72]. 
1.6.1 CDK11 and Caspase Cleavage 
Beyaert et al. (1997) subsequently determined that CDK11 isoforms 
underwent cleavage by members of the Caspase family during induction of 
apoptosis to generate CDK11p46 [26]. In a model of tumour necrosis factor-
mediated apoptosis, CDK11p110 was cleaved by both Caspase 1 and Caspase 
3 [26].  No cleavage by other members of the Caspase family was identified. 
Cleavage occurred at Asp393 within the amino acid sequence YVPDS and 
mutation of this Asp393 base to alanine abrogated cleavage by both Caspase 
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1 and Caspase 3 [26].  Further Caspase cleavage sites were identified on Fas-
mediated apoptosis, with a Caspase 8 cleavage site demonstrated at Asp387 
[101].  In addition, ancillary cleavage sequences were identified within the N-
terminal domain, resulting in the production of small CDK11 fragments on 
induction of apoptosis.  Serine phosphorylation was determined to influence 
cleavage at these N-terminal domain sites [101]. 
1.6.2 CDK11p46 Interacting Proteins 
Cleavage of proteins on apoptosis has two primary roles, which are either to 
ablate the function of proteins whose inactivity is required for apoptosis or to 
cleave proteins so as to release active fragments that execute the cell death 
program.  It has been reported that the cleavage, kinase activity and 
localisation of CDK11 influence apoptotic signaling [101-103]. CDK11p46 
represents the C-terminal fragment obtained following cleavage of the p110 
or p58 isoforms at the Asp387 or Asp393 sites and it is generated by cleavage 
uniquely found on apoptotic signaling [104].  CDK11p46 contains the kinase 
domain of the longer CDK11 isoforms, but lacks numerous N-terminal 
regulatory elements.  The p46 isoform has been reported to impart significant 
influence on anoikis, apoptosis induced by disruption of cell–matrix 
interaction, which it was found to mediate through interaction with p21-
activated kinase 1 (Pak1) [90].  Direct interaction of CDK11p46 and Pak1 was 
reported to result in reduced Pak1 activity, which correlated inversely with 
levels of anoikis following expression of the p46 isoform [90].  
Other protein interactions with CDK11p46 are reported and a yeast two-
hybrid assay identified that the p47 subunit of eukaryotic initiation factor 3 
(eIF3f) interacted with the p46 isoform [50].  This occurred through the 
Mov34 domain within the eIF3f protein and although weak interaction with 
CDK11p110 was observed, there was strong avidity for CDK11p46.  
CDK11p46 phosphorylates eIF3f at serine-46 and this phosphorylation is 
enhanced on induction of apoptosis [105].  On account of this interaction, Shi 
et al. (2003) interrogated the influence of CDK11p46 on translation and 
observed impaired synthesis of a reporter gene product on expression of 
CDK11p46 but not kinase-dead CDK11p46 [50].  This repression of protein 
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expression was mediated through translation as there was no reduction in 
transcript levels within the assay.  Subsequently, an additional site of 
CDK11p46-mediated phosphorylation was identified in eIF3f at Threonine-
119 within the Mov34 domain [106].  The significance of the dual-site 
phosphorylation of eIF3f protein by CDK11p46 was interrogated and this 
demonstrated that abrogation of phosphorylation through mutation of both 
serine-46 and threonine-119 to alanine reversed the apoptosis induced on 
CDK11p46 expression [106]. In contrast, phosphomimetic mutations at these 
residues upregulated apoptosis.  Phosphorylation of eIF3f was reported to 
increase association of the protein with the eIF3 core complex but the 
mechanisms by which this regulates both protein synthesis and apoptosis 
remain unclear [106]. 
Interactions of CDK11p46 with NOT2 and Ran-Binding Protein 9 (RANBP9) 
were both identified by yeast two-hybrid assays [107, 108]. NOT2 is a 
subunit of the CCR4-NOT complex that is engaged in regulating mRNA 
synthesis and degradation, with additional roles mediating repression of 
RNA Pol II transcription [109, 110]. NOT2 interacts with CDK11p46 via its 
NOT domain. Shi et al. (2005) found that overexpression of NOT2 enhanced 
apoptosis but the mechanism for this was not determined [107]. The 
interaction between CDK11p46 and RANBP9 was identified by Mikolajczyk 
et al. (2003) and was enabled by the SPRY domain within RANBP9. CK11p46 
was found to phosphorylate RANBP9 but the consequence of this interaction 
was not established [108]. 
1.6.3 CDK11p46 and Chaperone Proteins 
The CDK11p46 isoform remains predominantly nuclear following its 
generation by caspase cleavage and work has demonstrated that its stability 
is regulated through interaction with molecular chaperone proteins [104]. 
CDK11p46 binds to Heat Shock Protein 90 (Hsp90), CDC37, its co-chaperone, 
and Hsp70, with the kinase activity of CDK11 necessary for its interaction 
with the Hsp90–CDC37 complex [104]. The treatment of cells with 
geldanamycin, an Hsp90-specific inhibitor, leads to ubiquitin-mediated 
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proteasomal degradation of the p46 isoform. This degradation of CDK11p46 
was associated with a reduction in apoptosis [104].  
While this work demonstrates that chaperone molecules regulate the stability 
of the CDK11p46, a study by Li et al. (2005) reported that β 1,4-
Galactosyltransferase 1 (β 1,4-GT 1) regulates the generation of the p46 
isoform [111].  This work demonstrated that ectopic expression of beta 1,4-
GT 1 enhanced CDK11-mediated apoptosis induced by cycloheximide [111], 
whilst in the same model, β 1,4-GT 1 depletion effectively inhibited 
apoptosis. This β 1,4-GT 1 knockdown inhibited release of Cytochrome C 
and thereby Caspase cleavage, with the consequent attenuation of CDK11p46 
production.  The mechanism of this regulation remains elusive but β 1,4-GT 1 
is reported to interact with CDK11, despite its localisation at both the trans-
Golgi and cell membrane [112].  Indeed, the interaction of CDK11p58 with β 
1,4-GT 1 led to the first identification of CDK11 [20]. However, the relevance 
of this direct interaction to apoptotic signaling is unclear, as β  1,4-GT 1 acts 
upstream of the CDK11 cleavage required to generate the p46 isoform that 
mediates apoptosis. 
1.6.4 CDK11p60 
The majority of published studies interrogating the role of CDK11 at 
apoptosis have investigated the function of the catalytic CDK11p46 cleavage 
product. However, it is reported that the N-terminal cleavage product, 
CDK11p60, may also engage in apoptotic signaling [113].  The p60 isoform 
comprises the regulatory domain of CDK11p110 and unlike the p46 cleavage 
product, which remains nuclear in location, the p60 isoform translocates to 
mitochondria [113].  It is reported that this mitochondrial targeting disrupts 
mitochondrial membrane potential with the resultant release of Cytochrome 
C [113]. Furthermore, Feng et al. (2005) demonstrates interaction between 
CDK11p60 and mitochondrial Hsp70, which acts as a transport protein to 
provide a mechanism of CDK11p60 entry into the inner mitochondrial 
membrane [113]. 
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1.6.5 CDK11, Apoptosis and BCL-2 Family Proteins 
The influence of CDK11 on Bcl-2 protein family members has been 
investigated by Chen et al. (2006) [114]. The Bcl-2 protein family comprises 
proteins with paradoxical influences on apoptotic regulation, whilst 
members Bcl-2 and Bcl-xl promote survival, others such as BAD and BAX 
induce cell death. Chen et al. (2006) demonstrated the inhibition of Pak1 
kinase activity, secondary to CDK11p46 overexpression, correlated with a 
reduction in BAD phosphorylation on serine-112 and serine-136 [114]. This 
diminished phosphorylation caused the translocation of BAD to 
mitochondria and subsequent release of cytochrome c.  A phospho-refractory 
mutant of Pak1, which was uninhibited by CDK11p46, phosphorylated BAD 
and resulted in the release of Bcl-2, with the blockage of cytochrome c 
release. This demonstrated a mechanism of CDK11p46-mediated apoptosis.   
Furthermore, it was subsequently observed that CDK11p46 expression 
caused a reduction in Bcl-2 protein levels following cycloheximide-induced 
apoptosis, which was found to be dependent on CDK11 kinase activity [115].  
Reduced phosphorylation of Bcl-2 residues serine-70 and serine-87 was 
reported, although this reduction in phosphorylation appeared to correlate 
with overall reduction in Bcl-2.  Yun et al (2007) demonstrated that enforced 
Bcl-2 expression could rescue the increase in apoptosis observed on 
treatment with cycloheximide, following CDK11p46 overexpression [115]. 
However, no direct interaction between Bcl-2 and CDK11 was demonstrated.  
The authors noted no manifest increase in apoptosis with CDK11p58 
overexpression alone [115]. 
Hao et al. (2011) identified a novel interaction between CDK11p46 and 
Ribosomal Protein S8 (RPS8) that resulted in the inhibition of both cap-
dependent and IRES-mediated translation, with no reduction of mRNA 
levels on this assay using a bicistronic luciferase reporter [116].  The CDK11–
RPS8 interaction synergised Fas ligand-induced apoptosis and provides a 
novel mechanism for the mediation of translation by CDK11 during 
apoptotic signaling. 
1.7	  CDK11	  and	  Disease	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The accurate regulation of cellular physiology is requisite for normal 
development, homeostasis, repair, and ultimately survival of all organisms.  
Dysregulation of this precise control mediates a plethora of deleterious 
consequences and this thesis aims to interrogate the consequences of CDK11 
dysregulation in both cancer and developmental phenotypes.  The roles of 
CDK11 in regulating diverse cellular processes have been established but its 
contribution to disease phenotypes remains uncertain. 
1.7.1 1p36 Deletion and Cancer 
Deletion of the short arm terminus from human Chromosome 1 is an 
anomaly frequently observed in diverse tumour types.  The duplicate CDK11 
genes lie within this region at 1p36.3, a locus frequently deleted in 
neuroblastomas, malignant melanomas, ductal breast carcinoma, 
endometrial hyperplasia, non-Hodgkin lymphoma, and early childhood 
sinus tumours [117-121].   
1.7.1.1 1p36 and Neuroblastoma 
The deletion at 1p36 on Chromosome 1 is a consistent observation in 
advanced neuroblastoma and tumour-derived cells, with reports that it 
correlates with enhanced metastatic potential [119, 121].  The frequency of 
this deletion is proposed to indicate the presence of a tumour-suppressor 
gene at this locus.  On account of its mediation of mitosis and apoptosis, 
CDK11 has been considered a putative candidate tumour suppressor gene.  
Analysis of neuroblastoma-derived cells demonstrated deletion or 
translocation of one allele of both CDK11A and CDK11B in 18 of 20 cell lines 
examined [119].  Interestingly, not only did the 1p36 deletion correlate with 
metastatic potential but it was also associated with N-myc gene amplification 
[122].  The significance of this remains uncertain.  Subsequent work has 
questioned the validity of CDK11 as a putative tumour suppressor, with an 
alternate study reporting that the CDK11 locus was outside of the consensus 
region of allelic loss, albeit in a small cohort of samples [123]. 
1.7.1.2 1p36 Deletion and Melanoma 
Similar observations have been reported in melanoma [120, 124]; 1p36 
deletion is found primarily in nodular melanoma and melanoma metastases 
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[125].  Initial work analysing the CDK11 genes in melanoma-derived cells 
revealed deletion or translocation in 8 of the 14 lines investigated [120].  In 
addition, mutations of the 5’ promoter region of the CDK11B gene were 
observed in four discrete cell populations. However, this work was 
subsequently contradicted by analysis of the CDK11 locus and its promoter 
in tissue derived from 58 unique malignant melanomas [126].  This found 
only a single mutation within the promoter region in one melanoma tissue 
sample.  No mutations of the coding sequence itself were observed.  In other 
work, Feng et al. (2002) did not identify common mutations within the 
CDK11 coding region but did report different promoter polymorphisms and 
queried the potential implication of these for transcriptional regulations 
[124]. Nonetheless, although 1p36 deletion is commonly observed in certain 
cancers, the contribution of CDK11 to tumourigenesis in these cases has not 
been determined. 
1.7.1.3 CDK11 and Squamous Cell Skin Tumours 
Chandramouli et al. (2007) investigated the influence of CDK11 haplo-
insufficiency on tumourigenesis, adopting a murine model [127].  A single 
allele of the CDK11 gene was targeted using gene trap technology to generate 
haplo-insufficient mice.  The CDK11+/- and CDK11 WT mice were compared 
in a model of chemical-mediated skin carcinogenesis. This demonstrated 
enhanced susceptibility to tumour formation following the loss of a single 
allele of CDK11.  No other study has directly interrogated the contribution of 
CDK11 dysregulation to tumourigenesis. 
1.7.1.4 CDK11 and Wnt/β-catenin in Colonic Adenocarcinoma 
CDK11 was identified as a modulator of Wnt/β-catenin-dependent 
transcription, following an RNAi kinome screen for modulators of Wnt 
signaling in colorectal cancer cells [128]. Activation of Wnt signaling is 
observed constitutively in most colon adenocarcinomas [129].  These 
tumours are often reported to be addicted to Wnt/β-catenin signaling, with 
the signaling cascade integral to cell survival.  CDK11 was one of 11 kinases 
found to regulate this pathway, with CDK11 knockdown inhibiting Wnt-
driven transcription as assessed in a luciferase assay [128].  This work not 
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only demonstrated a role for CDK11 in regulating the Wnt signaling cascade 
but also identified CDK11 as a putative target in Wnt-addicted cancers.   
1.7.1.5 CDK11 and Multiple Myeloma 
Subsequently, CDK11 has been identified as a putative therapeutic target in 
two RNAi lethality screens of human multiple myeloma [130, 131].  In the 
first study, the lethality of 639 human kinases or putative kinases was 
assessed in two myeloma cell lines [131].  CDK11 was one of 15 kinases 
identified to significantly reduce viability after depletion by RNA 
interference.  The mechanism of this impaired viability is uncertain but other 
mitotic regulators such as Plk1 and Aurora A were identified, suggesting this 
may be mediated through mitotic dysregulation [131].  The second paper 
identified CDK11 as one of 57 potent myeloma survival genes, from an assay 
of 6,722 genes selected for putative ‘druggability’ [130].  This study was 
again undertaken in myeloma cell lines and once again identified mitotic 
regulator Plk1 and Aurora B in addition to CDK11 within the genes inducing 
lethality on knockdown. Therefore, both studies indicate CDK11 may be 
critical to myeloma cell survival and thereby a putative target for drug 
therapy. 
1.7.1.6 CDK11 and Sarcoma 
Recent work has reported CDK11 expression to be critical for osteosarcoma 
cell growth and proliferation [132].  This study undertook a viral-based 
shRNA kinase library assay to identify novel kinases that mediate 
osteosarcoma survival.  CDK11 knockdown caused reduced cell viability 
with enhanced apoptosis and was associated with a reduction in the 
expression of pro-survival genes Mcl-1 and Bcl-xL.  Further work 
interrogated this observation in vivo, via the subcutaneous injection of 
osteosarcoma cells into nude mice. Intra-tumoural administration of CDK11 
siRNA significantly suppressed tumour growth compared to both vehicle 
and non-targeting siRNA treatment [132].  The clinical implication of CDK11 
expression was assessed through analysis of CDK11 protein levels in tissue 
microarrays derived from human osteosarcoma.  Kaplan–Meier survival 
analysis demonstrated the outcome for patients with tumours with high 
CDK11 expression was significantly worse than those with low CDK11 
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expressing tumours.  This work indicates the importance of CDK11 and its 
expression to tumour biology. The reports of both tumour-suppressing and 
tumour-promoting functions initially appear paradoxical, with 
haploinsufficiency of CDK11 reported to enhance tumourigenesis but high 
CDK11 expression associated with tumour progression [127, 132]. It is 
proposed to indicate the importance of precise regulation of CDK11 
expression; dysregulated CDK11 expression may have deleterious 
consequences, which dependent on context may promote tumourigenesis or 
impair tumour cell survival. 
1.7.2 CDK11 in Diverse Disease Processes 
It is not only in tumour biology that a putative role for CDK11 is proposed.  
Published studies have indicated potential influence of CDK11 in diverse 
pathologies, including keloid disease, Alzheimer disease and type II diabetes 
[133-135].  The scope of these studies was limited and each had significant 
methodological deficiencies but these papers do advocate the need for 
further investigation of the role of CDK11 in disease pathogenesis.  The 
speculative contribution of CDK11 dysregulation and mislocalisation to 
Alzheimer disease is intriguing.  CDK11 is reported to mis-localise to the 
cellular cytoplasm, as opposed to the nucleus, in human Alzheimer disease 
tissue samples [133]. In addition, expression of both amyloid precursor 
protein and amyloid-β(25-35) caused enhanced CDK11 expression in 
neuronal M17 cells [133].  The significance of this is uncertain and is not 
explored in depth in this study but others have implicated CDK11 in 
neuronal inflammatory responses [116, 136]. 
1.7.3 1p36 Deletion Syndrome 
Deletion of the distal short arm of Chromosome 1 (1p36), including the 
CDK11 locus, is not only an anomaly identified in cancer but congenital 
deletion of 1p36 causes the developmental disorder termed 1p36 deletion 
syndrome [137]. This constitutes one of the more common described 
developmental disorders, with an estimated incidence of 1 in 5,000 live births 
[138].  The disorder conveys a wide phenotype of dysmorphology, with 
common features including growth delay, moderate to severe mental 
retardation, motor hypotonia, and a large anterior fontanelle [138].  The 
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single gene or multiple genes that contribute to the phenotypic spectrum 
remain uncertain.  It is considered probable that several genes within this 
locus influence the dysmorphology of the disorder, given the disparate 
clinical manifestations [138].  In addition, there is little work investigating the 
consequence of haploinsufficiency of individual genes within this locus. The 
influence of CDK11 on this developmental pathology therefore remains 
uncertain. However, no developmental phenotype was observed in 
haploinsufficient mice, although it is important to note that the murine Cdk11 
locus varies markedly from the human genome [81]. Intriguingly, single 
nucleotide polymorphisms (SNPs) within both the CDK11A and CDK11B 
genes were found to be significantly associated with language abilities in a 
genome-wide association meta-analysis of two large cohorts, derived from 
both Australia and the United Kingdom comprising over 6,500 children 
[139]. Nonetheless, the contribution of CDK11 to more profound intellectual 
impairment is not determined. 
Published literature implicates CDK11 and its dysregulation in the mediation 
of diverse disease processes.  It may play a role in both tumour suppression 
and tumour promotion, with evidence that it may represent a novel 
therapeutic target in cancer treatment.  Further work is required to better 
characterize the mechanisms through which CDK11 mediates its influence 
and to establish its roles in these diverse pathological processes. 
1.8	  Additional	  Reported	  Functions	  of	  CDK11	  
1.8.1 CDK11 and Hedgehog Signaling 
In addition to its roles in transcription, splicing, mitosis and apoptosis, 
CDK11 is reported to engage a variety of alternate processes.  Two studies, 
both using RNA interference screens, identified CDK11 as a regulator of 
Hedgehog signaling in both drosophila and mouse models [140, 141].  
Hedgehog signaling is critical for proper development, with its disruption 
associated with developmental abnormalities and cancer [142].  The 
mammalian Hedgehog (Hh) signaling pathway is activated through binding 
of Hh ligand to the Patched receptor [142].  This enables the translocation of 
Smoothened and initiation of downstream signaling cascades leading to the 
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ultimate activation of Glioma-associated (GLI) transcription factors [142].  
The protein Suppressor of Fused (SUFU) acts to negatively regulate this 
pathway; it undertakes this both through prevention of GLI entry into the 
nucleus and direct inhibition of GLI transcriptional activity.  It is reported to 
mediate this through recruitment of the SIN3-associated polypeptide 18 
(SAP18)-mSIN3 histone deacetylase repressor complex [143].  CDK11 was 
identified to bind SUFU and repress its inhibitory actions on GLI [140].  It is 
assumed, given the nuclear localisation of CDK11, that it acts to repress 
SUFU activity within the nucleus.  Other studies have since identified SAP18 
as a binding partner of CDK11 [60].  This demonstrates an alternative 
mechanism of transcriptional regulation by CDK11.   
1.8.2 CDK11 and Rho Signaling 
CDK11 is reported to modulate Rho signaling at cytokinesis in drosophila 
[144].  Using a drosophila phenotype reported to occur due to ineffective Rho 
activation at cytokinesis, this study performed a screen examining for genes 
that modulate the aberrant phenotype when over-expressed [144]. This 
found that over expression of PITSLRE (drosophila CDK11) suppressed the 
aberrant phenotype in this model. Notwithstanding the limitations of this 
model, this implicated CDK11 in the mediation of Rho signaling at 
cytokinesis [144]. 
1.8.3 CDK11p58 and Neuronal Inflammation 
Numerous papers from the laboratory of Shen and co-workers have 
interrogated the putative role of CDK11p58 in modulating inflammatory 
response in neuronal astrocytes, neurons and Schwann cells [136, 145].  These 
papers report that CDK11p58 mediates astrocytes activation caused by 
lipopolysaccharide (LPS), with it reported to involve activation of p38 and 
JNK pathways [146, 147].  In addition, it was reported that CDK11p58 
expression enhanced both neuronal apoptosis and Schwann cell apoptosis 
following LPS administration [145].  The functional significance of these 
reported observations remains uncertain but the authors propose that this 
implicates CDK11 in neuronal inflammation and neuronal degeneration 
[145].  Further work is required to clarify this but the same laboratory has 
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reported enhanced expression of CDK11p58 following spinal cord injury in a 
rat model [148].   
1.8.4 CDK11 and Autophagy 
Work from within this laboratory has recently identified CDK11 as a 
mediator of cellular autophagy [149].  Autophagy is an intracellular 
degradation system that delivers cytoplasmic constituents to the lysosome, 
within double membrane bound vesicles termed autophagosomes [150].  
Three distinct types of autophagy are described, which are macro-
autophagy, micro-autophagy and chaperon-mediated autophagy [150]. 
However, the term autophagy is classically used to distinguish macro-
autophagy and is the case within this thesis [150]. An RNA interference 
kinome screen was used to detect autophagy modulators in drosophila S2 
cells [149]. This demonstrated that CDK11, or PITLSRE, depletion caused the 
accumulation of autophagosomes. This thesis describes my initial work to 
characterize the mechanisms underlying this CDK11-mediated autophagy.   
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1.9	  Statement	  of	  Problem	  
Evidence summarized in this chapter demonstrates the fundamental role 
CDK11 plays in regulating diverse aspects of cell biology. CDK11 has an 
essential role in embryonic development, with loss of Cdk11 causing 
blastocyst lethality in murine models. Furthermore, CDK11 appears critical 
not only during development but in later health, with CDK11 dysregulation 
implicated in various disease states, including cancer. Overexpression of 
CDK11 correlates with poor prognosis in assorted tumours, with CDK11 
identified as a putative therapeutic target. The importance of CDK11 in both 
health and disease warrants further investigation to better understand its 
functions in these states.   
In this work, I aimed to examine the role of CDK11 in both cancer and 
developmental phenotypes. CDK11 depletion is reported to influence 
autophagy and cell migration in cancer cells. Initially, I investigated the 
influence of CDK11 in these two novel functions. Subsequently, I aimed to 
characterize the interactomes of discrete CDK11 isoforms to enable greater 
understanding of the mechanisms through which CDK11 mediates both 
novel and established functions. Work then aimed to sequence the CDK11 
locus, examining for causative genetic mutations in Cornelia de Lange 
Syndrome (CdLS).   
1.10	  Thesis	  Hypotheses	  
Published work indicates CDK11 has a critical role in cancer biology and 
may present a therapeutic target in the treatment of cancer. The principal aim 
of this thesis was therefore to identify mechanisms through which CDK11 
mediates its influence on cancer biology. A greater understanding of 
CDK11’s roles in both cancer and normal biology, including human 
development, may elucidate pathways that are unique to either, thereby 
enabling improved targeting of the protein in cancer therapy. Moreover, 
elucidating co-dependent pathways of specific importance in cancer may 
also enable synergistic targeting to effect synthetic lethality.  
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Novel work in this thesis addressed the discovery by others within the 
laboratory that CDK11 inhibition elicits an autophagy phenotype. 
Autophagy has been established to influence cancer biology and may 
provide mechanisms for cancer cells to mitigate cellular stress. It had been 
hypothesised that CDK11 acts directly on autophagy pathways, with 
inhibition triggering the autophagy phenotype. I aimed therefore to 
determine whether CDK11-mediated autophagy could be dissociated from 
established CDK11 functions. Furthermore, I aimed to investigate CDK11-
interacting proteins to determine whether CDK11 associates with autophagy-
related proteins. In addition, I aimed to investigate the role of autophagy 
following CDK11 knockdown.   
In this thesis, I also explored the hypothesis that CDK11 directly regulates 
cancer cell migration. I aimed to confirm the effects of CDK11 depletion on 
cancer migration (demonstrated in a published siRNA screen) and establish 
that this does not solely result from impaired cell proliferation. 
Subsequently, I aimed to elucidate alternate pathways underlying the 
migratory deficit on CDK11 knockdown. CDK11 contains both SH2 and SH3 
binding domains and has established roles in centriole biology. I therefore 
hypothesised that CDK11 may influence this migratory phenotype either via 
direct interaction with the cytoskeleton, specifically focal adhesions, or 
through effects on centriole biology and thereby cellular polarisation. Again, 
I aimed to characterize the CDK11 interactome through proteomic studies to 
examine for interaction with pathways involved in cell motility.  
Finally, I examined the hypothesis that CDK11A/B genes harbour causal 
mutations for the cohesinopathy developmental disorder Cornelia de Lange 
Syndrome. This hypothesis was proposed due to the discovery of deletion of 
the CDK11 locus in a patient with CdLS; furthermore CDK11 has established 
functions in cohesin biology at mitosis. I aimed to sequence CDK11A/B in a 
cohort of CdLS patients with no known causative mutation, to determine 












Falcon tissue culture dishes (60 mm, 
90 mm, 120 mm) 
Cell strainers (40 and 70μm) 
BD Biosciences, 
Oxford, UK 
Cell culture flasks (T25, T75, T150) 
96-well, 24-well, 12-well plates , 6-

















Cell culture reagents 
Sterile PBS ECRC Central Services 
DMEM 
Fetal calf serum 
L-Glutamine 200mM 
Trypsin solution 2.5% 
Library efficiency chemically 
competent cells, DH5α 
Invitrogen Life 
Sciences Ltd, Paisley, 
UK 
Dimethyl sulphoxide (DMSO) Sigma Chemical Co, Poole, UK 
Gel Extraction Kit 
Miniprep Kit 
Qiagen, Crawley, UK 
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Dimethyl sulphoxide (DMSO) 
Paraformaldehyde 
Sigma Chemical Co, 
Poole, UK 
 
T4 Ligase enzyme 
Ligation Buffer 
















Anti-Rat Alexa 488 Life technologies, UK 
Anti-BrdU antibody Santa Cruz, UK. 
FACSScalibur BD Biosciences Life, Sciences, UK. 
Immunofluorescence 





Anti-mouse/rabbit Alexa Fluor® 





Formaldehyde Sigma Chemical Co, Poole, UK 




Fluorescence In Situ 
Hybridization (FISH) 
Zytolight Fluorescence CEN 7 Probe 
Zytolight Fluorescence CEN 8 Probe 









20XSSC Ultrapure Life technologies, Paisley UK. 
Fluorochrome-conjugated Avidin 
(FITC/Texas Red)  





Peterborough, UK.  
Microscopy and 
Image Analysis 
ImageJ software National Institute of Health, Bethseda, USA 
Olympus FV1000 Confocal 
microscope 
Olympus ScanR/CellR microscope 
Olympus BX51 Microscope 
Olympus UK Ltd, 
Hertfordshire, UK 
Volocity 3D Image Analysis 
Software Perkin Elmer, USA 
Molecular biology 
techniques 
Tween 20 Acros Organics, Loughborough, UK 
2100 Bioanalyzer Agilent, Berkshire, UK 
Agarose gel 
DNA Hyperladder 1 
Bioline Reagents ltd., 
London, UK 
Complete ULTRA Tablets 







Sigma Chemical Co, 
Poole, UK 








Nuclease free water 
Life technologies, 
Paisley UK. 
1Kb DNA ladder Invitrogen, Paisle. 
100bp DNA ladder Promega, UK. 
 UV Transiluminator Bio Doc-IT 
system UVP, UK. 
Restriction enzymes and buffers NEB or Roche, UK. 
Scalpel blades Swann Morton, Sheffield, UK. 
Quik Change Site Directed 
Mutagenesis Kit 




BP800 spectrophotometer Biohit, Ellsmere Port, Cheshire, UK 
ECL reagent 
Semi-Dry and Rapid Blotting 
Systems 
 
Life Science, Biorad 
Laboratories,  
Hertfordshire, UK. 










New England Biolabs, 
Hertfordshire, UK 
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Nitrocellulose membrane Schleicher and Schuell, London, UK 
3MM filter paper Whatman, Maidstone, UK 
LB Broth ECRC Central Services 
GFP-Trap A Immunoprecipitation of 






GenomiPhi V2 Amplification kit 









GC Mix Reagent 
Roche Diagnositics, 
West Sussex, UK. 
 
BigDye® Terminator v3.1 and v1.1 
Cycle Sequencing Kits 










Ion Xpress Plus gDNA and 














Agencourt AMPure XP Kit Beckman Coulter, High Wycomb, UK. 
DynaMag-2 Magnetic Rack Life technologies, Paisley UK 
Eppendorf LoBind Tunes 1.5ml Sigma-Aldrich, Dorset, UK. 
100% Ethanol ECRC Central Services 
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2.1.2 Stock Solutions and Buffers 
All commomly used stock solutions were autoclaved or passed through a 
0.22μm filter.  
Buffer for DNA PCR product electrophoresis 
TBE – 5X: 
54g Tris Base 
27.5g Boric acid 
20ml 0.5M EDTA 
to 1000ml water 
	  
6xDNA Loading Buffer  
30% (v/v) glycerol 
0.4% (w/v) Orange 
Protein extraction and western blotting 
Blocking buffer 
0.2% Tween 20 in Tris Base Solution 
5% bovine serum albumin 
PBS–Tween 20 (PBST) 
1X PBS 
0.1% (v/v) Tween 20 
Radioimmuno-precipitation assay (RIPA) buffer 
50mM Tris/HCl, pH 7.4 (25ml of 1M) 
150mM NaCl (15ml 5M) 
1% sodium deoxycholate (5g) 
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1% NP40 (5ml) 
0.1% sodium dodecyl sulphate (SDS) (0.5g) 
to 500ml water 
Filter with 0.22μm filter prior to addition of Complete ULTRA Tablets 
Phosphatase inhibitor cocktail immediately before use.  
 
NP40 Buffer 
5M NaCl 30mls 
10% NP40 50mls 
1M Tris pH8 50mls 
Filter with 0.22μm filter prior to addition of Complete ULTRA Tablets 
Phosphatase inhibitor cocktail immediately before use.  
 
Running gel -10% 
4.43ml 30% acrylamide 
5ml Tris pH 8.8 
3.9ml H2O 
130ul 10% SDS 
125ul 10% APS 
6.6ul TEMED 
 
Sample buffer – 2x 
800ul 2-mercaptoethanol 
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1.3ml Tris pH 6.8 
2ml glycerol 
5ml 10% SDS 
1.3ml H2O 
Bromophenol to colour 
Stacker gel 
1.07ml 30% acrylamide 
0.83ml Tris pH 6.8 
4.67ml H2O 
70ul 10% SDS 
70ul 10% APS 
20ul TEMED 
Tank Buffer – 10x 
50mM Tris Base (60.4g) 
50mM glycine (288g) 
0.1% SDS (20g) 
to 2000ml water 
Transfer Buffer 
50mM Tris Base (60.4g) 
40mM glycine (230g) 
0.04% SDS (4g) 
20% methanol (400ml) 
to 2000ml water 
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Preparation of GST Fusion Proteins  
Lysis Buffer  
For 100ml  
500mM NaCl – 10ml 5M 
0.5% NP-40 – 5ml 10% 
50mM Tris pH 7.6 – 5ml 1M 
5mM EDTA – 1ml 0.5M 
5mM EGTA – 1ml 0.5M 






Prior to use  
0.5mM PMSF (Phenylmethanesulfonyl fluoride)  
Protease inhibitor cocktail 
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2.2	  Methods	  
2.2.1 Transfection of cultured mammalian cells  
2.2.1.1 Short interfering RNA transfections  
Short interfering RNA (siRNA) oligonucleotides (non targeting control 
siRNA or siRNA targeting CDK11) were transfected into monolayer cells 
using Oligofectamine [Invitrogen]. Cells were seeded in standard culture 
media (SCM) onto a 12 well plate at 1x104/100μl/1cm2 substrate. Cells were 
30-50% confluent at the time of transfection. siRNA was diluted in Opti-
MEM (final concentration 5μM) [Invitrogen] and incubated at room 
temperature for 5 minutes. 2μl Oligofectamine reagent was diluted in 5.5μl 
of Opti-MEM, gently mixed and incubated at room temperature for 5 
minutes. After the 5 minute incubation, the diluted oligonucleotide was 
combined with the diluted Oligofectamine reagent for 20 minutes before 
adding to each well of 12 well plate. The cells were incubated in 400 μ l of 
serum free media (SFM) with addition of 100 μ l of transfection mix (total 
volume 500 μ l) for 5 hours (37oC, 5% CO2) before replacing with SCM. 
Assays for target protein expression were performed post-transfection by as 
appropriate for experiment. The transfection protocol was scaled up or down 
for different substrate area.  
2.2.1.2 Lentiviral Production  
293T packaging cells were seeded in 6 cm tissue culture plates at 1.5x105 
cells/ml (6ml/plate) in SCM without antibiotic (DMEM 10% FCS). Cells 
were incubated for 24 hours (37oC, 5%vCO2) until the cells were 
approximately 70% confluent. Transfection plasmids (HIV1, VSV-
G/pMD2.G, Vector) were diluted in Opti-MEM to a final volume of 20 μl. 
Lipofectamine 2000 reagent (10 μl) [Invitrogen] was diluted in Opti-MEM (90 
μl). The plasmid mixture was added drop wise to the diluted Lipofectamine 
2000 and incubated at room temperature for 20 minutes.  This transfection 
mix was carefully transferred to the packaging cells in SCM (without 
antibiotic). Subsequent steps were conducted in a Category 2 tissue culture 
facility. Cells were incubated for 18 hours (37oC, 5% CO2). The transfection 
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mix was removed and replaced with 4mls 30% FCS growth media for viral 
harvest. The cells were incubated for 24 hours (37oC, 5% CO2). The media 
containing the lentivirus was harvested at approximately 40 hours post 
transfection. The media was transferred through a syringe filter into 
polypropylene storage tube. Media was replaced with 6ml 30%FCS growth 
media for further viral harvest. Lentivirus-containing media was then added 
to target cells directly or frozen at -40oC. 
2.2.1.3 DNA Transfections  
DNA was transfected into monolayer cells using Lipofectamine 2000. Cells 
were 70% to 90% confluent at time of transfection. For each transfection of 
cells plated in 12-well plates (~4cm2/well), two complexes were prepared. 
The first contained 1.6 μg of DNA in 100 μl of Opti-MEM I Medium and the 
second contained 4 μ l Lipofectamine in 100 μ l Opti-MEM. After 5-minute 
incubation at room temperature the solutions were combined, gently mixed 
and incubated for 20 minutes at room temperature before adding to the cells. 
The cells were incubated in 1 ml of SCM (without antibiotics) with the 
transfection mixture for 18 hours (37oC, 5% CO2) after which media was 
replaced with SCM.  
2.2.2 Cell Cycle Blockade and Cell Synchronisation 
2.2.2.1 Single Thymidine 
Thymidine [Sigma] was was reconstitued in sterile water and added to SCM 
to a final concentration 2mM. Transfection protocol was followed as above. 
Transfection media was replaced with SCM containing Thymidine after 5 
hours and incubated for 48 to 72 hours as appropriate for assay. The SCM 
and Thymidine were replaced every 24 hours.  
2.2.2.2 Double Thymidine Block, G1/S Cell Synchronisation 
Cells were grown in SCM to approximately 40% confluence. Thymidine was 
added to cells in SCM to a final concentration of 2mM and incubated for 19 
hours (37oC, 5% CO2). After 3 washes with PBS the media was replaced with 
SCM without thymidine and incubated for 9 hours (37oC, 5%CO2). 
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Thymidine was added again to a final concentration of 2mM and incubated 
for a further 16 hours (37oC, 5% CO2). Cells were again washed with PBS and 
media replaced with SCM. At this stage the cells were synchronous in G1 and 
were released to progress through the cell cycle over the proceeding 15 
hours; cells remain synchronous for 1 to 2 cell divisions.  
2.2.2.3	  Nocodazole	  Block	  
In order to achieve mitotic synchronisation, Thymidine was added to 
asynchronous cell in SCM to a final concentration of 2mM. Cells were 
incubated for 16 hours (37oC, 5% CO2) then washed in PBS and media 
replaced with SCM. Cells were cultured for a further 6 hours prior to the 
addition of Nocodazole [Sigma] at 100ng/ml. Cells were than incubated for 6 
hours in Nocodazole prior to careful washing with PBS, so as not to dislodge 
mitotic cells. Cells were culture for 30 minutes following release from 
Nocodazole block prior to lysis.  
2.2.3 Autophagy Flux 
Cells from each condition assayed were either left in SCM or treated with 
lysosomal inhibitor E64D (10μg/ml) [Sigma] and Pepstatin A (10μg/ml) 
[Sigma] 2 hours prior to lysis. Cells were lysed with RIPA in standard 
manner and lysate quantified. LC3 II levels were examined by Western 
blotting and conditions compared with and without the addition of 
lysosomal inhbitors.  
2.2.4 Agarose gel electrophoresis 
Nucleic acid samples were analysed on agarose gels (0.8% - 2% 
agarose/TBE). Agarose was dissolved in 60 ml of 1x TBE buffer by boiling, 
prior to the addition of ethidium bromide (final concentration 0.5ug/ml). 
Each sample was mixed with 6x DNA loading buffer and loaded on to the 
gel. A DNA ladder of appropriate size (1kB DNA Ladder [Invitrogen] or 
100bp DNA ladder [Promega]) was added for accurate size estimation of 
DNA. 120 volts were applied to resolve the nucleic acid fragments by size. A 
UV transilluminator was used to visualise the nucleic acids. 
Page 68
2.2.5 Restriction Digest and Purification  
Plasmid DNA was digested with the appropriate restriction endonuclease in 
the buffer supplied by the manufacturer [NEB or Roche]. 1 unit of the 
enzyme is reported to digest 1µg of DNA over 1 hour but for these digests 
enzyme was used in excess. The digest was performed with 5µg of DNA 
(approximately 2µl), 20 U of the appropriate enzyme(s), 5µl of compatible 
buffer made up to 50µl with Nuclease free water and incubated for 1 hour at 
37°C. For double digests the optimal buffer conditions were selected for both 
enzymes using the manufacturers’ guidelines. Where blunting was required, 
1µl dNTP (final concentration 10mM) and 1µl blunting enzyme were added 
and the DNA incubated for a further 60 minutes at 37oC.  
DNA fragments produced by restriction digestion were resolved by agarose 
gel electrophoresis. The DNA fragment of interest was excised and purified 
using the QiaQuick Gel Extraction kit [Qiagen] as per manufacturers 
protocol. The DNA was eluted in 30μl elution buffer and used directly or 
stored at 20 ̊C. 
2.2.6 Site Directed Mutagenesis 
2.2.6.1 Primers for site directed mutagenesis 
Mutagenic primers for use in site directed mutagenesis were designed using 
the Quikchange Primer Design Program [Agilent]. The following 
considerations were made in the design algorithm: The primers were 
between 25 and 55 bases in length, with a melting temperature (Tm) of ≥78 ̊C 
(see below) and the desired mutation was located near the middle of the 
primer with a minimum of 10–15 bases of correct sequence on either side. 
The Tm of primers was calculated using the following formula: 
Tm = 81.5 + 0.41 (%GC) – 675/N -  % mismatch 
N is the primer length in bases and the values for percentage GC and 
percentage mismatch are whole numbers. The algorithm aimed for an 
optimal GC content of 40%.  
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2.2.6.2 Site directed mutagenesis (QuikChange Method) 
Point mutations were introduced into plasmid vectors using the PCR based 
QuikChange [Agilent] method. In summary, two complimentary 
oligonucleotides containing the desired mutation were designed to anneal to 
the same sequence on opposite strands of the plasmid. The primers were 
extended by PCR generating a mutated plasmid. The PCR product is treated 
with DpnI; Dpn I endonuclease is specific for methylated DNA and was used 
to digest the parental DNA template, selecting for mutation-containing 
synthesized DNA. Almost all E. coli strains contain DNA that is dam 
methylated and therefore susceptible to DpnI digestion. 
The PCR was composed as follows: 50 ng plasmid, 0.25 mM dNTPs, 0.2 μM 
mutagenic oligonucleotide primers (forward and reverse), 1 X DNA 
polymerase buffer with MgCl2 and 1.25U of PfuUltra DNA polymerase. 
Cycling  parameters for site directed mutagenesis were as follows: 95oC for 30 
seconds for 1 cycle followed by 95 oC for 30 seconds, 55 oC for 1 minute, 68 oC 
for 1 minute/kb plasmid length for 18 cycles.  
The PCR product was incubated with 1μl of DpnI restriction enzyme 
(10U/ul) [NEB] at 37 ̊C for 1 hour to digest parental vector DNA. Following 
incubation, 1μl of the DpnI treated DNA was used for transformation into 
DH5α E. coli chemically competent cells as described. Resulting colonies 
were cultured in LB broth, mini-prepped and screened by sequencing.  
2.2.7 Ligation of Insert Into Vector  
Ligations were performed using T4 DNA ligase [Roche]. Briefly, in 10ul 
reaction vector and insert DNA were added at a 3:1 insert to vector ratio 
(corrected for DNA size) such that approximately 2.5ul of vector DNA (100-
200 ng), 1.5 ul of insert or control, 0.5 ul of DNA Ligase and 1x Ligation 
Buffer [Roche] were incubated for 5 hours at room temperature. Following 
incubation, 2μl ligation mixture was used to transform E. coli. 
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2.2.8 Transformation of chemically competent cells 
Approximately 2μl of T4 DNA ligation reaction was added to 50μl of 
competent DH5α E Coli cells. Cells and DNA were incubated on ice for 30 
min before heat-shock at 42 ̊C for 50 seconds. Following 2 minutes recovery 
on ice, cells were resuspended in 450μl of SOC media (preheated to 37oC) 
and incubated at 37 ̊C for 50 minutes with agitation. 500μl of cells were 
spread onto LB agar plates containing the appropriate antibiotic(s). The 
plates were incubated overnight at 37 ̊C to produce discrete colonies. 
Subsequently, colonies were cultured in LB broth, mini-prepped and 
screened by sequencing  
2.2.9 Fluorescence Activated Flow Cytometry (FAC) 
The cells were pulsed with BrdU at a final concentration of 10 μM for 30 
minutes (37oC, 5%CO2). Cells were harvested by trypsinisation and 
transferred to a 15ml falcon tube. Cells were centrifugation at 1200 rpm for 4 
minutes, washed once in PBS and then fixed by resuspending in 1 ml of ice-
cold 70% ethanol, added drop wise on vortex. Cells were incubated for at 
least 1 hour at 4oC or stored at -20 oC. Cells were centrifuged at 2500 rpm for 
4minutes and resuspended in 2mls of pre-warmed pepsin (37oC) with 
incubation for 30 minutes at 37oC. Cells were then centrifuged at 4000rpm for 
4 minutes and resuspended in 1ml 2M HCL for 15 minutes at room 
temperature. Cells were washed twice in PBS-EDTA at final concentration 
1mM prior to blocking with 1ml Antibody Buffer (49.5ml PBS, 1g BSA + 
500μl 10% Triton X) for 30 minutes at room temperature. Cells were 
centrifuged and resuspended in 100 μl anti-BrdU (1:75 with antibody buffer) 
30 minutes at room temperature. Cells were then washed with PBS-EDTA 
(1mM) and resuspended in 100μl anti-rat Alexa 488 (1:200 with antibody 
buffer) 30 minutes at room temperature. Subsequently cells were washed 
again with PBS-EDTA (1mM) and resuspended in PBS-EDTA containing 
0.1mg/ml RNAse A and 50 µg/ml propidium iodide for 60 min at 4oC in the 
dark. Cell sorting was performed on a FACScalibur by Elizabeth Freyer at 
MRC HGU.	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2.2.10 Immunofluorescence Microscopy 
Cells were plated on coverslips at 1x104 cells/cm2. At the time of sampling, 
media was removed and cells were fixed with 4% Paraformaldehyde (PFA) 
for 10 minutes at room temperature. Cells were washed with PBS and 
permeabilised with 0.25% Triton X-100 in PBS 20 minutes at room 
temperature. Cells were washed three times with PBS and coverslips blocked 
in 1% BSA in PBS for 10 minutes. Coverslips were incubated with 
appropriate primary antibody diluted in 1% BSA in PBS for two hours at 
room temperature in a humidified container. After washing three times for 5 
minutes in PBS, coverslips were incubated with an appropriate secondary 
fluorophore-conjugated antibody (1:200) diluted in 1% BSA in PBS for 1 hour 
at room temperature in the dark. Secondary antibody was removed and 
coverslips washes three times for 5 minutes in PBS, prior to nuclear staining 
with DAPI (1:2500) for 10 minutes. Coverslips were mounted facedown onto 
Super Frost Plus microscope slides and stored at 4°C. In control staining, the 
primary antibody was omitted as a control for non-specific binding of the 
secondary antibody. Imaging was performed using an Olympus 
fluorescent/brightfield microscope.  
2.2.11 Western Blotting 
Protein expression and quantification was undertaken using sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS PAGE) resolution. Cells 
were lysed with  lysis  buffer  (RIPA/NP40) and lysate protein quantified using 
the Micro Bicinchoninic Acid (BCA) [Thermo Fisher Scientific] protein assay 
kit as per manufacturers instructions. Absorbance was measured with a 
BP800 spectrophotometer at 562nm. 20μg of protein from each sample was 
made up to an equal volume with RIPA buffer prior to addition of 6 x SDS 
sample buffer. Alternatively cells were directly lysed with SDS sample 
buffer. Samples were denatured on the hot block at 95°C for 5 minutes and 
briefly centrifuged. 
Samples were loaded for separation into either a precast Bio-rad (stain free 
gel) or by 10% SDS PAGE and run at 180V, 230mA and 30W for 60 minutes.  
The proteins were transferred from the gel to a PVDF membrane (activated 
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in 80% methanol) or a nitrocellulose membrane in DDB transfer buffer (20% 
methanol) at 100V 400mA 50W for 70 minutes. Alternatively the Bio-rad semi 
dry transfer method was used as per manufacturers instructions. 5μl of pre-
stained molecular weight ladder was loaded into the first well of each gel to 
allow the molecular weight of the proteins species to be determined. 
Membranes were blocked with 5% Marvel milk in TBST for 60 minutes with 
gentle agitation. Membranes were then washed 3 times in TBST (10 minutes 
per wash). Subsequently, membranes were probed with primary antibody in 
2% BSA/TBST at appropriate concentrations (see table) at 4°C overnight, 
with gentle agitation. Antibody was removed and membranes were washed 
3 times with TBST (10 minutes per wash). Mouse or rabbit HRP-conjugated 
secondary antibodies (1:5000) in 2% BSA/TBST were used for detection. 
Detection was by enhanced chemiluminescence (ECL protocol). 1ml of ECL 
solution (1:1 mixture solution A : solution B) was pipetted on to the 
membrane and incubated at room temperature for 1 minute. The membrane 
was exposed to blue-light sensitive autoradiography film. The film was 
developed using an AGFA Curix 60 processor. Membranes were then 
washed with TBST 4 times (5 minutes per wash). After washing membranes 
were re-probed with loading control primary antibody, alpha-tubulin 
(1/25000) in 2% BSA TBST as described above.  
2.2.12 Silver Staining of protein gels 
SDS   PAGE   gels   were   further   analysed   by   silver   staining   using   the  
ProteoSilverTMPlus   Silver   Stain   Kit   [Sigma]   as   per   the   manufacturers  
instructions.	  
2.2.13 Wound Healing Assay 
MDA-MB-231 cells were subject to CDK11 or NTC siRNA transfection as 
described in 2.2.1.1. At 28 hours post-transfection, cells were re-plated to 
obtain a confluent monolayer. At 40 hours post-transfection, the monolayer 
was wounded using a pipette tip. Wound healing was tracked with 
sequential image capture every 15 minutes for 12 or 15 hours on an Olympus 
microscope; images were acquired using scan^R software as per software 
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developer’s instructions. Cell free area (mm2) at the start and completion of 
the assay was calculated using Image J software.  
2.2.14 Adhesion Dynamics Methods 
2.2.14.1 Random Migration Assay  
At 28 hours post-transfection, MDA-MB-231 cells were plated at low density. 
From 40 hours, cell migration was tracked with sequential image capture 
every 15 minutes for 12 hours on an Olympus microscope; images were 
acquired using scan^R software as per software developer’s instructions. The 
migration of individual cells was subsequently calibrated using Image J 
software. Collated migration patterns of 30 MDA-MB-231 cells were mapped 
using Image J Chemotaxis and Migration Tool.   
2.2.14.2 Cell Polarisation Assay 
The wound-healing assay was replicated with the use of glass coverslips as 
substrate. At 40 hours post-transfection, the monolayer was wounded with a 
pipette tip. At specified time-points, cells were fixed, permeabilised and 
subject to immunofluorescence (as described above) with GM130 antibody 
(marking Golgi Apparatus), Phalloidin and DAPI. Polarisation was assessed 
at each time point. Cells were scored as polarized if the Golgi lay in a 90o arc 
anterior to the nucleus, facing the wound edge. A minimum of 50 cells were 
assessed at each time and condition.  
2.2.14.3 Cell Adhesion Assay 
At 40 hours post-transfection, cells were trypsinised and placed in 
suspension for 1 hour at 4oC with rotation, during which samples were 
obtained for preparation of protein lysates. At 1 hour, cells were plated on 
collagen coated cover slips or tissue culture plastic for subsequent 
immunofluorescence or protein lysate analysis, respectively. At specified 
time points, cells were washed and cells fixed or lysed accordingly. Protein 
lysates were analysed by Western Blotting as described previously.  
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2.2.15 Mutation analysis, sequencing techniques 
2.2.15.1 Sanger Sequencing 
Genomic DNA was used as a template for whole genome amplification using 
GenomiPhi V2 DNA Amplification Kit as per manufacturer’s protocol. The 
amplicons encompassing the coding exons and the intronic splice junctions 
were designed using Primer3 (see below for oligonucleotide sequences). 
Target sequences were amplified by PCR (total volume 12μl) comprising: 
20ng whole-genome amplified DNA (gDNA), 1 X ReddyMix Custom PCR 
Master Mix, 0.4 mM forward oligonucleotide and 0.4 mM reverse 
oligonucleotide with the addition of 1 X GC-rich Solution as required. A 
uniform PCR cycling protocol was performed: 95 °C for 5 minutes followed 
by 32 cycles of 94 °C for 1 minute, 58 °C for 1 minute, 72 °C for 1 minute and 
subsequently 72 °C for 10 minutes. PCR products were detected using 
agarose gel electrophoresis to ensure adequate quantity and size of each exon 
fragment. Bidirectional direct sequencing using the universal primers was 
performed using BigDye Terminator v3.1 Cycle Sequencing Kit and resolved 
on an ABI 3730 DNA Analyzer by the IGMM sequencing service. Sequence 
files were analysed with Mutation Surveyor v3.30.  Cel1 enzymatic mutation 
detection assay was as described for endonuclease restriction digests.  
2.2.16 Ion semiconductor sequencing 
2.2.16.1 Preparing equimolar pool of short amplicons 
Amplicons (36 amplicons) were pooled in equimolar quantities for Ion 
Library construction to ensure coverage of target regions. DNA target 
sequence of interest was amplified by PCR (≤250bp) from 20ng gDNA and 
the individual amplicons purified. The final amplicon solution was 
resuspended in Nuclease-free water. 1μl of each amplicon product was 
analysed with the Bioanalyser instrument and an equimolar pool of 
amplicon DNA was prepared in nuclease free water. 1μl of this pooled DNA 
was analysed using the Bioanalyser.  
2.2.16.2 End repair and Purification of amplicons 
The end-repair reaction (in a LoBind tube) consisted of 72μl of pooled short 
amplicons (50ng) in nuclease free water combined with 20ul of 5 x End 
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Repair Buffer and 1μl of End Repair Enzyme made up to a final volume 
100μl with nuclease free water. This reaction was incubated for 20 minutes at 
room temperature. 	  
The end-repaired DNA was purified with the Agencourt AMPure XP Kit. 
180μl of Agencourt AMPure SP Reagent (1.8 x sample volume) containing 
beads was mixed with the DNA sample by pipetting, pulse spun and 
incubated at room temperature for 5 minutes. The mixture was then pulse 
spun and the magnetic beads precipitated using a magnetic rack. 
Supernatant was removed and beads washed in 70% ethanol twice. Beads 
were air dried at room temperature for 5 minutes. DNA was eluted from 
beads in 25μl of low TE and supernatant transferred to fresh LoBind Tubes.  
2.2.16.3 Ligate Ion Xpress P1, Barcode the adaptors and nick repair 
In 200μl PCR tubes, fragmented gDNA, short amplicons, 10X Ligase Buffer, 
Ion P1 adapter, Ion Xpress Barcode X, dNTP mix, nuclease free water, DNA 
ligase and nick repair polymerase were combined to a final volume of 100 ul 
as per manufacturer’s protocol. The thermal cycle conditions were as follows: 
25oC for 15 minutes, 72 oC for 5 minutes and hold at 4 oC. The reaction was 
transferred to 1.5ml LoBind tubes before continuing directly to purification. 
The end-repaired DNA was purified with the Agencourt AMPure XP Kit, 
magnetic rack and fresh 70% ethanol as described above.  
2.2.16.4 Amplifying and purifying the Amplicon library  
Again in 200μl PCR tubes, Platinum PCR Supermix High Fidelity, Library 
Amplification Primer Mix, size-selected unamplified library and short 
amplicon unamplified library were combined as per manufacturers protocol 
to a final volume of 26μl. PCR was performed with 6 cycles of the following 
thermal cycle conditions: 95oC for 5 minutes, 95oC for 15 seconds, 58oC for 15 
seconds, 70 oC for 1 minute and held at 4 oC. The DNA library was purified 
with the Agencourt AMPure XP beads (1.5 x the sample volume) as above. 
The Bioanalyser was used to quantify the samples and samples analysed 
using Ion Torrent semiconductor sequencer by the IGMM sequencing 
service. 
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2.2.17 Preparing GST Fusion proteins 
Glycerol stock of pGEX vector encoding GST.CDK11p58 in BL21 cells were 
inoculated into 10ml LB Broth and incubated for 1.5 hours at 37oC with 
agitation. After 3 washes bead slurry (20µl) was diluted 2-fold with lysis 
buffer. IPTG was added (final concentration 1mM) and the mixture shaken 
for 2.5 hours at 30oC. Ice was added to the culture before centrifuging at 
3000rpm for 10 minutes. The lysate was kept cold to minimise degradation. 
The pellet was resuspended in 1ml of cold lysis buffer and transferred to 
1.5ml tubes. The lysate was sonicated 3 times for 10 seconds and centrifuged 
in a tabletop microcentrofuge at maximum speed for 15 minutes at 4oC. The 
supernatant was transferred into a 1.5ml tube with gluthione-sepharose 
beads and put on a rotator for 10 minutes at 4oC. The tubes were spun briefly 
(3000rpm for 3 seconds) to pellet the beads. The supernatant was removed 
and discarded. The beads were washed 4 times with 800µl of cold lysate 
buffer.  
2.2.18 Immunoprecipitation of GFP-fusion proteins 
For one immunoprecipitation reaction, the cell pellet was resuspended in 
200μl ice-cold NP40 lysis buffer by pipetting. The tube was placed on ice for 
30 minutes with extensive pipetting every 10 minutes. The cell lysate was 
centrifuged at 20,000 x g for 10 minutes at 4°C. The supernatant was 
transferred to a pre-cooled tube and 750µl dilution buffer added. The GFP-
Trap_A beads were equilibrated in dilution buffer by resuspending 25μl of 
bead slurry in 500μl ice cold dilution buffer and centrifuging at 2.500 x g for 
2 minutes at 4°C. The supernatant was discarded and the beads washed 
twice more. The cell lysate was added to the equilibrated GFP-Trap_A beads 
and incubated on a rotator for 1 hour at 4oC. The mixture was then 
centrifuged at 2500 x g for 2 minutes at 4oC. The supernatant was discarded. 
The beads were washed twice with 500μl ice-cold dilution buffer and then 
frozen at –80oC and sent on dry ice sent to collaborators at University College 
Dublin.  
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2.2.19 Nuclear and Cytoplasmic Extracts 
Cells were washed twice in ice-cold PBS, lifted and suspended in 500μl ice-
cold PBS. Cells were then centrifuged at 13000rpm for 1 minute and the 
supernatant discarded. Cells were resuspended in 400μl Buffer 1 by 
pipetting and incubated on ice for 15 minutes. 25μl of 10% NP-40 was added 
and the mixture vortexed for 10 seconds. Cells were centrifuged again at 
13000rpm for 1 minute. The supernatant containing the cytoplasmic fraction 
was transferred to another tube and retained. 50μl of 0.5% NP40 buffer was 
added to the pellet and the mixture vortexed to mobilise the pellet. Samples 
were then incubated at 4oC for 15 minutes with agitation. Samples were then 
sonicated in twice for 30 seconds, followed by centrifugation at 13000rpm for 
15 minutes. The supernatant containing the nuclear fraction was transferred 
to a fresh tube and stored at –20oC.  
2.2.20 Fluorescence in situ hybridisation (FISH) 
2.2.20.1 Zytolight  Fluorescence in situ hybridisation (FISH) 
Cells were cultured on glass slides. The Zytolight CEN probe protocol was 
followed; in brief, 10μl of ZytoLight CEN 7 or 8 probe was added onto each 
slide, taking care to avoid prolonged exposure to light. Coverslips were 
placed over each slide with the probe and sealed with a layer of rubber 
cement. Slides were then denatured at 75oC for 10 minutes and transferred to 
a humidity chamber for hybridisation overnight at 37oC in the dark. Slides 
were subsequently washed with reducing concentrations of SCC and 
counterstained with DAPI.  
2.2.18.2 2D FISH Method  
Cells were suspended in 0.5% Trisodium Citrate/0.25% KCl followed by 
fixation in Methanol:Acetic Acid (3:1). Cells were droppedSlides were 
incubated in 100 mg/ml RNase A in 2 x SCC for 1 hour, washed in 2 x SCC 
and dehydrated through an alcohol series. Slides were denatured in 70% 
Formamide/2 x SCC for 75 seconds at 70°C. Approximately 100ng of biotin- 
and digoxigenin-labeled fosmid probes were used per slide, with 10mg of 
mouse Cot1 DNA and 10mg salmon sperm DNA. Probes were denatured at 
70°C for 5 minutes, reannealed with Cot1 DNA for 15 minutes at 37°C and 
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hybridized to the denatured slides overnight at 37°C. Slides were washed 4 
times for 3 minutes in 2X SSC at 45°C, 4 times for 3 minutes in 0.1XSSC at 
60°C and transferred to 4X SCC with 0.1% Tween20. Following incubation 
for 5minutes with blocking buffer (4X SCC with 5% Marvel) biotinylated 
probes were detected using fluorochrome-conjugated avidin (FITC or Texas 
Red) then biotinylated anti-avidin followed by fluorochrome-conjugated 
avidin. Digoxigenin-labeled probes were detected using FITC-conjugated 
anti-digoxigenin followed by FITC conjugated anti-sheep. Slides were 
counter-stained in 0.5mg/ml DAPI. 
Table	  2.1	  Primers	  
	  
CDK11	  Sequencing	  Primers	  
Exon	   Primer	   Sequence	  
1	   Forward	   TTTGGAGTCCTGGACCTGAG	  
1	   Reverse	   CAGTCGGAACTCACCCCTAC	  
1	   Forward	   TTTATGCGTCATCATCCCG	  
1	   Reverse	   CTCGGAAGAAAGACCTCGG	  
2	   Forward	   TGCTGTGTCCTGATGTAGGC	  
2	   Reverse	   GTTCTAATGGAAAAATGAGGGC	  
2	   Forward	   GCACCATAGCTTGCTGTGTC	  
2	   Reverse	   ATGGAAAAATGAGGGCAAAG	  
3	   Forward	   GGATGTTGCCCAGGTTTG	  
3	   Reverse	   ACAGTTGGGTCTTGCACATC	  
4	   Forward	   CACTTTCTCAAGCATGACGC	  
4	   Reverse	   GGGGAAGGCAGAAGAGTAGG	  
4	   Forward	   AATAGCCTGATGCTTTTCCG	  
4	   Reverse	   GCTTCTGTACCCCCTTCTGC	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4	   Forward	   ATGACGCAGTGCTGTTGTG	  
4	   Reverse	   TTTTCAGTGGTGCTCTGGG	  
5	   Forward	   GAAGTGAGGTTTCTTTGCATGAC	  
5	   Reverse	   CACGGCCCTTTCATAAAGTC	  
5	   Forward	   TCATTAGGGAAGCATGCTAGAG	  
5	   Reverse	   GCCAAATTCTTCTTCATTGCTG	  
5	   Forward	   GATTACAGGCGTAAGCCACC	  
5	   Reverse	   AAGTCCTCAACTGACCCAGC	  
6	   Forward	   CTGTTTAGGGGGAATGATGGC	  
6	   Reverse	   CTGTGACAGCAAGTGCCCAGC	  
7	   Forward	   CTGCTAGTGCCATCTCCCTC	  	  
7	   Reverse	   AAGACTCACACTGTGCTGGC	  	  
8	   Forward	   CACTAGTTTTGGGGTGGTGG	  
8	   Reverse	   AGACAGCAGAGCAGAGGGTG	  
9	   Forward	   CAGGTTCACCCTCTGCTCTGC	  
9	   Reverse	   CACAACACCTCACACAGTCG	  
10	   Forward	   CCTCCATATCCATTCTTGGG	  	  
10	   Reverse	   CTCGGAGACAGACAAGGAGG	  	  
11	   Forward	   GATCCTTACTTACTCCTAGCTTCG	  	  	  	  	  
11	   Reverse	   CTCCTGCTTGAGCTCGATGG	  
11	   Forward	   AGTTCCAGAGTCACGGTTCG	  	  
11	   Reverse	   CCCTGTGGTAACTCCGACTG	  
12	   Forward	   TGTCAGATGGTTTTGCAAGG	  
12	   Reverse	   ACTCCATAGGTGCCCTCCTC	  
12	   Forward	   CACTGAGACCTCACACAGGC	  	  	  	  	  
12	   Reverse	   GTAGCTGCTCAGGTGAAGCG	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13	   Forward	   AATGCCTCTCAGTGCCGTC	  
13	   Reverse	   GAGAGTGTAGGAAGCACCCG	  
13	   Forward	   ACCGTGACTTTGAGAATGCC	  	  
13	   Reverse	   GTCGGAAAAGCCTTCCACC	  	  
14	   Forward	   ACCGGAGGTCCTTACTGTCC	  	  
14	   Reverse	   AAGGGCTGTTTCATGGTCTC	  
14	   Forward	   CTGCAGGAGATTGTGGTGG	  
14	   Reverse	   AGAGGCTTCTCAGGGCTTTC	  
15	   Forward	   ACAGGGAAAGCCCTGAGAAG	  
15	   Reverse	   CAGCAGGTTGGACGTCTTG	  
15	   Forward	   GAAGACCCTGATGATCCAGC	  
15	   Reverse	   TTCAGAGGGGATCCGTACTC	  
16	   Forward	   ACCTCAAGACGTCCAACCTG	  
16	   Reverse	   TACCACTGGGTCACCACGAC	  
16	   Forward	   GAGTACGGATCCCCTCTGAAG	  
16	   Reverse	   CTAAGACGCCAGGAGAGGTG	  
17	   Forward	   TTGGTGCCAAGGTGAGTC	  
17	   Reverse	   GATCGATTTCCGAATTCCC	  
17	   Forward	   CGTGGACATGTGGTCAGTG	  	  
17	   Reverse	   TCCCGTCAGAGAAGACAAGC	  
18	   Forward	   CTTGGTGTGGCTGTTGAAGC	  
18	   Reverse	   ACTGGGAAGTCACCGCTATG	  	  
19	   Forward	   ACCACGTTCCAGAACTGCTC	  	  
19	   Reverse	   GAACATGGAGGGGTCGATGG	  
19	   Forward	   GCCTCAAGCATGAGTATTTCC	  
19	   Reverse	   CTCCTTCAGGTCGTCGTCAC	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20	   Forward	   CATCGACCCCTCCATGTTC	  
20	   Reverse	   TGGTTCGTGGTGGTAAGGTG	  
20	   Forward	   GTTCTCACGGTAGCCGACTC	  	  
20	   Reverse	   AGTTCCGAGTCTCATCGCAG	  
20	   Forward	   CTGAAGGTCAGAGTGGACCC	  	  
20	   Reverse	   AGATGCCCTGGCAAGTCAC	  
	  
SSU72	  Sequencing	  Primers	  
Exon	   Primer	   Sequence	  
1	   Forward	   GTAGCGCGACGGCCAGTGTGGAGTGCGGGTCTCTG	  
1	   Reverse	   CAGGGCGCAGCGATGACACCTGCCTTCCCTGTGATG	  
1	   Forward	   GTAGCGCGACGGCCAGTGACACCTTATGACGTCCTGTTG	  
1	   Reverse	   CAGGGCGCAGCGATGACGTATGCCGTGATTGTGTTGC	  
2	   Forward	   GTAGCGCGACGGCCAGTGCCCGGCCTAGATTAAAAAT	  
2	   Reverse	   CAGGGCGCAGCGATGACCAGGCTCCATGTGTATCAG	  
2	   Forward	   GTAGCGCGACGGCCAGTGCCCGGCCTAGATTAAAAAT	  
2	   Reverse	   CAGGGCGCAGCGATGACCACCAACCTGCAAAGGAAAT	  
3	   Forward	   GTCGCGCGACGGCCAGTCATCGCCCACTTTGTTTTCT	  
3	   Reverse	   CAGGGCGCAGCGATGACTGCTTCACACTCAGGTCTGC	  
3	   Forward	   GTAGCGCGACGGCCAGTGCTGTCCAGGCCTTCGTC	  
3	   Reverse	   CAGGGCGCAGCGATGACGAGAAAAGAGGCCCCTTGAA	  
4	   Forward	   GTAGCGCGACGGCCAGTTCAGGTTTCCTCGAACCATC	  
4	   Reverse	   CAGGGCGCAGCGATGACGTGCCAAAGCTGTGGAGTG	  
4	   Forward	   GTAGCGCGACGGCCAGTATTCATTGTGCTCCCCAAAC	  
4	   Reverse	   CAGGGCGCAGCGATGACGTGCCAAAGCTGTGGAGTG	  
5	   Forward	   GTA	  GCGCGACGGCCAGTCAGCTTCAGGTCCTGTGAGG	  
Page 82
5	   Reverse	   CAGGGCGCAGCGATGACATTGCTTTCATCTGGCGTTT	  
	  
Table	  2.2	  Antibodies	  
	  
Target	   Company	   Product	  No	   Source	   WB	   IHC	  
LC3	   Novus	   NB100-­‐2220	   Rabbit	   1	  in	  1000	   1	  in	  200	  
CDK11	   Novus	   NB100-­‐1816	   Rabbit	   1	  in	  2000	   1	  in	  200	  
CDK11	   Abcam	   AB19393	   Rabbit	   1	  in	  1000	   1	  in	  200	  
CDK11	   Abcam	   AB113266	   Rabbit	   1	  in	  1000	   -­‐	  
CDK11	   CST	   D88B3	   Rabbit	   1	  in	  1000	   1	  in	  200	  
CDK11	   Bethyl	   A300-­‐310A	   Rabbit	   1	  in	  1000	   1	  in	  200	  
CDK11	   BethylT	   A300-­‐311A	   Rabbit	   1	  in	  1000	   1	  in	  200	  
p62	   Novus	   2C11	   Mouse	   1	  in	  1000	   1	  in	  200	  
Alpha	  tubulin	   Invitrogen	   DM1A	   Mouse	   1	  in	  25000	   1	  in	  1000	  
BrdU	   Abcam	   AB6326	   Rat	   	   1	  in	  75	  FACS	  
GFP-­‐TRAP	   ChromoTEK	   GTA-­‐30	   	   	   	  
Pericentrin	   Abcam	   AB4448	   Mouse	   1	  in	  20000	   1	  in	  2000	  
FAK	   Transduction	   610088	   Mouse	   1	  in	  1000	   -­‐	  
FAK	   CST	   3285	   Rabbit	   1	  in	  1000	   1	  in	  100	  
CSK	   Santa	  Cruz	   SC-­‐285	   Rabbit	   1	  in	  500	   1	  in	  100	  
CSK	   Santa	  Cruz	   SC	  51580	   Mouse	   1	  in	  1000	   -­‐	  
KIF14	   Abcam	   AB3747	   Rabbit	   1	  in	  3000	   1	  in	  500	  
RAN	   CST	   4462	   Rabbit	   1	  in	  1000	   1	  in	  100	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Myc	  Tag	  (4A6)	   Sigma	   16-­‐219	   Mouse	   0.5ug/ml	  IP	   -­‐	  
Myc	  Tag	  (9E10)	   Pierce	   88842	   Mouse	   0.5ug/ml	  IP	   -­‐	  
Src	  36D10	   Cell	  Signalling	   2109	   Rabbit	   1	  in1000	   1	  in	  100	  
P-­‐Src	  Y419	   CST	   2101S	   Rabbit	   1	  in	  1000	   1	  in	  500	  
P-­‐Src	  Y527	   CST	   2105	   Rabbit	   1	  in	  1000	   -­‐	  
Mouse	  HRP	   Upstate	   12-­‐349	   Goat	   1	  in	  5000	   -­‐	  
Rabbit	  HRP	   Upstate	   12-­‐348	   Goat	   1	  in	  5000	   -­‐	  
Alexa	  Fluor	  
Secondary	  Ab	   Invitrogen	   	   Goat	   -­‐	   1	  in	  200	  
p53	   Neomarkers	   MS-­‐256-­‐P0	   Mouse	   1	  in	  1000	   -­‐	  
HSP	  90	   Transduction	   H38220	   Mouse	   1	  in	  1000	   -­‐	  
14-­‐3-­‐3e	   Transduction	   F46820	   Mouse	   1	  in	  1000	   -­‐	  
Cyclin	  L2	   Bethyl	   A301-­‐667A	   Rabbit	   1	  in	  1000	   -­‐	  
Fyn	  (FYN3)	   Santa	  Cruz	   16	   Rabbit	   1	  in	  2000	   -­‐	  
c-­‐Yes	  (F-­‐7)	   Santa	  Cruz	   8403	   Mouse	   1	  in	  1000	   1	  in100	  
Cyclin	  D3	  (C-­‐16)	   Santa	  Cruz	   182	   Rabbit	   1	  in	  2000	   -­‐	  
Acetylated	  alpha	  
Tubulin	   Abcam	   AB24610	   Mouse	   -­‐	   1	  in	  200	  
Paxillin	   Transduction	   610052	   Mouse	   -­‐	   1	  in	  200	  
GM130	   Abcam	   AB	  52649	   Rabbit	   -­‐	   1	  in	  100	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CHAPTER 3 
CDK11, Autophagy and Mitosis 
	  
3.1	  Introduction	  
This chapter describes work I undertook to investigate the effect of CDK11 
dysregulation on autophagy flux. Initially, I characterized CDK11-mediated 
autophagy in human cancer cells; I proceeded to examine the influence of 
mitotic dysregulation on this autophagy phenotype. Finally, I interrogated 
the role of autophagy following aberrant mitosis and its putative influence in 
the maintenance of the aneuploid karyotype.  
3.1.1 Autophagy 
Autophagy is an evolutionarily conserved catabolic process through which 
cellular proteins and organelles are sequestered in double-membrane 
vesicles (autophagosomes) and targeted to lysosomes for degradation [151]. 
Basal autophagy executes an important homeostatic role in cellular functions 
but induction of autophagy also affords cells a remodeling mechanism under 
the influence of numerous stimuli [151, 152]. Recent evidence indicates that 
these autophagy processes are not generic but comprise a panoply of cellular 
remodeling conduits targeting specific organelles and proteins, regulated by 
diverse signaling pathways [152, 153]. This can lead to profound effects 
many of which may be germane to tumour cells, for example cell survival in 
response to metabolic stress, regulation of cellular senescence and regulation 
of cellular signaling [154-157].  
Numerous proteins participate in the formation, passage and degradation of 
autophagosomes. LC3, the human analogue of Atg8, not only localizes to the 
autophagosome but plays a crucial role in its formation [158, 159]. As the 
autophagosome matures LC3 is converted to the lipid bound LC3 II; LC3 II 
has therefore become established as a gauge of autophagy [160]. Although 
considered a generic marker of autophagy, LC3 II is reported to contribute 
greatly to the selection of specific cargoes for autophagic degradation [159, 
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161]. It is thought to undertake this function through its Atg8-family 
interacting motif (AIM); this conjugates with adaptor molecules such as p62, 
Nbr1 and Ndp52 to enable the targeting of their specific cargoes to the 
autophagosome [159, 162, 163]. The interactions of these proteins are 
therefore critical to selective autophagy [159]. 
3.1.2 Aneuploidy 
Aberrant mitoses are a significant cause of chromosomal instability and 
potential path to aneuploidy [164]. In health, aneuploidy is poorly tolerated 
but it is a common finding in cancer. The influence of aneuploidy on 
tumorigenesis has been controversial; while some argue that it performs a 
critical role in tumour formation, others suggest it is merely a consequence of 
deregulated growth [164]. Chromosomal instability may enable the genetic 
diversity that provides cancer cells with the capacity to overcome xenobiotic 
stress. Recent study in yeast found aneuploidy conferred certain strains with 
a greater resistance to a panel of chemotherapeutic and antifungal drugs 
compared to euploid strains [165]. 
Mechanisms act to restrain chromosomal instability so that in health, cells 
successfully maintain an invariable complement of chromosomes. Cell cycle 
controls and mitotic checkpoints act to prevent potentially aberrant 
segregation of chromosomes and the development of aneuploidy. Indeed, 
prolonged mitosis itself has been demonstrated to impede further 
proliferation despite both the completion of mitosis and the accurate 
segregation of the genome [166]. This has been shown to be due to a 
permanent G1 arrest dependent on p38 and p53 [166]. The influence of p53 in 
curtailing chromosomal instability has been reported in numerous recent 
studies; these demonstrate that chromosome missegregation causes the 
accumulation of p53 and retardation of growth [167, 168]. In contrast the 
absence of p53 permits the propogation of aneuploidy [169].  
Aneuploidy itself conveys deleterious effects and is proposed to cause 
considerable metabolic stress [170]. The induction of aneuploidy in mouse 
embryonic fibroblasts, through the generation of individual chromosomal 
trisomies, leads to diminished proliferation and altered metabolism [170]. It 
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has been hypothesized that stoichiometric imbalance of cellular proteins may 
be a significant contributor to these effects [170]. Aneuploidy in yeast confers 
quantitative proteome alterations correlating closely to chromosome copy 
number [165].  
Aneuploid cancer cells must therefore escape cell cycle constraints and cope 
with the consequential proteotoxic and metabolic stress. This presents a 
potential frailty in the aneuploid cancer cell that may be exploited 
therapeutically [171]. It is therefore critical to understand the mechanisms 
through which cancer cells evade aneuploid-induced stress. A recent 
publication identified numerous aneuploidy-tolerating mutations and 
demonstrated the importance of ubiquitin-proteasomal degradation in 
suppressing aneuploid-related adverse effects [172].  
3.1.3 Autophagy and Aneuploidy 
The role of autophagy in the aneuploid cell and its relationship to 
chromosomal instability is unclear. Based on the finding of greater genomic 
instability in cells deficient in autophagy gene Beclin1, it has been reported 
that autophagy may suppress tumour progression by limiting chromosomal 
instability [173]. Autophagy has also been proposed to enable transition to 
cellular senescence following oncogenic stress [174]. However, autophagy 
may be employed to mitigate proteotoxic stress by the removal and 
degradation of excess imbalanced proteins in aneuploid cells. 
3.2	  Characterisation	  of	  CDK11-­‐mediated	  autophagy	  
This work aimed to characterize the autophagy response to CDK11 
knockdown. The capacity of CDK11 to influence autophagy was first 
identified in this laboratory. MDA-MB-231 breast carcinoma-derived cells 
were used for initial experiments, as these cells were the first human cells in 
which the CDK11-mediated autophagy response was described [149]. This 
followed its identification in a drosophila siRNA kinome screen utilizing S2 
cells. In subsequent work, I have demonstrated that the response is not 
unique to these cells but occurs in a variety of human cancer cells of different 
origin.  
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3.1A% At" 72" hours" following" transfecFons," MDA&MB&231" GFP&LC3" cells" demonstrate"
accumulaFon" of" GFP&LC3" puncta" and" nuclear" dysmorphology" following" CDK11" siRNA."
3.1B%Western"Blot"of"MDA&MB&231"cell"lysates"at"72"hours"demonstrates"knockdown"of"
CDK11"with"associated"accumulaFon"of" LC3" II."3.1C%At"72"hours" following" transfecFon"
MDA&MB&231"GFP&LC3" cells" demonstrate" significant" accumulaFon" of" LC3" puncta,"with"












I performed transfection of MDA-MB-231 cells with distinct CDK11-targeted 
and non-targeting control siRNA. At 72 hours following transfection, the 
population of cells subject to CDK11 knockdown demonstrated increased 
autophagy marker LC3 II on western-blot and increased LC3 puncta on 
immunofluorescence when compared to the control population [Fig. 3.1]. In 
addition, a significant increase in p62 puncta was observed following CDK11 
knockdown [Fig. 3.1]. p62 is a signaling adaptor protein reported to regulate 
the aggregation of polyubiquitinated proteins and their subsequent clearance 
through autophagy pathways [175]. It interacts with LC3 II and cytoplasmic 
puncta of p62 have been shown to accumulate in autophagy deficient cells 
[176]. The accumulation of p62 puncta following CDK11 knockdown 
provides further indication of dysregulated autophagy pathways. Further 
analysis revealed a marked association between LC3 and p62 puncta [Fig. 
3.2]. Due to the different immunofluorescence protocols necessary to 
optimize detection of LC3 and p62, MDA-MB-231 cells expressing a GFP-
tagged LC3 fusion protein were used to assess the relationship. 
Approximately 75% of cells demonstrating accumulation of LC3 puncta also 
showed accumulation of p62 puncta. However, confocal microscopy did not 
demonstrate clear co-localisation of LC3 and p62 cytoplasmic puncta [Fig. 
3.2]. While LC3 puncta were considered to represent autophagosomes, the 
p62 puncta were considered to represent polyubiquitinated aggregates. 
Quantification of LC3 II protein levels and cellular LC3 puncta are static 
parameters of dynamic autophagy pathways. Interpreting these measures 
alone is insufficient to fully appraise the state of autophagy within the cell 
[177-180]. Autophagy flux assays are required to determine whether the 
observed accumulation of autophagy components is a result of increased 
production or reduced clearance, i.e. whether autophagy is induced or 
inhibited. I performed a standard autophagy flux assay that demonstrated an 
inhibition of autophagy at 72 hours following CDK11 knockdown [Fig. 3.2]. 
This was consistent with the accumulation of p62 puncta observed, which are 
ordinarily cleared through autophagy pathways. This result correlated with 
published findings demonstrating an initial induction of autophagy, 
followed by inhibition at later time points after CDK11 depletion [149]. 
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of! both! LC3! and! p62,! with! parIal! co%localisaIon.! 3.2B! Autophagy! flux! assay! with!
lysosomal! inhibitors! E64D! and! PepstaIn! A! demonstrates! that! at! 72hours! following!
transfecIon! with! CDK11! siRNA,! there! is! no! further! accumulaIon! of! LC3! II;! LC3! II! in!
contrast!accumulates!significantly!in!the!siNTC!control!cells.!This!is!considered!indicaIve!
of! reduced! autophagy! flux! following! CDK11! siRNA.! 3.2C! demonstrates! a! significant!
associaIon!between!mulInucleaIon!and!LC3!punctaIon,!with!the!mulInucleated!cells!







i r ' . ' $ $231)cells)transfected)with)CDK1 )siRNA)(P2)+)P7))or)NTC)siRNA)(N1)+)
N2).)3.2A% t)72)hours)foll wing)CDK11)knockdown,)ther )is)a)significant)accumulaIon)of)
both)LC3)and)p62)in)cells.)3.2B%Autophagy)flux) ssay)with)lysosomal)inhibitors)E64D)and)
PepstaIn)A)demonstrates)th t)at)72hours)following)transfecIon)with)CDK11)siRNA,)there)
is) no) further) accumulaIon) of) LC3) II;) LC3) II) in) contrast) accumulates) significantly) in) the)
siNTC) control) cells.) This) is) considered) indicaIve) of) reduced) autophagy) flux) following)
CDK11)siRNA.)3.2C%demonstrates)a) significant)associaIon)betwee )mulInucleaIon)a d)
LC3)punctaIon,)with)the)mulInucleated)cells)observed)to)convey)the)greatest)proporIon)
of)cells)with)LC3)accumulaIon.)3.2D%demonstrates)significant)overlap)between)LC3)and)
p62) cellular) responses) (defined) as) >) 5) puncta) per) cells)) in) MDA$MB$231.) 3.2C+D)
represent)the)cumulaIve)results)from)3)biological)replicate)experiments.%)
Furthermore, elevated numbers of grossly aberrant nuclei, defined by the 
presence of multi-nucleation or micronuclei, were observed. This was 
consistent with the described features of mitotic dysregulation after CDK11 
depletion [25]. On analysis, a greater proportion of multinucleated cells 
displayed elevated LC3 puncta compared to cells with normal nuclei [Fig. 
3.2]. This indicated a correlation between anomalous mitosis and altered 
autophagy. However, this did not determine an association between the two 
processes, as these two phenotypes may merely co-exist as a manifestation of 
more profound CDK11 depletion. In addition, as the level of LC3 puncta 
after CDK11 depletion in cells without disrupted nuclear morphology was 
also elevated, albeit not to the same extent [Fig 3.2C], these multinucleated 
cells do not fully explain the elevated LC3 puncta observed after CDK11 
knockdown.  
CDK11 inhibition resulted in a reduction in cell numbers at 72hrs post-
transfection [Fig. 3.3]. On staining with propidium iodide, no increase in the 
sub-G1 population was observed, indicating this was primarily due to 
reduced proliferation rather than cell death. The absence of enhanced cell 
death at this time point, determined by sub-G1 population, did not support 
alteration in apoptosis secondary to CDK11 knockdown. Furthermore, the 
inhibition of autophagy flux observed was inconsistent with CDK11-
mediated autophagy contributing to an alternate ‘autophagic’ cell death. A 
defining characteristic of autophagic cell death is enhanced autophagy flux, 
although the existence of autophagic cell death is debated [181, 182]. Cell 
cycle analysis revealed a greater proportion of cells with 4n DNA content 
following CDK11 inhibition [Fig. 3.3]. This was due both to an increase in the 
proportion of cells in mitosis and the failure of cells to undergo cytokinesis, 
with the acquisition of a tetraploid karyotype. These data correlate with, and 
extend, previous findings demonstrating the influences of CDK11 on mitosis 
and autophagy.  
3.3	  The	  role	  of	  mitosis	  in	  CDK11-­‐mediated	  Autophagy	  
The roles of CDK11 in the regulation of mitosis, apoptosis, splicing and 
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Figure'3.3!CDK11'Knockdown,'Autophagy'and'Cell'Cycle'Inhibi>on.!MDA%MB%231!cells!
transfected!with!CDK11!siRNA!(P2!+!P7)!or!NTC!siRNA!(N1!+!N2)!then!cultures!in!SCM!or!
SCM! +! Thymidine! 2mM.! 3.3A! At! 72! hours,! cell! counts! were! undertaken;! this!
demonstrates! a! significant! reducLon! in! cell! number! following! CDK11! siRNA.! This! is!
further! reduced!with! addiLon!of! thymidine! (Thy.! Block)! (N=3).!3.3B! At! 72! hours,! cells!
were!methanol!fixed,!permeabilised!and!stained!with!Propidium!Iodide.!Flow!cytometric!
analysis!was! undertaken,!with! live! cells! selected! and! gated! according! to!DNA! content!
into!2N!representaLve!of!G1,!4N!considered!representaLve!of!G2/M!and! intermediate!
content!representaLve!of!S!Phase.!Graph!shows!the!proporLon!of!cells!at!each!stage!in!
the! cell! cycle.! This! demonstrates! a! greater! proporLon! of! cell! with! 4N! karyotype!
subsequent!to!CDK11!knockdown.!3.3C!demonstrates!Western!blot!accumulaLon!of!LC3!
II! following! CDK11! siRNA! that! is! reduced! with! the! addiLon! of! thymidine.! 3.3D!










autophagy was novel. I aimed to elucidate the mechanisms underlying 
CDK11-mediated autophagy and to determine whether this occurred due to 
direct mediation of autophagy pathways or indirectly through disruption of 
recognised CDK11 functions. Therefore, I attempted to determine whether 
the effects of CDK11 depletion on autophagy could be dissociated from its 
other roles. As described, a compelling correlation exists between aberrant 
mitoses and perturbed autophagy and this finding determined the course of 
subsequent investigations. Several approaches were employed to determine 
whether mitotic dyregulation could be separated from the autophagy 
response or whether the two processes were related.    
3.3.1 CDK11 Inhibition and Cell Cycle Blockade 
To investigate mitotic influences on the autophagy response after CDK11 
depletion, MDA-MB-231 cells were transfected with CDK11 and non-
targeting siRNA. Cells were then cultured either in the presence or absence 
of thymidine; thymidine excess blocks DNA synthesis resulting in the 
accumulation of cells at the G1/S boundary. This was undertaken to assess 
the effect of cell cycle blockade on the autophagy phenotype following 
CDK11 knockdown, on the rationale that inhibiting proliferation will limit 
any influence of mitotic dysregulation on the autophagy.  
I found that addition of thymidine diminished the elevation of LC3 II 
observed after CDK11 knockdown [Fig. 3.3], although did not result in its 
complete abrogation. Cell counts and propidium iodine staining 
demonstrated that thymidine block successfully reduced cell proliferation, 
although without complete cell cycle blockade. A significant reduction in 
both aberrant nuclei and LC3 puncta was observed [Fig. 3.3].  
To further examine the contribution of aberrant mitosis to the autophagy 
phenotype, MDA-MB-231 cells were synchronized using a double thymidine 
block following transfection with CDK11-targeted or non-targeting siRNA 
[Fig. 3.4]. Three days post-transfection, cells were released from thymidine 
block and sampled at 0, 3, 6, 9 and 12 hours following release. This 
demonstrated elevated LC3 II protein levels and p62 puncta following 
CDK11 knockdown, with a marked increase in these parameters as cells 
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Figure' 3.4' CDK11' Cell' Cycle' Analysis.! MDA%MB%231! Cells! were! transfected! with!
CDK11(P7)! or! NTC! (N2)! siRNA,! with! subsequent! cell! cycle! synchronizaGon! employing!
double! thymidine! block.!On!day! three,! cells!were! released! from!block! and! assayed! at!
specified! Gme! points! as! as! protocol! 3.4A.! 3.4B! Cells! at! specified! Gme! point! and!
condiGon,! underwent! Propidium! Iodide! staining! as! described! with! subsequent! flow!
cytometric! analysis.! This! demonstrates! the! cellular! DNA! content! and! is! therefore!
indicaGve! of! cell! cycle! stage.! This! demonstrates! that! at! both! CDK11! and! NTC! siRNA!
transfected!cells!undergo!mitosis!at!6!to!9!hours!following!release.!Subsequent!to!CDK11!
siRNA,! a! greater! proporGon! of! cells! following! retain! 4N! karyotype.! 3.4C! graphs! the!
elevaGon! in! mean! discrete! p62! puncta! per! cell,! demonstrated! on! passage! through!
mitosis! following!CDK11!knockdown,!with!a!minimum!100!cells!counted!per!condiGon.!
3.4D!Western!Blot!of! sample!buffer! lysates! from!specified!Gme!points!and!condiGons.!







underwent mitosis between 6 and 9 hours [Fig. 3.4]. Furthermore, at 12 hours 
following release, there remained a greater proportion of cells with a 
tetraploid chromosome complement following CDK11 knockdown. These 
findings indicated either failure to exit mitosis or exit of mitosis with failure 
of cytokinesis.   
These results implicated mitotic dysregulation in the autophagy phenotype 
observed after CDK11 depletion, indicating alterations in autophagy flux 
occurred secondary to aberrant mitoses. The single thymidine block 
demonstrated that limiting proliferation limits the autophagy response 
without an effect on the level of CDK11 depletion. The double thymidine 
block assay demonstrated a temporal correlation between passage through 
mitosis and altered autophagy flux [Fig 3.4]. These experiments provide 
evidence to indicate autophagy dysregulation occurs as a result of mitotic 
dysregulation after CDK11 depletion.  
3.3.2 Plk1 Inhibition 
Polo-like Kinase 1 (Plk1) is a serine/threonine kinase known to regulate 
mitosis [183]. During mitosis, it is integral both to spindle formation at the 
centrosome and to the regulation of centromeric chromosome cohesion [183-
186]. Consequently, both CDK11 and Plk1 regulate similar mitotic processes 
[83]. Specific inhibitors of Plk1 exist and are being trialed in the treatment of 
metastatic cancer [187, 188]. To examine whether autophagy dysregulation 
could be induced with inhibition of another mitotic kinase, MDA-MB-231 
cells were treated with Plk1 Inhibitor BI 2536. At 48 hours following 
treatment with either 10nM or 100nM BI 2536, there was an increase in LC3 
puncta, p62 puncta and LC3 II [Fig. 3.5]. Furthermore, aberrant nuclear 
morphology was prevalent among cells. Indeed, this was more exaggerated 
following Plk1 inhibition than following CDK11 depletion, with the majority 
of cells demonstrating multi-nucleation. The induction of a similar 
disturbance in autophagy after inhibition of another mitotic kinase supports 
my earlier findings, indicating that alterations in LC3 II expression and LC3 

















































II! on!Western!blot! following! treatment!with!BI2536;! there! is!no! significant! increase! in!





3.3.3 CDK11 ‘Rescue’ Constructs  
To elucidate the isoform required for autophagy regulation, I aimed to 
‘rescue’ the autophagy phenotype by introducing the different CDK11 
isoforms, with RNAi-refractory cDNA sequences. The primary established 
function of endogenous CDK11p58 is the regulation of mitosis, with reports 
that its native expression is limited to mitosis [21, 25]. If aberrant mitoses and 
autophagy dysregulation caused by CDK11 depletion are linked, CDK11p58 
should rescue both phenotypes. However, if CDK11p58 rescued the mitotic 
but not autophagy phenotype, it would indicate that the two functions could 
be dissociated. Furthermore, this work had the potential to demonstrate the 
specificity of siRNA CDK11 knockdown, if knockdown phenotypes were 
rescued with the reintroduction of RNAi-refractory sequences.  
Therefore, mutagenesis of cDNA encoding either CDK11p58 or CDK11p110 
was undertaken to introduce synonymous mutations that rendered the 
sequences refractory to siRNA (P2) degradation. In addition, the myc-tag 
was inserted 5’ to CDK11 sequences to allow identification of the fusion 
proteins. The resulting constructs were inserted into the pBabe vector and 
the vectors transduced into MDA-MB-231 cells, utilizing retroviral phoenix 
ecotopic cells. Stable expression of myc.CDK11p58 or myc.CDK11p110 
fusion protein was achieved, with transduction of the empty vector acting as 
a control. Probing for myc-tag on Western blot and immunofluorescence 
confirmed expression of both proteins, although heterogeneous in each cell 
population (data not shown). 
MDA-MB-231 cells expressing either myc.CDK11p58, myc.CDK11p110 or 
empty vector were transfected with CDK11 siRNA (P2) to determine 
whether either protein rescued the observed phenotypes. Following CDK11 
knockdown, LC3 II accumulation was observed in cells containing the empty 
vector alone [Fig 3.6]. In cells expressing either myc.CDK11p58 or 
myc.CDK11p110, the LC3 II accumulation was abrogated, indicating rescue 
of the autophagy phenotype [Fig 3.6]. There was also rescue of the aberrant 
nuclear morphology and the accumulation of p62 puncta with both proteins, 
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vector! (EV)! or! vector! containing! siRNA%refractory! CDK11p58! or! CDK11p110! constructs.!
These!cell! lines!were!then!transfected!with!CDK11!(P2)!or!NTC!(N1)!siRNA.!At!72!hours!
post%transfecNon! cells! were! fixed! and! stained! with! DAPI! and! p62.! Graph! 3.6A!
demonstrates! the! nuclear! phenotype!of! cell! populaNons;! this! shows! rescue! of!mitoNc!
phenotypes!with!both!CDK11p58!and!CDK11p110!constructs!(Minimum!200!cells!counted).!
3.6B! Western! Blot! demonstrates! CDK11! knockdown! and! rescue! with! RNAi! refractory!







i ' .6'CDK1 'Rescue'Assay.'MDA$MB$231)cells)were)transduced)with)empty)pBabe)vector)
(EV)) or) vector) containing) siRNA$refractory) CDK11p58) or) CDK11p110) constructs.) These) cell)
lines)were)then)transfected)with)CDK11)(P2))or)NTC)(N1))siRNA.)At)72)hours)post$transfecNon)
cells) were) fixed) and) stained) with) DAPI) and) p62.) Graph) 3.6A% demonstrates) the) nuclear)
phenotype)of)cell)populaNons;)this)shows)rescue)of)mitoNc)phenotypes)with)both)CDK11p58)
and) CDK11p110) constructs) (Minimum) 200) cells) counted).) 3.6B%Western) Blot) demonstrates)
CDK11) knockdown) and) rescue) with) RNAi) refractory) constructs;) there) is) rescue) of) LC3) II)
accumulaNon.)3.6C)demonstrates)rescue)of)p62)puncta)accumulaNon)and)3.6D)demonstrates)




This work demonstrated that both the mitotic and autophagy phenotypes 
could be rescued with CDK11p58. Although this does not prove a 
relationship between mitotic dysregulation and altered autophagy flux, it 
again provides evidence of their association. The rescue of autophagy by 
myc.CDK11p58, following CDK11 knockdown, definitively established that 
the  C-terminus of the protein is required for regulation of both autophagy 
and mitosis. It did not determine that rescue of these two phenotypes 
occurred by the same mechanism although this appears likely. Moreover, 
although it is the p58 isoform that regulates mitosis, my work demonstrated 
that the myc.CDK11p110 fusion protein was also capable of partial mitotic 
rescue after native CDK11 depletion. This may have occurred due to a 
functional IRES region within the myc.CDK11p110 protein, from which the 
p58 isoform could be translated.  
Interestingly, CDK11 knockdown did not lead to a reduction in native 
CDK11p58 on Western blot in MDA-MB-231 cells transduced with vector 
alone [Fig 3.6]. The CDK11 siRNA targeted a sequence common to all 
transcripts and should have depleted both CDK11 isoforms. On account of 
its size and its migration with myc.CDK11p58 fusion protein on Western 
blot, this species likely represented CDK11 rather than non-specific signal. 
Probing with myc antibody did not indicate contamination with the RNAi-
refractory p58 construct. An explanation may be that although there was no 
marked reduction in endogenous CDK11p58; this isoform is primarily 
expressed during mitosis. I demonstrated an approximate five-fold increase 
in the cells in mitosis (1.5% v 7.2%) following CDK11 knockdown [Fig 3.6A]. 
Therefore, although overall a similar quantity of protein was present, the 
number of mitotic cells expressing CDK11p58 was greater and the expression 
in individual cells reduced.  
Furthermore, I found that the expression of the myc.CDK11p110 fusion 
protein was lower compared to expression of the myc.CDK11p58 protein.  
Therefore despite its expression, it was not possible to fully rescue 
CDK11p110 protein levels following siRNA, or the resultant phenotypes. I 
was unable to generate cells expressing high levels of myc.CDK11p110 but 
this was not a unique finding as it has been reported by other laboratories 
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[23]. Certainly MDA-MB-231 cells did not tolerate strong exogenous 
CDK11p110 expression. 
3.3.4 Live Cell Time Lapse Imaging 
The ability to track individual cells over an extended period has the potential 
to determine whether a direct association exists between anomalous mitoses 
and alterations in autophagy flux following CDK11 knockdown. It may also 
identify whether there were subsets of cells that have not undergone 
aberrant mitoses but show an autophagy phenotype after CDK11 depletion. 
Live cell time-lapse microscopy with the use of fluorescent-tagged proteins 
allowed me to address this and was therefore undertaken. 
MDA-MB-231 cells were transduced with a retroviral vector that expressed 
Green Fluorescent Protein (GFP)-tagged Histone H2B with a puromycin 
resistance cassette to allow selection. Histone H2B.GFP localized to the 
chromatin structure of DNA and enabled visualization of individual 
chromosomes during mitosis. Following selection with puromycin, a second 
retroviral vector expressing Cherry-tagged p62, was transduced to track p62 
response; cells expressing Cherry.p62 were selected with blastocidin.   
MDA-MB-231 cells stably expressing both Cherry.p62 and H2B.GFP were 
transfected with CDK11-targeted and non-targeted siRNA. Initially, I 
confirmed that Cherry.p62 and H2B.GFP behaved in a similar manner to 
endogenous proteins (data not shown). Immunofluorescence confirmed that 
these cells display p62 puncta and multinucleation following CDK11 
knockdown at a similar frequency to my previous experiments. Likewise, 
these findings were absent in controls confirming the fusion proteins 
behaved appropriately.  
Unfortunately despite attempts to optimize the system, live-cell tracking 
using fluorescence microscopy failed to produce reliable results. The 
duration of microscopy and the frequency of laser exposure to monitor 
mitosis may have resulted in photo-toxicity [189], which could influence 
autophagy pathways. This work confirmed that the aberrant nuclear 
architecture observed after CDK11 depletion occurred due to mitotic 
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dysregulation. This was expected and consistent with published finding [25]. 
However using live cell imaging, I was unable to definitively determine that 
alteration in autophagy flux occurred only after mitotic dysregulation. 
Using the Cherry.p62 H2B.GFP MDA-MB-231 cells, I investigated the fate of 
cells demonstrating both grossly aberrant nuclear morphology and altered 
autophagy flux after CDK11 knockdown. If these cells fail to proliferate, their 
contribution to tumour growth and evolution would be limited as they could 
not propagate their genomic rearrangements caused by mitotic 
dysregulation. It was therefore important to establish whether these 
multinucleated cells could re-enter the cell cycle and proceed to cell division.   
Following either siRNA CDK11 knockdown or Plk1 inhibition (BI 2536), 
MDA-MB-231 cells, expressing H2B.GFP and Cherry.p62, were plated at low 
density. The position of multinucleated cells was recorded and these cells 
tracked for a period of 3 weeks. Although many of these multinucleated cells 
remained viable for this period in culture, there was no evidence that they re-
entered the cell cycle and formed colonies. Therefore although these 
multinucleated cells may contribute to the tumour micro-environment, based 
on this assay they do not appear to replicate.  
3.3.5 Conclusion 
This work provides evidence that dysregulation of mitosis causes the 
autophagy phenotype observed after CDK11 depletion. CDK11 has roles in 
other cellular processes, including transcription and splicing, and there may 
be other influences on the autophagy response, including direct mediation. 
However, my work indicated that the predominant contributor to CDK11-
mediated autophagy is mitotic dysregulation.  It remained unclear whether 
this is the case for the subset of cells demonstrating altered autophagy but 
with no nuclear dysmorphology. These cells may be more relevant to tumour 
biology than the multinucleated cells that do not appear to proliferate. 
Further work was required to establish whether these cells had also 
undergone aberrant mitosis or whether other mechanisms underlie their 
autophagy response. The work described below further interrogated this 
question.  
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3.4	  Autophagy	  and	  Chromosome	  Mis-­‐segregation	  
Preceding work in this chapter indicated aberrant mitoses are a cause of 
CDK11-mediated autophagy. I aimed to investigate what mediated this 
mitotic dysfunction-induced autophagy. Published studies indicate 
autophagy may be of importance to the propagation of aneuploid karyotypes 
[190, 191]. Certainly, published evidence indicates the requirement for 
protein degradation pathways in the propagation of aneuploid clones and 
demonstrates the sensitivity of trisomic clones to the autophagy / lysosome 
inhibitor, chloroquine [192].  However if autophagy is engaged during the 
acquisition or propagation of aneuploidy, its roles remain unclear. I opted to 
investigate whether chromosome mis-segregation could induce autophagy 
and if so the consequence of this autophagy response. Dissociating the 
influence of discrete mediators is challenging; chromosome mis-segregation 
requires mitotic dysregulation with the potential for confounding influences. 
To address this from an alternate perspective, I also aimed to investigate the 
consequences of autophagy disruption on the acquisition and propagation of 
aneuploidy. 
MDA-MB-231 cell are constitutively aneuploid, limiting their usefulness in 
the study of chromosome mis-segregation. Therefore, I elected to use the 
pseudo-diploid colorectal cancer-derived HCT116 cells to examine the 
influence of chromosome mis-segregation on autophagy. HCT116 cells are 
pseudo-diploid, which enables monitoring of karyotypic variation. For this 
reason, HCT116 cells have been used in numerous studies interrogating 
chromosomal mis-segregation and the acquisition of aneuploidy [167, 193].  
3.4.1 Characterisation of CDK11-mediated Autophagy in HCT116  
First, I aimed to determine whether depletion of CDK11 in HCT116 cells 
replicated the mitotic and autophagy phenotype previously observed in 
MDA-MB-231 cells. Furthermore, this would enable confirmation that 
CDK11-mediated autophagy was not unique to a single cell type. HCT116 
cells were transfected with CDK11-targeted and non-targeted siRNAs. 
Similar effects were observed on the autophagy marker LC3, with elevated 
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immunofluorescence [Fig. 3.7]. Interestingly, there was no associated 
increase in p62 puncta, as observed in MDA-MB-231 cells [Fig 3.8]. I 
investigated whether other signaling adaptor proteins Ndp52 or Nbr1, also 
involved in selective autophagy, were engaged in CDK11-mediated 
autophagy in the HCT116 cell line. There was no evidence of increased 
Ndp52 or Nbr1 puncta or colocalisation with LC3 (data not shown).  
At 72 hours following CDK11 knockdown, autophagy flux assays in HCT116 
cells demonstrated that autophagy was not inhibited and LC3 II accumulated 
at a similar rate to control cells; this was consistent with the absence of p62 
puncta [Fig. 3.7]. This differed from the response observed in MDA-MB-231 
cells. However as discussed, autophagy flux is induced in the MDA-MB-231 
cells at earlier time-points and it is only subsequently that autophagy is 
suppressed [149]. Wilkinson et al. (2011) proposed that, after initial 
stimulation of autophagy, suppression occurred due to inundation of 
autophagy pathways, as the necessary components are consumed and 
depleted [149]. It may be that this does not occur in the HCT116 cells or that 
it occurs at later time points.  
Furthermore, although there was an increase in aberrant nuclei post-
transfection, the proportion of cells demonstrating nuclear dysmorphology 
was markedly reduced in comparison to the MDA-MB-231 cells [Fig. 3.8]. 
The reason for this difference was unclear but may have contributed to the 
difference in autophagy flux described above. HCT116 cells are pseudo-
diploid and therefore retain mechanisms to suppress chromosomal 
instability, including a functional p53 [167, 168]. This may impact on their 
tolerance of mitotic dysregulation and alter cell fate with induction of cell 
death rather than mitotic slippage. However, I found no increase in 
apoptosis to support this in the HCT116 cells at 72 hours following CDK11 
knockdown.  
Therefore, after CDK11 depletion, HCT116 cells displayed a greater 
proportion of cells with normal nuclear morphology but altered autophagy. 
It was important to establish whether dysregulated mitosis occurred in cells 








	   	  






































































underlie their autophagy response. This would enable dissociation of the 
autophagy and mitotic phenotypes in HCT116 cells. 
3.4.2 Imaging of mitosis in HCT116 following CDK11 inhibition 
HCT116 cells were transduced with H2B.GFP, enabling observation of 
mitosis. HCT116 cells stably expressing H2B.GFP were selected and 
subsequently transfected with CDK11-targeted or non-targeting control 
siRNA. From 48 hours to 72 hours post-transfection, time-lapse microscopy 
was performed to interrogate the duration and accuracy of mitosis. I found 
that the average length of mitosis was significantly greater after CDK11 
depletion, despite the resultant interphase cells exhibiting few nuclear 
anomalies [Fig. 3.9]. Furthermore, there was an increase in aberrant mitoses, 
with lagging chromosomes or more profound chromosome mis-segregation 
occurring in a significantly greater proportion of cell divisions [Fig. 3.9]. 
Again, these cells often demonstrated no visible nuclear dysmorphology 
following dysfunctional mitoses. Although this did not establish that mitotic 
dysregulation induced altered autophagy, it did demonstrate that mitotic 
dysregulation occurs despite the reduced nuclear dysmorphology in HCT116 
cells. This indicated mitotic dysregulation may also contribute to the 
autophagy phenotype in cells with normal nuclear architecture.  
3.4.3 Assessing chromosome missegregation and autophagy  
To address whether chromosome mis-segregation influenced autophagy, I 
investigated whether there was a correlation between chromosome mis-
segregation and autophagy after CDK11 knockdown. To determine 
chromosome content and evidence of mis-segregation, fluorescence in-situ 
hybridisation (FISH) chromosome marking was performed. I aimed to use 
FISH in conjunction with immunofluorescence to examine both chromosome 
number and LC3 puncta. I aimed to determine whether an association 
existed between increased LC3 puncta and abnormal chromosome content, 
after CDK11 depletion. To undertake this work, I attempted to refine 
immuno-FISH protocols to optimise both LC3 signal and chromosome 
marking. FISH was performed using chromosome probes or paints (paints 
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Figure' 3.9' HCT116' Time1lapse' Mitosis.! HCT116! cells! were! transduced! using! the!
retroviral!vector!pBabe!GFP.H2B;!cells!with!successful!integraAon!of!the!construct!were!
selected!with! puromycin.! Subsequent! to! selecAon,! the! HCT116! GFP.H2B! cell! line! was!
plated! in! 6Gwell! plates! and! transfected! with! CDK11! or! NTC! siRNA.! At! 48! hours! post!
transfecAon,! plates! were! transferred! to! a! humidified! incubaAon! chamber! on! a!
fluorescent! Olympus! microscope.! Scan^R! soSware! was! used! to! acquire! sequenAal!
images!every!5!minutes!for!24!hours.!The!duraAon!of!mitosis!was!determined!from!the!
onset! of! prometaphase! to! the! compleAon! of! anaphase.! Evidence! of! lagging!
chromosomes! or! other! missegregaAon! events! were! recorded.! Cells! were! noted! to!






chromosome). Unfortunately, staining with chromosome paints proved too 
diffuse in interphase to allow accurate counting of chromosomes. In contrast, 
the signal from individual chromosome locus probes was too weak to 
reliably determine chromosome number. However, chromosome probes 
targeting alpha satellite regions within the pericentric heterochromatin were 
effective. Unfortunately, the staining protocols to enable FISH caused 
disruption of LC3 staining, limiting accurate assessment. Therefore, despite 
immuno-FISH proving unsuccessful, I was able to optimise of chromosome 
enumeration using the pericentric probes.   
3.4.4 Inducing chromosome missegregation with Monastrol 
Due to the technical limitations described above, I was not able to determine 
a specific association between CDK11-mediated autophagy and chromosome 
mis-segregation, despite the correlation with mitotic dysregulation being 
evident. Resolving the influence of chromosome missegregation and aberrant 
mitoses remained challenging, as a degree of mitotic dysregulation is 
required to induce chromosome missegregation. To address this question, 
stringent temporal regulation of mitotic inhibition was required to induce 
chromosome mis-segregation while limiting mitotic catastrophe or slippage, 
which may make results difficult to interpret. There were no commercially 
available inhibitors of CDK11 and no other specific inhibitors described in 
the literature. CDK11 knockdown with siRNA lacked the temporal control 
required and therefore alternate approaches were necessary to induce 
chromosome mis-segregation. 
Protocols have been developed to derive stochastic chromosome mis-
segregation using mitotic inhibitors [105, 194].  Monastrol is an inhibitor of 
the motor protein kinesin Eg5, a protein that co-locates with the mitotic 
spindles, playing a critical role in spindle dynamics and accurate cytokinesis 
[195, 196]. Pulsed treatment with monastrol causes cells to stall in mitosis, 
precipitating the formation of merotelic chromosomal attachments with 
subsequent chromosome mis-segregation on release from inhibition. 
Transient monastrol treatment has been used to induce chromosome mis-
segregation and interrogate the acquisition of aneuploidy [167, 168]. Other 
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mitotic inhibitors, such as nocodazole, have similar effects but published 
work has demonstrated that Monastrol is more efficient at eliciting mis-
segregation [168].    
3.4.5 Monastrol Induced Missegregation and Autophagy  
Using pulsed monastrol treatment of HCT116 cells, I aimed to determine 
whether there was altered autophagy following chromosome mis-
segregation. Two approaches were adopted to enrich for mitotic cells and 
enhance detection of any response. The first strategy was to perform a 
mitotic shake-off following 9 hours of monastrol (100μM) treatment; control 
cells were treated with an equal concentration of the monastrol solvent 
DMSO (10μl/ml) prior to mitotic shake-off. Cells were then plated on glass 
slides and fixed at specified time-points. This strategy did not demonstrate a 
significant difference in LC3 II or LC3 puncta between control cells and 
monastrol-treated cells [Fig. 3.10]. However, both control and monastrol-
treated cells demonstrated increased LC3 II and LC3 II puncta. Whilst the 
cause of this was uncertain, mechanical stress at mitotic shake-off may have 
engaged autophagy [197].  
The second strategy was to synchronise the cells at the G1/S boundary via 
double thymidine block. Cells were then released from block and after 6 
hours treated for a further 8 hours with monastrol or DMSO control. Slides 
and lysates were collected at specified time intervals after washout. With this 
approach, the cell cycle distribution of control and monastrol-treated cells 
was different, due to the monastrol-induced mitotic block. Nonetheless, it 
was not possible to detect a difference in autophagy markers between control 
and monastrol-treated cells [Fig. 3.10]. Furthermore, autophagy flux assays 
were performed at 12 hours following monastrol/DMSO washout. These 
assays did not demonstrate consistent alteration in autophagy flux after 
monastrol treatment. Therefore, these experiments failed to detect altered 
autophagy that could be attributed to monastrol treatment. Control cells in 
these experiments did demonstrate high background LC3 signal not 
observed in previous experiments. The reason for this effect is not clear but it 



























































increased# in# both# cohorts# at# 24# hours# following# pla-ng.# In# the# second,# cells# were#
synchronized#at#G1/S;#at#6#hours#following#release#cells#were#treated#with#Monastrol#or#
DMSO#for#8#hours.#Lysates#or#coverslips#were#obtained#at#given#-meNpoints#for#analysis.#
3.10B# No# significant# difference# in# LC3# puncta-on# was# observed# between# condi-ons#
(Technical# replicates# N=3# /# Error# bars# represent# 95%# CI).# 3.10C# No# difference# in#
autophagy#flux#was#observed#between#treatments#at#the#12Nhour#-meNpoint.#
treatment. Additionally, there are reports of autophagy induction following 
administration of DMSO, although it is not well understood [198].  
I was not able to demonstrate alteration of autophagy as a consequence of 
chromosome mis-segregation, although there were limitations to the 
experiments performed, with cells experiencing mitotic delay and potential 
off-target effects of drug treatment. Therefore, I could not reach definitive 
conclusions concerning any association between chromosome mis-
segregation and autophagy. Whilst in these experiments I did not 
demonstrate that pulsed monastrol induced chromosome mis-segregation, in 
subsequent work, I established that repeated monastrol treatment did induce 
mis-segregation and the development of aneuploidy. It is possible that one 
treatment with monastrol may not have induced sufficient mis-segregation 
to stimulate a detectable alteration in autophagy. Studies published since this 
work was undertaken, have demonstrated induction of autophagy genes 
following chromosome mis-segregation [191, 199]. 
3.4.6 Influence of Autophagy on Aneuploidy 
I wished to address the effect of autophagy on the acquisition and 
propagation of aneuploidy, following chromosome mis-segregation. To 
achieve this, I adopted methods from studies investigating aneuploidy [167, 
168]. The principal strategy was based on the work of Thompson et al. (2008) 
[167, 168]. In this paper, the generation of aneuploid cell populations was 
described using monastrol-induced mis-segregation [167, 168]. Thompson et 
al. (2010) used this strategy to demonstrate the importance of p53 loss in the 
propagation of aneuploid cells [167, 168]. 
3.4.6.1 Generating HCT116 Knockdown Cell Lines 
To investigate the role of autophagy, I aimed to establish cell populations 
deficient in autophagy to examine its influence on the generation of 
aneuploid cell populations. In addition, due to the importance of p53 in 
suppressing aneuploidy, it was necessary to generate cells with p53 
depletion. HCT116 have functional p53, which inhibits the generation of 
aneuploidy [167, 168]. Thompson et al. (2008) used p53-/- HCT116 cells 
generated by Bunz et al. (1998) [200]. For reasons discussed later, I decided to 
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knockdown both autophagy and p53 using small hairpin RNA (shRNA) that 
integrate into the genome to produce stable knockdown of targeted genes.  
Autophagy inhibition was achieved via shRNAs targeting integral 
autophagy components; knockdown of ATG5 or ATG7 was attempted but 
the ATG7 shRNA provided greater inhibition of autophagy and was used for 
all subsequent work [Fig. 3.11]. HCT116 cells with stable suppression of 
autophagy were generated through the retroviral transduction of ATG7 
shRNA, with non-targeting shRNA transduced into control cells. HCT116 
cells with suppression of autophagy were selected and p53 knockdown 
achieved via lentiviral transduction of p53-targeted shRNA or non-targeted 
shRNA. This approach generated 4 HCT116 clones: one displaying stable 
autophagy and p53 knockdown (shATG7.shp53), one displaying autophagy 
knockdown alone (shATG7.shNTC), one displaying p53 knockdown alone 
(shNTC.shp53) and one clone in which neither protein was knocked down 
(shNTC.shNTC).  
3.4.6.2 Sequential monastrol treatment, culture and assessment of karyotype 
The 4 HCT116 clones were then treated with monastrol (100μM) for 8 hours 
followed by mitotic shake-off. Cells were plated and allowed to complete cell 
division for 16 hours. Pulsed treatment with 8 hours of monastrol followed 
by washout and 16 hours of standard culture was repeated on 4 consecutive 
days. Following this protocol, all 4 HCT116 clone populations demonstrated 
significant deviation from the diploid karyotype [Fig 3.12]. The 4 HCT116 
clones were then plated at standard or low density and cultured for up to 45 
days. The populations plated at standard density were passaged as required 
and sampled at specified time points. Cells plated at low density were left to 
form individual clones, which were sampled after 45 days. 
At each time-point, FISH was performed to assess karyotype, using 
pericentric chromosome probes. Two chromosome probes to the alpha 
satellite regions on Chromosome 8 and Chromosome 7 were used. Both these 
chromosomes are diploid in HCT116 cells and both had been used to assess 
karyotype in published studies [167, 193]. In diploid cells, each probe marks 
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Figure' 3.11'Autophagy' and'Maintenance' of' the'Aneuploid' Karyotype.'To# inves)gate#
the# effects# of# autophagy# on# the# genera)on# and# maintenance# of# the# aneuploid#
karyotype,# pseudo:diploid# HCT116# cells# were# transduced# with# combina)ons# of# ATG7#
shRNA,# p53# shRNA# and# NTC# shRNA# to# generate# 4# cell# lines.# 3.11A# delineates# the#
protocol# for# genera)ng# aneuploid# cells# with# sequen)al# Monastrol# treatment# (WO# =#
Wash# Out)# followed# by# collec)ve# or# solitary# cell# culture.# The# aim# was# to# interrogate#
karyotype#with#chromosome#probes#through#out#the#experiment#to#assess#altera)ons#in#
chromosome#number.#This#protocol# is#adapted#from#published#work#by#Thompson#and#
Compton.# 3.11B# and# 3.11C# demonstrate# effec)ve# autophagy# knockdown# with# ATG7#
shRNA#following#chloroquine#treatment;#this#is#superior#to#knockdown#achieved#with#the#
ATG5#shRNA.#3.11D#Western#blot#of#p53#and#LC3#in#the#4#HCT116#cell# lines#generated;#
this# demonstrates# adequate# autophagy# and# p53# inhibi)on# in# the# relevant# lines# on#
commencing#the#experiment.###
indicates polyploidy or aneuploidy (if an uneven number of chromosomes 
are present). Obvious only two chromosomes were assessed but published 
studies demonstrate that this provides a valid representation of overall 
karyotype [167, 168]. At the final time point (Day 45), mitotic spreads were 
employed to determine chromosome number, to confirm and validate the 
results obtained by chromosome probes. Importantly, chromosome probes 
assess interphase chromosome number unlike metaphase spreads, which 
examine chromosome number only in dividing cells. Therefore, in cells that 
undergo aberrant mitoses and experience cell cycle arrest, the karyotype will 
be assessed by chromosome probes but not metaphase spreads. However, it 
is apparent that if these cells fail to proliferate, their proportion in the 
population will fall rapidly over time.  
Prior to monastrol treatment, the karyotype of all 4 HCT116 clones was 
assessed using both chromosome probes and mitotic spreads; no difference 
between the clones was identified. The karyotype of the HCT116 cells is 
45(43-45)X. The chromosome probes demonstrate approximately 5% of cells 
deviated from diploid karyotype at baseline, which is similar to the rate 
found by Thompson et al. (2008, 2010) [167, 168].  
3.4.6.3 HCT116 shNTC.shp53 and HCT116 shATG7.shp53 Karyotype Variation 
All 4 HCT116 clones displayed significant karyotype anomalies after 
sequential monastrol treatment. However, directly following treatment (Day 
0), a significantly smaller proportion of shATG7.shNTC cells deviated from 
diploid karyotype than the other 3 HCT116 clones [Fig. 3.12]. This may 
reflect impaired tolerance to chromosome mis-segregation following 
autophagy knockdown. Over time, comparison of the 4 HCT116 clones 
revealed that only the shNTC.shp53 cells differed from the others, with a 
significantly higher proportion of cells with aberrant karyotypes. This 
accorded with the published findings of Thompson et al. (2010) 
demonstrating that p53 depletion permits the propagation of aneuploidy 
[167]. Interestingly, the shATG7.shp53 cells that displayed autophagy 
knockdown in addition to p53 depletion, did not sustain similar karyotype 
variation. Again, this implicates autophagy in the survival and/or 
proliferation of cells with abnormal karyotypes.  
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At the final time point, shATG7.shp53 cells displayed a greater proportion of 
cells with abnormal karyotype than either shNTC.shNTC or shATG7.shNTC 
cells. Intriguingly, this was also true of shATG7.shp53 cells not treated with 
monastrol but cultured for 45 days in standard media as a control [Fig. 3.15]. 
However, these differences were not statistically significant but the trend 
would agree with data demonstrating loss of autophagy predisposes to 
chromosome instability [155, 201]. The apparent paradox that autophagy 
may both inhibit and support chromosomal instability [202] is discussed 
below. I found that control shNTC.shp53 cells, not treated with monastrol, 
did not display abnormal karyotypes above baseline at Day 45. Once more, 
this was in agreement with the published observation that p53 loss alone is 
insufficient to generate aneuploidy [203].    
At Day 45, chromosome counts on metaphase spreads were consistent with 
findings from the two individual chromosome probes, confirming the 
chromosome probes were a valid readout of karyotype [Fig. 3.13]. These 
metaphase spreads demonstrated that shNTC.shp53 HCT116 cells differed 
from normal karyotype to a greater degree than other cohorts, in agreement 
with the results from the chromosome probes.  
3.4.6.4 Individual cell clone chromosome counts 
Experiments to assess the growth of individual cell clones following 
monastrol treatment were not informative. No significant difference in the 
number of aneuploid clones was found between the 4 HCT116 cell types  
[Fig. 3.14]. This differed from the findings of Thompson et al. (2010), who 
reported a significantly greater proportion of aneuploid clones in p53 
deficient cells [167]. The reason for this difference is unclear but may be a 
sampling error as I counted only a limited number of clones.  
Interestingly, the individual cell clones that demonstrated aneuploidy 
displayed a background tetraploid population. There were few diploid cells 
in any of the individual colonies with marked aneuploid populations. Each 
individual colony was derived from a single progenitor cell and it was 
improbable that if this cell was aneuploid it would have derived a significant 





















































































































































































































































































































































































































































































































































































































































































have been a residual diploid population. Therefore, the high proportion of 
tetraploid cells, in the absence of diploid cells, indicated that aneuploidy in 
these populations was likely to have occurred via multipolar mitoses of 
tetraploid cells. Tetraploidy is recognized to be a metastable state and others 
have described the derivation of aneuploid clones from tetraploid 
progenitors [193, 204]. Therefore, my findings were consistent with work 
demonstrating tetraploidy as a mediator of chromosomal instability in 
tumourigenesis [193].  
3.4.6.5 Discussion of experiment methods 
I used shRNA to knockdown both p53 and autophagy. The advantage of this 
approach was that all cells in the experiment were derived from the same 
HCT116 cell population, providing confidence that the 4 HCT116 cell types 
were syngenic. The p53-/- HCT116 cells were generated clonally by Bunz et al 
(1998) over 15 years ago and therefore may differ from the wild-type HCT116 
cells used in my work. Furthermore, HCT116 cells with dual p53 and ATG7 
knockout did not exist and it was considerably easier to generate these cells 
utilizing shRNA knockdown.  
The disadvantage of shRNA over constitutive knockout includes the risk of 
off-target effects. I used a single shRNA for each target, ATG7 and p53, which 
may have increased this risk. Moreover, the effect of shRNA may be 
suppressed over time if there is a strong negative selection pressure due to 
its deleterious effects. In my experiment, autophagy knockdown was well 
maintained but there was a reduction in p53 knockdown over the 
experimental period [Fig. 3.15]. In addition, it is recognized that gene 
knockdown is not necessarily equivalent to gene knockout, although my 
results correlated well with the findings by Thompson et al. (2010), using 
cells with constitutive p53 knockout [167].  
3.4.6.6 Autophagy and Chromosomal Instability 
In this experiment, I found that autophagy knockdown impaired the capacity 
of cancer cell to tolerate abnormal karyotypes. This was demonstrated both 
by the lower proportion of shATG7.shNTC cells with aberrant karyotype 


















































































































































































































































































































































































































































































































































































































shATG7.shp53 cells with aberrant karyotype compared to shNTC.shp53 cells 
at Day 45 following treatment. My findings appeared contrary to previous 
studies on autophagy and chromosomal instability [155, 201], which indicate 
inhibition of autophagy leads to genetic instability. In one study, 
heterozygous loss of Beclin1 combined with expression of BCL2 predisposed 
cells to develop chromosomal instability [155]. Furthermore, a recent paper 
found loss of autophagy was associated with genetic instability under 
conditions of metabolic stress, such as starvation [201]. This appears to create 
a paradox where autophagy inhibition may both inhibit chromosomal 
instability and induce it.  However, these different findings are not 
irreconcilable and indeed the influence of autophagy depletion on 
tumourigenesis is similarly contradictory. This is discussed prominently in 
the literature, with autophagy loss found to both limit tumour survival and 
promote tumour progression [202, 205]. Autophagy enables the sequestration 
and degradation of cellular products and if accumulation of these products is 
deleterious then loss of autophagy may impair survival. However, if these 
products are genotoxic then loss of autophagy may impair their degradation 
and potentially enhance genetic instability in cell that survive. Chromosomal 
instability can induce protein imbalances leading to proteotoxic stress that 
autophagy may mitigate. Since my work was performed, other papers have 
demonstrated that chromosomal mis-segregation induces autophagy genes 
[191]. More recently, Santaguida et al. (2015) have demonstrated that 
aneuploidy and specifically chromosome mis-segregation induces autophagy 
phenotypes, with elevated LC3 II [206]. In addition, they demonstrated that 
autophagy targets such as protein aggregates accumulate in lysosomes and 
induce a lysosomal-stress response in aneuploid cells [206]. Furthermore, Lui 
et al. (2016) have found that increased autophagy flux rescues oxidative 
stress and apoptosis due to chromosomal instability [207]. These recent 
papers are consistent with my result.     
3.4.6.7 p53 and Autophagy 
It is established that p53 itself can regulate autophagy, with reports that it 
both stimulates selective autophagy pathways and inhibits basal autophagy 
[208-210]. Therefore, p53 inhibition in this setting may itself alter autophagy 
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responses. Furthermore, ATG7 is reported to modulate p53 function under 
conditions of metabolic stress, mediating cell survival [211]. In HCT116 cells, 
I found loss of p53 did not abrogate the increased LC3 II observed after 
CDK11 knockdown (data not shown). This indicated p53 is not an integral 
component in the CDK11-mediated autophagy response, which results from 
aberrant mitosis.  
The status of p53 appears to significantly influence the role of autophagy in 
tumorigenesis, emphasising the importance of examining influences of both 
p53 and autophagy individually and together. This is of particular relevance 
given the prevalence of p53 pathway disruption in cancer and the potential 
for any future use of autophagy inhibitors as chemotherapeutic agents.  A 
recent study undertaken by Rosenfeldt et al. (2013) demonstrates the 
influence of autophagy inhibition on tumourigenesis is dependent on p53 
status [212]. In a murine model of pancreatic adenocarcinoma driven by 
aberrant KRAS, autophagy inhibition was found to restrict tumour 
progression in the presence of a functional p53. Conversely, in the absence of 
p53, autophagy inhibition enhanced tumorigenicity. This paper indicates that 
abrogation of autophagy, by either genetic loss or chemical inhibition, 
enhanced tumour progression following loss of p53 [212]. Rosenfeldt et al. 
(2013) did not examine chromosomal stability or karyotype. 
3.5	  Conclusion	  
This chapter characterised the autophagy response observed on CDK11 
knockdown. My work demonstrated that the predominant influence on this 
phenotype is mitotic dysregulation. Aberrant mitoses appear to engage 
autophagy pathways. However, this work was unable to determine the 
influence of chromosomal mis-segregation itself on autophagy pathways. 
Subsequent papers have demonstrated up-regulated mRNA expression of 
autophagy genes following chromosome missegregation [190, 191]. More 
recently, upregulation of autophagy itself has also been found on 
chromosome mis-segregation and others have shown autophagy enhances 
tumour cell survival after chromosome mis-segregation [206].  
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Aneuploidy is common in cancer and its role in tumour progression is 
debated. Interestingly, my work indicates aneuploid clones in these 
experiments were generated through tetraploid intermediates. Published 
work demonstrates the survival advantages of the capacity to rapidly alter 
genetic content through loss of faithful genomic replication [213]. However 
this comes at a potential cost and there is increasing evidence that 
aneuploidy causes proteotoxic stress due to stoichiometric protein imbalance 
with corollary elevation in reactive oxygen species (ROS) [53]. This protein 
imbalance is proportional to the chromosomal regions duplicated [53] and 
ROS themselves are observed to stimulated autophagy responses [87, 88]. In 
addition, ROS are reported to induce further chromosomal instability [89], 
while autophagy may potentially mitigate this stress.  
This work indicates that autophagy has a role in the maintenance of the 
aneuploidy, with loss of autophagy impairing the survival of cells with 
aberrant karyotypes. Hopefully, further work will continue to assess the link 
between autophagy and aneuploidy, to identify either the beneficial or 




CDK11 and Cell Motility 
	  
4.1	  Introduction	  
4.1.1 Cell Migration 
The ability of cells to migrate is essential to all multicellular organisms [93]. It 
proves integral not only to their development but also subsequently to 
processes such as immune surveillance and wound healing. The strict control 
of cell migration is therefore essential to health and its dysregulation plays a 
significant role in human disease, particularly cancer. Dysregulated 
migration is fundamental to the capacity of the cancer cell to metastasize and 
it is this metastasis of the tumour from its site of origin that is responsible for 
the greatest burden of mortality. Indeed the ability of a tumour cell to both 
migrate and invade forms the basis of differentiating tumours into those 
categorized as benign or malignant. 
Cell migration requires the coordinated and dynamic regulation of 
numerous cellular processes and pathways. In essence, these pathways serve 
to integrate three fundamental elements, permitting and regulating cell 
migration; these are adhesion (and de-adhesion) to the extracellular matrix 
(ECM), cytoskeletal reorganization and cellular polarization [93]. Whilst 
multiple patterns of migratory behavior are recognized, these elements are 
integral to all patterns of migration.  
4.1.2 Migratory Morphologies 
Modes of cell migration are linked to cellular morphology [214]. Epithelial 
cells are characterized by planar polarity and strong inter-cellular adhesion 
with resultant limitations on motility [214]. The motility displayed is often 
that of collective migration of cell sheets. Mesenchymal cells, in contrast, 
display weak cellular contacts and enhanced motility [214]. Invasion and 
migration during both health and disease is frequently associated with 
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epithelial cells adopting a mesenchymal phenotype, termed epithelial-to-
mesenchymal transition [214]. Numerous mechanisms have been described 
to regulate this transition [90].  
Amongst mesenchymal cells, differing morphologies of migration are 
recognized, including protrusive and amoeboid phenotypes [215]. The best 
characterized is that of the protrusive phenotype, most prevalent in 2D 
systems, as described in this chapter. This involves protrusion of structures, 
termed lamellipodia, at the front of the cell with de-adhesion at the rear 
[215]. Actin assembly and regulation of adhesion are reported to be 
fundamental components to this mode of migration. In contrast, cells 
migrating with an ameoboid phenotype demonstrate a rounded 
morphology; this mode of migration is found to be less dependent on actin 
assembly and more so on actomyosin contractility [96]. Amoeboid cell 
migration is best described in 3D systems [215]. These two modes of 
migration are not considered mutually exclusive and the capacity of cells to 
transition from protrusive to amoeboid morphologies has been demonstrated 
[215]. These phenotypes have been defined in vitro and their relevance in vivo 
during health and disease remains uncertain. 
4.1.3 Integrins and Focal Adhesions 
Adhesion to the extra-cellular matrix, its regulation and the capacity to 
respond to external stimuli are integral to cellular migration. Integrins 
constitute the predominant receptor type that mediates adhesion to the 
extracellular matrix [103]. These trans-membrane integrin molecules are 
expressed at the cell surface as obligate heterodimers comprising non-
covalently associated α and β subunits [216]. Mammalian cells express a 
cohort of distinct α and β subunits (18 α and 8 β subunits) that derive a 
complement of unique heterodimers; these recognize numerous discrete 
ligands to enhance cellular sensitivity and specificity to environmental cues 
[216].  
Attachment to the extracellular matrix induces integrin receptor clustering 
[217]. This cluster of intracellular domains within the cytoplasm acts as a 
trigger for the recruitment of cytoskeletal and signaling complexes to initiate 
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the formation of structures termed focal adhesions [218]. The engagement of 
proteins including Talin, Vinculin and α -actinin enable linkage of these 
nascent adhesions to the actin cytoskeleton. Recruitment of ARP 2/3 further 
strengthens this connection with the capacity to nucleate novel actin 
filaments in the vicinity of integrin clusters [219]. These structures are 
subsequently able to augment integrin avidity through further clustering of 
integrin and actin components. These focal adhesions enable structural 
connectivity of the cytoskeleton to the cellular surroundings, with the 
establishment of tractile forces essential to cell motility [218]. 
Focal adhesions not only provide a physical link to the extracellular matrix 
but also act as signaling complexes to assimilate and interpret environmental 
stimuli and regulate cellular responses [218]. A plethora of signaling 
molecules locate to focal adhesions; prominent among these is the influential 
Focal Adhesion Kinase (FAK). FAK is a non-receptor tyrosine kinase that is 
engaged early in the formation of nascent adhesions and is a principal 
mediator of adhesion dynamics and signaling [220]. The mechanisms 
regulating FAK activation are well described [220]. Auto-phosphorylation of 
the tyrosine residue (Y397) on FAK, in response to various stimuli, causes 
conformational rearrangement of the protein to reveal a high-affinity binding 
site for the Src Homology 2 (SH2) domain [220]. This enables association of 
Src and FAK and Src activation. Src activation leads to phosphorylation of 
FAK at multiple tyrosine residues, in addition to phosphorylation of 
numerous other substrates. FAK phosphorylation both enables full 
enzymatic activation of FAK and creates further binding domains for other 
signaling molecules [220]. The influential FAK-Src complex acts to regulate 
adhesion dynamics and intracellular signaling, with evidence demonstrating 
its capacity to modulate adhesion, cellular polarity and the cytoskeleton [220-
222]. Indeed, FAK-Src signaling controls many facets of malignancy-
associated phenotypes [223]. 
4.1.4 Cell Polarity and the Cytoskeleton 
Cell polarity is defined by the acquisition of spatial asymmetry; this 
comprises the asymmetrical organization of cellular structures including cell 
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membrane, intracellular organelles and cytoskeleton [224]. Cell polarity is 
integral to sustained directional migration as it allows discrete, divergent 
molecular processes to occur at front and rear of the cell such as assembly of 
nascent adhesions at the leading edge with disassembly of adhesions at the 
rear [224]. The establishment of cell polarity obligates stringent temporal and 
spatial regulation of discrete cellular pathways. CDC42, a Rho GTPase, has 
been determined to be the master regulator of planar epithelial polarity [224, 
225]. It is found to act through effectors such as the PAR6/PAR3/aPKC 
complex [225]. These regulate polarization of the nucleus, golgi apparatus 
and centrosome. In slow migrating mesenchymal cells, such as described in 
this work, the nucleus moves rearward on polarization to lie posterior to 
both the golgi and centrosome [226]. The centrosome is the major 
microtubule organizing centre (MTOC) within the cell; through its regulation 
of microtubule dynamics it plays an integral role in the maintenance of cell 
polarity and migration [227]. The golgi apparatus co-locates with the 
centrosome in migrating cells and this interaction is found to be influential in 
the maintenance of polarity [228].  
The cytoskeleton is another element essential to operative cell migration 
[225].  Actin filaments contribute to the establishment of polarity, with 
actomyosin contractility fundamental to the generation of tractile forces 
required for cell motility. Microtubules play important roles in mediating 
polarization and the transportation of components necessary to enable the 
migration. Although many molecules are implicated in cell migration, the 
Rho GTPases including Rac, Rho and CDC42 are fundamental regulators of 
cytoskeletal dynamics [229]. Their activity is conformationally regulated by 
binding to GTP and GDP; they are activated on GTP binding and inactive 
when GDP-bound [229]. 	  
4.1.5 CDK11 and Cell Migration 
As described in previous chapters, CDK11 has defined roles in transcription, 
splicing and mitosis. Prior to commencing the work described in this 
chapter, there was little in the literature describing the role of CDK11 in cell 
migration. However, a large genetic screen utilizing siRNA mediated 
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knockdown of human phosphatases and kinases identified CDC2L1 
(CDK11B) as one of 66 putative regulators of cellular migration [230]. This 
paper undertook the high throughput screen using MCF10A cells, 
transformed, non-cancerous breast cells with epithelial morphology. The 
primary outcome measure was area of wound closure at 12 hours following 
wounding of a confluent monolayer, utilizing the 2-D ‘wound-healing’ or 
‘scratch’ assay [230]. Secondary outcomes included examination of cellular 
morphology and migratory behavior.  
Inhibition of CDK11 protein expression was linked to reduced cell migration; 
however, no gross alteration in cell morphology or migratory behaviour was 
observed following CDK11 knockdown [230]. The study did report aberrant 
nuclear rotation following knockdown of CDK11, indicating abnormal cell 
polarization [230]. However, no detailed examination was performed. Based 
on this evidence, I was interested to examine the role of CDK11 in cell 
migration because of its potential implication to cancer phenotypes. 
CDK11 is required for accurate centrosome duplication at mitosis [83]. 
Aberrations in centrosome biology during mitosis have implications for its 
function in interphase [231]. As described, the centrosome exercises a 
fundamental role in microtubule behavior and the maintenance of cellular 
asymmetry during migration. CDK11 may therefore influence migratory 
behavior through effects on centrosome function. Moreover, unpublished 
work has identified interaction between CDK11 and various cytoskeletal 
proteins including tubulin [106]. CDK11 is implicated in the regulation of 
microtubule dynamics at mitosis and may be engaged in similar processes 
through interphase [84, 89]. Finally the role of CDK11 in cellular adhesion 
has not been previously examined but CDK11 contains a Src Homology 2 
(SH2) binding domain [47]. No interaction with Src family kinases is 
reported but this domain may provide a mechanism through which CDK11 
may influence cellular adhesion and migration. However, numerous proteins 
with diverse roles contain SH2 domains and the functionality of this domain 
within CDK11 remains untested.  
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4.2	  CDK11	  and	  Cell	  Migration	  
I aimed to determine whether published findings on the role of CDK11 in cell 
migration could be recapitulated in other cell lines, with the aim of 
subsequently elucidating the underlying mechanisms. It was decided to 
undertake initial experiments utilizing the simple wound healing or scratch 
assay. Although this assay has limitations, its use is prevalent in published 
literature and it has informed understanding of cell migratory behaviour. In 
addition, the assay was employed in the study by Simpson et al. (2008) that 
predicated this chapter [230]. Therefore, it was considered a valid initial 
strategy, as any findings could be subsequently interrogated in a more 
detailed manner.  
4.2.1 Results of the Wound Healing Assay 
I aimed to determine the optimal conditions to perform the migration assays. 
Over time, the predominant phenotype observed following CDK11 knock-
down is one of mitotic dysregulation, demonstrated by nuclear 
dysmorphology. Determining the time, following siRNA transfection, at 
which to undertake the assay was critical. Simpson et al. (2008) performed 
the assay at 56 hours following transfection, during which period the mitotic 
phenotype caused by CDK11 knockdown becomes prominent in MDA-MB-
231 cells [230]. I aimed to determine the shortest time following transfection 
at which consistent knockdown of protein levels, of 75% or greater, could be 
achieved. This was undertaken to reduce the influence of the marked mitotic 
phenotype, demonstrable at 72 hours following transfection, as this was 
likely to impair cell migration. Time course experiments, utilizing the MDA-
MB-231 cells, identified that at 40 hours consistent knockdown of the 
required magnitude (≥75%) could be achieved using pooled siRNAs. Pooled 
siRNAs were used to reduce the influence of off-target effects of a single 
siRNA. Increasing siRNA concentration did not lead to a more rapid 
reduction in CDK11 protein levels. Therefore I opted to undertake the assay 
at 40 hours following siRNA transfection. This represented a compromise 
between attaining optimal reduction in protein level whilst limiting time-
dependent confounding effects attributable to the role of CDK11 in mitosis. 
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It was decided to undertake this work using two cell lines: MCF-7 cells and 
the MDA-MB-231 cells. The MCF-7 cells represent oestrogen receptor 
positive breast cancer-derived cells and display an epithelial morphology, 
with the capacity to form monolayers in 2D culture. MDA-MB-231 cells are 
derived from a hormone receptor negative breast cancer and have a 
mesenchymal phenotype. Work confirmed that similar knockdown of 
CDK11 could be achieved with both cell lines at 40 hours following 
transfection. These cells were used to interrogate migratory effects in cells 
displaying either mesenchymal or epithelial morphology, given their known 
different modes of migration. Simpson et al. (2008) examined migration only 
in an epithelial cell line [230]. Therefore my experiments had the potential to 
broaden the generality of any findings.  
In order to reduce the impact of differences in cell density caused by CDK11 
inhibition, cells were plated at equal density 12 hours prior to wounding. No 
alteration was visible in the adhesion of CDK11-depleted or control cells that 
may have challenged the validity of the assay. The absence of altered 
adhesion was consistent with findings described later in this chapter. Plastic 
plates without collagen coating were used to reduce the potential for error 
created by the variable loss of the collagen coating during wounding, a 
recognized limitation of 2-D wound healing assays [232, 233]. 
Initial work was undertaken using time-lapse microscopy, visualizing the 
wound edge for up to 15 hours following wounding. This allowed not only 
quantification of the area recovered following wounding but also study of 
the general migratory behaviour of the cells during this process. Both the 
MCF-7 and MDA-MB-231 cells transfected with CDK11 siRNA showed 
significant retardation of migration into the wound, compared to cells 
transfected with non-targeted siRNA [Fig 4.1]. Time-lapse images 
demonstrated that this deficit was temporal, i.e. cells took longer to migrate 
into the wound, but there was no gross morphological change in the 
migratory patterns between either cell type on knockdown of CDK11. These 
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4.2.2 Dissociating the effects of CDK11 on proliferation and migration 
Having established that CDK11 depletion impaired cell migration, I aimed to 
identify the underlying mechanism. Cell proliferation can influence 
migration assays and I have demonstrated a significant reduction in 
proliferation on CDK11 knockdown, primarily observed between 48 hours 
and 72 hours (Chapter 3). It was important to determine whether the 
impaired migration observed on CDK11 knockdown resulted from its effect 
on proliferation. Furthermore, CDK11 inhibition caused an accumulation of 
cells with aberrant nuclear morphology that may migrate differently. 
Although I aimed to reduce these proliferative/mitotic effects by 
undertaking the assay at 40 hours following siRNA transfection, this did not 
exclude their influence. This work therefore aimed to assess the influence of 
aberrant mitosis and reduced proliferation on the impaired migration 
demonstrated in the 2-D scratch assays. Several approaches were used for 
these further investigations. The first approach was to attempt to rescue 
migration with the different CDK11 isoforms, attempting to dissociate 
proliferation and migration. The CDK11p58 isoform is integral to mitosis and 
this isoform rescues mitosis following CDK11 knockdown, as described in 
Chapter 3. If the CDK11p58 isoform could not rescue migration as it did 
mitosis, it would indicate that the impaired migration was unrelated to 
mitotic dysregulation.  
4.2.2.1 Migratory Rescue with CDK11 Isoforms 
I performed this work using the MDA-MB-231 cells expressing CDK11p58, 
CDK11p110 or empty vector that had been created and validated in my 
earlier work (Chapter 3). In this experiment a single CDK11 siRNA (P2), was 
used as the CDK11 constructs were mutated to be refractory to this 
oligonucleotide. Both CDK11p58 and CDK11p110 were found to rescue the 
migratory deficit caused by CDK11 knockdown in the empty vector MDA-
MB-231 cells [Fig 4.2]. As both CDK11p58 and IRES-competent CDK11p110 
rescued migration, I was unable to dissociate the impaired migration and 
mitotic dysregulation. However in this assay, I established that the C-
Terminus of CDK11 was required for normal migration. 
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Figure' 4.2.' Wound' Healing' Assay.! 4.2A.! MDA%MB%231! cells! transduced! with! vector!
constructs!CDK11!p58!(MDA!p58),!CDK11!p110!(MDA!p110)!or!empty!vector!(MDA!EV)!
were! subject! to! transfecIon! with! CDK11! (P2! oligo)! or! NTC! (N1! oligo)! siRNA! and! the!
wound!healing!assay!performed!as!previously!described.!Graph!4.2A!shows!area!closed!
at! 12hour! Ime! point! in! each! condiIon;! expression! of! CDK11! p58! or! p110! construct!
rescues!the!migratory!deficit,!subsequent!to!CDK11! inhibiIon,!seen! in!MDA!EV!control!
cells.!4.2B.!MDA%MB%231!cells!subject!to!siRNA!transfecIon!as!described!were!plated!at!
28hours.! Subsequent! culture! was! undertaken! in! standard! serum! containing! media!
(SCM),! standard! serum!containing!media!+! thymidine! (2mM)! (SCM!+!Thy!Bl)!or! serum!
free!media! (SFM)! and!wound!healing! assay!performed!as! previously! described.!Graph!
4.2B!shows!the!area!closed!at!12hours.!Culture!in!serum!free!media!significantly!retards!










Expression of the recombinant CDK11p58 or CDK11p110 proteins did not 
affect migration compared to the empty vector [Fig 4.2], indicating that 
overexpression of CDK11 did not appear to promote or inhibit migration in 
the MDA-MB-231 line. This was consistent with a recently published study 
that found CDK11p58 expression inhibited migration through oestrogen 
receptor (ER) dependent mechanisms [234]. The authors found no effect on 
migration in MDA-MB-231 (ER negative) cells with CDK11p58 expression 
but reported impaired migration with its expression in ZR-75-30 (ER 
positive) breast cancer-derived cells [234]. However, I have demonstrated 
CDK11 knockdown inhibits migration in both MCF-7 (ER positive) cells and 
MDA-MB-231 (ER negative) cells. 
4.2.2.2 Impact of inhibiting proliferation on the CDK11 mediated migration 
The second approach I adopted to investigate the influence of proliferation 
on CDK11-mediated mitosis was to repeat the migration assay following 
CDK11 knockdown, whilst inhibiting proliferation. Inhibiting proliferation 
would reduce the effect of proliferation or mitosis on migration in the scratch 
assay. I used two strategies to inhibit cell proliferation; in the first, cells were 
treated with thymidine and in the second, cells were cultured in serum free 
media. In both cases, these treatments were applied after plating, 12 hours 
prior to the scratch assay. Both treatments may have consequences other than 
blockade of cell proliferation but both methods have been used to discern 
proteins that regulate migration through proliferation [99, 235]. I 
demonstrated that both thymidine-treated cells and serum deprived cells 
deviate in their migration from cells cultured in standard media, with 
thymidine enhancing migration and serum deprivation inhibiting migration 
[Fig. 4.2]. However, there remained a significant inhibition of migration 
following CDK11 knockdown in each condition. Interestingly, thymidine 
block enhanced migration in this assay contrary to its negative influence on 
proliferation, an effect that has only been previously described in endothelial 
cells [236].  
Suppressing proliferation failed to abrogate the impaired migration 
following CDK11 knockdown. This indicated that the impaired migration 
Page 134
observed on CDK11 knockdown did not result from its effects on mitosis or 
proliferation. Thymidine and serum-free media were only applied to cells 12 
hours prior to the assay, in order to obtain sufficient cells for seeding of a 
confluent monolayer. Therefore, a proportion of cells may have undergone 
aberrant mitosis prior to these culture conditions but this was unlikely to 
significantly influence the result given the established timeframe and kinetics 
of CDK11 knockdown.   
4.2.2.3 Results of random cell migration following CDK11 knockdown 
I utilized random migration assays as the final approach to exclude the 
influence of cell proliferation on CDK11-mediated migration. I interrogated 
migration of individual MDA-MB-231 cells, tracked by single cell imaging, 
following transfection with CDK11 siRNA or non-targeting siRNA. 
Although similar pathways regulate both directional and random migration, 
random migration represents a mode of migration that lacks the directional 
impulse of external cues and instead relies on intrinsic motility [237]. 
Migration of isolated cells in this assay is not driven by proliferation. 
Following CDK11 knockdown, cells were plated at low density both to 
enable tracking of individual cells and reduce the influence of cellular 
contacts on migration. Cells were then imaged using time-lapse microscopy 
and cell motility quantified using Image J software. This conclusively 
demonstrated impaired random migration following CDK11 knockdown 
compared to control [Fig 4.3]. Again, this indicated that proliferation did not 
cause the migratory deficit on CDK11 knockdown. Furthermore, it showed 
that CDK11 is required for optimal random migration of cells. 	  
4.3	  CDK11	  and	  Cell	  Polarity	  
Having established impaired migration after CDK11 depletion was not a 
consequence of aberrant mitosis or impaired proliferation, I aimed to identify 
other factors that may explain the altered migration observed. Simpson et al. 
(2008) proposed that aberrant cell polarisation caused the impaired 
directional migration detected following CDK11 knockdown in the 2D 
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following CDK11 knockdown. The wound-healing assay was replicated at 40 
hours post-transfection with CDK11 or non-targeting siRNA using MDA-
MB-231 cells plated onto glass coverslips. This confirmed that the impaired 
migration on CDK11 knockdown also occurred when cultured on glass. In 
subsequent assays, cells were fixed immediately following wounding and at 
30 minutes, 90 minutes, 180 minutes and 360 minutes after wounding. Cells 
were permeabilised and stained to localize the golgi apparatus, the 
centrosome, the nucleus and the actin cytoskeleton. Polarity was assessed on 
fluorescence microscopy as previously described [238]. Cells were 
considered polarized if the golgi was positioned anterior to the nucleus, 
relative to the ‘wound’ edge. The percentage of polarized cells at each time 
point was assessed. Approximately 20% of cells display ‘polarization’ at 
wounding, consistent with the 25% expected to show ‘polarization’ by 
random positioning of the golgi. At subsequent time points, the proportion 
of polarized cells at the wound edge increased [Fig 4.4]. The percentage of 
cells demonstrating cell polarization was lower than that previously 
described in similar assays but the time course for polarization was 
comparable [239, 240]. There was no significant decrease in polarized cells 
observed following CDK11 knockdown at any time point [Fig 4.4]. 
Centrosome staining revealed no visible dissociation of this structure from 
the golgi apparatus following CDK11 knockdown, with it displaying similar 
polarity. This demonstrated that under these conditions and contrary to the 
mechanism of CDK11-mediated migration proposed by Simpson et al. (2008) 
[230], CDK11 knockdown did not impair cell polarization. Furthermore, no 
marked morphological effect on cytoskeletal components was detected 
during this polarization assay, with no significant alteration in the 
localization of actin, tubulin or acetylated tubulin, a marker of stable 
microtubules. However, more subtle effects on cytoskeletal networks cannot 
be excluded.  
4.4	  CDK11	  and	  Focal	  Adhesions	  
Adhesion to the extracellular matrix is also important for cell migration. 
Therefore I aimed to identify whether CDK11 knockdown affected cellular 
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onto! glass! coverslips.! At! specified! 0meGpoints,! cells! were! fixed,! permeabilised! and!
subject! to! immunofluorescence! with! GM130! an0body! (marking! Golgi! Apparatus),!
Phaelloidin! and! DAPI.! Polarity! was! assessed! at! each! 0me! point:! cells! were! scored! as!
polarized! if! the! golgi! lay! in! a! 90o! arc! anterior! to! the! nucleus,! facing! the!wound! edge!
(WE).! A! minimum! of! 50! cells! was! assessed! at! each! 0me! and! condi0on.! Graph! 4.4A!
demonstrates!percentage!of!cells!polarized!at!the!wound!edge!at!each!0me!point;!there!
is! no! significant! divergence! between! control! or! CDK11! knockdown! cells.! Error! Bars! at!
90minutes! indicate! 95%! confidence! intervals;! this! represents! 3! replicate! experiments.!




adhesions [Fig. 4.5, Fig 4.6, Fig 4.7]. At 40 hours following transfection with 
non-targeting or CDK11 siRNA, MDA-MB-231 cells were treated with 
trypsin and placed in suspension on a rotor at 4°C for one hour, to enable 
disassembly of focal adhesions. After one hour, cells were plated on 
collagen-coated substrates for immunofluorescence or cell lysis. Adhesion 
was assayed at predetermined time points after the plating. Representative 
images demonstrated no morphological difference between cells after CDK11 
knockdown [Fig. 4.5]. Images from the adhesion experiment, clearly 
demonstrated initial spreading of cells from their rounded morphology in 
suspension. Cells then adopted a mesenchymal phenotype, irrespective of 
whether CDK11 was depleted or not, with numerous protrusions extending 
from the cell body. This morphological change suggests functional adhesions 
were formed and appropriately linked to the actin cytoskeleton. 
This adhesion assays demonstrated that not only was morphological change 
absent after CDK11 knockdown but there appeared to be no alteration in the 
number of adherent cells. To confirm the latter observation, equal number of 
control or CDK11 knockdown cells were plated onto collagen coated plates. 
Plates were subsequently washed to remove non-adherent cells and nuclei 
stained with fluorescent marker DRAQ5. The fluorescent signal was 
quantified utilising a LiCor plate reader. There was no significant difference 
in fluorescent signal after CDK11 knockdown, confirming no demonstrable 
difference in the number of adherent cells. In addition, this study 
demonstrated that the majority of cells adhere rapidly (within 15 minutes) to 
the matrix, with no significant increase in adherent cells over time [Fig. 4.7B].  
Signaling events at nascent adhesions were examined. Cell lysates collected 
prior to and after plating were quantified and resolved by SDS-PAGE prior 
to Western blot analysis. FAK and Src are influential in regulating adhesion 
and adhesion-dependent signaling pathways and I examined for alteration in 
their protein levels or activation.  
Activation was determined by probing for phosphorylation of FAK at 
Tyrosine 397 (Y397) and phosphorylation of Src at Tyrosine 419 (Y419). No 
alteration in total FAK or phosphorylated FAK (Y397) was identified after 
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Figure' 4.5.' Cell' Adhesion'Assay.!MDA%MB%231! cells!were! subject! to! pooled! CDK11!or!
NTC! siRNA! transfec@on!as!described.!At! 40!hours! cells!were! trypsinised! and!placed! in!
suspension! for! 1! hour! at! 4oC! on! a! rotor,! during! which! samples! were! retrieved! for!
prepara@on!of!protein!lysates.!At!1!hour,!cells!were!plated!on!collagen!coated!coverslips!
or! @ssue! culture! plas@c! for! subsequent! immunofluorescent! or! protein! lysate! analysis!
respec@vely.! At! specified! @mepoints,! slides! were! washed! and! cells! fixed! or! lysed!
accordingly.! Images! in! this! figure! show! representa@ve! images! of! cells,! at! given! @mes!
points,! following! pla@ng! in! both! control! and! CDK11! knockdown! cohorts.! This!
demonstrates!there!is!no!significant!morphological!divergence!between!cohorts.!Cells!of!
both!cohorts!demonstrate!the!adop@on!of!a!mesenchymal!phenotype!with!development!
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and! cell! adhesion! assay! as! described! previously.! Cells! were! lysed! on! ice! using! RIPA!
buffer;!lysates!were!quan<fied!prior!to!separa<on!on!SDS%Page!gel.!4.6A!demonstrates!
representa<ve!Western!Blot! images!of! lysates!collected!at!specified!<me%points!during!
suspension! or! following! pla<ng! (Adherent).! These! do! not! demonstrated! significant!
altera<ons! in! levels! of! FAK,! phosphorylated! FAK! (Y397)! or! Src.! There! is! a! significant!
decrease! in! levels!of!phosphorylated!Src! (Y419)! following!pla<ng! in!both! cohorts.!Plot!



























CDK11 knockdown, either in suspension or following plating [Fig. 4.6]. A 
marked increase in phosphorylated FAK (Y397) was demonstrated after 
plating but this occurs, irrespective of CDK11 depletion. Again, no alteration 
in total Src was observed but there was a marked reduction in 
phosphorylated Src (Y419) following plating, occurring largely both with and 
without CDK11 knockdown. After plating, a small but significant reduction 
in phosphylated Src (Y419) was observed at 30 minutes in the CDK11 
knockdown cells [Fig. 4.6B]. Given the small reduction, the biological 
relevance remains uncertain. At later time points, alterations in 
phosphorylated Src (Y419) after CDK11 knockdown were inconsistent and 
no significant difference was observed.  
For immunofluorescence, cells were fixed and permeabilised after plating. 
Immunofluorescence was performed to examine for altered localization of 
Src [Fig. 4.7A], phosphorylated Src (Y419), FAK, Actin or Paxillin following 
CDK11 knockdown. No altered localization of these proteins was observed 
at all time points examined. 
4.5	  CDK11	  and	  Src	  
Published work has demonstrated that CDK11 contains an SH2 binding 
domain [47], which was identified using the Blk SH2 domain to affinity 
purify CDK11p110. The SH2 domain within Blk has significant homology to 
the Src SH2 domain. Therefore, I decided to investigate whether the Src SH2 
domain could bind to CDK11.  
Glutathione S-transferase (GST) recombinant proteins comprising GST fused 
to the Src SH2 domain, the Src SH3 domain or both the SH2 and SH3 
domains combined were synthesised in bacterial cells, purified and 
conjugated to glutathione-coated agarose beads. These GST fusion protein 
were added individually to asynchronous MDA-MB-231 cell lysate and 
affinity purification undertaken. GST-conjugated agarose beads were used as 
the control. All three GST fusion proteins comprising the SH2 domain, the 
SH3 domain and the SH2/SH3 domains were able to precipitate different 
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domain primarily precipitated CDK11p110, while the SH3 domain 
precipitated CDK11p58. Additionally in the SH3 pull-down, a slower 
migrating species was demonstrated. As CDK11p110 is the longest isoform 
that can be generated from known transcripts, the slower migration of this 
species was presumed to be a consequence of post-translational modification. 
The size differential was not consistent with phosphorylation and may 
represent another modification such as sumoylation; CDK11 is found to be 
sumoylated in screens of sumoylated proteins. However, further work is 
required to characterize this larger species.  
 
Having confirmed that isolated domains of Src could interact with CDK11, I 
attempt to determine whether Src and CDK11 interacted in vivo. No 
peripheral co-localisation was observed on immunoflorescence staining with 
Src and CDK11 targeted antibodies. Moreover, no co-immunoprecipitation of 
either CDK11 with Src, or Src with CDK11, could be demonstrated when 
precipitating endogenous proteins. Precipitation of myc-tagged CDK11 
fusion protein also failed to co-precipitate Src. Therefore no interaction could 
be identified between endogenous Src and CDK11 in cells. As discussed 
previously, SH2 domains are distributed widely across the proteome and the 
role of the SH2-binding domain within CDK11 remains unclear. Although no 
interaction with Src was identified under these experimental conditions, this 
does not exclude interaction with other Src family members or indeed Src 
under specific conditions not tested, such as cellular stress or mitosis. 
4.6	  CDK11	  and	  the	  Cytoskeleton	  
A further element important in cell motility is the actin cytoskeleton. As 
described, no morphological alterations in migratory pattern were observed 
after CDK11 knockdown. In addition, there was no morphological change in 
individual cells either upon adhesion or during migration. Furthermore, 
MDA-MB-231 cells expressing the exogenous CDK11 proteins at supra-
physiological levels, were morphologically indistinguishable from cells 
transduced with empty vector.  
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or migration assays, on staining with phalloidin. This was also true of the 
interphase microtubule network, with localisation of both tubulin and 
acetylated tubulin similar between control and CDK11 knockdown cells 
stained with tubulin or acetylated tubulin antibodies. Cell polarity requires 
both a functional microtubule network and actin cytoskeleton and the 
absence of altered polarity in my work was indicative of an operative 
cytoskeleton. These adhesion and polarity assays therefore provide insight 
into cytoskeletal dynamics and did not demonstrate any alteration in the 
cytoskeleton or adhesion after CDK11 inhibition.  
4.7	  Conclusion	  
Work presented in this chapter has confirmed there is a migratory deficit 
mediated by CDK11 knockdown. This is true of both epithelial and 
mesenchymal cancer cells and in the context of both directional and random 
migration. I did not find any effect of CDK11 on mesenchymal cell 
polarisation, cytoskeleton dynamics or cell spreading following CDK11 
depletion. Despite containing SH2 and SH3 binding domains, I was unable to 
demonstrate any interaction between CDK11 and Src that may regulate 
CDK11-mediated migration. Furthermore, I have demonstrated this 
migratory deficit on CDK11 depletion is not related to the function of CDK11 
in mitosis / proliferation.  
The diverse functions of CDK11 could impinge on cell motility indirectly, 
irrespective of whether CDK11 also directly mediates migratory pathways. 
CDK11’s role in transcription and splicing may have a role in indirectly 
regulating migratory pathways. Rescue of the phenotype by the p58 isoform 
demonstrates that the C-terminus of CDK11 is sufficient to mediate motility. 
However, a role for endogenous CDK11p58 in transcription and splicing has 
not been established and the endogenous protein is primarily expressed in 
mitosis. Work described in Chapter 5 indicates that CDK11p58 may indeed 
have a role in splicing. Furthermore, although there is evidence that 
CDK11p58 participates in nuclear receptor signaling pathways, it is reported 
that p58 and p110 isoforms have opposing roles in these signaling pathways 
[65]. This finding is not consistent with my data indicating both isoforms 
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similarly rescue migration. A recent paper by Tamura et al. (2016) has 
reported CDK11p58 to mediate migration in prostate cancer cells through 
interaction with GADD45 α and γ [241]. This complex enhances migration 
via degradation of the epithelium-specific Ets transcription factor SPDEF, 
which suppresses migration and invasion [241]. During subsequent 
interrogation of the CDK11 interactome (Chapter 5), I was unable to 
precipitate GADD45 α or γ  with CDK11p58 but did detect potential 
interaction with GADD45 γ binding protein (GADD45GIP). On account of 
the work by Tamura et al. (2016), this finding requires further investigation.  
CDK11 knockdown therefore inhibits migration but I did not determine the 
precise mechanism. Further characterization of the CDK11 interactome may 
be beneficial in order to identify interacting partners that may directly 
mediate migration. Preliminary work has been undertaken to investigate 
CDK11 interacting partners, which is described in Chapter 5. 
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CHAPTER 5 
Characterization of the CDK11 Interactome 
	  
5.1	  Introduction	  
This chapter describes work I undertook to interrogate the CDK11 
interactome.  CDK11 regulates transcription, splicing, apoptosis and mitosis 
[22, 23, 24]. In addition, I have previously demonstrated the roles of CDK11 
in mediating autophagy and cell migration. The following work aimed to 
provide a greater understanding of how CDK11 regulates these processes by 
further characterizing the proteins and pathways with which it interacts. 
5.1.1	  CDK11	  Protein-­‐Protein	  Interactions	  
The capacity of a protein to form various distinct protein-protein interactions 
enables it to undertake multiple roles within diverse cellular processes and 
pathways [242]. These interactions may be dynamic, modulatory, stable or 
transient; in addition, they may be both spatially and temporally defined 
[242]. Characterization of these interactions is fundamental to understanding 
the biology of a protein.  
The disparate roles performed by CDK11 are enabled not only by its varied 
protein interactions but also by the regulated expression of discrete CDK11 
isoforms. Published studies have identified numerous CDK11 interactors, 
reviewed in Chapter 1 [Table S1 (Appendix)]. However, there remains 
uncertainty regarding the role of individual isoforms, their distinct 
interactomes and the precise mechanisms of their action.  
NCBI records 55 proteins that interact with CDK11A and 42 proteins that 
interact with CDK11B; 13 of these proteins are common to both CDK11 gene 
products [243, 244]. A further 30 proteins not listed by NCBI, are reported to 
interact with human CDK11 or its eukaryote homologues [23, 41, 60, 62, 107]. 
Therefore in total 114 interacting proteins are reported. Although certain 
protein interactors have been assigned to either the CDK11A or CDK11B 
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protein, this differentiation often appears arbitrary, as the gene products 
cannot be differentiated when performing immunoprecipitation or affinity 
purification of endogenous protein. Furthermore, several studies have not 
stated which gene (CDK11A or CDK11B) was used in determining the 
interaction when employing other methods [63, 91, 112]. Moreover, only the 
human genome contains two CDK11 genes therefore protein interactions 
identified in other species cannot be accurately assigned to either of these 
specific human proteins. Certainly no study has demonstrated, or indeed 
examined, whether any interaction is specific to CDK11A or CDK11B and at 
present it is assumed the two proteins are functionally equivalent.  
5.1.1.1	  Methods	  Used	  in	  Characterizing	  the	  CDK11	  Interactome	  
Various methods have been described to characterize the CDK11 
interactome; I aimed to adopt different strategies to identify novel 
interactions and elucidate CDK11 biology. The majority of early studies 
interrogating CDK11 interactions used the yeast two-hybrid system; this 
method was integral in the initial identification of CDK11’s interaction with 
splicing components and responsible for characterizing a significant 
proportion of the established CDK11 interactome [41]. All published CDK11 
interactions identified using the yeast two-hybrid system have been 
confirmed using immunoprecipitation or GST affinity purification, which 
although limiting false positives, may also have resulted in the rejection of a 
number of true interactions.  
Co-purification with column-based fast protein liquid chromatography has 
been used to identify proteins that associate with CDK11, which fractionates 
with large macromolecular complexes [23]. Subsequent analysis of these 
complexes led to the identification of FACT and CK2 as interactors, with 
these interactions confirmed by immunoprecipitation [23].  
Co-immunoprecipitation with subsequent analysis by mass spectrometry or 
Western blotting has been used to determine numerous CDK11 interactors 
[22, 60]. This has been undertaken using both immunoprecipitation of 
endogenous protein and tagged recombinant CDK11 [245, 246]. The 
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interaction between Chk2 and CDK11 was identified through TAP tag 
purification of Chk2 [60].  
5.1.1.2	  Methods	  to	  Characterise	  Protein-­‐Protein	  Interactions	  
Numerous approaches exist to characterise protein-protein interactions. 
These approaches may be classified as in vitro, in vivo or in silico [247] and 
may identify physical protein-protein interactions (direct or indirect) or 
functional protein-protein interactions. In vitro methods include affinity 
purification and co-immunoprecipitation. In vivo techniques comprise the 
yeast two-hybrid system, synthetic lethality assays and siRNA screens. 
Synthetic lethality assays and siRNA screens may be used to demonstrate 
functional interactions, which may or may not require physical interaction 
[248, 249]. Large-scale siRNA screens have demonstrated the functional 
interplay of CDK11 with Hedgehog signaling pathways [141, 144] and were 
integral in the first identification of CDK11-mediated autophagy. In silico 
techniques include gene expression profiling, protein structural approaches 
and phylogenetic analysis. These approaches are used to support functional 
interactions, with the concept that interacting partners will share aspects of 
expression pattern, protein evolution or related structural elements [247]. As 
I aimed to identify direct or indirect physical interaction with CDK11 to 
elucidate specific pathways in which it functions, I planned primarily to use 
in vitro assays to investigate these interactions.	  
5.1.1.2.1	  The	  Yeast	  Two-­‐Hybrid	  System	  
The yeast two-hybrid system has been critical in characterizing the known 
CDK11 interactome. It enables the identification of protein-protein 
interactions in a transcriptome-wide screen. Furthermore, prior knowledge 
of potential interactors or involved pathways is not required and it therefore 
facilitates identification of novel aspects of protein biology. It allows weak or 
transient interactions to be identified more easily as the reporter gene 
strategy results in significant signal amplification [250]. The system detects 
direct protein-protein interactions but as a result of the binary nature of these 
interactions, it provides less information regarding the wider associated 
protein network. Other disadvantages of the system include the potential for 
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false positive results arising from the non-physiological distribution of 
interacting proteins. Proteins are generated in yeast and interactions that 
require post-translational modification may not be identified. Furthermore, 
yeast two-hybrid interactions occur in the nucleus and therefore cytoplasmic 
proteins that undergo nuclear-export may not be identified. Moreover, the 
whole protein sequence may not be utilized to generate bait or prey altering 
the interaction profile. Since completion of genome sequencing by the human 
genome project and the greater accessibility of mass spectrometry, the 
importance of the yeast two-hybrid system has diminished. 
5.1.1.2.2	  Affinity	  Purification	  and	  GST-­‐Pulldown	  
Affinity purification or affinity chromatography relies on specific covalent 
binding interactions. A ligand is coupled to an insoluble matrix and 
molecules with specific binding affinity to the ligand are separated from the 
solution. Examples include purification of polyhistidine (His) through 
binding to metal ions, such as cobalt or nickel, Glutathione S-Transferase 
(GST) pull-down through its interaction with glutathione and avidin 
purification via biotin. The fusion of these protein tags (His/GST/Avidin) to 
the protein of interest enables its affinity purification. 
Adaptions of this technique allow the GST-tagged fusion protein to be first 
captured to a glutathione support via the glutathione-GST affinity interaction 
and immobilized. The immobilized GST-tagged fusion protein can then be 
used to affinity purify binding partners. Affinity purification using the GST-
tag is an established technique in protein interaction studies [251]. Primarily, 
it is used to interrogate specific protein-protein interactions and is commonly 
employed to determine the domains required for interaction. Classically, the 
GST-tagged recombinant protein is synthesized in bacterial cells, purified 
and applied to the assay of putative targets. Affinity purification is achieved 
via the glutathione coupled affinity matrix.  
The use of GST affinity purification as a proteome-binding assay coupled 
with mass spectrometry has been reported, with proponents describing it as 
a protein based yeast two-hybrid equivalent [23, 252]. It involves addition of 
the GST-tagged protein of interest to cell lysates with subsequent purification 
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and mass spectrometry. Again, this strategy has both strengths and 
weaknesses. Major attributes include its simplicity and the lack of any 
requirement for exogenous protein expression within cultured cells. 
Dependent on the wash strategy applied to the matrix, weaker interaction 
may be identified as interactions need only to be maintained briefly in high 
stringency lysis buffer [247]. Inversely, weaknesses include the promiscuity 
of the GST-tag and the synthesis of GST recombinant protein in bacterial 
cells; proteins may therefore not have the correct conformation or necessary 
post-translational modifications to capture binding partners. Furthermore, in 
similarity to the yeast two-hybrid system, false positive interactions may 
occur due to the lack of target compartmentalization. 
5.1.1.2.3	  Co-­‐immunoprecipitation	  
Co-immunoprecipitation is integral to the study of protein-protein 
interactions [247]. In principle, antibody targeted to the protein of interest 
forms immune complexes with the protein, which are then precipitated 
using an affinity matrix that adheres to the primary antibody. The resultant 
matrix with the captured protein of interest is washed and binding partners 
can be assessed, most frequently using Western blot or mass spectrometry. 
Co-immunoprecipitation may be performed on endogenous protein or with 
tagged fusion protein, following its expression in cells. 
Immunoprecipitation of endogenous protein allows the protein of interest to 
be captured at physiological levels in its native state, potentially making 
interactions identified more biologically relevant [253]. It avoids the 
difficulties that may arise with expression of recombinant fusion protein, 
discussed below. However, caveats exist to immunoprecipitation of native 
protein.  
The first concern relates to the protein of interest, which must be expressed at 
sufficient levels to enable precipitation of the target above background non-
specific binding that can occur with any antibody or affinity matrix. The 
target protein must be within the soluble fraction and contain epitopes 
amenable to antibody derivation and binding. Consequently, 
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immunoprecipitation of endogenous protein may be less suited to discerning 
rare or weak interactions [247].  
The second concern relates to the antibody, which must recognize the protein 
in a physiological conformation at an epitope accessible under assay 
conditions. It must be of sufficient sensitivity to extract adequate quantity of 
target, while demonstrating specificity to minimize the direct precipitation of 
non-target proteins.  
The third concern relates to experimental controls. There should ideally be a 
control to determine non-specific binding of both the antibody and affinity 
matrix [254]. Cells with constitutive knockout of the protein of interest 
provide the optimal control to determine non-specific binding patterns but 
may not exist.  
Immunoprecipitation of recombinant tagged protein is commonly used. 
However recombinant protein is not equivalent to endogenous protein and 
localization, expression and binding may all differ from its native form. 
Therefore it is necessary to validate the recombinant protein prior to use. 
However, tagged fusion proteins do offer advantages; they enable protein 
over-expression that may permit the identification of weak or rare protein 
interactions. Reliable, validated antibodies targeting the tag are available and 
facilitate not only precipitation but also confirmation of protein co-
localization to confirm putative interactors. In addition, cells expressing the 
protein tag alone may act as the immunoprecipitation control. Synthesis of 
recombinant tagged protein remains the only mechanism available to 
undertake discrete precipitation of the CDK11p58 isoform. However, 
overexpression of fusion protein may also inhibit certain interactions as it 
distorts the reaction equilibrium in a ‘prozone’ effect [255]. 
5.1.1.2.4	  Other	  in	  vitro	  Methods	  in	  Protein	  Interaction	  Detection	  
Tandem affinity purification involves double tagging of the protein of 
interest and is often combined with mass spectrometry [256]. Purification of 
both tags is achieved sequentially either by affinity purification or 
immunoprecipitation, with cleavage of the primary tag prior to secondary 
purification. This strategy enhances specificity of the assay [247]. It is 
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however a more complex precipitation strategy, which can adversely affect 
both yield and sensitivity [257].   
Other in vitro assays exist including Phage Display, which uses a 
transcriptome library to express proteins on the surface of bacterial phages; 
these phages are then exposed to the protein of interest immobilized on a 
solid support [247]. The support matrix is washed and phages expressing 
protein that binds to the target remain. This cycle can be repeated to enrich 
for binding phages, termed panning. Protein microarrays can be used for 
interactions studies with thousands of full-length proteins spotted on slides 
in precise locations [247]. The protein of interest is purified and added to the 
assay with binding at individual spots detected by immunofluorescence. 
Protein complementation assays employ a reporter protein that is split, with 
half the reporter protein covalently linked to the protein of interest [247]. The 
other half of the reporter protein is linked to individual proteins from a 
transcriptome library. Interaction between the prey and bait proteins leads to 
formation of full-length reporter protein and a detectable signal output. All 
these techniques provide distinct mechanisms to identify protein interactions 
but can be expensive and are complex to initiate without prior experience, 
with no evidence of these producing more reliable results than affinity 
purification or immunoprecipitation strategies. 
5.1.1.3	  Interpreting	  the	  Results	  of	  Protein	  Interaction	  Assays	  
Correlation between protein-protein detection methods varies and can be 
low. Estimates of false positives for the yeast two-hybrid system lie between 
30 to 60%, with high through put assays estimating it may be higher still 
[257-259]. However, the poor correlation may not only arise from false 
positive and false negative results but can occur due to the different 
interactions (direct or indirect) that different assays identify [258]. The yeast 
two-hybrid system detects binary direct interactions where as affinity 
purification and co-immunoprecipitation identifies both direct and indirect 
interactions, as whole protein complexes may be precipitated. These 
precipitation methods therefore provide a wider analysis of the interacting 
networks but as a consequence do not necessarily demonstrate direct contact. 
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No method alone can provide definitive evidence of true interactions, which 
should be confirmed by different techniques. Interpretation of the results 
must take account of several potential pitfalls. False positives interactions 
may occur due to non-specific binding or loss of protein localization, 
allowing proteins without endogenous co-location to bind. Co-
immunoprecipitation, although often considered the most valid gauge of 
interaction, is not necessarily specific, as all precipitation strategies and 
affinity matrices can generate non-target binding [260, 261]. Again, co-
immunoprecipitation cannot prove direct interaction, as precipitation may 
occur through binding intermediaries.  
Protein interactions are not optimized to occur in buffer even if corrected for 
osmolality and pH. All protein –protein interactions within the cell occur in a 
concentrated milieu of macromolecules with protein concentrations in the 
cytosol reaching that of protein crystals [257]. This macromolecular crowding 
is likely to effect differences in binding affinities in vivo and in vitro.  
5.1.2	  Proteomics	  
Improvements in mass spectrometric detection and analysis have enabled 
significant advances in the study of the proteome. Current techniques enable 
not only identification of protein interactors but their accurate quantification 
[262].  
Prior to recent advances, accurate protein quantification by mass 
spectrometry was dependent on metabolic labeling such as Stable Isotope 
Labeling with Amino acids in Cell culture (SILAC) [262]. However, SILAC 
quantification is not only expensive but requires intricate culture conditions, 
which can limit experimental methods [263]. Label-free mass spectrometry 
enables quantification without protein labeling, relying instead on either 
calculation of mean ion intensity or spectral counting. The technical advances 
in both mass spectrometers and software tools permit the reliable analysis of 
the complex datasets and have led to significant improvements in the 
accuracy of label-free methods [263]. Several recent studies have reported the 
reliable and accurate quantification of dynamic protein interactions by label-
free methods [264, 265].  
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5.1.2.1	  Label-­‐free	  On-­‐bead	  Mass	  Spectrometry	  
Improvements in label free quantification had enabled the adoption of label-
free on-bead mass spectrometric analysis [265]. Traditional mass 
spectrometric analysis of protein from affinity purification or 
immunoprecipitation assays involved resolution of precipitates with SDS-
PAGE. Gels were subsequently silver stained and unique bands present in 
target protein precipitate but not control were excised and analysed with 
mass spectrometry. Obviously this allowed high specificity as unique bands 
were selected but sensitivity with the technique was poor as only proteins 
sufficiently enriched to demonstrate a differential band on silver stain could 
be assessed. In the on-bead method, accurate quantification enables multiple 
proteins in target and control precipitate to be assessed and quantified; 
proteins significantly enriched in the target precipitate, representing putative 
interactors, can be determined. This on-bead protocol reduces the steps 
necessary prior to mass spectrometry, therefore not only simplifying 
experiments but reducing the potential for contamination or protein loss 
[265]. This has the potential to significantly enhance sensitivity, although 
there is the potential for a loss of specificity and a high rate of false positive 
results if specific precipitation cannot be achieved. However, this label-free 
on-bead protocol is proven to achieve accurate analysis, although replication 
is critical in ensuring reliable results, with two technical replicates for each of 
three biological replicates analysed at each condition [265]. Our laboratory 
has successfully used label-free on-bead mass spectrometry, demonstrating 
good correlation of results to labeled mass spectrometry but at a significant 
reduction in cost. The on-bead digestion and mass spectrometry was 
undertaken at our collaborating institution. 
5.1.3	  Experimental	  Plan	  
There are no published studies that interrogate and compare the discrete 
interactomes of the two major CDK11 isoforms, CDK11p110 and 
CDK110p58. Better characterization of these individual interactomes may 
elucidate novel CDK11-associated pathways. Furthermore, no study has 
investigated the CDK11 interactome during mitosis. CDK11p58 regulates 
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mitosis but few interacting proteins have been identified that are specific to 
mitosis. Moreover, although CDK11p110 is established to regulate splicing in 
interphase, the function of this protein in mitosis is uncertain.  
I elected to use three distinct strategies to precipitate CDK11 and its binding 
partners, with the intention of undertaking label-free on-bead mass 
spectrometry on the precipitates. I aimed to undertake these precipitation 
assays in both asynchronous cells and mitotic cells. The first approach was to 
immunoprecipitate endogenous protein using CDK11-targeted antibody. The 
second approach was to undertake affinity purification with GST.CDK11 
recombinant protein. The third approach was to co-immunoprecipitate 
binding partners via tagged CDK11 fusion proteins.  
The precipitation of the two CDK11 isoforms offers particular challenges. 
The principal difficulty arises in differentiating the binding partners of the 
alternate native isoforms. Antibodies targeting the N-Terminus of 
CDK11p110 exist and therefore discrete precipitation of CDK11p110 may be 
possible. However the protein sequence of the CDK11p58 is identical to the 
C-Terminus of the CDK11p110 isoform and it is not possible to generate an 
antibody that will specifically differentiate the p58 isoform. Discrete 
immunoprecipitation of CDK11p58 must therefore be performed with tagged 
CDK11 fusion protein. 
5.2	  Immunoprecipitation	  of	  Endogenous	  CDK11	  	  
The first method I used investigated the CDK11-interactome via immuno-
precipitation of endogenous CDK11 from MDA-MB-231 cell lysates. 
Employing this strategy, there is no disturbance of cellular physiology or 
protein conformation prior to lysis. Furthermore, there is no requirement to 
introduce recombinant protein expression vectors.  
5.2.1	  Immunoprecipitation	  with	  Commercial	  CDK11	  Antibodies	  
Proprietary antibodies reported to immunoprecipitate CDK11 were 
identified and 5 distinct antibodies purchased. I undertook 
immunoprecitiation using asynchronous MDA-MB-231 cell lysate. 
Antibodies were used at the concentration indicated in the material data 
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sheet. Experimental conditions were optimized with a trial of alternate 
conditions varying lysis buffer, wash buffer and wash frequency to enhance 
CDK11 immunoprecitation. No marked variation in precipitation of 
CDK11p110 or Cyclin L2 was observed between conditions and I elected to 
use NP40 0.5% as both lysis and wash buffer (data not shown). This provided 
a compromise between the high stringency RIPA buffer and less stringent 
detergents. The choice of lysis buffer may impact significantly on co-
immunoprecipitate and represents a balance between higher stringency 
buffers that enhance specificity but reduce sensitivity, and lower stringency 
buffers with the opposite effect. 
I was unable to demonstrate immunoprecipitation of CDK11p58. Several 
factors contributed to this. First, levels of the p58 isoform in the lysate were 
low. Second, only one mouse antibody to CDK11 was commercially available 
and I found staining with this unreliable; the rabbit Abcam antibody used to 
probe Western blots could not be used due to the position of CDK11p58 
relative to the heavy chain of rabbit antibody used in immunoprecipitation. 
To overcome this, I used CDK11-targeted biotin-conjugated rabbit antibody 
with a streptavidin-HRP conjugate for the secondary step in detection. 
Again, this identified CDK11p110 but not CDK11p58, although staining was 
not optimal (data not shown).   
Using NP40 0.5%, asynchronous MDA-MB-231 cells were lysed and the 
lysate quantified. Immunoprecipitation was undertaken using the panel of 
CDK11 antibodies. This demonstrated precipitation of CDK11p110 and its 
major cyclin partner Cyclin L2 with 3 of the 5 antibodies: Abcam, Bethyl N-
Terminus and Bethyl C-Terminus [Fig 5.1]. Under the experimental 
conditions, the Bethyl C-Terminus antibody was the most efficient at 
precipitating CDK11 and Cyclin L2 and this antibody was chosen for further 
experiments.   
Next, I examined whether other established CDK11 interactors could be 
detected following immunoprecipitation. Antibodies to CDK11 interactors 
HSP90 and 14-3-3ε were obtained and the precipitate probed on Western blot 
following SDS-PAGE resolution. This demonstrated co-precipitation of both 
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stained" with" CDK11" and" Cyclin" L2" anAbodies;" CDK11p58" was" not" visualised" due" to"
proximity" to" the" precipitant" heavy" chain" anAbody." This" demonstrates" precipitaAon" of"
CDK11"with"Abcam,"Bethyl"C"Term."and"Bethyl"N"Term."Cyclin"L2"is"demonstrated"to"co&
precipitate." Western" blot" 6.1B" demonstrates" co&precipitaAon" of" known" CDK11"
interactors"HSP90"and"14&3&3"E"with"CDK11,"using"Bethyl"C"Term"anAbody;" there" is"no"
precipitaAon" using" control" Rabbit" IgG" anAbody." Table" 6.1C! shows" putaAve" epitopes"
within" the" N" Terminus" and" C" Terminus" of" CDK11" derived" by" Eurogentec." These"were"
curated"for"homologous"sequences"and"a"single"pepAde"(marked"with"+)"within"each"the"
N"Terminus"and"C"Terminus"used"for"custom"anAbody"preparaAon."Custom"anAbody"was"
interrogated"on" lysates" obtained" from"MDA&MB&231" cells" subject" to" siNTC"or" siCDK11"
RNAi."Western"blot"6.1D"demonstrates"the"idenAficaAon"of"CDK11"(marked"with"arrow)"
using"both"anAbodies"but" there"are"a" significant"number"of"non&specific"bands"on" the"
blot."This"precludes"their"use"in"the"planned"IP"assay.""
"
Figure' 5.1' Immunoprecipitation' of' endogenous' CDK11." MDA&MB&231" cells" were" lysed"
with" NP40" buffer;" the" lysate" was" quantified" and" subject" to" immunoprecipitation" with" a"
panel" of" commercial" CDK11"antibodies" followed"by"Protein"A" conjugated"agarose"beads."
The" precipitate"was"washed" and" resolved" utilizing" SDS&PAGE" gel."Western" blot"5.1A%was"
probed" with" CDK11" and" Cyclin" L2" antibodies;" CDK11p58" was" not" visualised" due" to"
proximity" to" the" precipitant" heavy" chain" antibody." This" demonstrates" precipitation" of"
CDK11" with" Abcam," Bethyl" C" Term" and" Bethyl" N" Term" antibodies." Cyclin" L2" is"
demonstrated" to" co&"precipitate." " " Western" blot" 5.1B% demonstrates" co&precipitation" of"
established" CDK11" interactors" HSP90" and" 14&3&3E" with" CDK11" using" Bethyl" C" Term"
antibody;" there" is" no" precipitation" using" control" Rabbit" IgG" antibody." Table" 5.1C% shows"
putative"epitopes"within"the"N"Terminus"and"C"Terminus"of"CDK11"derived"by"Eurogentec."
These"were"curated"for"homologous"sequences"and"a"single"peptide"(marked"with"+)"within"
both" the" N" Terminus" and" C" Terminus" used" for" custom" antibody" preparation." Custom"
antibody"was"used"to"interrogated"lysates"obtained"from"MDA&MB&231"cells"subject"to"siNTC"




Therefore I had demonstrated immunoprecipitation of endogenous CDK11 
with co-precipitation of its major cyclin partner and selected established 
interactors. However, to undertake mass spectrometry, it was critical to 
demonstrate both the efficiency and specificity of CDK11 co-
immunoprecipitation over control. I repeated co-immunoprecititation and 
resolved the precipitate using SDS-PAGE. The polyacrylamide gel was then 
subject to silver staining. This demonstrated two obstacles to further analysis 
by mass spectrometry. The first was the inability to discern a discrete band 
representative of CDK11p110 above background on silver stain. The second 
was the high background in the control precipitate.  
Despite optimization of conditions, the efficiency of immunoprecipitation of 
CDK11 remained relatively low. To illustrate this the input on the western 
blots in Fig 5.1A represents approximately 2% of the lysate used in each 
precipitation assay. This may be due to poor accessibility of the epitope 
under these experimental conditions.  
The inability to distinguish CDK11 on silver stain indicated that the result of 
mass spectrometric analysis of the immunoprecipitate would likely have 
been invalid. However, although I was unable to demonstrate the specificity 
necessary to enable label-free on-bead mass spectrometry, I was able to 
optimize endogenous CDK11 immunoprecipitation strategies.  
5.2.2	  Novel	  CDK11	  Antibodies	  
Having demonstrated the efficiency of CDK11 immunoprecipitation using 
proprietary antibodies was not sufficient to allow analysis by mass 
spectrometry, I decided to generate novel CDK11 antibodies in an attempt to 
overcome this obstacle. Due to time constraints and experience, this work 
was undertaken in partnership with biotechnology firm, Eurogentec, an 
approach used successfully within our laboratory. I chose to derive two 
antibodies, one targeting an epitope within the N-Terminus of CDK11p110 
and a second targeting a C-Terminal epitope. The aim was to allow discrete 
precipitation of CDK11p110 via the N-Terminus derived antibody. 
The design requirements and protein sequence of CDK11 were 
communicated to Eurogentec. A list of suitable peptide epitopes was 
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determined using proprietary models. To lessen off-target binding, I curated 
peptides from this list to exclude those containing non-related homologous 
sequences, using NCBI peptide blast. An N-Terminus sequence and a C-
Terminus sequence were identified that shared the least homology to 
alternate peptides and these were chosen for antibody derivation [Fig. 5.1]. 
Following peptide synthesis, antibodies were derived in rabbit using a rapid 
28-day four-stage inoculation protocol. Serum was obtained and the 
polyclonal antibody purified prior to delivery.  
The performance of these two antibodies was assessed using MDA-MB-231 
lysates, with or without siRNA CDK11 knockdown. This demonstrated that 
both antibodies had the capacity to detect CDK11 on Western Blot but with 
significant non-specific staining despite the use of various blocking strategies 
[Fig 5.1]. This precluded the reliable use of the antibody in 
immunoprecipitation experiments. The sites of the antibody epitopes was 
similar to that described for other antibodies derived against CDK11, with 
the short epitope sequence potentially contributing to poor specificity.  
In this work, I was unable to achieve adequate specificity or efficiency of 
endogenous CDK11 immunoprecipitation to allow mass spectrometry. On 
account of the on-bead method, specificity is critical as the precipitate is not 
resolved on SDS-PAGE prior to analysis. Immunoprecipitation of native 
CDK11 was always going to prove challenging given the inability to 
adequately differentiate distinct CDK11 isoforms, the low level of 
endogenous CDK11p58 expression and the absence of a knockout control. 
Nonetheless, the advantages of endogenous immunoprecipitation made the 
technique worth pursuing. However, my work did enable optimization of 
endogenous immunoprecipitation. 
5.3	  Affinity	  Purification	  of	  GST	  and	  GST-­‐CDK11	  
CDK11p58 cDNA was inserted into the pGEX 4T3 vector, with the GST-tag 5’ 
of the insertion site. Following sequencing to confirm correct insertion, the 
vector was transformed into the E Coli BL21 cell line. The production of 
GST.CDK11p58 was optimized through adjustments to induction conditions. 
CDK11p110 cDNA was also successfully inserted into the pGEX 4T3 vector 
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but its expression could not be induced despite alterations to induction 
temperature and IPTG concentration.  Potentially the recombinant protein 
was too large for synthesis using this system, based on the recommended 
maximum construct length, and full-length GST.CDK11p110 fusion protein 
could not be generated. Work proceeded with the GST.CDK11p58 protein 
alone [Fig. 5.2]. GST and GST.CDK11p58 were conjugated to the agarose 
bead matrix through glutathione.  
Asynchronous MDA-MB-231 cells and MDA-MB-231 cells synchronised in 
mitosis by nocodazole block were lysed and the lysate quantified. Prior to 
incubation with lysates, the agarose-bound GST proteins were quantified to 
confirm a similar level of both GST and GST.CDK11p58 protein was added 
to the lysate. Lysates were incubated with unconjugated agarose beads prior 
to the assay as a pre-clearing strategy to reduce subsequent non-specific 
binding. The agarose beads conjugated to the GST proteins were incubated 
with lysates then washed and frozen at -80oC. The experiment was repeated 
in triplicate to improve accuracy of mass spectrometric analysis. The 
resultant affinity matrix agarose beads were sent for on-bead digestion and 
mass spectrometry at University College Dublin, the institution that devised 
the label-free on-bead protocol adopted.   
Proteins identified within each condition were quantified using label-free 
methods and the average of these quantifications used to generate a list of 
proteins enriched in the GST.CDK11p58 affinity purifications over GST alone 
for both asynchronous and mitotic lysate. Significant enrichment was 
determined on the ratio of averages and significance testing, with proteins 
found to be both enriched 2-fold (or greater) and above the threshold of 
significance (t-test p<0.05) considered significant. This method to determine 
significant enrichment has been reported by the collaborating institution 
[265].  
5.3.1	  Mass	  Spectrometry	  Results	  
In total 41 proteins were significantly enriched in GST.CDK11p58 affinity 
purifications, with 35 from the mitotic lysate and 22 from the asynchronous 































































the" GST" vector" pGEX4T3." The" vectors" were" sequenced" to" confirm" fidelity" and"
transformed" into" BL21" bacterial" cells." ProducKon" of" the" GST.CDK11p58" and"
GST.CDK11p110" fusion" proteins" was" induced" with" the" addiKon" of" IPTG." Bacterial" cells"
were" lysed"and"protein"purified"with"conjugaKon"to"GSHPAgarose"beads."6.2A" shows"a"
TGX" StainPfree" Gel" of" purified" GST" proteins;" CDK11p110" could" not" be" synthesised"
correctly."In"addiKon"6.2A"delineates"the"protocol"for"affinity"purificaKon"of"GST.CDK11"
from"MDAPMBP231"lysates;"samples"were"subsequently"sent"for"on"bead"digesKon"and"
mass" spectrometry." Subsequent" to" labelPfree" quanKficaKon," proteins" found" to" be"
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reciprocal proteins. Importantly, the mass spectrometric analysis revealed 
that CDK11 represented the most enriched protein present in both the 
mitotic and asynchronous GST.CDK11p58 affinity purifications. 
The enriched proteins identified by this technique were considered to be 
putative CDK11 interactors. Analysis of these proteins revealed two 
predominant classes within the interactors; these were ribosomal proteins 
and chaperone proteins. Ribosomal proteins comprised 13 (33%) of the 
proteins identified. Apoptosis-related CDK11p46 interacts with ribosomal 
protein RPS8 but no ribosomal interaction has been identified with the 
longer isoforms [246]. However, ribosomal proteins are frequently reported 
to contaminate purification assays [261, 266].  
The second class identified was cellular chaperone proteins, with 5 (13%) 
proteins enriched. HSP70, HSP90 and CDC37 proteins are established 
binding partners of CDK11 but of these only a different member of the 
HSP70 family was identified in this assay. Furthermore, although CDK11 
binds chaperone proteins, these proteins commonly bind mis-folded 
proteins. The production of the GST.CDK11p58 in bacteria for this assay may 
result in aberrant conformation and may explain the frequency of this class 
of proteins in the results [266].  
The list of 40 putative interacting proteins was compared to the 114 
established CDK11 interactors. No established CDK11 binding partner was 
identified in this assay. Obviously this raised concerns as to the validity of 
the affinity purification strategy. However, there are caveats that may 
explain the absence of established interactors. First, few studies have 
exclusively examined CDK11p58 binding partners and those that have 
primarily used the yeast two-hybrid system [63, 91]. Correlation between the 
results of different protein-protein interaction assays is often poor and this 
may be particularly relevant with use of the yeast two-hybrid system [258, 
267]. No study has interrogated CDK11p58 interactors exclusively in mitotic 
cells as undertaken here with mitotic synchronization.  
5.3.2	  Validating	  Putative	  CDK11	  Interactors	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To validate this list of putative interactors, interactors were curated and 
proteins of interest identified. Although interaction with either ribosomal or 
chaperone proteins may be genuine, due to the caveats discussed above, I 
considered it appropriate to correlate these results with those of the co-
immunoprecipitation before pursuing these putative interactors. Initially, 
three other proteins were chosen for validation due to aspects of their 
biology that align with established CDK11 functions; these were RAN, KIF14 
and CSK.  
5.3.2.1	  Identifying	  Interactors	  for	  Validation	  
CDK11 is a RAN-GTP dependent microtubule stabilizer in mitosis but no 
direct interaction between CDK11 and RAN has been demonstrated [84]. 
RAN is integral in this role to microtubule dynamics at mitosis [84]. CDK11 
interacts with the RAN Binding Protein 9 but it was the apoptotic p46 
isoform, not the larger isoforms, for which this was established [108]. 
Therefore, the identification of RAN in this screen was of interest.  
KIF14 is a member of the Kinesin-like family. The kinesin superfamily of 
microtubule-associated motors plays important roles in intracellular 
transport and cell division [268]. KIF14 functions during mitosis, localizing to 
the spindle body at anaphase and is believed to mediate abscission and 
cytokinesis [269, 270]. CDK11 also plays a critical role in these processes [144, 
271]. 
 C-terminal Src Kinase (CSK) regulates members of the Src family kinases 
through phosphorylation of their C-terminal domain [272]. It phosphorylates 
Src at Tyrosine 527, resulting in suppression of Src activity [272]. CSK 
contains both an SH2 and SH3 domain and as identified in Chapter 4 Src SH3 
was able to precipitate CDK11p58. Src regulates cell adhesion and motility 
but is also reported to mediate mitotic pathways [273-275].  
5.3.2.2	  Repeating	  Affinity	  Purification	  to	  Identify	  CSK,	  RAN,	  KIF14	  	  
To confirm the validity of the mass spectrometry results, affinity purification 
with GST and GST.CDK11p58 was repeated and the precipitate probed on 
Western blot following SDS-PAGE resolution. I was able to demonstrate 
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affinity purification of CSK with GST-CDK11p58 [Fig. 5.3]. However, RAN 
and KIF14 could not be detected following affinity purification with 
GST.CDK11p58. The reasons for this remain unclear as both proteins were 
significantly enriched in the GST-CDK11p58 precipitate on mass 
spectrometry, representing enrichment in three biological replicate 
experiments. Following receipt of the mass spectrometry results, the 
GST.CDK11p58 fusion protein was resynthesized in E. Coli BL21 cells using 
the same conditions as previously but it is possible the conformation of the 
protein was altered, which may explain the failure to bind.  
Despite the inability to replicate the mass spectrometry results for KIF14 and 
RAN, I decided to investigate all three putative interactors further prior to 
classifying any as false positives. I investigated for evidence of interaction 
using co-immunoprecipitation, protein localization with 
immunofluorescence and protein expression following CDK11 knockdown.  
5.3.2.3	  Immunoprecipitation	  of	  CSK,	  RAN,	  KIF14	  and	  CDK11	  
Asynchronous MDA-MB-231 or synchronized mitotic MDA-MB-231 cells 
were lysed and lysate quantified. Immunoprecipitation from both 
asynchronous and mitotic lysate was performed using antibodies targeted to 
KIF14, CSK and RAN. No co-immunoprecipitation of endogenous 
CDK11p58 or CDK11p110 was detected with either KIF14 or CSK precipitate 
in either asynchronous or mitotic conditions [Fig. 5.3]. I was unable to obtain 
satisfactory immunoprecipitation of RAN to probe interactors. Furthermore, 
I was unable to detect KIF14, RAN or CSK following the reverse 
immunoprecipitation of endogenous CDK11 or tagged CDK11 fusion 
protein. These putative CDK11 interactors were identified using CDK11p58 
and the endogenous levels of this isoform were low even in the synchronized 
mitotic cells. However, immunoprecipitation of CDK11p58 fusion protein, 
expressed at supra-physiological levels, did not identify any interaction with 
these proteins. Therefore on co-immunoprecipitation, I could not 
demonstrate that these interactions were genuine. This did not exclude any 
interaction between the proteins as any interaction may occur at low 
frequency or in a highly-regulated spatiotemporal manner, which was not 































































Figure' 6.3' GST.CDK11p58' Affinity' Purifica>on." Agarose" beads" conjugated" to" GST" or"
GST.CDK11p58" were" incubated" with" MDA?MB?231" lysates" for" 1" hour." Beads" were"
subsequently" washed" twice" with" both" RIPA" and" PBS" sequenJally," as" per" the" affinity"
purificaJon" protocol" in" Fig$ 6.2A." Sample" buffer" was" added" to" the" beads" and" the"
precipitate" resolved" with" SDS?PAGE" and" Western" blot." Western" blot" 6.3A% confirms"
purificaJon"of"CSK"with"GST.CDK11p58"from"asynchronous"MDA?MB?231"lysates"but"fails"
to" demonstrate" pull?down" of" KIF14" or" RAN." Western" blot" 6.3B" demonstrates" that"
GST.CDK11p58"does"not"pull?down"other" Src" SH3"domain" containing"proteins," including"
Src," Yes" and" Fyn." ImmunoprecipitaJon" of" KIF14" from" mitoJc" (6.3C)% or" asynchronous"
(6.3D)%MDA?MB?231" lysates"fails"to"demonstrate"co?precipitaJon"of"either"CDK11p58"or"
CDK11p110." Similarly," immunoprecipitaJon" of" CSK" from"mitoJc" (6.3E)%or" asynchronous"
(6.3F)%MDA?MB?231"lysates"also"fails"to"show"co?precipitaJon"of"CDK11"isoforms."Blots"
were"probed"with"CSK"murine"anJbody"and"CDK11"anJbody"conjugated"to"bioJn"with"





























































Figure' 6.3' GST.CDK11p58' Affinity' Purifica>on." Agarose" beads" conjugated" to" GST" or"
GST.CDK11p58" were" incubated" with" MDA?MB?231" lysates" for" 1" hour." Beads" were"
subsequently" washed" twice" with" both" RIPA" and" PBS" sequenJally," as" per" the" affinity"
purificaJon" protocol" in" Fig$ 6.2A." Sample" buffer" was" added" to" the" beads" and" the"
precipitate" resolved" with" SDS?PAGE" and" Western" blot." Western" blot" 6.3A% confirms"
purificaJon"of"CSK"with"GST.CDK11p58"from"asynchronous"MDA?MB?231"lysates"but"fails"
to" demonstrate" pull?down" of" KIF14" or" RAN." Western" blot" 6.3B" demonstrates" that"
GST.CDK11p58"does"not"pull?down"other" Src" SH3"domain" containing"proteins," including"
Src," Yes" and" Fyn." ImmunoprecipitaJon" of" KIF14" from" mitoJc" (6.3C)% or" asynchronous"
(6.3D)%MDA?MB?231" lysates"fails"to"demonstrate"co?precipitaJon"of"either"CDK11p58"or"
CDK11p110." Similarly," i munoprecipitaJon" of" CSK" from"mitoJc" (6.3E)%or" asynchronous"
(6.3F)%MDA?MB?231"lysates"also"fails"to"show"co?precipitaJon"of"CDK11"isoforms."Blots"
were"probed"with"CSK"murine"anJbody"and"CDK11"anJbody"conjugated"to"bioJn"with"





























































Figure' 6.3' GST.CDK11p58' Affinity' Purifica>on." Agarose" beads" conjugated" to" GST" or"
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to" demonstrate" pull?down" of" KIF14" or" RAN." Western" blot" 6.3B" demonstrates" that"
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Figure# 5.3# GST.CDK11p58# Affinity# Purification." Agarose" beads" conjugated" to" GST" or"
GST.CDK11p58" were" incubated" with" MDA?MB?231" lysates" for" " h ur." Beads" were"





down" other" Src" SH3" domain" containing" proteins," including" Src," Yes" and" Fyn."
Immunoprecipitation" of" KIF14" from" mitotic" (5.3C)" or" asynchronous" (5.3D)" MDA?MB?231"
lysate" fails" to" demonstrate" co?precipitation" of" either" CDK11p58" or" CDK11p110." Similarly,"
immunoprecipitation"of"CSK"from"mitotic"(5.3E)"or"asynchronous"(5.3F)"MDA?MB?231"lysate"
also" fails" to"show"co?precipitation"of"CDK11" isoforms."Blots"were"probed"with"CSK"murine"
antibody" and" CDK11" antibody" conjugated" to" biotin" with" secondary" streptavidin" HRP" to"




5.3.2.4	  Interrogating	  CSK	  Affinity	  Purification	  	  	  
Interesting, on the Western blot following GST.CDK11p58 pull-down, the 
CSK species in the lysate appeared to migrate differently to the species 
precipitated. The slower migration on SDS-PAGE of the precipitated species 
was replicated in further pull-down assays. The reason for this was unclear 
but may have represented precipitation of the protein following post-
translational modification. I probed for CSK-Homology Kinase (CHK) to 
confirm this species did not represent CHK, as cross-reaction of CSK 
antibody to CHK is reported, but no CHK was detected in the precipitate 
(data not shown). Western blot following immunoprecipitation of CSK 
demonstrated two CSK species in the lysate, the smaller species of which was 
precipitated. This finding may explain why immunoprecipitation of CSK did 
not precipitate CDK11, as GST.CDK11p58 may have affinity purified the 
larger species. However, neither species was identified following 
immunoprecipitation of the CDK11 fusion protein.  
In addition, CDK11p58 is reported to contain an SH3 binding domain and 
my work in Chapter 4 confirmed precipitation of CDK11p58 with the Src 
SH3 domain. CSK contains a similar SH3 domain. Given the ability of 
GST.CDK11p58 to affinity purify CSK, I examined whether this was specific 
to CSK or whether CDK11p58 could also precipitation SH3 domain-
containing Src family members. The ubiquitously expressed members of the 
Src family kinases, Src, Yes and Fyn, contain SH3 domains but none of these 
proteins were affinity purified with GST.CDK11p58 [Fig. 5.3].  
5.3.2.5	  Localisation	  of	  CSK,	  KIF14	  and	  RAN	  	  
MDA-MB-231 cells, plated on glass coverslips, were transfected with CDK11 
targeted or non-targeted siRNA. At 48hrs, cells were fixed and 
permeabilised. Immunoflourescence demonstrated CSK and KIF14 
predominantly localized to the cytoplasm at interphase, which has been 
previously described [270, 276]. Staining with RAN antibody was poor, with 
little signal above background. At mitosis, CSK and KIF14 localised to the 
nucleoplasm with no localization to the mitotic spindle or other structures. 
However, at anaphase KIF14 clearly localized to the midbody consistent with 
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its role in cytokinesis and abscission. No similar localization of CSK was 
observed.  
Although myc.CDK11p58 fusion protein localised to both the cytoplasm and 
nucleus during interphase, native CDK11 was localised solely in the nucleus 
throughout interphase, as demonstrated by immunofluorescence and cell 
fractionation. At mitosis, CDK11 was distributed throughout the 
nucleoplasm. I was unable to identify localization of CDK11 to the 
centrosome, mitotic spindle or midbody. There was no evidence that it may 
co-localise to the mid-body with KIF14.  
No marked alteration in CSK localization was observed after CDK11 
depletion, indicating that any interaction did not regulate protein 
localization [Fig 5.4]. Following CDK11 knockdown, KIF14 continued to 
localize to the midbody; in certain cells, the signal appeared more diffuse but 
this finding was inconsistent [Fig 5.4]. Furthermore, interpretation was 
complicated by the markedly abnormal morphology of the midbody/spindle 
complex following CDK11 depletion.  
5.3.2.6	  Expression	  of	  CSK,	  KIF14	  and	  RAN	  after	  CDK11	  Depletion	  	  
Next, I examined for alteration in KIF14, CSK and RAN expression, after 
CDK11 knockdown. In addition, I assessed Src expression and Src activation, 
using phosphorylated Src (Y419) and phosphorylated Src (Y527) antibodies. 
The rationale for performing this was due to the role of CSK in regulating Src 
activation. The effects of CDK11 depletion may differ through the cell cycle 
and therefore MDA-MB-231 cells were synchronized at G1/S via double 
thymidine block. At 48 hours post transfection with CDK11 targeted or non-
target siRNA, MDA-MB-231 cells were released from thymidine block. Cells 
were lysed at specified time points following release. This enabled 
interrogation of protein levels through the cell cycle. No significant alteration 
in level of RAN or KIF14 was observed after CDK11 depletion; an elevation 
in CSK was identified at 6 hours following release but was not consistent in 
repeat experiments [Fig 5.5]. Interestingly, although no alteration in Src was 
found, there was a marked increase in phosphorylated Src (Y419) during S-














were! fixed! with! 10%! PFA! and! permeabilised! with! Triton%X.! Cells! were! subsequently!
stained!with!a!combinaJon!of!anJbodies!targeted!to!CSK,!α!Tubulin!and!KIF14!with!DAPI!
nuclear!stain.!6.4A!shows!representaJve!images!of!CSK!localizaJon!in!cells!at!interphase!
and! metaphase.! CSK! localizes! to! both! the! cytoplasm! and! nucleus! at! interphase! and!
throughout!the!!nucleoplasm!at!mitosis.!6.4B!shows!localizaJon!of!KIF14!to!the!midbody!






Figure' 5.4' CSK' and' KIF14' Localisation.' MDA$MB$231) cells,) cultured) on) glass)
coverslips,) were) fixed) with) 10%) PFA) and) permeabilised) with) Triton$X.) Cells) were)
subsequently) stained)with)a) combination)of)antibodies) targeted) to)CSK,)α)Tubulin)
a d) KIF14) with) DAPI) nuclear) stain.) 5.4A% shows) representative) images) of) CSK)
localization) in) cells) at) int rphase) and) metaphase.) CSK) localizes) to) both) the)
cytoplasm) and) nucleus) t) interpha e) and) thr ughout) the) ucleoplasm)at) itosis.)
5.4B%sh ws)localization) f)KIF14)to)the)midbody)at)cytokinesis.)Throughout)earlier)
stages) of) mitosis) it) localizes) throughout) the) nucleoplasm) (not) shown);) no)
localization)to)the)centrosome) is)seen.)5.4B%demonstrates) that)KIF14)continues)to)
localize) to) the) midbody) following) CDK11) knockdown.) Aberrant) cytokinesis) is)
recognized) following) CDK11) dysregulation.) It) is) however) noted) that) fewer) cells)
show)normal)midbody) formation) following)CDK11)knockdown;) this)may) therefore)
represent)cells)with)lesser)CDK11)knockdown.)
)
change in phosphorylated Src (Y527) was observed, which is the site of CSK 
phosphorylation. However, our laboratory has found inconsistencies in 
commercial antibody staining of this phosphorylated residue and no positive 
control was present to confirm the validity. These alterations in 
phosphorylated Src (Y419) were not a consequence of altered cell cycle phase 
as demonstrated by propidium iodide and BrdU staining performed in 
parallel [Fig 5.5]. BrdU demonstrated no alteration in the duration of S-
phase. Obviously further experiments are required to confirm the results, 
assess its relevance and investigate the mechanism of regulation.  
5.3.2.7	  Src	  Activation	  in	  S-­‐Phase	  following	  CDK11	  Depletion	  
Although CSK may regulate this Src activation, no consistent alteration in 
CSK or phosphorylated Src (Y527) was observed after CDK11 knockdown. 
Furthermore, no interaction between CDK11 and CSK has been 
demonstrated in vivo and therefore Src activation may occur via other 
mechanisms. Src activation is reported to regulate G1/S progression via 
phosphorylation of p27KIP [277]. Phosphorylation of p27KIP causes the loss 
of repression of the CDK2, with subsequent CDK2/Cyclin E mediated 
degradation of p27KIP [277]. In addition, Src may regulate aspects of mitosis, 
including promotion of satisfactory spindle orientation and abscission [275, 
278]. The significance of increased Src activation after CDK11 depletion was 
not clear; this occurred at 6 hours and 9 hours following release when cells 
were progressing through S-phase and entering mitosis. My work 
demonstrated that Src activation following CDK11 knockdown did not effect 
cell cycle progression. Further work is therefore required to investigate this 
observation.  
5.3.3	  Conclusion	  GST	  Affinity	  Purification	  Experiment	  
In summary, the validity of the results of GST affinity purification is 
questionable given the inability both to demonstrate established interactors 
and to confirm putative interactions in vivo. Moreover, only one of the three 
proteins was validated on repeat affinity purification. The alteration in Src 
activation after CDK11 depletion was interesting and further work is 
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Figure' 6.5' Cell' cycle,' CDK11'Knockdown'and'Puta;ve' Interactors.!MDA%MB%231! cells!
were!subject!to!transfec8on!with!siCDK11!or!siNTC!RNAi!prior!to!synchronisa8on!at!G1/S!
with! double! thymidine! block.! On! release! from! block,! cells! were! assayed! at!
predetermined!8me!points;!cells!were!pulsed!with!BrdU!at!3!hours!following!release!to!
enable!tracking!of!cells!through!S%Phase.!At!each!8me!point,!cells!were!either!fixed!with!
methanol! for! FACS! cell! cycle! analysis! or! lysed! for! protein! quan8fica8on.! This! was!
undertaken! to! interrogate! for! levels! of! puta8ve! interactors! or! altera8on! to! Src! /! Src!
ac8va8on,! a! target! of! CSK.! This! does! not! demonstrate! altera8on! in! levels! of! RAN! or!
KIF14.! A! small! increase! in! CSK! levels! was! observed! at! 6! hours! following! CDK11!
knockdown.!No! altera8on! in! total! Src!was!observed!but! a! pronounced! increase! in! Src!
[Try416]! phosphoryla8on! was! demonstrated! following! CDK11! knockdown.! This!
appeared!maximal! during! S%Phase.! There!was! no! reciprocal! altera8on! in! Src! [Try! 527]!
phosphoryla8on.! ! Cell! cycle! analysis! determined! this! was! not! clearly! a[ributable! to!
altered! cell! cycle! phase;! no! gross! altera8on! in! the! dura8on! of! S%Phase!was! observed!
(data!not!shown).!This!blot!is!representa8ve!of!two!replicate!experiments;!further!work!
is!required!to!confirm!findings.!!
p"Src&[Tyr419]&" &[ 9 &
Figure''5.5''Cell''cycle,''CDK11''Knockdown''and''Putative''Interactors.''MDA$MB$231)cells)
were) subject) to) transfection) with) siCDK11) or) siNTC) RNAi) prior) to) synchronisation) at)
G1/S) with) double) thymidine) block.) On) release) from) block,) cells) were) assayed) at)
predetermined)time)points;)cells)were)pulsed)with)BrdU)at)3)hours)following)release)to)
enable)tracking)of)cells)through)S$Phase.)At)each)time)point,)cells)were)either)fixed)with)
ethanol) for) FACS) cell) cycle) analysis) or) lysed) for) protein) quantification.) This) was)
undertaken) to) interrogate) for) levels) of) putative) interactors) or) alteration) to) Src) /) Src)
activation,) a) target) of) CSK.) This) does) not) demonstrate) alteration) in) levels) of) RAN) or)
KIF14.) A) small) increase) in) CSK) levels) was) observed) at) 6) hours) following) CDK11)
knockdown.)No)alteration) in) total) Src)was)observed)but)a)pronounced) increase) in) Src)
[Try419]) phosphorylation) was) demonstrated) following) CDK11) knockdown.) This)
appeared) axi al) during) S$Phase.) There)was)no) reciprocal) alteration) in) Src) [Try) 527])
phosphorylation.)Cell)cycle)analysis)determined)this)was)not)attributable)to)altered)cell)
cycle)phase;)no)gross)alteration)in)the)duration)of)S$Phase)was)observed)(data)not)shown).)
This) blot) is) representative) of) two) replicate) experiments;) further) work) is) required) to)
confirm)findings.)
!
5.4	  Immunoprecipitation	  of	  recombinant	  tagged	  CDK11	  
Next, I aimed to use tagged CDK11 fusion proteins to co-immunoprecipitate 
CDK11 interacting proteins. As the construction of such tagged recombinant 
proteins may compromise both the functionality and binding of the protein, 
it was important to confirm that any fusion protein localized and functioned 
in a similar manner to endogenous protein. 
5.4.1	  Immunoprecipitation	  of	  myc.CDK11	  
The myc.CDK11 fusion proteins had been synthesized and validated in 
earlier work (Chapter 3), with the ability to rescue CDK11 knockdown. These 
recombinant proteins were therefore used in initial experiments. I undertook 
immunoprecipitation in the stable expressing MDA-MB-231. The use of the 
stable expressing cells has both advantages and disadvantages compared to 
transient construct expression. The stable cell lines express CDK11 at a level 
tolerable to cells. Cells enduring transient transfection potentially suffer not 
only significant stress as a result of the transfection but the high level of 
protein expression may alter protein interactions and have other deleterious 
effects.  Paradoxically, the potential disadvantage of stable expressing cells is 
that high levels of protein expression may not to be achieved, reducing the 
likelihood of identifying novel low-level interactors.  
MDA-MB-231 cells expressing myc.CDK11p58, myc.CDK11p110 or empty 
vector were lysed with NP40 buffer and the lysate quantified. To optimize 
precipitation, immunoprecipitation of the myc.CDK11 fusion proteins was 
performed with two distinct myc-targeted antibodies, conjugated to agarose 
or magnetic beads. I demonstrated successful immunoprecipitation of the 
CDK11 fusion proteins using this strategy [Fig. 5.6]. However, despite the 
successfully precipitation of the myc.CDK11 fusion proteins, significant 
background signal was apparent. This once again prevented the 
identification of bands enriched in the CDK11 precipitates on silver stain 
[Fig. 5.6]. Others both within the laboratory and externally have reported 
similar difficulties with the myc-tag [279], often attributed to precipitation of 









































Figure' 6.6' Myc' Tag' Immunoprecipita5on' CDK11.' MDA$MB$231) cell) lines,) stably)
expressing) myc) tagged) CDK11p110) or) CDK11p58,) were) lysed) with) NP40) buffer.) Lysates)
were)quanKfied)and)between)1mg)and)5mg)protein)aliquoted)dependent)on)assay.)AnK$
myc) tag)anKbodies)conjugated)to)agarose)or)magneKc)beads)were)used)to)precipitate)
the)myc.CDK11) chimeric) proteins.) Beads)were)washed)with) NP40) buffer,) prior) to) the)
addiKon)of)sample)buffer)and)resoluKon)with)SDS$PAGE)and)Western)blot.)Western)blot)
6.6A) shows) the) successful) precipitaKon) of) CDK11) with) agarose) conjugated) anK$myc)
anKbody) 4A6;) CDK11p58) appears) most) efficiently) precipitated.) ) Western) blot) 6.6B)
demonstrates) immunoprecipitaKon) of) both) CDK11) isoforms) with) anK$myc) anKbody)
9B11) conjugated) to) magneKc) beads.) 6.6C) demonstrates) silver) stain) of) SDS$PAGE) gel)










the)myc.CDK11) chimeric) proteins.) Beads)were)washed)with)NP40) buffer,) prior) to) the)
addition)of)sample)buffer)and)resolution)with)SDS$PAGE)and)Western)blot.)Western)blot)
5.6A% shows) the) successful) precipitation) of) CDK11) with) agarose) conjugated) anti$myc)
antibody) 4A6;) CDK11p58) appears) most) efficiently) precipitated.) Western) blot) 5.6B%
demonstrates) immunoprecipitation) of) both) CDK11) isoforms) with) anti$myc) antibody)







had been created. I decided due to both the high background signal and the 
lack of control cell line to generate a novel CDK11 fusion protein. 
5.4.2	  Generating	  Stable	  Cell	  Lines	  Expressing	  GFP.CDK11	  
Numerous tags are available with differing strengths and weaknesses. Small 
tags may be less likely to influence protein function but others within the 
unit had successfully utilized the GFP Trap system. The GFP-tag has limited 
interactions with mammalian proteins and therefore less non-specific or tag 
specific immunoprecipitation [260]. In addition, the GFP-tag enables 
proteomic work to be correlated more easily with co-localisation using 
immunofluorescence.  
CDK11 isoforms, again containing RNAi refractory sequences, were inserted 
in-frame into the EGFP-N vector. The EGFP-CDK11 cassettes were then 
excised and inserted into the pBabe retroviral vector to allow transduction. 
The constructs were sequenced to confirm their fidelity and transduced into 
both the HCT116 and MDA-MB-231 cell lines.   
5.4.2.1	  Confirming	  Localisation	  and	  Function	  of	  GFP.CDK11	  
Following successful transduction of the GFP.CDK11 constructs, I aimed to 
validate these fusion proteins, confirming similar behavior and function of 
the proteins to endogenous CDK11. Localisation of both GFP.CDK11p110 
and GFP.CDK11p58 was similar to that of both endogenous CDK11 and the 
validated myc.CDK11 fusion proteins. GFP.CDK11p110 was demonstrated to 
be primarily nuclear throughout the cell cycle. GFP.CDK11p58 was both 
cytoplasmic and nuclear at interphase, while localized to the nucleoplasm 
through mitosis. This was the case in both HCT116 and MDA-MB-231 cells. 
Although putative nuclear localizing sequences are described in the p58 
isoform, the localization of these in the vicinity of the kinase domain may 
render them functionally irrelevant. In addition, endogenous CDK11p58 is 
primarily mitotic at which time no nuclear envelope exists [23].  
In my experiments, CDK11 was not demonstrated to localize to either the 
mitotic centrosome or the mitotic spindle; this was the case for the myc-tag 
proteins, the GFP-tag proteins and endogenous CDK11, localised with 










































casseEe( was( then( excised( and( cloned( into( the( pBabe( retroviral( vector.( Following(
sequence( verificaLon,( the( constructs(were( transduced( into(MDA:MB:231( and(HCT116(
cell(lines.(LocalisaLon(of(the(fluorescent(fusion(proteins(was(examined(with(microscopy.(
The( distribuLon( of( GFP.CDK11p110( and( GFP.CDK11p58( was( found( to(mirror( that( of( the(
myc:tagged(constructs.(GFP.CDK11p110(was(primarily(nuclear(during(interphase(similar(to(
endogenous( protein;( GFP.CDK11p58( was( both( nuclear( and( cytoplasmic( at( interphase(
(data( not( shown).( 6.7A( demonstrates( similar( localizaLon( of( GFP.CDK11p58( and(
endogenous( CDK11( during( mitosis( to( the( nucleoplasm.( Unlike( other( reports,( no(
localizaLon(to(the(centrosome(or(spindle(was(idenLfied(with(anLbody(or(fusion(protein.(
Western(blot(6.7B( shows( rescue(of( LC3( II( accumulaLon(72(hours( following(siCDK11(or(
siNTC( transfecLon( in(HCT116( cell( lines( expressing( both(GFP.CDK11( constructs( but( not(




Figure' 5.7' Validating' GFP.CDK11' Constructs.' CDK11p58( and( CDK11p110( were(
cloned(into(the(pEGFP:N1(vector(i (f ame,(with(the(removal(of(the(myc:tag.(The(
GPF.CDK11(cassette(was(then(excised(and(cloned(into(the(pBabe(retroviral(vector.(
Following( sequence( verification,( the( constructs(were( transduced( into(MDA:MB:
231( and( HCT116( cell( lines.( Localisation( of( the( fluorescent( fusion( proteins( was(
examined( with( microscopy.( The( distribution( of( GFP.CDK11p110( and(
GFP.CDK11p58( was( found( to( mirror( that( of( the( myc:tagged( constructs.(






transfection( in(HCT116( cell( lines( expressing( both(GFP.CDK11( constructs( but( not(
the(control(cell(line(expressing(GFP(alone.(5.7C%shows(rescue(of(aberrant(nuclear(
morphology(at(72(hours(following(CDK11(knockdown(with(siRNA;(again(this(occurs(
with(both(MDA:MB:231( cell( lines( expressing(GFP.CDK11( constructs(but(not(GFP(
alone.(This(indicates(the(constructs(are(functional.(
!
been reported, these reports are inconsistent as to its precise location [83]. 
One paper observed localization to the centrosome [23], while the other 
demonstrated robust localization to the spindle itself [83]. The inability to 
show localization of CDK11 to the spindle was not unique, as others groups 
have also failed to observe spindle localization [217].  
This work therefore established that the GFP.CDK11 localized in a similar 
manner to endogenous CDK11. However as discussed, although similar 
localization is important, it is also necessary to determine functionality of the 
chimeric proteins.  Therefore, I aimed to confirm the ability of both 
GFP.CDK11 proteins to rescue the phenotypes mediated by CDK11 
depletion. In the MDA-MB-231 cells, both GFP.CDK11p58 and 
GFP.CDK11p110 rescued the marked mitotic phenotype and in HCT116 cells 
the fusion proteins rescued the autophagy phenotype [Fig. 5.7]. This 
demonstrated that both GFP.CDK11 proteins were functional and would 
provide a valid tool for co-immunoprecipitation. 
5.4.3	  GFP-­‐Trap	  Immunoprecipitation	  
Having demonstrated functionality of the GFP proteins, I confirmed the 
successful immunoprecipitation of both GFP.CDK11p58 and 
GFP.CDK11p110 using the GFP-Trap system. In addition, I confirmed the co-
precipitation of regulatory partner Cyclin L1. The decision was made to 
undertake co-immunoprecipitation and mass spectrometry using the 
HCT116 cells. Not only had these cells been used in the mitotic experiments 
but also higher expression of GFP.CDK11p110 was achieved in these cells.  
Both asynchronous and mitotic synchronized HCT116 cells were used for the 
co-immunoprecipitation. Additionally, I decided to undertake precipitation 
on nuclear extracts in the asynchronous HCT116 cells. Published studies 
have used this strategy to enrich for the CDK11p110 [176] and recombinant 
GFP.CDK11p110 was also primarily nuclear, as demonstrated on 
immunofluorescence and on cell fractionation [Fig 5.8]. Furthermore, cell 
fractionation reduced the potential for non-physiological interactions caused 
by GFP.CDK11p58 within the cytoplasm during interphase. During mitosis, 



























GFP.CDK11p110,! GFP.CDK11p58! or! GFP,! were! cultured! without! synchronizaEon! or!
synchronized! in! mitosis.! MitoEc! synchronizaEon! was! achieved! with! the! addiEon! of!
thymidine!to!culture!media!for!16!hours!followed!by!release;!9!hours!following!release!
nocodazole! was! added! to! culture! media! for! 6! hours.! Cells! were! released! from!
nocodazole!block! for!30!minutes!prior! to!sampling.!MitoEc!cells!were! lysed!with!NP40!
buffer;!asynchronous!cells!underwent!nuclear!extracEon!prior!to!addiEon!of!NP40!buffer!
to! the! nuclear! fracEon.! ImmunoprecipitaEon! of! GFP! or! GFP! fusion! protein! was!
undertaken!with!the!GFPRTRAP!agarose!beads.!Western!blot!6.8A!shows!localizaEon!of!
endogenous! CDK11p110! and! GFP.CDK11p110! to! the! nuclear! extract;! GFP.CDK11p58,! as!
determined! with! immunofluorescence,! localizes! to! both! the! nuclear! and! cytoplasmic!
fracEons.!6.8B!shows!the!silver!stain!of!an!SDSRPAGE!gel!comprising!GFP!precipitate!of!
asynchronous! nuclear! lysates! of! the! three!HCT116! cell! lines.! Bands! represenEng!GFP,!
GFP.CDK11p58! and! CDK11p110! are! marked! with! arrows.! Prior! to! mass! spectrometry!
experiments,!further!work!was!undertaken!to!reduce!the!putaEve!contaminaEon!bands!
seen!in!this!gel.!!!
Figure' 5.8' GFP.CDK11' Immunoprecipitation.' HCT116& cell& lines,& with& stable&
expression& of& GFP.CDK11 110,& GFP.CDK11p58& or& GFP,& were& cultured& without&
synchronization&or&synchronized&in&mitosis.&Mitotic&synchronization&was&achieved&
with&the&addition&of&thymidine&to&culture&media&for&16&hours&followed&by&release;&
6& hours& following& release& nocodazole& was& added& to& culture&media& for& 6& hours.&
Cells& were& released& from& nocodazole& block& for& 30& minutes& prior& to& sampling.&
Mitotic&cells&were&lysed&with&NP40&buffer;&asynchronous&cells&underwent&nuclear&
extraction& prior& to& additio & of& NP40& buffer& t & the& nuclear& fraction.&
Immunoprecipitation&of&GFP&or&GFP&fusion&protein&was&undertaken&with&the&GFPP
TRAP& agarose& beads.& Western& blot& 5.8A% s ows& localization& of& endogenous&
CDK11p110& and& GFP.CDK11p110& to& the& nuclear& extract;& GFP.CDK11p58,& as&
determined& with& immunofluorescence,& localizes& to& both& the& nuclear& and&
cytoplasmic&fractions.&5.8B%shows&the&silver&stain&of&a &SDSPPAGE&gel&comprising&





Prior to mass spectrometry, I confirmed that GFP proteins could be detected 
above background on silver stain and that background signal was acceptable 
[Fig. 5.8]. The GFP Trap antibody was used to precipitate either GFP or 
GFP.CDK11 proteins from asynchronous HCT116 nuclear extract lysate or 
mitotic HCT116 whole cell lysate. These lysates were incubated for 1 hour 
with GFP-Trap agarose beads prior to precipitation and washing. 
Supernatant was removed and the agarose beads sent frozen at -80oC for on-
bead digestion and mass spectrometric analysis at the collaborating 
institution. Experiments were repeated in triplicate for mass spectrometry. 
Proteins identified within each precipitate were quantified and significant 
enrichment determined. Once again, significant enrichment was determined 
by average enrichment of two fold or greater and significance of p<0.05.  
Approximately 200 proteins were enriched over GFP in each of the 4 
conditions: GFP.CDK11p110 asynchronous, GFP.CDK11p58 asynchronous, 
GFP.CDK11p110 mitotic and GFP.CDK11p58 mitotic [Tables S2 – S5 
(Appendix)]. Graphs demonstrate the distribution of identified proteins 
plotted with ratio enrichment against significance [Fig 5.9]. This showed a 
skew to the right consistent with greater enrichment in the GFP.CDK11 
precipitates. 
5.4.4	  Mass	  Spectrometry	  Results	  
First, in order to confirm the quality and reproducibility of the experimental 
results, I undertook statistical correlation of the mass spectrometry results of 
each biological and technical replicates. This demonstrates excellent 
correlation between technical replicates [Fig 5.10] and good correlation 
between biological replicates, similar to that reported by other studies [265].  
To further assess the validity of the experimental results, I compared the 
putative interactors identified with established CDK11 interactors. I 
identified 554 unique proteins significantly enriched following co-
immunoprecipitation with mitotic or asynchronous CDK11 isoforms. As 
discussed, in published literature, there are 114 proteins reported to interact 
with human CDK11 or its eukaryote homologues. Of these established 



























































































cells,* with* stable* expression* of* GFP.CDK11p110,* GFP.CDK11p58
*
or* GFP,* were* lysed* as*
described.*5mg*of*protein*was*subjected*to*immunoprecipitation*using*GFPHTRAP*agarose*
beads.* Beads* were* subsequently* washed* and* placed* at* H80
o
C;* samples* were* then*
transferred* on* dry* ice* to* the* collaborating* institute* for* onHbead* digestion* and* mass*
spectrometric* analysis.* Three* biological* replicates* were* obtained* for* each* culture*
condition* (asynchronous* or* mitotic)* for* each* of* the* three* HCT116* cell* lines* (GFP,*
GFP.CDK11p110*and*GFP.CDK11p58).*5.9*plots*the*ratio*(Log2)*of*each*protein*detected*in*
GFP.CDK11*to*GFP*coHimmunoprecipitate;*this*is*based*on*the*mean*protein*quantification*
in* each* condition* across* biological* and* technical* replicates.* * The* ratio* of* enrichment* is*
plotted* against* its* statistical* significance* (HLog10)* [THTest].* The* smaller* graph* for* each*
condition* shows* all* proteins* detected,* while* the* larger* graph* shows* only* proteins* with*
smaller* ratios* of* enrichment,* to* enable* better* visualization.* The* blue* square*marks* the*
proteins*on*the*graph*that*are*considered*to*be*significantly*enriched*(Fold*increase*>2*+*
p<0.05)* in* GFP.CDK11* precipitates.* CDK11p58* Nuc* and* CDK11p110* Nuc* represent* the*
asynchronous* conditions,* while* CDK11p58* Mit* and* CDK11p110* Mit* represent* the*
conditions*synchronized*in*mitosis.*
Importantly, both CDK11 and Cyclin L were significantly enriched in all 
CDK11 precipitates. In addition, other established interactors achieved the 
level of significance but not enrichment to be identified as interactors on this 
assay. Furthermore, numerous proteins identified as interactors on this assay 
were of a similar class to CDK11-interacting proteins or were subunits of 
complexes containing CDK11-interacting proteins. Moreover, although 114 
interactors are reported, many of these interactions were identified with 
other cell lines, other species or other CDK11 isoforms, i.e. CDK11p46 and 
CDK11p60.  Therefore, this experiment identified a substantial number of 
known CDK11 interactors. The high correlation of replicates and the high 
number of established CDK11 interactors identified provide confidence in 
the validity of the results.  
The enriched proteins (putative CDK11 interactors) were analysed using 
DAVID, STRING and KEGG pathway databases. I used these tools to 
determine enrichment of Gene Ontology (GO) terms or KEGG pathways 
among the putative CDK11 interactors from each precipitate. The KEGG 
pathways enriched for each CDK11 precipitate are reported in Table 5.1.  
5.4.4.1	  Mitotic	  GFP.CDK11p58	  Interacting	  Proteins	  
In the mitotic GFP.CDK11p58 precipitate, 210 proteins were significantly 
enriched. Of these putative CDK11 interacting proteins, 122 were unique to 
mitotic CDK11p58 and 88 interactors were identified in other GFP.CDK11 
precipitates. 72 interacting proteins were detected in both the mitotic 
GFP.CDK11p58 and the mitotic GFP.CDK11p110 precipitates. On KEGG 
pathways enrichment analysis, spliceosome-associated proteins were the 
most enriched protein group found to interact with mitotic CDK11p58, with 
26 spliceosome-associated proteins. Comparison with asynchronous 
GFP.CDK11p58 precipitate revealed that spliceosome-associated proteins 
were also significantly enriched among asynchronous CDK11p58 interactors, 
although not to an equal extent with only 7 spliceosome-associated proteins 
identified. The role of CDK11 in splicing is established but this primarily 
relates to CDK11p110. No published study has reported the interaction of 
CDK11p58 with the spliceosome in vivo, although CDK11p58 is reported to 


























































Figure' 6.9' Mass' Spectrometry' Replicates." Asynchronous" or" mito/cally" synchronous"
HCT116"cells,"with"stable"expression"of"GFP.CDK11p110,"GFP.CDK11p58"or"GFP,"were"lysed"
as" described." 5mg" of" protein" was" subjected" to" immunoprecipita/on" using" GFPITRAP"
agarose" beads." Beads" were" subsequently" washed" and" placed" at" I80oC;" samples" were"
then"transferred"on"dry"ice"to"the"collabora/ng"ins/tute"for"onIbead"diges/on"and"mass"
spectrometric" analysis." Three" biological" replicates" were" obtained" for" each" culture"
condi/on" (asynchronous" or" mito/c)" for" each" of" the" three" HCT116" cell" lines" (GFP,"
GFP.CDK11p110" and" GFP.CDK11p58)." 6.9" shows" plots" of" biological" and" technical"
replicates" from"a" single"experimental" condi/on,"asynchronous"HCT116"GFP.CDK11p58;"
similar"results"were"obtain"for"the"other"experimental"condi/ons."These"plot"the"mean"
intensity" measurement" for" each" protein" iden/fied," based" on" integrals" of" composite"
pep/de"ion"intensi/es,"on"logarithmic"axes"for"each"of"the"corresponding"replicates."The"
figure" in" the" top" leQ" of" each" plot" is" the" calculated" Spearman" Correla/on" Coefficient."












culture"condition" (asynchronous"or"mitotic)" for"each"of" the" three"HCT116"cell" lines"
(GFP," GFP.CDK11p110" and" GFP.CDK11p58)." 5.10% shows" plots" of" biological" and"
technical" replicates" from" a" single" experimental" condition," asynchronous" HCT116"
GFP.CDK11p58" (p58" Nuc);" similar" results" were" obtain" for" the" other" experimental"
conditions."These"plot"the"mean"intensity"measurement"for"each"protein"identified,"
based"on"integrals"of"composite"peptide"ion"intensities,"on"logarithmic"axes"for"each"
of" the" corresponding" replicates." The" figure" in" the" top" left" of" each" plot" is" the"



















































the N-Terminal regulatory domain of CDK11p110, which contains the RE 
domain important for spliceosome interaction. However, CDK11p58 did 
interact with both Cyclin L1 and Cyclin L2, which contain RNA-binding RS 
domains that enable binding to splicing proteins. Therefore, the interaction 
of CDK11p58 with splicing proteins may occur through its cyclin partners, 
Cyclin L1 or L2. Alternately, CDK11p58 may form a heterodimer with the 
CDK11p110 isoform and interact indirectly with the spliceosome via the 
longer isoform. However, although homodimerisation of both the CDK11p58 
and CDK11p110 isoforms are described [61] [56], there is no published 
evidence for dimerization between the distinct isoforms. Certainly in my 
work immunoprecipitation of CDK11p58 or CDK11p110 did not precipitate 
the alternate isoform [Fig 5.3].  
GO term and KEGG pathway enrichment analysis revealed the significant 
enrichment of proteins related to mRNA surveillance, RNA transport and 
viral infection within the mitotic CDK11p58 interacting proteins. 
Furthermore, the second most enriched protein group identified among 
mitotic CDK11p58 interactors was the proteasome-related proteins, with 9 
proteins identified. No enrichment of proteasomal proteins was identified in 
other CDK11 precipitates, particularly among asynchronous GFP.CDK11p58 
interactors. Precipitation of GFP.CDK11p58 in asynchronous cells was 
performed on nuclear extracts rather than whole cell lysate but proteasomes 
are recognized to locate to both the nucleus and cytoplasm in interphase. No 
interaction has previously been determined between CDK11 and 
proteasomes, although CDK11p58 is recognized to target certain nuclear 
receptors for proteasomal degradation [2, 65]. The GFP.CDK11p58 fusion 
protein was expressed at supra-physiological levels and the protein excess 
may have been targeted to the proteasome for degradation, explaining these 
interactions. However, proteasome protein enrichment was not 
demonstrated with asynchronous GFP.CDK11p58, which was similarly over-
expressed. Nonetheless, proteasomal degradation plays an integral role in 
mitotic control and the putative interaction between mitotic CDK11p58 and 
proteasomes requires further investigation. In addition, I did not identify 
Cyclin D3 or PAK1 as interacting proteins with mitotic GFP.CDK11p58. I 
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confirmed this finding with further immunoprecipitation and Western blot 
analysis (data not shown). Cyclin D3 and PAK1 are reported to be essential 
for the mitotic function of CDK11p58 [89] but this does not appear to be the 
case in HCT116 cells. This finding indicates other mechanisms/proteins may 
also regulate the mitotic functions of CDK11. 
5.4.4.2	  Asynchronous	  GFP.CDK11p58	  Interacting	  Proteins	  
In the asynchronous nuclear GFP.CDK11p58 precipitate, 155 interacting 
proteins were identified, with 95 proteins occurring in other CDK11 
precipitates and 60 unique to asynchronous CDK11p58. The predominant 
protein networks enriched relate to RNA processing, with spliceosome-
associated proteins again the most significantly represented. The significance 
of CDK11p58 interactions out with mitosis is uncertain, as expression of 
native protein through interphase is low or absent.  
5.4.4.3	  Mitotic	  GFP.CDK11p110	  Interacting	  Proteins	  
In the mitotic GFP.CDK11p110 precipitate, 183 putative interacting proteins 
were found, with 99 proteins unique to mitotic CDK11p110. The protein 
group demonstrating greatest enrichment was the spliceosome-associated 
proteins, with 29 proteins identified. Although the role of CDK11p110 in 
mRNA splicing is well characterised, the interaction of CDK11p110 with 
splicing components in mitosis had not been established. As discussed, 
enrichment of spliceosomal proteins was also evident in the mitotic 
GFP.CDK11p58 precipitate. CDK11p110 is reported to enhance splicing 
activity on in vitro splicing assays whilst CDK11p58 inhibits splicing on 
similar assays [55]. However, the effect of either protein on splicing may 
differ both in vivo and during mitosis. Furthermore, splicing is suppressed 
during open mitosis in eukaryotes following nuclear envelope dissolution, 
with the disassembly of many spliceosomal complexes [280]. Therefore, the 
interaction of both CDK11 proteins with splicing components during mitosis 
would benefit from further characterization.  
Numerous spliceosome components are found to engage in mitotic 
regulation, with inhibition resulting in aberrant mitosis [280]. The 
mechanism of this regulation remains unclear. Whilst there is evidence to 
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indicate that it occurs due to splicing dysregulation during interphase that 
results in the incorrect splicing of mitotic proteins [280], others argue that it 
occurs as a consequence to splicing independent functions during mitosis 
[281].  
The second most enriched protein group detected among mitotic CDK11p110 
interacting proteins was the ribosomal proteins, with 21 ribosome-associated 
proteins identified by KEGG pathway enrichment analysis. Ribosomal 
proteins represented a significant proportion (33%) of the enriched proteins 
identified on GST.CDK11p58 affinity purification but in this 
immunoprecipitation assay there was no significant enrichment of ribosomal 
proteins with the CDK11p58. The affinity purification was undertaken with 
the p58 isoform not the p110 isoform. However, the GST.CDK11p58 protein 
was not expressed in human cell but synthesised in bacteria and applied in 
vitro, therefore interactions detected with this p58 protein bait may be 
relevant to both the p110 and p58 isoforms given the shared peptide 
sequence. Nonetheless, only 3 of the ribosomal proteins identified by either 
assay were present in both assays. As discussed, no published interaction has 
been identified between the CDK11p58 or CDK11p110 and any ribosomal 
proteins. Ribosomal proteins are recognized to contaminate precipitation 
assays but there was no enrichment with mitotic GFP.CDK11p58 to indicate 
this was non-specific contamination, particularly given the greater 
precipitation of GFP.CDK11p58 due to its higher expression. The significance 
of this interaction with ribosomal proteins that is unique to the mitotic 
CDK11p110 also requires further investigation. 
Interestingly, in both mitotic CDK11p58 and mitotic CDK11p110 interactors, 
there was significant enrichment of proteins involved in ribosome 
biogenesis. CDK11 has been identified previously as a component of 
Parvulin 14 complexes, which are involved in ribosome biogenesis [282]. 
Furthermore, this work and unpublished work of others has identified the 
interaction of CDK11 with DDX15 [106], a helicase with roles in both 
spliceosome disassembly and ribosome biogenesis. 
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! Fig$ 5.11$ Putative$ mitotic$ CDK11$ Interacting$ Proteins$ and$ the$ Spliceosome." Proteins"
significantly" enriched" in" mitotic" GFP.CDK11" co:immunoprecipitates" over" mitotic" GFP" co:
immunoprecipitates" were" analysed" using" KEGG" pathway" terms." 29" mitotic" CDK11p110"
interactors" were" associated" with" the" spliceosome," while" 26" mitotic" CDK11p58" interactors"
were"spliceosome:associated."In"addition,"11"established"CDK11"interactors"were"associated"
with" the" spliceosome." 5.11" illustrates" these" proteins" on" the" KEGG" spliceosome" pathway."
Analysis"performed"at"KEGG"website"(http://www.genome.jp/kegg/kegg2.html),"with" image"
downloaded" following" analysis." Red" highlighted" proteins" represent" mitotic" CDK11p58"
interactors," blue" highlighted" proteins" represent"mitotic" CDK11p110" interactors" and" purple"
highlighted"proteins"are"found"to"interact"with"both"mitotic"CDK11p110"and"CDK11p58."Red"
boxes" mark" established" CDK11" interacting" proteins." SR" proteins" and" hnRNPs" comprise" a"
number"of"proteins"including"CDK11"interactors"SRSF1,"SRSF2"and"SRSF7"(SR"proteins)."
In the asynchronous nuclear CDK11p110 precipitate, 208 putative interacting 
proteins were identified, with 90 shared CDK11 interactors and 118 proteins 
unique to asynchronous CDK11p110. Although 13 established interactors 
were identified in these 208 proteins, there was no significant pathway 
enrichment as determined by KEGG pathway enrichment analysis. GO terms 
enrichment analysis revealed there was enrichment in proteins that function 
in tRNA processing and modification but there was no enrichment of 
proteins associated with established CDK11p110 functions. This is surprising 
as it is during interphase when this CDK11p110 is considered to exercise its 
primary influence on transcription and splicing. In contrast, all other CDK11 
precipitates were found to contain significant enrichment of spliceosomal 
components. Whilst this was the one condition that would be expect to 
enrich these proteins, this may be related to the poor expression of 
GFP.CDK11p110 in the HCT116 cells, resulting in significantly less CDK11 
precipitation with GFP.CDK11p110, especially in the asynchronous cells. 
Therefore, this may have limited the identification of enriched pathways, 
although overall, there were no less putative interactors (208 proteins) 
identified with asynchronous CDK11p110.  
Interestingly, established CDK11p110 interactors were identified including 
CK2 and components of the Mediator complex. Mediator complex 
interaction with CDK11 had not been demonstrated previously in metazoan 
species but these findings indicate that the interaction may occur in humans. 
5.4.4.5	  Autophagy,	  Cell	  Motility	  and	  the	  CDK11	  Interactome	  
I have demonstrated a role for CDK11 in mediating autophagy and 
migration. CDK11-mediated autophagy is predominantly a response to 
dysregulated mitosis, as I established in Chapter 3. Therefore, CDK11 may 
have no direct interaction with autophagy proteins. To investigate this, I 
examined all the putative CDK11 interactors found on co-
immunoprecipitation to discern autophagy-related proteins. The only core 
autophagy-related proteins identified were ATG4 and MTOR; these proteins 
were both co-immunoprecipitated with GFP.CDK11p110 in asynchronous 
cells. The significance of this is unclear as ATG4 and MTOR do not interact. 
Furthermore, neither protein was enriched in GFP.CDK11p58 precipitates, 
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with CDK11p58 established to rescue CDK11-mediated autophagy.  
Moreover, there was no enrichment of autophagy-related proteins as 
determined by GO term and KEGG pathway enrichment analysis.  
The mechanism of CDK11-mediated migration has not been fully 
characterized. A recent study reported that CDK11 enhanced migration 
through interaction with GADD45α and GADD45γ, resulting in the 
degradation of Ets transcription factor SPDEF [241]. I identified GADD45γ 
binding protein in both CDK11p58 and CDK11p110 mitotic but not 
asynchronous precipitate. However, I was unable to identify interaction with 
GADD45α and GADD45γ. There was no enrichment for proteins assigned to 
the cell motility KEGG pathway or GO terms related to cell polarization, the 
actin cytoskeleton or cell adhesion.  
5.4.4.6	  Significant	  Enrichment	  and	  Correction	  for	  Multiple	  Testing 
The method I employed to determine significant enrichment and therefore 
putative interactors was adopted from published protocols. This used both 
enrichment level and significance testing to determine significant 
enrichment. These protocols used a significance level of p < 0.05 on Students 
T-test. Although this method included fold enrichment, there was no 
correction for multiple testing. In my immunoprecipitation assays, 
approximately 3000-4000 proteins were detected in each sample, therefore 
the risk of false positives using an uncorrected significance level is high.  
However, I utilized these co-immunoprecipitation assays with mass 
spectrometric analysis as a screen to identify novel CDK11 interactions and 
protein networks, with subsequent enrichment analysis. Enrichment analysis 
provides greater confidence in interactors identified if other associated 
proteins are also precipitated. In addition, any putative interactor would 
require confirmation prior to more in depth study. Given that it is accepted 
that putative interactions require verification, it was reasonable to tolerate a 
greater proportion of false positive interactions rather than false negative 
interactions.  
If the Bonferroni correction for multiple testing were applied to my results 
only 7 proteins in total remain significantly enriched: CDK11, Cyclin L1, 
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HSP90, DERP6, DERL2, ZNF8 and PAM16. If instead the Benjamini-
Hochberg correction were applied to control False Discovery Rate the 
number of detected CDK11 interacting proteins increased to 64 but only 8 
established CDK11 interactors would be detected. Therefore, the False 
Discovery Rate correction resulted in the loss of 75% known interactors from 
the assay, with the loss of true interactors that have not been previously 
established likely to be similar. Therefore, although it is reported that FDR 
calculations may provide the best balance between false positive and false 
negative results [283], this did not appear to be the case for my results. 
The reverse analysis demonstrated between 40 and 80 proteins significantly 
enriched with GFP precipitates over each of the asynchronous or mitotic 
CDK11 precipitates. These may have represented either true protein binding 
to GFP or the result of multiple statistical testing. However, KEGG pathway 
enrichment analysis of these enriched GFP ‘interacting’ proteins revealed no 
KEGG pathway enrichment, thus demonstrating the validity of my methods. 
5.4.4.7	  Discussion	  of	  Experimental	  Methods	  
In these co-immunoprecipitation assays, the direct comparability of the 
different assays was compromised. The control GFP precipitates were valid 
and therefore interactors in each precipitation assays could be accurately 
established relative to control. However, the relative interaction with a 
specific protein between one CDK11 isoform and the other isoform could not 
be accurately determined, i.e. I was unable to determine that CDK11p58 
interacted with a certain protein twice as much as CDK11p110. This occurred 
for two principal reasons. First, the level of CDK11 precipitated varied 
markedly between the conditions and ideally this should have been uniform. 
The major cause of this discrepancy was the poor expression of the 
CDK11p110 compared to the p58 isoform. This was noted with both the myc-
tagged and GFP-tagged proteins and as discussed has been observed by 
other laboratories [176]. 
In addition the strategies for preparation of the samples varied. Although the 
final cellular or nuclear lysis buffer in all conditions was NP40, the sample 
preparation techniques were different with either nuclear extraction in 
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asynchronous cells or whole cell lysis in mitotic cells. This again had the 
potential to compromise the validity of any direct comparison of the relative 
levels of interactors between mitotic and nuclear CDK11 precipitates. 
Purification of CDK11 from nuclear extracts has been used commonly in 
published studies and the benefits of both CDK11 enrichment and limiting 
cytoplasmic interaction of the CDK11p58 fusion protein have been discussed.  
The use of the stable cells lines may also have influenced the different levels 
of GFP.CDK11p110, GFP.CDK11p58 and GFP tag expression. Potentially, the 
transient transfection of fusion protein constructs may have enabled not only 
more equitable protein expression but also higher expression of the proteins. 
In retrospect, this would have certainly been an easier methodology and may 
have even allowed use of the myc.CDK11 constructs. The higher exogenous 
protein expression may have provided greater confidence in the reliability of 
the CDK11p110 asynchronous interactors. However, the cancer cells I used 
did not tolerate high levels of CDK11p110 and it is therefore possible that 
transient transfection may have had deleterious effects that would influence 
the interactome identified.  
The nocodazole synchronization method is the predominant method of 
mitotic synchronization described in published literature and is validated to 
synchronise cells at prometaphase [284]. In addition, published work using 
HCT116 cells has demonstrated that following release from nocodazole block 
the majority of cells progress though telophase within 1 hour [285], thus I 
lysed cells 30 minutes following release. However, any synchronization 
method (particularly drug-induced) may have undesired effects on cellular 
physiology; in my work, this had the potential to lead to the identification of 
abnormal or mitotic arrest-related interactions. Certainly, there was no clear 
evidence of this on GO term or KEGG pathway enrichment, with CDK11 
interacting in described pathways and with established interactors. The 
duration in nocodazole block represents a balance between mitotic 
enrichment and the potential for mitotic disruption, with longer block 
increasing mitotic cells but impairing recovery from mitotic arrest [285]. I 
elected to release from nocodazole block at 6 hours consistent with the 
published methods [285]. Not all cells undergoing mitotic synchronization 
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were in mitosis but there was marked enrichment of mitotic cells following 
nocodazole synchronization. Although I did not formally undertake FACS to 
confirm mitotic synchronization, this was evident on account of the rounded 
mitotic appearance of cells and elevated phospho-Histone H3 staining (data 
not shown). Furthermore, this approach, using nocodazole synchronization, 
has been used in published work examining the mitotic interactome of 
proteins by mass spectrometry [286]. 
Although, the on-bead digestion lacks the specificity of conventional 
techniques that digest and analyse unique bands on silver stain, it is 
substantially more sensitive, with 3000 to 4000 proteins identified in each of 
my assays. Obviously this caused it’s own difficulties such that within the 
putative interacting proteins identified, there are likely to be numerous false 
positives. In addition, this co-immunoprecipitation did not prove direct 
interaction and indeed many ‘interactors’ may have been detected due to 
precipitation of protein complexes. Nonetheless, irrespective of whether 
interactions are direct or indirect, this work has enabled further 
characterization of the CDK11 interactome.  
5.4.4.8	  Comparison	  with	  GST	  Affinity	  Purification	  
Results were compared to the findings of the GST affinity purification to 
assess for correlation. This demonstrated that only 6 interacting proteins 
were identified in both screens (15% GST assay pulldowns); these were 
FASTKD5, DNAJA1, DNAJA2, RPS6, RPS7, RPS27L. Putative interactors 
identified on GST pulldown, CSK, KIF14 and RAN, were not identified with 
the co-immunoprecipitation assays. Overall, the correlation was poor and 
this was consistent with the inability to identify any established CDK11 
interactors in the affinity purification assay. 
As discussed the interaction with ribosomal proteins in both assays is 
interesting although there was relatively limited correlation in the ribosomal 
protein identified and therefore the validity remains uncertain. However, it 
would be useful to exclude ribosome interaction in mitosis. The inhibition of 
cap-dependent translation is critical in accurate mitotic progression and in 
published studies, CDK11 is reported to be a downstream regulator of 
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mitosis secondary to suppression of cap-dependent translation and 
subsequent IRES translation of CDK11p58 [79, 287]. It would be useful to 
exclude any upstream effects on ribosome translation that would itself 
explain the mitotic rescue, by CDK11, of cells that fail to suppress of cap-
dependent translation, particularly given the requirement for 14-3-3σ in the 
suppression of cap-dependent translation and the established mitotic 
binding of CDK11p110 to 14-3-3 [287]. 
5.5	  Conclusions	  
This chapter presented work intended to identify novel binding partners of 
CDK11 and elucidate interacting networks. The work could not achieve 
adequate immunoprecipitation of endogenous protein to enable mass 
spectrometric analysis. Furthermore, the GST affinity purification was also of 
limited success, with only one of three putative interactors assessed being 
confirmed on repetition of the assay. Interaction with CSK could not be 
subsequently confirmed in vivo, although further work is required to 
investigate both this and the other finding of differential Src activation on 
CDK11 depletion. 
The immunoprecipitation of GFP-tagged CDK11 was successful, based on 
the reproducibility of biological replicates and the number of established 
interactors identified. These assays have yielded a number of results of 
significant interest. However, it is difficult to reliably interpret the 
significance of these results without further validation. Unfortunately, the 
results of co-immunoprecipitation returned at the completion of my project 
and I was unable to take forward any validation work. Future projects will 
hopefully explore the findings identified and assess their validity.  
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CHAPTER 6 
Screening for CDK11 Mutations in a Cornelia de 
Lange Syndrome Cohort 
6.1	  Cornelia	  de	  Lange	  Syndrome	  
Cornelia de Lange syndrome (CdLS) is a rare development disorder 
comprising anomalies of multiple organ systems [288]. It is characterised by 
a classical facial dysmorphology, pre and post-natal growth retardation, 
intellectual disability, limb malformations and assorted visceral anomalies 
[288]. The distinctive facial features of CdLS include low set ears, a flattened 
mid-face with short nose and long philtrum, arched eyebrows and 
synophrys [288]. Although the precise incidence of CdLS remains uncertain, 
estimates lie between 1 in 10000 and 1 in 50000 live births [289]. Traditionally 
the diagnosis of CdLS was clinical, based solely on the identification of a 
number of the disorder’s characteristic features. Over the last decade, as 
disease-associated genes have been identified, suspected cases are routinely 
screened for known causative genetic mutations [289].   
6.1.1 CdLS Genetics 
Causative genetic mutations have been identified in approximately 65% of 
patients with CdLS [290].  The vast majority of these mutations occur de novo 
and familial cases of CdLS are rarely reported, with most inherited cases 
found to be a consequence of genetic mosaicism [291, 292].  The majority of 
cases are caused by mutations of the NIPBL gene, which are ubiquitously 
dominant, haploinsufficient mutations [292]. Mutation of NIPBL gives rise to 
the classical phenotype of CdLS, described above [292]. 
Four other disease-associated genes have been identified; these are SMC1A, 
SMC3, Rad21 and HDAC8. Mutations within these four genes combined 
cause approximately 5% of CdLS cases [290]. The phenotypes associated with 
mutation of these genes differ from the classical phenotype but possess a 
number of the principal features by which the disorder is characterized.  
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Despite the identification of these disease-associated genes, the causative 
genetic mutation remains undiscovered in approximately 40% of patients. It 
has recently been reported that NIPBL mutations may cause a far greater 
proportion of CdLS cases [293]; this study found that NIPBL mosaicism 
explained the genetic aetiology in a further 25% of cases. However, this 
report was based on only a small case series of 44 patients and the generality 
of its findings require clarification [293]. Depending on the contribution of 
mosacism, there still remains no identified mutation in between 15% and 
40% of cases.  
In mutation negative cases, the identification of novel causative variants can 
provide a genetic diagnosis to patients and families, not only elucidating 
disease causation but also basic cellular physiology. In addition, it allows 
clinicians to determine, through parental sequencing, whether the mutation 
is indeed de novo or whether it represents a recessive inherited variant. This 
clarification of heritability provides parental certainty over the risk of the 
disorder occurring in their future offspring. 
6.1.2 Cohesin and Cohesinopathies 
Cohesin is an evolutionally conserved multi-subunit protein complex, 
comprising a heterodimer of two structural maintenance of chromosomes 
(SMC) proteins, SMC1A and SMC3, and two non-SMC proteins, RAD21 and 
STAG [86]. Numerous proteins are established to mediate cohesin biology, 
such as its loading and removal from chromatin; these proteins include 
NIPBL, WAPL, PDS5 and Sororin [86].  
All established CdLS-associated genes are either components of the cohesin 
complex or regulators of cohesin biology [86]. NIPBL is not only the gene 
most commonly mutated but also was the first CdLS-associated gene to be 
identified [291]. NIPBL is the human homologue of drosophila Nipped-B and 
yeast Sister Chromatid Cohesion 2 (Scc2). It mediates the loading of the cohesin 
complex onto chromatin [86]. SMC3, Rad21 and SMC1A are all components 
of the cohesin complex itself, which topologically embraces the DNA 
molecule to mediate cohesion. HDAC8 is the most recently identified gene 
found to harbor causative mutations [294]. It was identified as the human 
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orthologue of yeast HOS1, which encodes a protein established to 
deacetylate SMC3 at anaphase and considered to enable the proper function 
of SMC3 throughout the subsequent cell cycle [294]. This finding led to the 
identification of mutations within the gene in the CdLS cohort [295]. 
Although HDAC8 acts during mitosis to regulate cohesin, it is yet to be fully 
characterised how or if it influences cohesin biology outside of mitosis. No 
mutations in other cohesin-associated genes, such as WAPL and PDS5, have 
been identified to explain the latent genetic causation of CdLS [296]. 
The role of the cohesin complex is best characterised in mitosis, where it 
plays an integral role in the maintenance of sister chromosome cohesion 
[296]. This enables the accurate segregation of the genome at mitosis. 
Dysregulation of cohesion predisposes to chromosomal missegregation and 
mutations in cohesin complex subunits are frequently reported in cancer 
[296]. However, studies indicate that the maintenance of cohesion in mitosis 
is not integral to the developmental disorder. Although variable defects in 
sister chromatid cohesion are observed in CdLS cohorts [297], the majority of 
studies report no precocious sister chromatid separation [298]. Certainly, 
there is no reported increase in the incidence of malignancy in CdLS patients 
[289]. The mechanisms through which these mutations cause CdLS remain 
uncertain but it is widely held that it is through disruption of cohesin’s role 
at transcription [299, 300]. As discussed in Chapter 1, cohesin is involved at 
different stages of transcription; these included mediating chromatin looping 
to facilitate enhancer and promoter apposition and regulating proximal 
pausing during transcription [36].   
CdLS is classified as a cohesinopathy based on the fundamental role cohesin 
is considered to play in the pathogenesis of the disorder [301]. CdLS is not 
the only cohesinopathy and Robert’s syndrome is also termed a 
cohesinopathy. Robert’s syndrome has a distinct phenotype and is 
predominantly caused by mutations in the ECSO2 gene [301]. ESCO2 
mediates the acetylation of cohesin, enabling the establishment of cohesion in 
early S-phase [302].  
Page 196
Despite this, debate continues as to the precise contribution of the cohesin 
complex to the syndrome, with some suggesting classical CdLS caused by 
NIPBL mutation results from other NIPBL functions unrelated to cohesion 
[303, 304]. However, most dismiss this proposition, given both the 
phenotypic similarities of CdLS cases caused by the mutation of different 
cohesin-associated genes and the finding that NIPBL and cohesin mediate 
the expression of a similar cohort of genes [299, 301].   
6.1.3 Screening approaches in CdLS Cohort 
To confidently identify novel disease-causing mutations, a rigorous 
screening protocol is required. The Fitzpatrick laboratory within the Human 
Genetics Unit, Edinburgh is an internationally recognized group with 
expertise in this disorder. The work presented was undertaken in this 
laboratory, which has developed the following screening strategy for CdLS 
patients. First the validity of the clinical diagnosis is confirmed, with 
verification of phenotypic features consistent with CdLS. It is then necessary 
to those identify cases with mutation of established causative genes and 
therefore sequencing of SMC1A, SMC3, HDAC8, NIPBL and Rad21 is 
performed. Cases without mutation of known causative genes are further 
investigated with array Comparative Genomic Hybridisation (aCGH) to 
identify regions of chromosomal loss or gain. It was the identification of a 
common regional deletion on Chromosome 5 in CdLS cases that led to the 
original discovery of NIPBL mutations [291]. 
At the time this work was undertaken, the Fitzpatrick CdLS cohort with no 
established causative mutation comprised 84 patients. Prior to the outset of 
this project, several cases within the cohort were identified to have deletion 
of chromosomal regions on aCGH. In one case, this regional deletion was 
found to involve the HDAC8 gene and concurrent work in other laboratories 
identified mutations of HDAC8 as pathogenic [294]. This led to the 
sequencing of HDAC8 in others within the cohort and the identification of 
two additional cases with HDAC8 mutations. The final stage in the screening 
protocol is to undertake whole exome sequencing (WES), which has 
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significant cost implications. When undertaken, WES is performed as a trio, 
with the DNA of both biological parents.  
One proband (Dutch13) within the CdLS cohort was established to have a 
1.1Mb deletion of the 1p36.3 locus, with loss of both CDK11 alleles in 
addition to 44 other genes [Fig. 6.1]. This predicated the work, described in 
this chapter, to screen the CdLS cohort for putative causative genes 
contained within this region.  
6.1.4 1p36 Deletion  
The identification of a 1.1Mb deletion, involving the short arm of 
chromosome 1 at 1p36, required further characterization of the case’s 
phenotype. As described in Chapter 1, deletion of this locus has been shown 
to cause the disorder termed 1p36 Deletion Syndrome. Although there are 
features common to both disorders, there is significant divergence in the 
characteristic dysmorphology. Prior to further investigation, it was 
important to discern whether this case had 1p36 Deletion Syndrome or 
CdLS. The phenotypic features and clinical history were reviewed by three 
geneticists with international expertise in dysmorphology including 
Professor Fitzpatrick; they concluded that the features were indicative of 
CdLS not 1p36 Deletion Syndrome. They used recognized CdLS diagnostic 
classifications, with the phenotypic features fulfilling the criteria for the 
diagnosis of CdLS. On account of the limited understanding of the 
mechanisms underlying these disorders, but particularly 1p36 Deletion 
Syndrome, it is possible that common aetiologies underlie both syndromes.  
Regarding the validity of clinical diagnostic criteria for CdLS, HDAC8 
mutations were identified in cases diagnosed with CdLS. The phenotypes of 
these cases differ from the classical CdLS phenotype but still meet the criteria 
for the diagnosis of the disorder [295]. This demonstrates the capacity to 
identify cases with cohesin-associated gene mutations based on their 
phenotype using diagnostic criteria for CdLS. This validates the diagnostic 
criteria for CdLS and adds support to the proposal that this case with 1p36 
deletion case may have a cohesin-associated gene mutation.  
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6.1.4.1 1p36.3 Genome Mapping 
The locus 1p36.33 within the human genome had been identified as an area 
of sequence ambiguity. This arose due to duplication within the region and 
the resulting sequence homology; CDK11A/B and MMP22/23 are tandemly 
duplicated in the human genome. At the time this work was undertaken, the 
human genome reference sequence lacked Exon 4 and Exon 5 in the CDK11B 
gene due to this ambiguity. However, Exon 4 and 5 were present in 
transcripts ascribed to both CDK11A and CDK11B. This led UCSC to overlay 
the first exons of both CDK11A and CDK11B in their mapping, with the 
implication that exons 1 to 6 were shared between the genes. In contrast, 
NCBI aligned the genes separately and did not include Exon 4 and Exon 5 in 
CDK11B. Whilst the absence of Exons 4 and 5 in CDK11B was generally held 
to be a consequence of error in the reference sequence, this required 
clarification. Furthermore, this ambiguity compromises the accuracy of 
whole genome/exome strategies to identify mutations within this region, 
due to the erroneous alignment of sequences to the duplicate gene.  
6.1.4.2 Screening candidate genes 
The 1.1Mb deletion at 1p36.3 results in the loss of 46 genes.  These genes 
were interrogated to identify genes that may engage cohesin or mediate its 
function. The function and interactions of each gene was interrogated using 
NCBI to determine genes with a reported role in cohesin biology or 
interactions with members of the cohesin complex or its accessory proteins. 
Genes with unforeseen roles in cohesin biology may have been excluded but 
this is a common approach used to identify candidate genes to reduce the 
experimental cost and complexity of subsequent sequencing. 
This assessment of the deleted genes identified three with described roles in 
cohesin biology; these were CDK11A, CDK11B and SSU72. Both CDK11 and 
SSU72 have been implicated in aspects of cohesin biology and therefore are 
plausible candidate genes. In addition, both genes may present difficulties to 
analysis by WES/WGS protocols, providing a further rationale for screening 
these two genes in the CdLS cohort. The problem with analysis by 
WES/WGS occurs due to both the duplication of CDK11 genes and the 
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presence of 8 SSU72 pseudogenes; these SSU72 pseudogenes with 
homologous sequences lack introns. The homologous sequences related to 
both CDK11A/B and SSU72 may reduce the identification of any causative 
mutation in WES/WGS due to incorrect alignment of sequences, as 
discussed below. 
If no plausible causative mutations were identified on my sequencing of 
candidate genes, this cohort would be subject to WES, enabling assessment of 
other genes within the region. I decided to undertake sequencing of the 
exons of both candidate genes. Although mutations within introns and 
promoter regions may contribute to genetic disorders, it is more often 
difficult to determine causality.  
6.2	  Screening	  for	  CDK11	  mutation	  in	  a	  CdLS	  Cohort	  
There are no reports of direct interaction between CDK11 and the cohesin 
complex but CDK11 mediates the maintenance of sister chromatid cohesion 
at mitosis. Although the mechanism of this regulation remains uncertain, it 
indicates CDK11 is directly or indirectly engaged in the mitotic cohesin cycle. 
As demonstrated with HDAC8, disruption of the mitotic cohesin cycle may 
lead to deleterious consequences [294]. In addition, CDK11 is engaged in the 
regulation of similar transcriptional events to the cohesin complex, with 
involvement in transcription initiation and elongation. It is possible that 
CDK11 may mediate these pathways through similar mechanisms to cohesin. 
Initially, this work therefore aimed to investigate for the presence of CDK11A 
or CDK11B mutations in the CdLS cohort.  
6.2.1 Next Generation Sequencing v Sanger 
In deciding on experimental design, I had to consider the most appropriate 
sequencing method. Sanger sequencing is highly accurate and the method 
most commonly used to identify mutations within a single gene. It remains 
the ‘gold standard’ sequencing method employed to confirm mutations 
identified through next generation sequencing techniques [305]. However, 
the major disadvantage of Sanger sequencing in this experiment was the 
homology of CDK11A and CDK11B. Due to this homology, I was unable to 
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uniquely prime sequences discrete to each gene. A mutation within an allele 
of either gene will consequently be diluted within sequence from four alleles 
of the two genes, impairing its detection using conventional Sanger 
sequencing techniques. The heterozygous variant/mutation of a gene with 
two alleles should be detected in approximately 50% of sequences. In 
practice, this does not occur due to the different priming efficiencies of 
alternate alleles, often as a consequence of distinct single nuclear 
polymorphisms (SNPs). CDK11A and CDK11B, due to the homology of the 
duplicate genes, comprise in effect four alleles and therefore the frequency of 
a mutation within retrieved sequence could fall to considerable less than the 
expected 25%. This renders detection problematic above background 
sequencing signal.   
Next generation sequencing  (NGS) with the ability to sequence regions of 
the genome in depth has the potential to overcome these difficulties. 
However, NGS techniques also have disadvantages. The combined influence 
of sequence depth and inherent inaccuracies that occur with all NGS 
platforms, may lead to the identification of false positive variants [306]. To 
overcome these difficulties, software exists to minimize false positives 
through increased stringency of variant calling in areas of sequence known 
to cause NGS errors, such as homopolymers. This enhanced curation of 
sequencing data improves accuracy, but any increased stringency may 
impair sensitivity over specificity. However, recent studies have 
recommended the adoption of NGS strategies for the sequencing of 
individual genes or loci, stating the accuracy achieved may equate to 
traditional Sanger sequencing [307]. 
The Human Genetics Unit (HGU), Edinburgh uses the Ion Torrent system for 
these applications. This system is one of the numerous available NGS 
technologies. During sequencing, the incorporation of a nucleotide into the 
advancing DNA molecule by the polymerase causes release of a hydrogen 
ion [308]. This positively charged proton causes a local distortion in pH that 
is detected by the sequencer. Each microwell on the chip contains clonally 
amplified copies of a single DNA sequence. The Ion Torrent chip is 
sequentially flooded with each individual nucleotide. The addition of a 
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nucleotide complementary to the sequenced DNA causes electrochemical 
fluctuations within the microwell that are detected and recorded. If two 
identical consecutive bases are present within the sequence, two nucleotides 
will be incorporated and the voltage output doubled accordingly. This 
sequencing method enables the rapid sequencing of DNA molecules, with 
the 314 Chip successfully used to sequence nucleotide amplicons of up to 250 
base pairs (bp) in length. 
6.2.2 Primer Design 
The next important method to consider was the design of sequencing 
primers. As discussed, due to sequence homology, it was not possible to 
design primers for the majority of CDK11 exons that would exclusively 
prime one gene. Therefore the decision was made to design primers that 
would prime both CDK11A and CDK11B. Primer design was undertaken 
using Primer 3 software. All primers were designed with similar length, GC 
content and thermodynamic properties to enable the concurrent PCR of all 
amplicons. On account of the limitation in length of readable sequence 
obtained using the Ion Torrent system, the maximum amplicon size was set 
at 250 bp. If any exon could not be covered by a single amplicon, additional 
amplicons were designed across the exon. Importantly all primers were 
checked to exclude those with possible off-target priming, using the NCBI 
nucleotide blast software. It was not always possible to design primers with 
exact homology to both sequences. To minimize the potential for preferential 
priming of one gene over the other, primers were designed so as not to 
contain more than two mismatched nucleotides or single nucleotide 
polymorphisms (SNPs) and none within the 3’ end of the primer. This 
strategy resulted in the design of 36 primer pairs, to obtain 36 amplicons, 
covering the 20 exons of both CDK11A and CDK11B. 
6.2.3 CDK11 Dominant v Recessive Model  
To filter variants identified on sequencing CDK11, it was important to 
consider the genetic dominance of any putative pathogenic variant. Almost 
all causative genetic mutations identified in CdLS are autosomal dominant, 
with mutation of a single allele resulting in the disease phenotype [289]. 
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However, although causative mutations in CdLS are autosomal dominance, 
this is not the case for all cohesinopathies [309]. An example being Robert’s 
syndrome which is an autosomal recessive disorder caused by homozygous 
mutations within ESCO2 [309]. Furthermore, autosomal recessive 
monogenetic disease may also be caused be compound heterozygous 
mutations such as in Miller Syndrome, where different rare recessive 
mutations of DHODH occur in each alleles of the gene [310].  Therefore the 
analysis of any variants must consider both the possibility of an autosomal 
dominant and an autosomal recessive model.  
The phenotype of Dutch13, the CdLS proband with the 1p36.3 deletion, may 
arise through either a dominant or recessive model. In the dominant model, 
loss of a single allele within this region (i.e. the regional deletion observed) 
would cause the disorder, reflecting haploinsufficiency. In the recessive 
model, deletion of this region may potentiate a deleterious recessive variant 
within the remaining allele. The phenotype of this Dutch13 differs from the 
typical 1p36 Deletion Syndrome and more closely resembles CdLS, therefore 
a recessive model may better explain the difference in phenotype between 
this case and patients with 1p36 Deletion Syndrome. However, obviously 
this would require the co-existence of two rare genetic events.  
In the dominant model, a causative single heterozygous mutation will cause 
the disorder and therefore will not be present in databases of known human 
SNPs in carriers without developmental phenotypes. Therefore any variant 
present either in unaffected parents or in Exome Variant Server can be 
excluded from analysis in this model. Exome Variant Server collates SNPs 
identified through NGS exome sequencing; it comprises data from over 6000 
patients without reported developmental disorders.  
In the recessive model, either homozygous or compound heterozygous rare 
SNPs may contribute to the disorder and therefore these cannot be excluded 
from analysis. To interrogate this, any variant identified was screened 
against databases of known SNPs. Given the incidence of the disorder, only a 
combination of rare variants could contribute. On account of the published 
incidence of CdLS at between 1 in 10000 and 1 in 50000 live births, 
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particularly as in at least 60% of cases the causative mutation is established, it 
is implausible that SNP variants with a frequency of greater than 1 in 200 
would contribute to the disorder. To minimize the possibility of erroneously 
excluding variants, in this analysis only variants with a frequency of greater 
than 1 in 100 were excluded.  
6.2.4 Disease Causation 
On account of the autosomal dominance of established pathogenic mutations 
in CdLS, it is more plausible that any mutation would occur de novo. 
However, no deleterious developmental phenotype is reported with 
heterozygous loss of CDK11 in murine models [127]. As discussed, the 
murine locus differs substantially from the human locus, with the major 
difference being the presence of a single CDK11 gene. Nonetheless, if this 
observation of normal development with haplo-insufficiency remains valid 
in humans, it would indicate that a causative CDK11 mutation must be 
dominant negative or recessive, rather than haplo-insufficient.  
The second important element to consider is how to determine causation of 
any putative mutant variant identified. This is obviously more difficult on 
account of the duplication, as the significance of the two CDK11 genes 
remains uncertain. It is not known whether one gene is able to amply 
compensate for the loss of the other or whether they are both requisite. 
Certainly the promoter regions and promoter binding motifs differ, with the 
expression of the two genes reported to vary in certain tissues [112, 142]. This 
would suggest both genes are indeed necessary but this remains untested. In 
addition, it cannot be excluded that a dominant negative mutation of a single 
CDK11 gene may affect the function of the alternate CDK11 gene product.  
To determine causation, any novel variant, or combination of variants in the 
recessive model, would require not only be unique to the case over both 
unaffected parents but also for mutation of the gene to be observed in more 
than one solitary case. This remains a critical tenet in the determination of 
genetic causation, with the significance of novel variants in single 
individuals difficult to definitively establish. Corroboration in multiple cases 
reduces the possibility of identifying novel SNPs, with no functional 
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consequence, as causative mutations. The putative causative variant 
identified should result in a non-synonymous amino acid alteration. Again, 
synonymous changes may contribute to disease phenotypes but determining 
both causation and mechanism are challenging. Programs such as PolyPhen-
2 are of use in determining the likely deleterious consequences of observed 
variants. In part, these programs undertake comparisons of amino acid 
variation in the protein through speciation to determine the likelihood it is 
pathogenic. Obviously subsequent interrogation of protein function, with the 
generation of mutant protein, would be required to validate the findings.  
6.2.5 CDK11 Sequencing Protocol 
The Fitzpatrick CdLS cohort comprised cases from around the world, with 
DNA samples collected internationally. Genomic DNA of each CdLS case 
was extracted from blood or buccal swabs within the Human Genetic Unit, 
Edinburgh. Due to the limited quantity of genomic DNA available, 
sequencing was undertaken on whole genome amplified (WGA) DNA. 
Whole genome amplification of patient samples was performed using the 
Illustra GenomiPhi V2 Amplification Kit (GE Healthcare Life Sciences). 
The designed primers were tested to confirm adequate reaction efficiency, 
with similar quantities of product synthesized following PCR. This also 
enabled determination that there was no visible anomalous product derived 
from putative off target reactions. All primers appeared to produce adequate 
quantity of product without addition products observed [Fig 6.2]. 
The Ion Torrent system was used for the sequencing. This required 
preparation of amplicon libraries for sequencing [Fig 6.3]. The amplicons 
were obtained through PCR of genomified patient DNA, using the designed 
primers. The amplicons for each patient were pooled and end repair 
undertaken in preparation for ligation of adapter sequences, necessary for 
sequencing on the Ion Torrent. These samples were than purified and the 
adapter ligated to each end of the amplicon using nick repair polymerase. In 
order to sequence greater than one case on each chip, barcode adapters were 
used. A distinct barcode sequence was ligated to all the amplicons from a 
single patient so that their sequences would be identifiable subsequently. 
Page 206
	   	  
1" 2" 3" 4" 5" 6" 7" 8"
9" 10" 11" 12" 13" 14" 15" 16"
17" 18" 19" 20" 21" 22" 23" 24"
25" 26" 27" 28" 29" 30" 31" 32"
33" 34" 35" 36"
Amplicons"1"5"36"


































Primer3' to' sequence' the' CDK11' exome.' Due' to' homology' between' CDK11A' and'
CDK11B,'primers'were'designed'to'prime'both'sequences'simultaneously.'On'account'of'
limitaCons'imposed'by'Ion'Torrent,'all'amplicons'were'designed'with'a'maximum'length'
of' 250bp;' larger' exons'were' subdivided' for' sequencing.' In' total' 36' primer' pairs'were'
designed' to' sequence' the' 20' exons' of' both' CDK11A' and' CDK11B.' 5.2A' shows' the'
product'of'each'primer'pair'following'PCR'of'control'human'DNA'resolved'by'agarose'gel'
electrophoresis.'Each'product'is'of'the'correct'size'and'there'is'no'evidence'of'addiCon'
bands' to' indicate' offQtarget' priming' or' primerQdimer.' 5.2B' shows' quanCCes' of' PCR'
product' for' two' representaCve' paCent' samples' R32B9' and' R32F2' using' SYBR' Green'
quanCficaCon.'This'demonstrates'adequate'concentraCon'of'each'amplicon'to'proceed'
with'library'preparaCon.'





36' primer' pairs' were' designed' to' sequence' the' 20' exons' of' both' CDK11A' and'
CDK11B.! 6.2A! shows' the' product' of' each' primer' pair' following' PCR' of' control'
human'DNA'resolved'by'agarose'gel'electrophoresis.'Each'product'is'of'the'correct'
size' and' there' is' no' evidence' of' addition' bands' to' indicate' offPtarget' priming' or'
primerPdimer' formation.' ' 6.2B! shows' the' qua tification' of' PCR' roducts' for' two'
representative'patient'samples'R32B9'and'R32F2'using'SYBR'Green'quantification.'




	   	  
!
Amplicons 
•  No >250bp 
•  >1 primer pair over large exons  
•  36 Amplicons over 20 Exons  
Purify & End-Repair  
Primer Design  
•  Prime CDK11A + 
CDK11B 
•  No Mismatch near 3’  
•  No SNP near 3’  
Combine 36 Amplicons 
Ligate P1 Adapter and Barcode (Case Specific)  
Amplify / Quantify / Combine Libraries   
Run Ion Torrent 314 Chip  
120,000 
60,000 
X 1 2 3 4 
X 1 2 3 4 5 6 7 8 X 1 2 3 4 5 6 7 8 
X 1 2 3 4 5 6 7 8 X 1 2 3 4 5 6 7 8 
X 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
X 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 



































recorded% for% each% case% (X% Axis% –% Barcode% label)% across% all% 8% chips% (prefixed% SN1@).%
Initially%4%cases%were%combined%and%sequenced%on%a%single%chip;%it%was%apparent%due%




Samples were again purified prior to amplification of the library to increase 
the read depth. Each library, with its unique barcode ligated, was then 
quantified utilizing the Agilent Bioanalyser. Equal quantities of each patient 
library were then collated and delivered to the core sequencing department 
for cloning onto Ion Spheres and placement on the 314 Ion Torrent Chip.  
6.2.6 Ion Torrent Sequencing Results 
The chip contains internal control sequences to confirm accuracy of the 
sequencing run. In addition, sequencing outputs are aligned with the given 
reference sequence as a further control of sequencing. Initially, as similar 
sequencing had not previously been undertaken in the unit, 4 cases were 
combined on each chip. Subsequently, it was apparent on account of the read 
depth that additional samples could be sequenced on each chip. 
Consequentially, 8 cases then 16 cases were successfully sequenced per chip. 
The total valid library reads for each patient sample is shown [Fig 6.3B]. The 
parameters of chip sequencing are also shown [Fig 6.4 and Table 6.1]. This 
demonstrated good sequence quality and read depth. The percentage of 
valid library reads is considered a quality indicator, with 70% valid library 
reads considered an excellent output. A figure of approximately 70% was 
achieved with all but one chip. The proportion of Q20 reads was also higher 
than that reported in the literature. This indicated that the sequencing runs 
were of acceptable quality.  
Any areas where read depth fell below 10 reads were in addition sequenced 
with Sanger sequencing. The amplicon sequencing Exon 9 in 6 cases and the 
last 20 bases of Exon 13 in 5 cases were the only two regions where read 
depth fell below this requirement. Indeed in over 95% of regions, read depth 
exceeded 100. 
The sequencing data generated was analysed using NextGene software. 
Reference sequences for CDK11A and CDK11B were obtained from NCBI 
and input into the analysis software for alignment. The NextGene software 
enables the analysis to be customized to the preferences of the user. This 
allows the sensitivity of the assay to be enhanced for the detection of low 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































increased false positive rate. The mutation detection rate was established at 
10% of reads, i.e. a variant present in 10% or more of sequences was 
identified. As explained above, any single allele variant that could not 
correctly be aligned to either CDK11A or CDK11B should make up 25% of 
total sample reads. To compensate for any differential allele priming, a lower 
thresh-hold was set for the mutation detection rate (10%). In effect, this 
constituted a compromise between sensitivity and specificity. Mosaic 
mutations may pass undetected but this was accepted given the potential 
difficulties of determining the significance of mosaicism in either CDK11 
gene, especially due to the inherent complexities of this region.    
Across the 84 patient samples, 3592 variants were detected, at an average of 
42.8 variants per patient (Range 36-64). It was noted that the vast majority of 
variants identified were common to most if not all samples. This occurred for 
two principal reasons. The first was that the variants identified were 
common SNPs within either CDK11A or CDK11B. The second reason was the 
identification of variants that arose as a result of sequencing errors. All NGS 
sequencing platforms have particular susceptibility to certain errors. 
Bidirectional sequencing reads were obtained, allowing a reduction in the 
error rate compared to unidirectional strategies. Erroneous sequencing was 
identified by both its the occurrence in the majority of cases, including the 
two control cases, and its the distribution in a non-allele specific manner. 
Control cases were those within the cohort, in which a mutation in a 
established causative gene had been identified. As discussed many next 
generation sequencing strategies are expressly vulnerable to errors at sites of 
homopolymers. This occurs due to the method of sequencing, with 
sequences of multiple consecutive identical nucleotides leading to difficulty 
in ascertain the precise number of nucleotides incorporated. These 
homopolymer errors are recorded as insertions or deletions. Virtually all 
variants were excluded as either common SNPs, with a reported frequency of 
greater that 1 in 100, or as erroneous sequencing.  
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6.2.7 Novel Variants in CDK11 Identified 
Following exclusion of the variants as described, there remained two 
variants within CDK11A or CDK11B in the cohort that did not constitute 
either common reported SNPs or sequencing error. Neither of these SNP 
variants had been previously described in Exome Variant Server, dbSNP or 
COSMIC databases; in addition both variants were non-synonymous. 
6.2.7.1 Variant in Case R32F11 
The first comprised a variant within coding Exon 4 of case R32F11, with this 
mutation of guanine to cytosine causing a change of amino acid residue from 
Glycine (118) to Arginine. This variant appeared to occur within CDK11A, 
although as discussed the CDK11B reference sequence does not contain Exon 
4 for comparison. This mutation was present in 196 of 1196 reads (16%), with 
all reads at this exon aligned to CDK11A. This amino acid sits within the 14-
3-3 binding domain and putatively may alter its function. This residue is 
conserved through all vertebrates and PolyPhen-2 predicted this mutation to 
be damaging. The PolyPhen-2 score was 1, the maximum obtainable score to 
indicate damaging potential. To interrogate this further, the parental samples 
were obtained, as neither had been previously collected. Following this, both 
parents were sequenced using Sanger sequencing for the presence of the 
mutation. This demonstrated the mother of R32F11 had the same variant [Fig 
6.5]. There was no rare SNP in the alternate allele to indicate a recessive 
disorder and the mother did not suffer with CdLS. Therefore, this variant 
was determined to be a novel SNP variant, as it had not been previously 
identified in SNP databases, but the variant was not causative.   
6.2.7.2 Variant in Case R34A6 
The second variant comprised a base substitution within coding Exon 7 in 
case R34A6. This mutation of guanine to adenine encoded Lycine in place of 
Glutamate. This residue is adjacent to the SH2 binding domain and may 
putatively alter SH2 binding. PolyPhen-2 also predicted this mutation to be 
damaging, with a score of 0.934. Sanger sequencing to confirm the presence 
of the mutation demonstrated that this variant would not have been detected 
using conventional Sanger sequencing due to low signal [Fig 6.6]. This 
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variant was present in 56 of 237 reads aligned to CDK11A and 60 of 472 
aligned to CDK11B, with the variant sequence aligned to both genes due to 
sequence homology and therefore software was unable to differentiate 
between the two genes. This variant therefore was present in 116 of 709 reads 
in total (16%). As this variant could not be robustly differentiated on Sanger 
sequencing, it was decided to undertake CEL1 restriction. This variant was 
the only nucleotide mismatch within this amplicon between both alleles, 
enabling CEL1 restriction. CEL1 restricts DNA at sites of heterozygosity. 
Amplicons of this locus were generated and annealed. Addition of CEL1 to 
the WGA DNA of R34A6 generated a fragment corresponding to the size 
expected by restriction at the variant. Surprisingly, no variant was observed 
in the parental samples or the stock DNA sample of R34A6 [Fig 6.6B]. The 
presence of the variant in the whole genome amplified DNA but not the 
stock DNA inferred that either the variant was introduced during 
amplification or the amplified DNA had been incorrectly assigned during 
processing and constituted an alternate patient DNA. To interrogate this, 
CEL1 restriction was undertaken on all 15 stock DNA cases amplified in 
parallel with R34A6 but the variant was not present in this stock DNA. It was 
therefore concluded that this variant must have resulted from an error 
introduced in whole genome amplification.  
Finally, examination of sequencing from case Dutch13 with the deletion of 
1p36 did not reveal any low frequency SNP or other variants to indicate loss 
of heterozygosity in either CDK11A or CDK11B gene. Interesting, analysis of 
the CDK11 sequence for proband Dutch13 with known monosomy at this 
locus, demonstrated the presence of two alleles of both Exon 4 and Exon 5. 
This was the region of ambiguity lacking Exon 4 and Exon 5 in the reference 
sequence. This sequencing demonstrated that there were indeed two Exon 4 
and two Exon 5 sequences within this region and confirms that contrary to 
the UCSC alignment, the genes did not share Exons. This was expected and 
entirely consistent with the accepted paradigm. Both UCSC and NCBI 
alignments have been altered to reflect this in the most recent genome build.   
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6.3	  Screening	  the	  CdLS	  Cohort	  for	  SSU72	  Mutation	  
SSU72 is an established cohesin binding protein that not only mediates sister 
chromatid cohesion during mitosis but is also involved in transcription as a 
RNA Polymerase II CTD phosphatase [311, 312]. Both its role in cohesin 
biology and its role in transcription made it an interesting candidate in the 
search for novel causative mutations in CdLS. 
6.3.1 SSU72 sequencing  
CDK11 sequencing was planned using the Ion Torrent NGS sequencing 
platform. This had not been undertaken in the unit previously and its 
suitability for this strategy was unclear, with particular uncertainty over the 
quality and length of sequencing that would be obtained. Therefore, it was 
decided to undertake only the CDK11 screen using the Ion Torrent. The 
second gene identified as a putative candidate, SSU72, was sequenced using 
traditional Sanger sequencing. The SSU72 genomic sequence holds different 
challenges compared to sequencing of CDK11, with regions of the genomic 
sequence containing high GC content. However, there was no intronic 
homology to prevent the synthesis of specific exon amplicons.  
Primers pairs were designed using Primer 3, with similar length, GC content 
and thermodynamic properties to those described above. There was no 
limitation on amplicon length and all exons could be primed with a single 
amplicon. Once again primer product was assessed prior to sequencing, 
confirming both adequate reaction efficiency and the absence of off-target 
priming. During primer design, it was apparent that the SSU72 sequence 
contained areas of high GC content, which can impair sequencing reactions. 
This was evident during primer testing and the reaction required the 
addition of GC-rich mix to enhance sequencing. With the use of this, it was 
possible to achieve adequate amplicon production.  
To exclude variants, bidirectional sequencing was required. Sequencing 
using the GC-rich mix was generally adequate to achieve this. For the few 
cases where this remained inadequate, a second primer set was used, in 
addition to further replication of amplification with the original primer pairs. 
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account$ of$ the$ absence$ of$ sequence$ varia0on$ between$ the$ two$ genes$ at$ this$ site;$
sequence$could$therefore$be$aligned$to$either$gene$with$equal$accuracy.$This$sequence$
duplica0on$resulted$ in$ the$variant$being$difficult$ to$discern$by$Sanger$sequencing$ (Red$
Arrow).$The$presence$of$a$variant$was$confirmed$by$CEL1$restric0on;$this$nuclease$cuts$
at$ sites$ of$ mismatches;$ this$ variant$ was$ the$ only$ variant$ in$ this$ amplicon.$ This$
demonstrates$the$genera0on$of$a$fragment$of$the$correct$size$on$CEL1$restric0on$in$the$
WGA$DNA$(5.6B).$This$ is$not$present$ in$either$parents$or$stock$DNA.$Following$ further$
inves0ga0on$this$was$considered$to$be$a$muta0on$inserted$during$WGA.$$
Figure' 6.6' Sequencing' Case' R34A6.' Ion$ Torrent$ sequencing$ identified$ a$ novel$ variant$ in$
case$ R32A6.$ This$ comprised$ a$ base$ substitution$ at$ Exon$ 7$ with$mutation$ of$ guanine$ to$
adenine;$this$was$nonDsynonymous$with$conversion$of$Glutamate$218$to$Lysine.$This$was$
again$a$highly$conserved$residue$with$preservation$throughout$vertebrate$species.$This$was$
predicted$ damaging$ with$ PolyPhen$ software.$ It$ is$ adjacent$ to$ the$ SH2$ binding$ domain$
within$ the$ N$ Terminus$ of$ CDK11p110.$ Subsequent$ Sanger$ sequencing$ confirmed$ the$
presence$of$the$variant$in$whole$genome$amplified$(WGA)$DNA$compared$to$DNA$of$case$
R33F11$ with$ no$ identified$ mutation$ of$ this$ region.$ This$ demonstrates$ the$ difficulty$ of$
Sanger$ sequencing$ CDK11% (6.6A).$ The$ variant$ aligned$ to$ both$ CDK11A% and$ CDK11B% on$
account$of$the$absence$of$sequence$variation$between$the$two$genes$at$this$site;$sequence$
could$therefore$be$aligned$to$either$gene$with$equal$accuracy.$This$sequence$duplication$
resulted$ in$ the$ variant$ being$ difficult$ to$ discern$ by$ Sanger$ sequencing$ (Red$ Arrow).$ The$
presence$of$a$variant$was$confirmed$by$CEL1$restriction,$as$this$variant$was$the$only$variant$
in$ this$ amplicon.$ CEL1$ nuclease$ cuts$ at$ sites$ of$ mismatches.$ This$ demonstrates$ the$




The core HGU sequencing service undertook sequencing. Sequencing data 
obtained was aligned to the reference genomic sequence of SSU72 using 
Mutation Surveyor software. Few variants from the reference sequence were 
observed in the CdLS cohort and no rare variants of a frequency below 1 in 
100 were identified in any of the cases. Therefore, I did not identify a 
causative mutation in the SSU72 gene.  
In retrospect, due to the success of Ion Torrent sequencing, the SSU72 Sanger 
sequencing could have been performed on the Ion Torrent platform 
concurrently with CDK11 sequencing. This would have reduced the 
requirement for additional sequencing and therefore cost. However, it is 
uncertain whether the high GC content would have impaired SSU72 
sequencing with this strategy.  
6.4	  Conclusion	  
This chapter described work to screen for causative genetic mutations within 
a cohort of CdLS cases. This work was predicated by the identification of a 
1p36 deletion in a patient diagnosed with CdLS. Sequencing failed to identify 
a novel causative mutation within any of three candidate genes (CDK11A, 
CDK11B and SSU72) at this locus. Two novel variants were identified in 
these cases but one was inherited from an asymptomatic parent, while the 
other resulted from error introduced during genome amplification. Given the 
putative involvement of these gene products in cohesin biology, in addition 
to the difficulty in sequencing these genes using WES, individual sequencing 
of both genes remained a valid approach.  
The question remains of whether this case truly represents the cohesinopathy 
CdLS or whether it may represent an atypical presentation of 1p36 Deletion 
Syndrome. 1p36 Deletion Syndrome is recognized to cause a wide spectrum 
of phenotypes due to the different loci and genes involved in the deletion. 
Papers have described regions of minimum deletion in 1p36 Deletion 
Syndrome but these do not always overlap and the disorder may result from 
the disruption of a differing combination of genes [313, 314]. An overlap with 
CdLS cannot be excluded until mechanisms underlying both syndromes are 
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better understood. Nonetheless, Gervasini et al. recently reported genomic 
imbalances in 8% of mutation negative CdLS probands, which may provide 
an alternate explanation for their developmental phenotype [315]. 
This work therefore did not identify any mutation to explain the latent 
genetic aetiology of CdLS. It did however demonstrate that the human 
reference sequence of the 1p36.33 locus was erroneous. The identification of 
two Exon 4 and two Exon 5 alleles within CDK11 at this area of monosomy 
confirmed the presence of discrete Exons 4 and Exons 5 in CDK11A and 
CDK11B. This is consistent with accepted knowledge of the CDK11 gene 
locus. Further exploration of the exomes of this CdLS cohort will be 






7.1	  CDK11	  and	  Disease	  Phenotypes	  
The work in this thesis explores novel roles of CDK11 in cancer and 
developmental phenotypes. CDK11 has an essential role in embryonic 
development, with loss of Cdk11 causing blastocyst lethality in murine 
models [81]. Furthermore, CDK11 appears critical not only during 
development but in later health, with CDK11 dysregulation implicated in the 
pathogenesis of various disease states, including cancer. Overexpression of 
the protein has been associated with poor prognosis in malignancies, such as 
breast cancer, ovarian cancer and osteosarcoma [316-318]. Moreover, 
numerous studies have identified CDK11 as a potential therapeutic target in 
cancer [130, 316, 318].  
The importance of CDK11 in both health and disease warrants further 
investigation to better understand its functions in these states. Characterising 
these CDK11 functions may not only provide a greater understanding of cell 
biology but also enable better targeting of CDK11 and synergistic pathways 
in diseases, such as cancer. CDK11 engages in transcription, splicing, mitosis 
and apoptosis. This thesis has interrogated novel functions of CDK11 in 
cancer cells, including its mediation of autophagy and cell migration. 
Additionally, I have investigated the CDK11 interactome in order to 
elucidate the mechanisms that underlie both novel and established CDK11 
functions. Finally, I have investigated CDK11A/CDK11B as candidate 
disease-associated genes in the developmental disorder CdLS. 
7.2	  CDK11	  and	  Autophagy	  
Autophagy is recognised to influence both tumorigenesis and subsequent 
tumour proliferation; it may perform functions beneficial or deleterious to 
tumour biology, depending on the cellular components targeted for 
degradation by selective autophagy. The initial work in this thesis explored 
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the altered autophagy flux observed following CDK11 depletion. The aim 
was to provide a greater understanding of CDK11-mediated autophagy and 
its influence in cancer cells. I studied this CDK11-mediated autophagy in 
KRAS mutant cancer cells (MDA-MB-231 and HCT116). Although KRAS 
mutant cancers are reported to demonstrate increased dependence on 
autophagy pathways [319], this autophagy phenotype is not unique to KRAS 
mutant cells and is observed in other non-cancer cells, including drosophila 
S2 cells [149]. 
I demonstrated that the autophagy phenotype could be abrogated by 
inhibition of the cell cycle and replicated by chemical inhibition of mitotic 
regulator PLK1. Furthermore, there appeared to be a temporal relationship 
between passage through mitosis and the subsequent autophagy phenotype. 
This indicated that the autophagy phenotype occurred secondary to mitotic 
dysregulation rather than due to direct effects on autophagy pathways. 
Matsui et al. (2013) reported that inhibition of autophagy in states of nutrient 
starvation led to mitotic delay and aberrant mitoses, with associated genomic 
instability [201]. This demonstrates the capacity of dysregulated autophagy 
to influence the cell cycle and faithful chromosome segregation during 
mitosis. However, my work does not indicate that CDK11’s regulation of 
mitosis occurs through disruption of autophagy. My work was undertaken 
in nutrient replete states, where the autophagy phenotype occurred 
secondary to mitotic dysregulation rather than the opposite.  
The autophagy phenotype I investigated was the significant accumulation of 
LC3 II protein and LC3 puncta following CDK11 depletion; it was this 
phenotype that was associated with mitotic dysregulation. I did not exclude 
that more minor alterations in autophagy flux could be directly mediated by 
CDK11, separate to its mitotic function. Other splicing proteins components 
are recognized to influence tumour biology and specifically autophagy 
through modulation of stress pathways and regulation of MTOR [320]. 
However, CDK11-mediated autophagy is primarily a consequence of mitotic 
dysregulation.  
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7.3	  Autophagy,	  Mitosis	  and	  Chromosome	  Missegregation	  
Mitotic catastrophe results from aberrant mitosis with failure of chromosome 
segregation; it describes a process of cell death or senescence that occurs 
through apoptosis, necrosis or nuclear fragmentation [321]. Autophagy 
induction is recognized to occur following mitotic catastrophe [321]. In this 
thesis, I have demonstrated inhibition rather than induction of autophagy at 
72 hours following CDK11 knock-down in MDA-MB-231 cells. However, this 
was not replicated in HCT116 cells, with continued autophagy flux despite 
LC3 accumulation. These findings are consistent with those of others in the 
laboratory that demonstrate autophagy induction at early time-points, with 
subsequent autophagy inhibition [149]. This is proposed to occur secondary 
to inundation of autophagy pathways, with resultant depletion of autophagy 
proteins [149]. Mitotic catastrophe is therefore likely to explain the CDK11-
mediated autophagy phenotype; in my work, multinucleated cells that 
display the autophagy phenotype appear to undergo cell senescence, 
remaining viable for extended periods in culture but failing to undergo 
further cell division.  
Aneuploidy is a consequence of chromosome missegregation and is a 
common occurrence in cancer. Debate persists as to its contribution to 
tumorigenesis but aneuploidy does result in stoichiometric imbalances 
within the proteome [165]. Published studies indicate the resulting proteomic 
stress may drive ROS production, with deleterious consequences for 
aneuploid cells [322, 323]. These deleterious effects present a potential 
vulnerability within aneuploid cancer cells; pathways that mitigate the 
associated proteomic stress may therefore provide therapeutic targets [324].  
I aimed to assess whether autophagy may function to mitigate the cellular 
stress caused by chromosome missegregation/aneuploidy. Although effects 
on autophagy following aberrant mitosis are evident, I was unable to 
demonstrate altered autophagy following chromosome missegregation itself.  
However, others laboratories have subsequently demonstrated this, with 
induction of autophagy following chromosome missegregation [191, 206].  
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I have presented evidence in this thesis that autophagy is important for the 
survival of aneuploid cells. I demonstrated that loss of autophagy (through 
ATG5 knock-down) impaired the maintenance of aneuploid cell populations, 
in the absence of p53. Further work is required to confirm these findings, 
which were again observed in KRAS mutant tumour cells. Moreover, ATG5 
has recently been reported to mediate mitotic catastrophe through 
mechanisms other that autophagy [325]. Further work is required to assess 
how this may have influenced my results but it appears unlikely that loss 
(rather than gain) of ATG5-mediated mitotic catastrophe would have 
impaired the maintenance of aneuploid populations. 
7.4	  CDK11	  and	  Cell	  Migration	  
The evidence presented in this thesis demonstrates that CDK11 depletion 
impairs breast cancer cell motility. This occurred with both mesenchymal 
hormone-receptor negative and epithelial oestrogen-receptor positive breast 
tumour cells. I demonstrated that this was not simply a consequence of 
CDK11’s effect on cell proliferation, with motility impaired in both 
directional and random migration assays. The mechanism of this impaired 
migration could not be ascribed to a specific deficiency in cell adhesion or 
cell polarization.  
CDK11 is not unique among CDKs in mediating cell migration, with CDK5 
established to regulate cell motility [326]. However, the localization and 
structure of CDK5 is markedly different to CDK11; CDK11 does not clearly 
locate to the cell periphery and remains predominantly nuclear. In the RNAi 
screen undertaken by Simpson et al. (2008), CDK4 and CDK9 also impaired 
cell migration, although CDK9 had confounding effects on cell 
viability/proliferation [230]. CDK2, CDK6, CDK7 and interesting CDK5 had 
no effect on cell motility in this assay.  
Interactome studies in Chapter 5 did not identify enrichment of proteins 
associated with cellular motility among CDK11 interactors (as determined by 
GO annotation). Furthermore, I did not identify significant alteration in 
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localization or phosphorylation of focal adhesions proteins FAK and Src 
during adhesion assays or interphase following CDK11 depletion; I have not 
examined whether CDK11 directly modulates other signaling proteins 
involved in cell migration. CDK11 may influence cell motility through its 
effects on splicing, with other mediators of splicing established to influence 
cell migration [327]. Furthermore, cancer cells are reported to vary from non-
cancerous cells in their use of alternate splice sites and this has been 
postulated to contribute to tumour biology and phenotypes such as cell 
migration [328]. This may therefore contribute to the effect of CDK11 on 
migration, as CDK11 is established to influence alternate splicing decisions 
[55]. 
Further work to interrogate the influence of CDK11 on migration may 
involve examining associated signaling pathways, such as with reverse 
protein arrays. Once again, it will be difficult to accurately interpret the 
results due to the wide-ranging effects of siRNA-mediated CDK11 depletion 
on transcription, splicing and mitosis. Unfortunately there are no specific 
inhibitors of CDK11 currently available to enable precise temporal regulation 
of the protein activity to characterize its influences more accurately. 
However, specific CDK11 inhibitors are under production for trial in the 
treatment of cancer; these inhibitors may facilitate this work.  
7.5	  CDK11	  Proteomics	  
My work examining the CDK11 interactome has identified numerous novel 
putative interactors. However, affinity purification of GST-tagged CDK11 
protein did not generate reproducible results, with only one of three 
interactors, chosen for validation, subsequently confirmed on repetition of 
the assay. Moreover, although GST.CDK11p58 consistently precipitated 
endogenous CSK, I was not able to demonstrate the interaction in vivo. These 
difficulties were likely a reflection of inherent weaknesses in the affinity 
purification protocol. However, work predicated on this finding did reveal 
alterations in Src phosphorylation during S phase on CDK11 knock-down; 
this requires further validation prior to investigation of its significance.  
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Immunoprecipitation of GFP-tagged CDK11 identified a significant number 
of established interactors, providing confidence in the validity of the assay. 
The good correlation between results of biological replicate experiments is 
also reassuring, when considering the reliability of the results.  
Examination of the CDK11 interactome revealed significant enrichment of 
spliceosomal proteins among putative CDK11 interactors in three of the four 
GFP.CDK11 co-immunoprecipitates. Interestingly, this was identified in both 
GFP.CDK11p58 co-immunoprecipitates and particularly at mitosis. It is 
uncertain whether this interaction with spliceosomal proteins contributes to 
CDK11’s mitotic regulation. CDK11p58 has not been implicated in splicing 
previously, although it too interacts with Cyclin L proteins containing RS 
domains. This result may indicate a role for CDK11p58 in splicing at mitosis, 
although splicing is generally considered to be suppressed during M phase. 
However, numerous spliceosomal proteins are reported to influence mitotic 
regulation. It remains unclear whether this occurs due to dysregulation of 
splicing in preceding interphase, dysregulated mitotic splicing or alternate 
non-splicing functions.  
I did not have the opportunity to confirm any novel CDK11 interactors but 
these findings may provide a foundation for further investigation by others. 
Several potentially interesting interactions were noted, including the 
interaction of CDK11p110 with members of the human Mediator complex. 
This is consistent with findings in yeast but it has not been demonstrated 
previously in metazoan species. In addition, I identified a putative role for 
CDK11 in ribosome biogenesis; this finding supports published work 
identifying CDK11 as a constituent of complexes engaged in ribosome 
biogenesis. Unpublished work has also identified the interaction of CDK11 
with DDX15, homologue of yeast PRP43, which has role in both splicing and 
ribosome biogenesis. My work confirms DDX15 as a putative CDK11 




7.6	  Review	  of	  Thesis	  Hypotheses	  
The overarching hypothesis predicating this thesis was that CDK11 may 
provide a therapeutic target in cancer. The aim of this thesis was to 
investigate CDK11’s role in both cancer and developmental phenotypes, 
through which to understand better the influence of CDK11 in cancer 
biology and its related pathways. This may allow the development of 
targeted synergistic therapies.  
In the Chapter 3, I explored the hypothesis that CDK11 directly mediates 
autophagy to effect the autophagy phenotype observed on CDK11 depletion. 
I aimed to determine whether the effects of CDK11 on autophagy were 
dissociable from its established roles at mitosis and transcription. It was 
apparent that the autophagy phenotype was closely associated with mitotic 
dysregulation. On CDK11 knockdown, there was a clear association between 
nuclear dysmorphology and accumulation of LC3 / p62 puncta. I established 
a temporal relationship between passage through mitosis and the autophagy 
phenotype, while cell cycle blockade abrogated both nuclear dysmorphology 
and the autophagy phenotype. Furthermore, the autophagy phenotype could 
be replicated through inhibition of an alternate mitotic regulator (PLK1). My 
findings therefore indicate that the autophagy phenotype observed on 
CDK11 depletion is primarily a response to mitotic catastrophe rather than 
direct mediation of autophagy.  
Whilst alone this does not exclude a direct influence on autophagy by 
CDK11, it does exclude a direct influence as the mechanism for the 
autophagy phenotype observed on CDK11 depletion. Furthermore, work 
undertaken in Chapter 5 did not demonstrate enrichment of autophagy-
related proteins in the any of the CDK11 co-immunoprecipitates. Moreover, 
although a small number of autophagy proteins were among the putative 
interactors, none were reciprocal between CDK11 isoforms, with both 
isoforms established to rescue the autophagy phenotype.  
In addition, in investigating the role of autophagy following aberrant 
mitoses, I examined the effect of autophagy depletion on the survival of 
aneuploid cell populations following induced chromosome mis-segregation. 
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I hypothesized that autophagy may mitigate the cellular stress engendered 
following aberrant chromosome segregation; therefore I aimed to establish 
whether autophagy depletion impaired the survival of aneuploid cell 
populations. I demonstrate evidence to support this hypothesis; furthermore 
studies published subsequent to my work also endorse this proposition. 
In Chapter 4, I examined the hypothesis that CDK11 directly regulates cancer 
cell migration. I confirmed that CDK11 depletion impaired cancer cell 
migration in breast cancer cells. I then aimed to determine whether this effect 
was distinct to its influence on mitosis and proliferation. I demonstrated that 
neither culture in serum free media or cell cycle blockade with thymidine 
abrogate the effect of CDK11 depletion, despite inhibiting cell mitosis and 
proliferation. I also demonstrate the impairment of migration following 
CDK11 knockdown with the use of single cell random migration assays, 
excluding the influence of impaired cell proliferation. 
CDK11 contains both SH2 and SH3 binding domains and has established 
roles in centriole biology; I therefore examined the hypothesis that CDK11 
may influence cell migration either via direct interaction with the 
cytoskeleton, specifically focal adhesions, or through effects on centriole 
biology and thereby cellular polarisation. I was unable to demonstrate direct 
interaction between CDK11 and focal adhesions or their prime constituents. 
Furthermore, following CDK11 depletion, I was unable to demonstrate 
consistent effects on focal adhesion signaling (via assays of Src and FAK 
phosphorylation) or influence on cellular adhesion to a substrate following 
culture in suspension. In addition, I did not demonstrate any significant 
effect on cellular polarisation using directional wound healing assays. 
Finally in Chapter 6, I explored the hypothesis that mutations within 
CDK11A/B may cause the cohesinopathy CdLS. This hypothesis was 
proposed due to the discovery of deletion of the CDK11 locus in a patient 
with CdLS and the established functions of CDK11 in cohesin biology at 
mitosis. I found no potentially causative variants within CDK11A or CDK11B 
in a cohort of CdLS probands, with no known causative mutation. 
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7.7	  CDK11:	  a	  therapeutic	  target	  in	  cancer	  
CDK11 inhibitors are currently under development, based on work in 
myeloma and osteosarcoma indicating CDK11 may present a therapeutic 
target. Understanding the biology of CDK11 both in cancer and in health 
may improve targeting or the development of synergistic therapies. Several 
inhibitors of alternate mitotic regulators are currently under investigation in 
the treatment of cancer, including PLK1 inhibitors. It is improbable that any 
of these therapies alone will constitute Ehrlich’s ‘zauberkugel’ or ‘magic 
bullet’. 
The majority of traditional chemotherapy agents target dividing cells, relying 
primarily on the rapid division of cancer cells to provide their limited 
specificity. Identifying pathways or proteins that are up-regulated in cancer 
cells may enable more specific therapies, limiting the side-effect of such 
agents. Moreover, these pathways or proteins may gain in influence in cancer 
cells such that these elements become critical for tumour survival. However, 
difficulties in targeting these pathways or proteins remain due to their 
functions in the biology of healthy, non-cancerous cells; this is true of 
CDK11. 
Nonetheless, identifying interdependent pathways specific to cancer cells 
may allow the development of combination chemotherapies that induce 
synthetic lethality. Autophagy appears to play a role following mitotic 
dysregulation; my work and that of others indicate that it is important for the 
survival of aneuploid cell populations. Targeting mitotic regulators such as 
CDK11 in addition to autophagy may therefore synergise therapy. Further 
work is required to investigate this hypothesis.  
7.8	  Conclusion	  
In conclusion, this thesis describes work I undertook to interrogate the role of 
CDK11 in cancer and developmental phenotypes. I have demonstrated the 
impact of mitotic dysregulation on autophagy and the role of autophagy in 
the maintenance of aneuploid populations in KRAS mutant cancer cells. I 
have identified both novel putative CDK11 interactors and novel 
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mechanisms through which CDK11 may mediate its functions. Further work 
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Protein	  significantly	  enriched	  in	  	  








Cyclin-­‐dependent	  kinase	  11B	   CDK11B	   9.04E+02	   8.29E-­‐06	  
Heat	  shock	  protein	  HSP	  90-­‐beta	   HSP90AB1	   4.79E+00	   8.19E-­‐08	  
Hsp90	  co-­‐chaperone	  Cdc37	   CDC37	   4.76E+01	   1.77E-­‐05	  
SAP30	  Binding	  Protein	   SAP30BP	   4.45E+02	   2.54E-­‐04	  
Heat	  shock	  protein	  HSP	  90-­‐alpha	   HSP90AA1	   7.32E+00	   4.16E-­‐07	  
Cyclin-­‐L1	   CCNL1	   9.62E+02	   1.03E-­‐06	  
Peptidyl-­‐prolyl	  cis-­‐trans	  isomerase	  FKBP5	   FKBP5	   1.88E+01	   7.80E-­‐04	  
Cyclin-­‐L2	   CCNL2	   2.19E+02	   2.78E-­‐04	  
Serine/arginine	  repetitive	  matrix	  protein	  
2	   SRRM2	   2.29E+00	   2.43E-­‐05	  
Cellular	  nucleic	  acid-­‐binding	  protein	   CNBP	   2.44E+00	   1.16E-­‐02	  
Pinin	   PNN	   1.09E+01	   3.08E-­‐02	  
Histone	  deacetylase	  complex	  subunit	  
SAP18	   SAP18	   2.93E+00	   1.98E-­‐02	  
Mitochondrial	  import	  inner	  membrane	  
translocase	  subunit	  TIM16	   PAM16	   3.99E+00	   2.85E-­‐06	  
Serine/arginine-­‐rich	  splicing	  factor	  6	   SRSF6	   3.21E+00	   2.60E-­‐03	  
CREB-­‐binding	  protein	   CREBBP	   2.01E+00	   1.81E-­‐02	  
Serine/arginine-­‐rich	  splicing	  factor	  1	   SRSF1	   2.21E+00	   6.27E-­‐03	  
Translocon-­‐associated	  protein	  subunit	  
gamma	   SSR3	   2.32E+00	   3.84E-­‐05	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BAG	  family	  molecular	  chaperone	  
regulator	  2	   BAG2	   2.56E+00	   1.50E-­‐03	  
RNA-­‐binding	  protein	  8A	   RBM8A	   4.60E+00	   1.87E-­‐02	  
26S	  proteasome	  non-­‐ATPase	  regulatory	  
subunit	  14	   PSMD14	   2.07E+00	   2.59E-­‐02	  
RNA-­‐binding	  protein	  with	  serine-­‐rich	  
domain	  1	   RNPS1	   3.47E+00	   3.36E-­‐02	  
Transformer-­‐2	  protein	  homolog	  beta	   TRA2B	   3.84E+00	   1.59E-­‐02	  
Survival	  of	  motor	  neuron-­‐related-­‐splicing	  
factor	  30	   SMNDC1	   2.50E+00	   1.51E-­‐02	  
Zinc	  finger	  protein	  638	   ZNF638	   2.06E+00	   1.70E-­‐03	  
Myosin-­‐11	   MYH11	   3.43E+08	   1.06E-­‐05	  
1-­‐phosphatidylinositol	  4,5-­‐bisphosphate	  
phosphodiesterase	  beta-­‐3	   PLCB3	   2.15E+00	   3.14E-­‐03	  
Myeloid	  leukemia	  factor	  2	   MLF2	   3.67E+00	   1.22E-­‐03	  
Serine/arginine-­‐rich	  splicing	  factor	  10	   SRSF10	   2.25E+00	   1.54E-­‐02	  








SERPINE1	  mRNA	  Binding	  Protein	   SERBP1	   3.13E+00	   2.69E-­‐02	  
Nibrin	   NBN	   2.03E+00	   2.95E-­‐03	  
Prefoldin	  subunit	  3	   VBP1	   2.50E+00	   4.95E-­‐02	  
Serine/threonine-­‐protein	  phosphatase	  5	   PPP5C	   2.13E+00	   1.11E-­‐03	  
Envoplakin	   EVPL	   3.75E+00	   4.39E-­‐02	  
Protein	  NPAT	   NPAT	   5.68E+00	   1.50E-­‐02	  
AN1-­‐type	  zinc	  finger	  protein	  3	   ZFAND3	   2.53E+00	   3.50E-­‐02	  
DnaJ	  homolog	  subfamily	  B	  member	  6	   DNAJB6	   2.26E+00	   7.13E-­‐03	  
Phospholipase	  A-­‐2-­‐activating	  protein	   PLAA	   2.21E+00	   2.40E-­‐02	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Serine/threonine-­‐protein	  kinase	  38	   STK38	   4.47E+00	   2.40E-­‐02	  
Tripartite	  motif-­‐containing	  protein	  38	   TRIM38	   2.01E+00	   3.13E-­‐02	  
Caspase-­‐3	   CASP3	   2.73E+00	   1.98E-­‐02	  
Transformer-­‐2	  protein	  homolog	  alpha	   TRA2A	   4.34E+00	   3.83E-­‐02	  
Protein	  YIF1A	   YIF1A	   3.78E+00	   3.38E-­‐03	  
Tubulin	  alpha-­‐4A	  chain	   TUBA4A	   2.49E+00	   1.61E-­‐02	  
Cell	  division	  cycle	  protein	  20	  homolog	   CDC20	   2.12E+00	   1.94E-­‐05	  
Adenylate	  kinase	  isoenzyme	  6	   TAF9	   3.54E+00	   4.37E-­‐02	  
Apolipoprotein	  D	   APOD	   5.03E+00	   1.08E-­‐04	  
DNA-­‐binding	  protein	  inhibitor	  ID-­‐1	   ID1	   3.25E+00	   8.43E-­‐03	  
Diphosphomevalonate	  decarboxylase	   MVD	   2.21E+00	   6.47E-­‐03	  
Inositol-­‐tetrakisphosphate	  1-­‐kinase	   ITPK1	   5.50E+00	   8.56E-­‐03	  
Signal	  peptidase	  complex	  subunit	  3	   SPCS3	   3.20E+00	   7.32E-­‐03	  
Transmembrane	  protein	  11,	  
mitochondrial	   TMEM11	   2.34E+00	   1.55E-­‐02	  
ERO1-­‐like	  protein	  alpha	   ERO1L	   2.03E+00	   1.04E-­‐02	  
RNA	  polymerase	  II	  subunit	  A	  C-­‐terminal	  
domain	  phosphatase	   CTDP1	   2.34E+00	   2.22E-­‐02	  
Proteasome	  subunit	  beta	  type-­‐7	   PSMB7	   3.07E+00	   4.38E-­‐03	  
Pachytene	  checkpoint	  protein	  2	  homolog	   TRIP13	   3.17E+07	   1.45E-­‐02	  
Peptide	  chain	  release	  factor	  1,	  
mitochondrial	   MTRF1	   1.36E+01	   2.34E-­‐02	  
Calcium-­‐binding	  mitochondrial	  carrier	  
protein	  SCaMC-­‐2	   SLC25A25	   3.36E+00	   4.07E-­‐02	  
Tumor	  protein	  p53-­‐inducible	  protein	  11	   TP53I11	   2.63E+00	   1.96E-­‐03	  
YLP	  motif-­‐containing	  protein	  1	   YLPM1	   2.26E+00	   1.05E-­‐03	  
Inactive	  tyrosine-­‐protein	  kinase	  7	   PTK7	   2.13E+00	   4.79E-­‐02	  
Receptor	  expression-­‐enhancing	  protein	  5	   REEP5	   2.35E+00	   2.43E-­‐02	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Aurora	  kinase	  B	   AURKB	   7.02E+00	   8.82E-­‐03	  
Cleft	  lip	  and	  palate	  transmembrane	  
protein	  1	   CLPTM1	   3.03E+00	   2.73E-­‐02	  
Amine	  oxidase	  [flavin-­‐containing]	  B	   MAOB	   2.05E+00	   1.05E-­‐04	  








Pre-­‐mRNA-­‐splicing	  factor	  CWC22	  
homolog	   CWC22	   2.44E+00	   4.02E-­‐02	  
Syntaxin-­‐18	   STX18	   2.04E+00	   1.87E-­‐02	  
E3	  ubiquitin-­‐protein	  ligase	  LRSAM1	   LRSAM1	   3.71E+00	   5.08E-­‐04	  
Protein	  FAM60A	   FAM60A	   3.21E+00	   3.42E-­‐03	  
A-­‐kinase	  anchor	  protein	  8	   AKAP8	   2.73E+00	   2.17E-­‐02	  
Forkhead	  box	  protein	  K2	   FOXK2	   6.54E+00	   4.57E-­‐02	  
Nitrilase	  homolog	  1	   NIT1	   1.43E+01	   1.45E-­‐02	  
UPF0510	  protein	  INM02	   C19orf63	   2.50E+00	   1.04E-­‐02	  
FAST	  kinase	  domain-­‐containing	  protein	  5	   FASTKD5	   5.96E+00	   6.17E-­‐04	  
Neurogranin;NEUG(55-­‐78)	   NRGN	   6.08E+00	   3.21E-­‐04	  
Ferritin	  heavy	  chain;Ferritin	   FTH1	   2.44E+01	   8.03E-­‐05	  
Sperm-­‐associated	  antigen	  7	   SPAG7	   2.65E+07	   1.49E-­‐02	  
Melanoma-­‐associated	  antigen	  G1	   NDNL2	   2.68E+00	   3.23E-­‐02	  
Ribonucleoprotein	  PTB-­‐binding	  2	   RAVER2	   2.21E+00	   2.84E-­‐02	  
AP-­‐1	  complex-­‐associated	  regulatory	  
protein	   AP1AR	   2.67E+00	   2.42E-­‐02	  
DnaJ	  homolog	  subfamily	  B	  member	  14	   DNAJB14	   4.36E+00	   9.94E-­‐07	  
Serine/threonine-­‐protein	  phosphatase	  6	  
regulatory	  subunit	  3	   PPP6R3	   1.01E+01	   5.34E-­‐03	  
NADH	  dehydrogenase	  [ubiquinone]	  1	   NDUFB3	   2.20E+00	   1.16E-­‐03	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beta	  subcomplex	  subunit	  3	  
Fanconi	  anemia	  group	  D2	  protein	   FANCD2	   3.22E+00	   2.27E-­‐04	  
Mitochondrial	  carnitine/acylcarnitine	  
carrier	  protein	  CACL	   SLC25A29	   4.49E+00	   3.04E-­‐02	  
Kelch-­‐like	  protein	  11	   KLHL11	   6.91E+00	   4.31E-­‐02	  
Histone	  H2B	  type	  3-­‐B	   HIST3H2BB	   3.36E+00	   1.48E-­‐03	  
ATP	  synthase	  subunit	  s-­‐like	  protein	   ATP5SL	   3.24E+00	   6.89E-­‐03	  
ADP-­‐ribose	  pyrophosphatase,	  
mitochondrial	   NUDT9	   2.06E+00	   1.50E-­‐02	  
Chitobiosyldiphosphodolichol	  beta-­‐
mannosyltransferase	   ALG1	   3.85E+07	   9.66E-­‐04	  
Probable	  tRNA	  pseudouridine	  synthase	  1	   TRUB1	   5.52E+00	   2.05E-­‐03	  
Nuclear	  pore	  glycoprotein	  p62	   NUP62	   6.85E+00	   1.31E-­‐02	  
Oxysterol-­‐binding	  protein-­‐related	  
protein	  9	   OSBPL9	   3.55E+00	   6.97E-­‐03	  
Polymerase	  delta-­‐interacting	  protein	  2	   POLDIP2	   2.90E+00	   1.00E-­‐02	  
GPN-­‐loop	  GTPase	  1	   GPN1	   2.27E+00	   1.69E-­‐04	  
Protein	  bicaudal	  D	  homolog	  2	   BICD2	   6.94E+00	   3.41E-­‐03	  
Serine/threonine-­‐protein	  phosphatase	  6	  








Spindle	  and	  kinetochore-­‐associated	  
protein	  3	   SKA3	   1.55E+07	   1.28E-­‐02	  
Ankyrin	  repeat	  domain-­‐containing	  
protein	  27	   ANKRD27	   3.47E+00	   9.44E-­‐03	  
52	  kDa	  repressor	  of	  the	  inhibitor	  of	  the	  
protein	  kinase	   PRKRIR	   9.32E+00	   9.62E-­‐05	  
Ubiquitin	  carboxyl-­‐terminal	  hydrolase	  
isozyme	  L5	   UCHL5	   2.23E+00	   1.82E-­‐02	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Ester	  hydrolase	  C11orf54	   C11orf54	   1.21E+07	   2.21E-­‐02	  
Ankyrin	  repeat	  domain-­‐containing	  
protein	  10	   ANKRD10	   1.87E+01	   1.27E-­‐02	  
Fanconi	  anemia	  group	  I	  protein	   FANCI	   2.29E+00	   9.47E-­‐03	  
Cell	  division	  control	  protein	  45	  homolog	   CDC45	   1.16E+01	   1.98E-­‐02	  
CTTNBP2	  N-­‐terminal-­‐like	  protein	   CTTNBP2NL	   2.50E+00	   4.08E-­‐02	  
Protein-­‐tyrosine	  phosphatase	  
mitochondrial	  1	   PTPMT1	   8.04E+00	   4.93E-­‐02	  
LysM	  and	  putative	  peptidoglycan-­‐binding	  
domain-­‐containing	  protein	  2	   LYSMD2	   6.75E+00	   1.61E-­‐02	  
Tubulin-­‐-­‐tyrosine	  ligase	   TTL	   2.23E+00	   3.97E-­‐02	  
Junction	  Plakoglobin	   JUP	   5.30E+00	   2.48E-­‐02	  
Calmodulin-­‐regulated	  spectrin-­‐
associated	  protein	  1	   CAMSAP1	   2.36E+00	   6.83E-­‐03	  
Nucleoside	  diphosphate	  kinase	  
6;Nucleoside	  diphosphate	  kinase	   NME6	   2.37E+00	   1.02E-­‐02	  
Peroxisomal	  membrane	  protein	  PEX14	   PEX14	   4.26E+00	   4.11E-­‐03	  
Box	  C/D	  snoRNA	  protein	  1	   ZNHIT6	   3.71E+00	   1.07E-­‐03	  
Syntaxin-­‐17	   STX17	   2.18E+00	   8.08E-­‐03	  
Neuroblastoma-­‐amplified	  sequence	   NBAS	   2.80E+00	   4.24E-­‐02	  
Nuclear	  pore	  complex	  protein	  Nup214	   NUP214	   2.10E+00	   4.08E-­‐02	  
DNA	  polymerase	  subunit	  gamma-­‐1	   POLG	   3.74E+00	   4.83E-­‐03	  
Mitochondrial	  import	  inner	  membrane	  
translocase	  subunit	  Tim17-­‐A	   TIMM17A	   2.31E+00	   1.35E-­‐03	  
H(+)/Cl(-­‐)	  exchange	  transporter	  3	   CLCN3	   2.22E+00	   3.86E-­‐02	  
Sentrin-­‐specific	  protease	  5	   SENP5	   3.24E+00	   1.24E-­‐02	  
Required	  for	  meiotic	  nuclear	  division	  
protein	  1	  homolog	   RMND1	   6.34E+00	   1.14E-­‐02	  
Protein	  Hook	  homolog	  1	   HOOK1	   2.24E+00	   5.57E-­‐03	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Serine/arginine-­‐rich	  splicing	  factor	  8	   SRSF8	   4.83E+00	   4.44E-­‐02	  
Neurotensin	  receptor	  type	  1	   NTSR1	   2.24E+00	   1.59E-­‐03	  
Heat	  shock	  70	  kDa	  protein	  12A	   HSPA12A	   7.04E+00	   3.88E-­‐05	  
Exonuclease	  1	   EXO1	   3.94E+00	   2.34E-­‐02	  








Protein	  transport	  protein	  Sec61	  subunit	  
gamma	   SEC61G	   2.84E+00	   3.26E-­‐02	  
SWI/SNF-­‐related	  matrix-­‐associated	  actin-­‐
dependent	  regulator	  of	  chromatin	  
subfamily	  E	  member	  1-­‐related	  
HMG20B	   1.41E+01	   3.70E-­‐04	  
Unconventional	  prefoldin	  RPB5	  
interactor	  1	   URI1	   3.51E+00	   2.96E-­‐04	  
Prostate	  tumor-­‐overexpressed	  gene	  1	  
protein	   PTOV1	   3.08E+00	   3.65E-­‐02	  
POU	  domain,	  class	  2,	  transcription	  factor	  
1	   POU2F1	   4.32E+00	   1.76E-­‐02	  
5-­‐3	  exoribonuclease	  1	   XRN1	   2.37E+00	   3.82E-­‐02	  
SH3	  domain-­‐binding	  protein	  1	   SH3BP1	   5.57E+00	   2.40E-­‐03	  
Solute	  carrier	  family	  25	  member	  46	   SLC25A46	   1.02E+01	   9.53E-­‐03	  
Peroxisomal	  acyl-­‐coenzyme	  A	  oxidase	  3	   ACOX3	   5.39E+00	   3.26E-­‐02	  
COMM	  domain-­‐containing	  protein	  6	   COMMD6	   5.26E+06	   1.17E-­‐03	  
Iron-­‐sulfur	  protein	  NUBPL	   NUBPL	   2.38E+00	   1.06E-­‐02	  
Absent	  in	  melanoma	  1	  protein	   AIM1	   4.64E+00	   2.05E-­‐02	  
Zinc	  finger	  protein	  8	   ZNF8	   1.09E+01	   2.77E-­‐06	  
Forkhead-­‐associated	  domain-­‐containing	  
protein	  1	   FHAD1	   2.00E+06	   1.13E-­‐02	  
Protein	  FAM168B	   FAM168B	   2.91E+07	   2.47E-­‐02	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Afadin	   MLLT4	   3.13E+00	   3.07E-­‐02	  
Transmembrane	  protein	  9	   TMEM9	   8.90E+00	   2.42E-­‐02	  
Bifunctional	  arginine	  demethylase	  and	  
lysyl-­‐hydroxylase	  JMJD6	   JMJD6	   1.09E+07	   1.16E-­‐03	  
Squalene	  monooxygenase	   SQLE	   3.83E+06	   1.30E-­‐02	  
R3H	  domain-­‐containing	  protein	  1	   R3HDM1	   8.25E+00	   3.26E-­‐02	  
Kinase	  D-­‐interacting	  substrate	  of	  220	  kDa	   KIDINS220	   9.36E+06	   1.36E-­‐02	  
Meiosis	  arrest	  female	  protein	  1	   KIAA0430	   5.40E+06	   1.29E-­‐02	  
Transmembrane	  protein	  85	   TMEM85	   2.09E+07	   1.04E-­‐02	  
Dermal	  papilla-­‐derived	  protein	  6	   DERP6	   5.72E+06	   8.42E-­‐04	  
Derlin-­‐2	   DERL2	   1.18E+07	   8.15E-­‐04	  
Zinc	  finger	  CCHC	  domain-­‐containing	  
protein	  10	   ZCCHC10	   7.69E+00	   4.89E-­‐02	  
	  
	  




Protein	  significantly	  enriched	  in	  	  
GFP.CDK11p110	  Nuc	  (Asynchronous)	  Co-­‐immunoprecipitate	  





Cyclin-­‐dependent	  kinase	  11B	   CDK11B	   1.62E+02	   2.07E-­‐04	  
Hsp90	  co-­‐chaperone	  Cdc37	   CDC37	   2.38E+00	   4.79E-­‐03	  
SAP30	  Binding	  Protein	   SAP30BP	   9.39E+01	   2.20E-­‐03	  
Cyclin-­‐L1	   CCNL1	   1.15E+02	   2.22E-­‐04	  
Cyclin-­‐L2	   CCNL2	   7.93E+01	   7.71E-­‐03	  
Cellular	  nucleic	  acid-­‐binding	  protein	   CNBP	   2.58E+00	   5.64E-­‐03	  
Pinin	   PNN	   2.15E+00	   3.85E-­‐02	  
Mediator	  of	  RNA	  polymerase	  II	  
transcription	  subunit	  23	   MED23	   2.17E+00	   3.16E-­‐02	  
Major	  vault	  protein	   MVP	   8.67E+00	   3.93E-­‐02	  
Retinoblastoma-­‐associated	  protein	   RB1	   2.37E+00	   3.78E-­‐02	  
Translocon-­‐associated	  protein	  subunit	  
gamma	   SSR3	   2.49E+00	   1.56E-­‐02	  
Negative	  elongation	  factor	  E	   RDBP	   2.24E+00	   1.31E-­‐05	  
Myosin-­‐11	   MYH11	   4.33E+08	   1.32E-­‐02	  
1-­‐phosphatidylinositol	  4,5-­‐bisphosphate	  
phosphodiesterase	  beta-­‐3	   PLCB3	   2.23E+00	   7.69E-­‐03	  
Glycerol-­‐3-­‐phosphate	  dehydrogenase,	  
mitochondrial	   GPD2	   2.34E+00	   1.55E-­‐02	  
Casein	  kinase	  II	  subunit	  alpha	   CSNK2A1	   1.06E+01	   1.04E-­‐02	  
Mitotic	  checkpoint	  serine/threonine-­‐
protein	  kinase	  BUB1	  beta	   BUB1B	   2.20E+00	   5.68E-­‐03	  
Peptidyl-­‐prolyl	  cis-­‐trans	  isomerase	  D	   PPID	   2.13E+00	   2.87E-­‐02	  
Ras-­‐related	  protein	  Rab-­‐1B	   RAB1B	   2.99E+00	   3.30E-­‐03	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SERPINE1	  mRNA	  Binding	  Protein	   SERBP1	   2.68E+00	   1.98E-­‐02	  
Pumilio	  homolog	  2	   PUM2	   2.90E+00	   1.85E-­‐02	  
Etoposide-­‐induced	  protein	  2.4	  homolog	   EI24	   2.26E+00	   9.82E-­‐03	  
Uncharacterized	  protein	  C19orf43	   C19orf43	   2.03E+00	   3.33E-­‐02	  
Prefoldin	  subunit	  3	   VBP1	   2.50E+00	   1.03E-­‐04	  
Pseudouridine	  synthase	   PUS1	   2.37E+00	   1.56E-­‐02	  
Serine/threonine-­‐protein	  kinase	  mTOR	   MTOR	   2.01E+00	   1.44E-­‐04	  
Cleavage	  and	  polyadenylation	  specificity	  
factor	  subunit	  4	   CPSF4	   2.82E+00	   4.81E-­‐02	  
AN1-­‐type	  zinc	  finger	  protein	  3	   ZFAND3	   2.52E+00	   1.74E-­‐02	  
DnaJ	  homolog	  subfamily	  B	  member	  6	   DNAJB6	   2.13E+00	   2.20E-­‐02	  
Phospholipase	  A-­‐2-­‐activating	  protein	   PLAA	   2.65E+00	   8.21E-­‐03	  
Small	  acidic	  protein	   SMAP	   2.14E+00	   6.33E-­‐04	  
Espin	   ESPN	   2.19E+00	   1.05E-­‐02	  





StAR-­‐related	  lipid	  transfer	  protein	  7,	  
mitochondrial	   STARD7	   2.22E+00	   2.48E-­‐02	  
Mediator	  of	  RNA	  polymerase	  II	  
transcription	  subunit	  27	   MED27	   3.15E+00	   8.20E-­‐03	  
Tripartite	  motif-­‐containing	  protein	  38	   TRIM38	   2.19E+00	   7.16E-­‐03	  
Poly	  [ADP-­‐ribose]	  polymerase	  4	   PARP4	   3.17E+00	   1.40E-­‐02	  
Caspase-­‐3;Caspase-­‐3	  subunit	  
p17;Caspase-­‐3	  subunit	  p12	   CASP3	   2.79E+00	   2.51E-­‐04	  
Tyrosine-­‐protein	  kinase	  Fer	   FER	   2.18E+00	   1.06E-­‐02	  
Dolichyl-­‐phosphate	  beta-­‐
glucosyltransferase	   ALG5	   2.01E+00	   3.39E-­‐02	  
Cell	  division	  cycle	  protein	  20	  homolog	   CDC20	   2.25E+00	   3.54E-­‐03	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Aurora	  kinase	  A	   AURKA	   2.19E+00	   8.35E-­‐04	  
Adenylate	  kinase	  isoenzyme	  6	   TAF9	   3.94E+00	   3.48E-­‐02	  
Interferon	  regulatory	  factor	  3	   IRF3	   8.92E+00	   1.38E-­‐02	  
Golgi	  resident	  protein	  GCP60	   ACBD3	   2.29E+00	   2.81E-­‐02	  
Exosome	  complex	  component	  RRP43	   EXOSC8	   2.42E+00	   2.77E-­‐02	  
DNA-­‐binding	  protein	  inhibitor	  ID-­‐1	   ID1	   3.27E+00	   2.17E-­‐03	  
Potential	  tRNA	  (adenine(58)-­‐N(1))-­‐
methyltransferase	  subunit	  TRMT61B	   TRMT61B	   2.39E+00	   1.61E-­‐02	  
Ubiquitin-­‐associated	  domain-­‐containing	  
protein	  2	   UBAC2	   2.76E+00	   4.04E-­‐02	  
Thymopoietin	   TMPO	   2.03E+00	   1.25E-­‐02	  
Diphosphomevalonate	  decarboxylase	   MVD	   2.53E+00	   1.55E-­‐03	  
Lupus	  La	  protein	   SSB	   2.27E+00	   1.84E-­‐03	  
Inositol-­‐tetrakisphosphate	  1-­‐kinase	   ITPK1	   5.62E+00	   4.04E-­‐02	  
Ubiquitin-­‐conjugating	  enzyme	  E2	  H	   UBE2H	   2.78E+00	   3.99E-­‐02	  
Tyrosine—tRNA	  ligase,	  cytoplasmic	   YARS	   3.28E+00	   4.06E-­‐02	  
Signal	  peptidase	  complex	  subunit	  3	   SPCS3	   2.45E+00	   1.84E-­‐02	  
Transmembrane	  protein	  11,	  
mitochondrial	   TMEM11	   2.05E+00	   2.33E-­‐02	  
Proteasome	  subunit	  beta	  type-­‐7	   PSMB7	   2.77E+00	   2.25E-­‐02	  
Type	  I	  inositol	  3,4-­‐bisphosphate	  4-­‐
phosphatase	   INPP4A	   2.54E+00	   5.38E-­‐03	  
Peptide	  chain	  release	  factor	  1,	  
mitochondrial	   MTRF1	   1.00E+01	   4.81E-­‐04	  
Protein	  NDRG1	   NDRG1	   2.86E+00	   3.33E-­‐03	  
Tumor	  protein	  p53-­‐inducible	  protein	  11	   TP53I11	   2.33E+00	   1.04E-­‐02	  
Translation	  initiation	  factor	  eIF-­‐2B	  
subunit	  beta	   EIF2B2	   2.05E+00	   4.39E-­‐02	  
RNMT-­‐activating	  mini	  protein	   FAM103A1	   2.06E+00	   7.85E-­‐03	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Zinc	  finger	  protein	  217	   ZNF217	   2.48E+00	   1.17E-­‐02	  





Receptor	  expression-­‐enhancing	  protein	  
5	   REEP5	   2.55E+00	   1.13E-­‐02	  
Aurora	  kinase	  B	   AURKB	   3.75E+00	   6.17E-­‐03	  
FERM	  domain-­‐containing	  protein	  8	   FRMD8	   2.23E+00	   3.83E-­‐03	  
Cyclin-­‐G-­‐associated	  kinase	   GAK	   2.04E+00	   4.75E-­‐03	  
SEC23-­‐interacting	  protein	   SEC23IP	   5.92E+00	   6.56E-­‐03	  
Pre-­‐mRNA-­‐splicing	  factor	  CWC22	  
homolog	   CWC22	   2.60E+00	   1.74E-­‐03	  
Receptor-­‐interacting	  serine/threonine-­‐
protein	  kinase	  2	   RIPK2	   2.60E+00	   4.94E-­‐03	  
Syntaxin-­‐18	   STX18	   2.39E+00	   8.93E-­‐03	  
39S	  ribosomal	  protein	  L52,	  
mitochondrial	   MRPL52	   2.28E+00	   4.34E-­‐03	  
Cytochrome	  c	  oxidase	  subunit	  6B1	   COX6B1	   2.27E+00	   3.79E-­‐02	  
FAST	  kinase	  domain-­‐containing	  protein	  
5	   FASTKD5	   8.15E+00	   7.21E-­‐05	  
ETS-­‐related	  transcription	  factor	  Elf-­‐2	   ELF2	   3.94E+00	   2.49E-­‐03	  
Bystin	   BYSL	   2.03E+00	   1.66E-­‐02	  
Selenoprotein	  O	   SELO	   3.06E+00	   3.43E-­‐02	  
Casein	  kinase	  II	  subunit	  alpha	   CSNK2A2	   1.04E+01	   1.76E-­‐02	  
Cyclin-­‐T2	   CCNT2	   2.15E+00	   4.22E-­‐03	  
ZW10	  interactor	   ZWINT	   3.72E+00	   3.41E-­‐03	  
Ribonucleoprotein	  PTB-­‐binding	  2	   RAVER2	   3.19E+00	   1.27E-­‐02	  
AP-­‐1	  complex-­‐associated	  regulatory	  
protein	   AP1AR	   2.39E+00	   2.56E-­‐02	  
DnaJ	  homolog	  subfamily	  B	  member	  14	   DNAJB14	   5.09E+00	   2.73E-­‐02	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Coatomer	  subunit	  gamma-­‐2	   COPG2	   2.64E+00	   7.83E-­‐03	  
Adenylyltransferase	  and	  
sulfurtransferase	  MOCS3	   MOCS3	   2.51E+00	   3.53E-­‐02	  
Ankyrin	  repeat	  and	  KH	  domain-­‐
containing	  protein	  1	   ANKHD1	   2.14E+00	   1.75E-­‐03	  
Serine/threonine-­‐protein	  phosphatase	  6	  
regulatory	  subunit	  3	   PPP6R3	   5.53E+00	   3.41E-­‐02	  
Protein	  PRR14L	   PRR14L	   2.02E+00	   2.82E-­‐02	  
DnaJ	  homolog	  subfamily	  C	  member	  17	   DNAJC17	   3.29E+00	   7.34E-­‐03	  
Fanconi	  anemia	  group	  D2	  protein	   FANCD2	   2.88E+00	   1.67E-­‐03	  
Kelch-­‐like	  protein	  11	   KLHL11	   6.53E+00	   2.37E-­‐02	  
ATP	  synthase	  subunit	  s-­‐like	  protein	   ATP5SL	   3.41E+00	   5.09E-­‐03	  
ADP-­‐ribose	  pyrophosphatase,	  
mitochondrial	   NUDT9	   2.33E+00	   1.02E-­‐02	  
Decaprenyl-­‐diphosphate	  synthase	  
subunit	  2	   PDSS2	   2.01E+07	   2.42E-­‐03	  
Actin-­‐binding	  LIM	  protein	  1	   ABLIM1	   2.24E+00	   3.43E-­‐02	  





Leucine-­‐rich	  repeat-­‐containing	  protein	  
41	   LRRC41	   2.17E+00	   3.11E-­‐03	  
Probable	  tRNA	  pseudouridine	  synthase	  
1	   TRUB1	   6.54E+00	   1.98E-­‐03	  
Nuclear	  pore	  glycoprotein	  p62	   NUP62	   7.37E+00	   8.06E-­‐03	  
Uncharacterized	  protein	  C18orf25	   C18orf25	   4.70E+00	   3.54E-­‐03	  
Origin	  recognition	  complex	  subunit	  6	   ORC6	   2.13E+00	   4.20E-­‐03	  
Eyes	  absent	  homolog	  3	   EYA3	   2.02E+00	   1.73E-­‐03	  
Oxysterol-­‐binding	  protein;Oxysterol-­‐
binding	  protein-­‐related	  protein	  9	   OSBPL9	   2.97E+00	   3.96E-­‐03	  
Serine—tRNA	  ligase,	  mitochondrial	   FBXO17	   2.74E+00	   1.39E-­‐02	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Protein	  FAM169A	   FAM169A	   2.33E+00	   4.16E-­‐02	  
Microtubule-­‐associated	  protein	  RP/EB	  
family	  member	  2	   MAPRE2	   3.72E+00	   3.99E-­‐02	  
D-­‐beta-­‐hydroxybutyrate	  dehydrogenase,	  
mitochondrial	   BDH1	   2.03E+00	   2.64E-­‐02	  
Transcription	  factor	  12	   TCF12	   2.57E+00	   1.44E-­‐03	  
Protein	  bicaudal	  D	  homolog	  2	   BICD2	   4.23E+00	   1.54E-­‐02	  
Serine/threonine-­‐protein	  phosphatase	  6	  
regulatory	  subunit	  1	   PPP6R1	   7.19E+00	   9.09E-­‐03	  
Ubiquinol-­‐cytochrome	  c	  reductase	  
complex	  chaperone	  CBP3	  homolog	   UQCC	   7.73E+00	   1.05E-­‐03	  
Lysophosphatidylcholine	  acyltransferase	  
1	   LPCAT1	   2.08E+00	   2.41E-­‐02	  
WD	  repeat-­‐containing	  protein	  70	   WDR70	   2.82E+00	   2.65E-­‐02	  
Long-­‐chain-­‐fatty-­‐acid—CoA	  ligase	  1	   ACSL1	   2.93E+00	   8.58E-­‐03	  
UPF0760	  protein	  C2orf29	   C2orf29	   2.17E+00	   1.17E-­‐02	  




DAK	   2.22E+00	   1.27E-­‐03	  
Mitochondrial	  tRNA-­‐specific	  2-­‐
thiouridylase	  1	   TRMU	   2.13E+00	   4.02E-­‐02	  
Pseudouridylate	  synthase	  7	  homolog	   PUS7	   6.17E+00	   1.79E-­‐03	  
Tripartite	  motif-­‐containing	  protein	  26	   TRIM26	   6.16E+00	   1.76E-­‐04	  
Ester	  hydrolase	  C11orf54	   C11orf54	   1.40E+07	   3.62E-­‐03	  
Unconventional	  myosin-­‐IXb	   MYO9B	   2.98E+00	   4.51E-­‐02	  
Fanconi	  anemia	  group	  I	  protein	   FANCI	   2.34E+00	   6.89E-­‐03	  
Cell	  division	  control	  protein	  45	  homolog	   CDC45	   1.06E+01	   7.66E-­‐03	  
Alpha-­‐1,3/1,6-­‐mannosyltransferase	  
ALG2	   ALG2	   3.86E+00	   3.62E-­‐02	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CTTNBP2	  N-­‐terminal-­‐like	  protein	   CTTNBP2NL	   2.10E+00	   2.53E-­‐02	  
Protein-­‐tyrosine	  phosphatase	  
mitochondrial	  1	   PTPMT1	   6.21E+00	   4.42E-­‐02	  





DNA	  primase;DNA	  primase	  small	  
subunit	   PRIM1	   5.01E+00	   4.58E-­‐03	  
Golgin	  subfamily	  A	  member	  4	   GOLGA4	   3.35E+00	   4.44E-­‐03	  
Probable	  asparagine—tRNA	  ligase,	  
mitochondrial	   NARS2	   2.38E+00	   2.38E-­‐02	  
UPF0544	  protein	  C5orf45	   C5orf45	   2.03E+00	   2.80E-­‐03	  
Tubulin-­‐specific	  chaperone	  D	   TBCD	   2.12E+00	   3.73E-­‐02	  
Cysteine	  protease	  ATG4B	   ATG4B	   2.24E+00	   7.56E-­‐03	  
Pantothenate	  kinase	  4	   PANK4	   3.02E+00	   1.47E-­‐02	  
Calmodulin-­‐regulated	  spectrin-­‐
associated	  protein	  1	   CAMSAP1	   2.41E+00	   5.24E-­‐03	  
Ephexin-­‐1	   NGEF	   7.02E+00	   3.77E-­‐02	  
Nucleoside	  diphosphate	  kinase	  6	   NME6	   2.04E+00	   7.12E-­‐03	  
Peroxisomal	  membrane	  protein	  PEX14	   PEX14	   3.53E+00	   4.33E-­‐02	  
G	  patch	  domain-­‐containing	  protein	  8	   GPATCH8	   2.27E+00	   1.39E-­‐02	  
Box	  C/D	  snoRNA	  protein	  1	   ZNHIT6	   3.37E+00	   8.13E-­‐03	  
Syntaxin-­‐17	   STX17	   2.64E+00	   4.08E-­‐03	  
Neuroblastoma-­‐amplified	  sequence	   NBAS	   5.89E+00	   3.02E-­‐03	  
Solute	  carrier	  family	  12	  member	  2	   SLC12A2	   4.13E+00	   1.97E-­‐04	  
Integrin	  alpha-­‐6;Integrin	  alpha-­‐6	  heavy	  
chain	   ITGA6	   3.65E+00	   9.99E-­‐03	  
6-­‐phosphofructo-­‐2-­‐kinase	   PFKFB4	   6.51E+00	   3.11E-­‐02	  
E3	  ubiquitin-­‐protein	  ligase	  UBR3	   UBR3	   2.21E+00	   3.20E-­‐02	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Fragile	  X	  mental	  retardation	  protein	  1	   FMR1	   3.03E+00	   1.30E-­‐02	  
Eukaryotic	  translation	  initiation	  factor	  
2D	   EIF2D	   1.33E+07	   4.20E-­‐02	  
Eukaryotic	  translation	  initiation	  factor	  3	  
subunit	  M	   EIF3M	   2.34E+00	   4.81E-­‐02	  
Protein	  NEDD1	   NEDD1	   2.06E+00	   4.01E-­‐02	  
Transmembrane	  protein	  209	   TMEM209	   5.59E+00	   2.26E-­‐02	  
Arginine-­‐glutamic	  acid	  dipeptide	  repeats	  
protein	   RERE	   3.66E+07	   8.35E-­‐04	  
A/G-­‐specific	  adenine	  DNA	  glycosylase	   MUTYH	   2.22E+00	   6.78E-­‐03	  
Neurotensin	  receptor	  type	  1	   NTSR1	   2.44E+00	   3.63E-­‐03	  
Heat	  shock	  70	  kDa	  protein	  12A	   HSPA12A	   5.75E+00	   4.28E-­‐02	  
Exonuclease	  1	   EXO1	   6.49E+00	   7.47E-­‐04	  
Presenilin-­‐1	   PSEN1	   9.13E+06	   1.62E-­‐03	  
Coiled-­‐coil-­‐helix-­‐coiled-­‐coil-­‐helix	  
domain-­‐containing	  protein	  8	   CHCHD8	   5.63E+00	   4.43E-­‐03	  





Enoyl-­‐CoA	  delta	  isomerase	  1,	  
mitochondrial	   ECI1	   3.03E+00	   4.61E-­‐02	  
SWI/SNF-­‐related	  matrix-­‐associated	  
actin-­‐dependent	  regulator	  of	  chromatin	  	   HMG20B	   9.25E+00	   4.00E-­‐02	  
Prostate	  tumor-­‐overexpressed	  gene	  1	  
protein	   PTOV1	   4.07E+00	   2.20E-­‐02	  
Guanine	  nucleotide-­‐binding	  protein	  
G(I)/G(S)/G(O)	  subunit	  gamma-­‐7	   GNG7	   5.80E+00	   3.93E-­‐03	  
YY1-­‐associated	  factor	  2	   YAF2	   5.29E+00	   5.02E-­‐03	  
POU	  domain,	  class	  2,	  transcription	  
factor	  1	   POU2F1	   3.67E+00	   1.12E-­‐02	  
5-­‐3	  exoribonuclease	  1	   XRN1	   2.48E+00	   2.94E-­‐02	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SH3	  domain-­‐binding	  protein	  1	   SH3BP1	   4.81E+00	   1.45E-­‐02	  
Solute	  carrier	  family	  25	  member	  46	   SLC25A46	   6.53E+00	   4.93E-­‐02	  
MAP7	  domain-­‐containing	  protein	  1	   MAP7D1	   2.40E+00	   2.36E-­‐02	  
Peroxisomal	  acyl-­‐coenzyme	  A	  oxidase	  3	   ACOX3	   5.48E+00	   1.66E-­‐02	  
Frizzled-­‐6	   FZD6	   2.49E+00	   3.20E-­‐02	  
Protein	  C10	   C12orf57	   2.69E+00	   3.26E-­‐02	  
COMM	  domain-­‐containing	  protein	  6	   COMMD6	   7.28E+06	   4.56E-­‐03	  
Zinc	  transporter	  ZIP10	   SLC39A10	   2.01E+00	   9.41E-­‐03	  
Cation-­‐independent	  mannose-­‐6-­‐
phosphate	  receptor	   IGF2R	   3.33E+06	   1.25E-­‐02	  
Exocyst	  complex	  component	  6	   EXOC6	   7.23E+00	   3.72E-­‐02	  
Transmembrane	  emp24	  domain-­‐
containing	  protein	  1	   TMED1	   3.07E+00	   3.21E-­‐02	  
Galectin-­‐3-­‐binding	  protein	   LGALS3BP	   2.73E+00	   2.37E-­‐02	  
Protein	  RUFY3	   RUFY3	   7.36E+06	   1.09E-­‐02	  
Pre-­‐B-­‐cell	  leukemia	  transcription	  factor-­‐
interacting	  protein	  1	   PBXIP1	   2.21E+00	   9.77E-­‐03	  
UPF0554	  protein	  C2orf43	   C2orf43	   3.96E+00	   3.26E-­‐02	  
Armadillo	  repeat	  protein	  deleted	  in	  
velo-­‐cardio-­‐facial	  syndrome	   ARVCF	   3.26E+00	   3.87E-­‐02	  
Apolipoprotein	  A2	   APOA2	   3.81E+00	   4.59E-­‐02	  
Coxsackievirus	  and	  adenovirus	  receptor	   CXADR	   3.10E+00	   4.94E-­‐02	  
Vacuolar	  protein	  sorting-­‐associated	  
protein	  VTA1	  homolog	   VTA1	   2.85E+00	   1.37E-­‐02	  
R3H	  domain-­‐containing	  protein	  1	   R3HDM1	   1.54E+01	   9.08E-­‐05	  
Gephyrin	   GPHN	   2.84E+00	   3.85E-­‐03	  
Vacuole	  membrane	  protein	  1	   VMP1	   9.30E+06	   1.78E-­‐02	  
Thrombospondin-­‐2	   THBS2	   1.63E+07	   2.23E-­‐02	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Zinc	  fingers	  and	  homeoboxes	  protein	  2	   ZHX2	   4.75E+00	   2.94E-­‐02	  
Dermal	  papilla-­‐derived	  protein	  6	   DERP6	   7.22E+06	   3.62E-­‐07	  





Derlin-­‐2	   DERL2	   1.31E+07	   1.88E-­‐06	  
Zinc	  finger	  protein	  292	   ZNF292	   8.66E+00	   3.99E-­‐02	  
Signal	  transducing	  adapter	  molecule	  2	   STAM2	   4.56E+00	   3.78E-­‐03	  
Serine/threonine-­‐protein	  kinase	  Chk2	   CHEK2	   6.56E+00	   2.65E-­‐04	  
Glutathione	  peroxidase	  1	   GPX1	   2.45E+00	   1.70E-­‐02	  
Pyruvate	  carboxylase,	  mitochondrial	   PC	   2.41E+00	   1.17E-­‐02	  
Kinesin-­‐like	  protein	  KIF7	   KIF7	   2.96E+00	   3.30E-­‐03	  
Transcription	  factor	  Sp6	   SP6	   3.09E+00	   1.31E-­‐02	  
Tight	  junction-­‐associated	  protein	  1	   TJAP1	   5.65E+00	   4.88E-­‐02	  
Probable	  alpha-­‐ketoglutarate-­‐
dependent	  dioxygenase	  ABH5	   ALKBH5	   4.07E+00	   3.36E-­‐03	  
Fidgetin-­‐like	  protein	  1	   FIGNL1	   2.53E+06	   4.99E-­‐02	  
Protein	  phosphatase	  1	  reg.	  subunit	  21	   PPP1R21	   5.28E+00	   1.42E-­‐02	  
Poly(ADP-­‐ribose)	  glycohydrolase	   PARG	   3.06E+00	   8.64E-­‐03	  
Neuron	  navigator	  1	   NAV1	   1.32E+01	   1.72E-­‐02	  
F-­‐box	  only	  protein	  30	   FBXO30	   3.50E+06	   3.19E-­‐03	  
Zinc	  finger	  CCHC	  domain-­‐containing	  
protein	  10	   ZCCHC10	   1.27E+01	   1.24E-­‐02	  
WD	  repeat-­‐containing	  protein	  C2orf44	   C2orf44	   1.57E+09	   6.06E-­‐04	  




Protein	  significantly	  enriched	  in	  	  
GFP.CDK11p58	  Mit	  (Synchronised	  Mitosis)	  Co-­‐immunoprecipitate	  





Cyclin-­‐dependent	  kinase	  11B	   CDK11B	   1.89E+03	   3.16E-­‐04	  
Heat	  shock	  protein	  HSP	  90-­‐beta	   HSP90AB1	   1.87E+01	   1.96E-­‐06	  
Hsp90	  co-­‐chaperone	  Cdc37	   CDC37	   5.45E+01	   3.76E-­‐04	  
SAP30	  Binding	  Protein	   SAP30BP	   3.76E+02	   1.96E-­‐03	  
Tubulin	  beta-­‐4B	  chain	   TUBB4B	   2.65E+00	   2.30E-­‐02	  
Tubulin	  alpha-­‐1B	  chain	   TUBA1B	   2.72E+00	   4.05E-­‐02	  
Heat	  shock	  cognate	  71	  kDa	  protein	   HSPA8	   3.25E+00	   1.40E-­‐02	  
Heat	  shock	  protein	  HSP	  90-­‐alpha	   HSP90AA1	   4.40E+01	   1.42E-­‐05	  
Cyclin-­‐L1	   CCNL1	   1.78E+03	   1.93E-­‐03	  
78	  kDa	  glucose-­‐regulated	  protein	   HSPA5	   3.58E+00	   2.76E-­‐03	  
RuvB-­‐like	  2	   RUVBL2	   2.53E+00	   2.50E-­‐02	  
Tubulin	  beta	  chain	   TUBB	   3.01E+00	   2.77E-­‐02	  
RuvB-­‐like	  1	   RUVBL1	   2.90E+00	   4.35E-­‐02	  
Peptidyl-­‐prolyl	  cis-­‐trans	  isomerase	  
FKBP5	   FKBP5	   1.28E+02	   7.31E-­‐03	  
Eukaryotic	  initiation	  factor	  4A-­‐III	   EIF4A3	   6.37E+00	   4.58E-­‐02	  
Cyclin-­‐L2	   CCNL2	   9.99E+02	   1.00E-­‐02	  
60S	  ribosomal	  protein	  L38	   RPL38	   2.44E+00	   1.61E-­‐02	  
Heat	  shock	  70	  kDa	  protein	  1A/1B	   HSPA1B	   4.39E+00	   3.58E-­‐02	  
Ribosomal	  Protein	  L10	   RPL10	   2.81E+00	   4.11E-­‐02	  
Translational	  activator	  GCN1	   GCN1L1	   2.08E+00	   3.00E-­‐02	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Serine/arginine-­‐rich	  splicing	  factor	  3	   SRSF3	   3.63E+00	   3.94E-­‐02	  
Polyadenylate-­‐binding	  protein	  1	   PABPC1	   3.42E+00	   1.97E-­‐03	  
60S	  acidic	  ribosomal	  protein	  P2	   RPLP2	   2.65E+00	   4.42E-­‐02	  
Cyclin-­‐dependent	  kinase	  1	   CDK1	   2.15E+00	   2.91E-­‐02	  
Long-­‐chain-­‐fatty-­‐acid-­‐-­‐CoA	  ligase	  5	   ACSL5	   2.21E+00	   4.87E-­‐03	  
Ras-­‐related	  protein	  Rab-­‐14	   RAB14	   2.64E+00	   4.27E-­‐02	  
Trans-­‐2,3-­‐enoyl-­‐CoA	  reductase	   TECR	   5.00E+00	   3.95E-­‐02	  
Exportin-­‐1	   XPO1	   3.61E+00	   4.22E-­‐03	  
Complement	  component	  1	  Q	  
subcomponent-­‐binding	  protein	   C1QBP	   5.37E+00	   1.52E-­‐02	  
DnaJ	  homolog	  subfamily	  A	  member	  1	   DNAJA1	   3.96E+00	   2.82E-­‐02	  
Translocon-­‐associated	  protein	  subunit	  
delta	   SSR4	   2.23E+00	   4.05E-­‐02	  
60S	  ribosomal	  protein	  L39	   RPL39	   2.97E+00	   2.87E-­‐02	  
Ras-­‐related	  protein	  Rab-­‐11B	   RAB11B	   2.15E+00	   3.85E-­‐02	  
U5	  small	  nuclear	  ribonucleoprotein	  200	  
kDa	  helicase	   SNRNP200	   2.78E+00	   3.66E-­‐02	  





Mitochondrial	  import	  inner	  membrane	  
translocase	  subunit	  TIM44	   TIMM44	   2.50E+00	   4.57E-­‐02	  
Heterogeneous	  nuclear	  
ribonucleoprotein	  L	   HNRNPL	   4.85E+00	   4.59E-­‐02	  
DNA	  topoisomerase	  1	   TOP1	   2.36E+00	   3.37E-­‐02	  
40S	  ribosomal	  protein	  S26	   RPS26	   2.94E+00	   3.94E-­‐02	  
Thyroid	  hormone	  receptor-­‐associated	  
protein	  3	   THRAP3	   6.06E+00	   4.87E-­‐03	  
THO	  complex	  subunit	  4	   ALYREF	   3.31E+00	   2.73E-­‐02	  
Emerin	   EMD	   2.45E+00	   4.57E-­‐02	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26S	  protease	  regulatory	  subunit	  10B	   PSMC6	   3.37E+00	   3.39E-­‐02	  
Perilipin-­‐3	   PLIN3	   2.04E+00	   4.18E-­‐02	  
Bcl-­‐2-­‐associated	  transcription	  factor	  1	   BCLAF1	   5.28E+00	   8.15E-­‐04	  
Mitochondrial	  import	  inner	  membrane	  
translocase	  subunit	  TIM16	   PAM16	   9.99E+00	   1.51E-­‐03	  
26S	  protease	  regulatory	  subunit	  6B	   PSMC4	   3.19E+00	   4.85E-­‐02	  
Putative	  pre-­‐mRNA-­‐splicing	  factor	  ATP-­‐
dependent	  RNA	  helicase	  DHX15	   DHX15	   3.51E+00	   1.72E-­‐02	  
Serine/arginine-­‐rich	  splicing	  factor	  6	   SRSF6	   4.45E+00	   2.08E-­‐02	  
Hemoglobin	  subunit	  alpha	   HBA1	   4.10E+00	   1.82E-­‐02	  
Nuclear	  pore	  complex	  protein	  Nup93	   NUP93	   2.43E+00	   3.46E-­‐02	  
Serine/arginine-­‐rich	  splicing	  factor	  1	   SRSF1	   7.07E+00	   1.64E-­‐02	  
Polyadenylate-­‐binding	  protein	  4	   PABPC4	   3.53E+00	   1.51E-­‐03	  
Heterogeneous	  nuclear	  
ribonucleoproteins	  C1/C2	   HNRNPC	   4.31E+00	   9.32E-­‐03	  
Calnexin	   CANX	   2.50E+00	   2.69E-­‐02	  
Methionine-­‐-­‐tRNA	  ligase,	  cytoplasmic	   MARS	   2.25E+00	   3.09E-­‐02	  
RNA-­‐binding	  motif	  protein,	  X	  	   RBMX	   2.72E+00	   2.72E-­‐02	  
Exportin-­‐2	   CSE1L	   2.10E+00	   2.93E-­‐02	  
Pre-­‐mRNA-­‐processing-­‐splicing	  factor	  8	   PRPF8	   2.72E+00	   2.05E-­‐02	  
Proteasome	  subunit	  beta	  type-­‐2	   PSMB2	   2.19E+00	   3.31E-­‐02	  
Enhancer	  of	  rudimentary	  homolog	   ERH	   5.10E+00	   2.86E-­‐03	  
26S	  protease	  regulatory	  subunit	  6A	   PSMC3	   2.79E+00	   4.26E-­‐02	  
U5	  small	  nuclear	  ribonucleoprotein	  40	  
kDa	  protein	   SNRNP40	   4.31E+00	   3.02E-­‐02	  
26S	  proteasome	  non-­‐ATPase	  regulatory	  
subunit	  11	   PSMD11	   4.91E+00	   3.65E-­‐02	  
Aspartyl/asparaginyl	  beta-­‐hydroxylase	   ASPH	   2.76E+00	   2.96E-­‐02	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Serine/arginine-­‐rich	  splicing	  factor	  7	   SRSF7	   6.86E+00	   1.23E-­‐02	  
Cell	  division	  cycle	  5-­‐like	  protein	   CDC5L	   3.33E+00	   3.07E-­‐02	  
Cytoskeleton-­‐associated	  protein	  5	   CKAP5	   2.59E+00	   4.23E-­‐02	  





26S	  proteasome	  non-­‐ATPase	  regulatory	  
subunit	  14	   PSMD14	   3.64E+00	   4.72E-­‐02	  
Signal	  recognition	  particle	  receptor	  
subunit	  alpha	   SRPR	   2.12E+00	   4.70E-­‐03	  
RNA-­‐binding	  protein	  with	  serine-­‐rich	  
domain	  1	   RNPS1	   7.72E+00	   2.26E-­‐02	  
TFIIH	  basal	  transcription	  factor	  complex	  
helicase	  XPD	  subunit	   ERCC2	   2.63E+00	   6.39E-­‐03	  
4F2	  cell-­‐surface	  antigen	  heavy	  chain	   SLC3A2	   2.91E+00	   4.01E-­‐02	  
Serine/arginine-­‐rich	  splicing	  factor	  4	   SRSF4	   3.07E+00	   2.84E-­‐02	  
Tyrosine-­‐protein	  phosphatase	  non-­‐
receptor	  type	  1	   PTPN1	   2.71E+00	   4.15E-­‐02	  
Aldehyde	  dehydrogenase	  X,	  
mitochondrial	   ALDH1B1	   2.21E+00	   2.52E-­‐02	  
Proteasome	  activator	  complex	  subunit	  
3	   PSME3	   2.93E+00	   4.46E-­‐02	  
Pre-­‐mRNA-­‐processing	  factor	  19	   PRPF19	   2.43E+00	   2.97E-­‐02	  
Uncharacterized	  protein	  C12orf50	   C12orf50	   5.41E+01	   4.41E-­‐02	  
1-­‐acyl-­‐sn-­‐glycerol-­‐3-­‐phosphate	  
acyltransferase	  epsilon	   AGPAT5	   3.05E+00	   1.59E-­‐02	  
Ubiquitin	  carboxyl-­‐terminal	  hydrolase	  
L5	   UCHL5	   2.97E+00	   4.62E-­‐02	  







PISD	   2.69E+00	   3.60E-­‐02	  
Lysine-­‐-­‐tRNA	  ligase	   KARS	   2.19E+00	   3.79E-­‐02	  
RNA-­‐binding	  protein	  39	   RBM39	   2.19E+00	   3.54E-­‐02	  
Leucine-­‐zipper-­‐like	  transcriptional	  
regulator	  1	   LZTR1	   1.84E+01	   2.87E-­‐02	  
NADH	  dehydrogenase	  [ubiquinone]	  
iron-­‐sulfur	  protein	  7,	  mitochondrial	   NDUFS7	   2.21E+00	   4.88E-­‐02	  
Histone	  acetyltransferase	  KAT8	   KAT8	   7.34E+00	   1.76E-­‐02	  
Casein	  kinase	  II	  subunit	  alpha	   CSNK2A1	   5.60E+00	   2.77E-­‐02	  
HIG1	  domain	  family	  member	  1A	   HIGD1A	   2.57E+00	   2.42E-­‐02	  
Abl	  interactor	  2	   ABI2	   2.37E+01	   2.15E-­‐02	  
Apoptotic	  chromatin	  condensation	  
inducer	  in	  the	  nucleus	   ACIN1	   7.65E+00	   2.15E-­‐02	  
Myeloid	  leukemia	  factor	  2	   MLF2	   2.35E+00	   6.76E-­‐03	  
Serine/arginine-­‐rich	  splicing	  factor	  10	   SRSF10	   7.73E+00	   1.74E-­‐02	  





Suppressor	  of	  tumorigenicity	  14	  protein	   ST14	   2.14E+00	   3.77E-­‐02	  
Growth	  arrest	  and	  DNA	  damage-­‐
inducible	  proteins-­‐interacting	  protein	  1	   GADD45GIP1	   3.07E+00	   4.15E-­‐02	  
Serine/arginine-­‐rich	  splicing	  factor	  9	   SRSF9	   7.62E+00	   1.02E-­‐02	  
Prostaglandin	  E	  synthase	  2	   PTGES2	   2.14E+00	   4.24E-­‐03	  
Tumour	  Protein	  D52	   TPD52	   2.02E+00	   2.30E-­‐03	  
Syntaxin-­‐binding	  protein	  3	   STXBP3	   2.33E+00	   3.37E-­‐02	  
Myb-­‐binding	  protein	  1A	   MYBBP1A	   2.28E+00	   4.07E-­‐02	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Sodium-­‐coupled	  neutral	  amino	  acid	  
transporter	  2	   SLC38A2	   3.04E+00	   4.78E-­‐02	  
Integrator	  complex	  subunit	  1	   INTS1	   2.29E+00	   3.32E-­‐02	  
Origin	  recognition	  complex	  subunit	  3	   ORC3	   5.16E+00	   3.10E-­‐02	  
Cleavage	  and	  polyadenylation	  
specificity	  factor	  subunit	  2	   CPSF2	   4.12E+00	   4.36E-­‐02	  
U1	  small	  nuclear	  ribonucleoprotein	  70	  
kDa	   SNRNP70	   3.62E+00	   4.53E-­‐02	  
Stromal	  interaction	  molecule	  2	   STIM2	   3.32E+00	   2.13E-­‐02	  
Coiled-­‐coil	  domain-­‐containing	  protein	  
51	   CCDC51	   3.71E+00	   2.66E-­‐02	  
DnaJ	  homolog	  subfamily	  A	  member	  2	   DNAJA2	   4.33E+00	   2.91E-­‐02	  
Uncharacterized	  protein	  C2orf47,	  
mitochondrial	   C2orf47	   2.88E+00	   9.16E-­‐03	  
26S	  proteasome	  non-­‐ATPase	  regulatory	  
subunit	  13	   PSMD13	   3.42E+00	   2.79E-­‐02	  
Matrin-­‐3	   MATR3	   2.37E+00	   4.99E-­‐02	  
TATA-­‐binding	  protein-­‐associated	  factor	  
172	   BTAF1	   2.86E+00	   2.37E-­‐02	  
Multidrug	  resistance-­‐associated	  protein	  
1	   ABCC1	   3.28E+00	   2.96E-­‐02	  
Serine/threonine-­‐protein	  kinase	  PLK1	   PLK1	   2.31E+00	   2.95E-­‐02	  
Serine/threonine-­‐protein	  phosphatase	  
5	   PPP5C	   5.39E+00	   1.90E-­‐02	  
60	  kDa	  SS-­‐A/Ro	  ribonucleoprotein	   TROVE2	   3.68E+00	   2.24E-­‐02	  
Zinc	  transporter	  SLC39A7	   SLC39A7	   1.28E+01	   7.59E-­‐03	  
Stromal	  cell-­‐derived	  factor	  2-­‐like	  
protein	  1	   SDF2L1	   4.28E+00	   4.56E-­‐02	  
Ras-­‐related	  protein	  Rab-­‐21	   RAB21	   2.50E+00	   2.05E-­‐02	  
Proteasome	  activator	  complex	  subunit	  
1	   PSME1	   2.83E+00	   2.18E-­‐02	  
Page 273
Tubulin	  beta-­‐2A	  chain	   TUBB2A	   2.19E+00	   3.78E-­‐02	  
Ubiquilin-­‐1	   UBQLN1	   2.40E+00	   3.04E-­‐04	  





Pre-­‐mRNA-­‐processing	  factor	  40	  
homolog	  A	   PRPF40A	   4.09E+00	   2.11E-­‐02	  
Activating	  signal	  cointegrator	  1	  complex	  
subunit	  3	   ASCC3	   2.11E+00	   4.54E-­‐02	  
Calcium-­‐transporting	  ATPase	  type	  2C	  
member	  1	   ATP2C1	   2.06E+00	   3.90E-­‐02	  
Pre-­‐mRNA-­‐splicing	  factor	  SPF27	   BCAS2	   2.91E+00	   2.88E-­‐02	  
Reticulon-­‐4	   RTN4	   3.22E+00	   4.59E-­‐04	  
Protein	  LLP	  homolog	   LLPH	   7.29E+00	   1.28E-­‐02	  
Mitotic	  spindle-­‐associated	  MMXD	  
complex	  subunit	  MIP18	   FAM96B	   2.28E+00	   2.13E-­‐02	  
Alpha-­‐globin	  transcription	  factor	  CP2	   TFCP2	   2.92E+00	   2.07E-­‐02	  
Suppressor	  of	  G2	  allele	  of	  SKP1	  
homolog	   SUGT1	   3.66E+00	   1.87E-­‐02	  
3-­‐beta-­‐hydroxysteroid-­‐
Delta(8),Delta(7)-­‐isomerase	   EBP	   3.66E+00	   2.26E-­‐03	  
Heterogeneous	  nuclear	  
ribonucleoprotein	  U-­‐like	  protein	  2	   HNRNPUL2	   5.35E+00	   3.98E-­‐02	  
Multiple	  myeloma	  tumor-­‐associated	  
protein	  2	   MMTAG2	   2.47E+00	   2.89E-­‐02	  
Cleavage	  and	  polyadenylation	  
specificity	  factor	  subunit	  3	   CPSF3	   7.01E+00	   3.94E-­‐02	  
Transformer-­‐2	  protein	  homolog	  alpha	   TRA2A	   1.40E+01	   2.13E-­‐02	  
RNA-­‐binding	  protein	  Raly	   RALY	   2.54E+00	   1.91E-­‐02	  
Programmed	  cell	  death	  protein	  6	   PDCD6	   6.60E+00	   3.23E-­‐02	  
SRSF	  protein	  kinase	  1	   SRPK1	   2.77E+00	   4.22E-­‐02	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Importin-­‐5	   IPO5	   3.28E+00	   2.75E-­‐02	  
Ras-­‐related	  protein	  Rab-­‐6A	   RAB6A	   4.69E+00	   3.17E-­‐02	  
Protein	  mago	  nashi	  homolog	  2	   MAGOHB	   5.11E+01	   2.25E-­‐02	  
Acetolactate	  synthase-­‐like	  protein	   ILVBL	   2.06E+00	   3.30E-­‐02	  
Lysine-­‐specific	  histone	  demethylase	  1A	   KDM1A	   2.31E+01	   3.14E-­‐02	  
LanC-­‐like	  protein	  2	   LANCL2	   9.96E+00	   4.66E-­‐02	  
Uridine-­‐cytidine	  kinase	  2	   UCK2	   2.26E+00	   4.81E-­‐02	  
ADP-­‐ribosylation	  factor	  5	   ARF5	   4.27E+00	   1.22E-­‐02	  
Ceroid-­‐lipofuscinosis	  neuronal	  protein	  6	   CLN6	   1.10E+01	   9.00E-­‐03	  
Microsomal	  glutathione	  S-­‐transferase	  1	   MGST1	   1.61E+01	   1.04E-­‐02	  
Splicing	  factor	  3B	  subunit	  4	   SF3B4	   4.12E+00	   3.41E-­‐02	  
Zinc	  finger	  and	  BTB	  domain-­‐containing	  
protein	  7A	   ZBTB7A	   7.32E+00	   1.96E-­‐02	  
Phenylalanine-­‐-­‐tRNA	  ligase,	  
mitochondrial	   FARS2	   3.85E+00	   4.72E-­‐02	  






mitochondrial	   GCDH	   2.28E+00	   3.88E-­‐02	  
Nuclear	  receptor	  subfamily	  2	  group	  F	  
member	  6	   NR2F6	   3.93E+01	   2.51E-­‐02	  
E3	  ubiquitin-­‐protein	  ligase	  UBR4	   UBR4	   3.83E+00	   3.33E-­‐02	  
Ceramide	  synthase	  2	   CERS2	   2.02E+00	   1.85E-­‐02	  
Mortality	  factor	  4-­‐like	  protein	  1	   MORF4L1	   4.28E+00	   4.79E-­‐02	  
FAST	  kinase	  domain-­‐containing	  protein	  
5	   FASTKD5	   2.89E+00	   4.64E-­‐02	  
Methyltransferase-­‐like	  protein	  7B	   METTL7B	   3.73E+00	   2.64E-­‐03	  
Ferritin	  heavy	  chain;Ferritin	   FTH1	   5.38E+01	   2.16E-­‐02	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Thioredoxin-­‐related	  transmembrane	  
protein	  2	   TMX2	   3.43E+00	   7.04E-­‐03	  
Ubiquitin-­‐like	  protein	  4A	   UBL4A	   3.16E+00	   2.28E-­‐02	  
N-­‐acetyltransferase	  14	   NAT14	   8.30E+00	   1.69E-­‐02	  
Guanine	  nucleotide-­‐binding	  protein-­‐like	  
3-­‐like	  protein	   GNL3L	   2.86E+00	   4.62E-­‐02	  
G2/mitotic-­‐specific	  cyclin-­‐B1	   CCNB1	   2.86E+00	   2.88E-­‐02	  
Cyclin-­‐dependent	  kinase	  4	   CDK4	   7.63E+00	   1.38E-­‐02	  
Microtubule-­‐associated	  protein	  RP/EB	  
family	  member	  2	   MAPRE2	   1.01E+01	   2.35E-­‐02	  
D-­‐beta-­‐hydroxybutyrate	  
dehydrogenase,	  mitochondrial	   BDH1	   3.42E+00	   1.56E-­‐03	  
Serine	  hydroxymethyltransferase	   SHMT1	   1.34E+01	   3.47E-­‐02	  
Protein	  bicaudal	  D	  homolog	  2	   BICD2	   6.52E+00	   1.07E-­‐02	  
Periphilin-­‐1	   PPHLN1	   3.05E+00	   3.47E-­‐02	  




DAK	   2.53E+00	   2.93E-­‐02	  
WD40	  repeat-­‐containing	  protein	  SMU1	   SMU1	   8.67E+00	   3.79E-­‐02	  
Translation	  initiation	  factor	  eIF-­‐2B	  
subunit	  delta	   EIF2B4	   2.53E+00	   2.73E-­‐04	  
Serine/threonine-­‐protein	  phosphatase	  
4	  catalytic	  subunit	   PPP4C	   3.41E+00	   4.08E-­‐02	  
Bcl-­‐2-­‐like	  protein	  1	   BCL2L1	   5.20E+01	   8.92E-­‐04	  
Bifunctional	  protein	  NCOAT	   MGEA5	   5.84E+00	   4.07E-­‐02	  
ADP-­‐ribosylation	  factor-­‐like	  protein	  1	   ARL1	   1.68E+01	   2.52E-­‐02	  
Ephexin-­‐1	   NGEF	   6.35E+00	   3.63E-­‐02	  
Cirhin	   CIRH1A	   4.48E+00	   4.15E-­‐02	  
COBW	  domain-­‐containing	  protein	  6	   CBWD6	   2.79E+00	   1.49E-­‐02	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HLA	  class	  I	  histocompatibility	  antigen,	  
Cw-­‐18	  alpha	  chain	   HLA-­‐C	   3.46E+07	   3.30E-­‐03	  
AP-­‐2	  complex	  subunit	  sigma	   AP2S1	   1.08E+01	   3.71E-­‐02	  
HLA	  class	  I	  histocompatibility	  antigen,	  
B-­‐37	  alpha	  chain;HLA	  class	  I	  
histocompatibility	  antigen,	  B-­‐48	  alpha	  
chain	  
HLA-­‐B	   1.59E+01	   1.79E-­‐03	  
Transmembrane	  protein	  201	   TMEM201	   2.30E+00	   6.49E-­‐04	  
Ubiquitin	  carboxyl-­‐terminal	  hydrolase	  
15;Ubiquitin	  carboxyl-­‐terminal	  
hydrolase	  
USP15	   3.24E+07	   1.93E-­‐02	  
Multidrug	  resistance-­‐associated	  protein	  
4	   ABCC4	   5.31E+00	   1.28E-­‐02	  
TBC1	  domain	  family	  member	  15	   TBC1D15	   3.21E+00	   1.74E-­‐03	  
Atlastin-­‐3	   ATL3	   3.98E+00	   1.22E-­‐02	  
Fragile	  X	  mental	  retardation	  protein	  1	   FMR1	   2.71E+00	   4.11E-­‐02	  
NF-­‐kappa-­‐B	  inhibitor-­‐interacting	  Ras-­‐
like	  protein	  1	   NKIRAS1	   7.77E+00	   3.56E-­‐02	  
BCL2	  Associated	  Transcription	  Factor	   BCLAF1	   7.26E+01	   3.06E-­‐02	  
Sorting	  nexin-­‐4	   SNX4	   1.24E+07	   6.27E-­‐03	  
Transmembrane	  emp24	  domain-­‐
containing	  protein	  1	   TMED1	   6.64E+00	   3.16E-­‐02	  
Bifunctional	  arginine	  demethylase	  and	  
lysyl-­‐hydroxylase	  JMJD6	   JMJD6	   5.59E+07	   6.78E-­‐03	  
UPF0554	  protein	  C2orf43	   C2orf43	   4.98E+00	   5.04E-­‐03	  
Gasdermin-­‐D	   GSDMD	   4.55E+07	   1.86E-­‐02	  
Rho-­‐related	  GTP-­‐binding	  protein	  RhoC	   RHOC	   3.55E+00	   2.14E-­‐02	  
Paraoxinase	  2	   PON2	   2.79E+00	   1.67E-­‐02	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Importin-­‐8	   IPO8	   2.65E+00	   4.80E-­‐02	  
Carboxypeptidase	  D	   CPD	   2.93E+00	   3.07E-­‐02	  
GTPase	  NRas	   NRAS	   4.80E+00	   1.40E-­‐02	  
Kit	  ligand;Soluble	  KIT	  ligand	   KITLG	   4.27E+00	   1.67E-­‐02	  
rRNA	  maturation	  factor	  homolog	   YBEY	   9.34E+00	   1.60E-­‐02	  
Periodic	  tryptophan	  protein	  2	  homolog	   PWP2	   3.30E+00	   4.91E-­‐02	  
Ribosomal	  RNA-­‐processing	  protein	  7	  
homolog	  A	   RRP7A	   2.97E+07	   5.16E-­‐03	  
	  
	  




Protein	  significantly	  enriched	  in	  	  
GFP.CDK11p110	  Mit	  (Synchronised	  Mitosis)	  Co-­‐immunoprecipitate	  





Cyclin-­‐dependent	  kinase	  11B	   CDK11B	   2.61E+02	   1.98E-­‐05	  
Hsp90	  co-­‐chaperone	  Cdc37	   CDC37	   3.40E+00	   6.23E-­‐04	  
SAP30	  Binding	  Protein	   SAP30BP	   1.34E+02	   1.92E-­‐04	  
Cyclin-­‐L1	   CCNL1	   4.72E+02	   4.07E-­‐05	  
40S	  ribosomal	  protein	  S6	   RPS6	   2.16E+00	   3.60E-­‐02	  
Peptidyl-­‐prolyl	  cis-­‐trans	  isomerase	  
FKBP5	   FKBP5	   2.85E+00	   7.17E-­‐03	  
Cyclin-­‐L2	   CCNL2	   3.22E+02	   2.56E-­‐03	  
60S	  ribosomal	  protein	  L27	   RPL27	   2.27E+00	   1.56E-­‐02	  
60S	  ribosomal	  protein	  L35	   RPL35	   2.69E+00	   9.76E-­‐03	  
60S	  ribosomal	  protein	  L18	   RPL18	   2.15E+00	   4.63E-­‐02	  
60S	  ribosomal	  protein	  L38	   RPL38	   2.38E+00	   1.01E-­‐02	  
60S	  ribosomal	  protein	  L23a	   RPL23A	   2.16E+00	   1.01E-­‐02	  
60S	  ribosomal	  protein	  L10	   RPL10	   2.49E+00	   8.58E-­‐03	  
60S	  ribosomal	  protein	  L10a	   RPL10A	   2.90E+00	   2.06E-­‐02	  
Serine/arginine-­‐rich	  splicing	  factor	  3	   SRSF3	   2.59E+00	   3.91E-­‐02	  
60S	  ribosomal	  protein	  L31	   RPL31	   2.05E+00	   4.12E-­‐03	  
Albumin	   ALB	   2.13E+00	   3.99E-­‐02	  
60S	  acidic	  ribosomal	  protein	  P2	   RPLP2	   2.42E+00	   1.81E-­‐02	  
60S	  ribosomal	  protein	  L36	   RPL36	   2.72E+00	   3.82E-­‐02	  
60S	  ribosomal	  protein	  L32	   RPL32	   2.65E+00	   4.37E-­‐02	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SWI/SNF-­‐related	  matrix-­‐associated	  
actin-­‐dependent	  regulator	  of	  
chromatin	  subfamily	  E	  member	  1	  
SMARCE1	   2.89E+00	   3.88E-­‐02	  
Exportin-­‐1	   XPO1	   2.51E+00	   1.75E-­‐02	  
Complement	  component	  1	  Q	  
subcomponent-­‐binding	  protein	   C1QBP	   4.92E+00	   1.71E-­‐02	  
60S	  ribosomal	  protein	  L22-­‐like	  1	   RPL22L1	   2.26E+00	   3.38E-­‐02	  
40S	  ribosomal	  protein	  S7	   RPS7	   4.98E+00	   1.15E-­‐02	  
U5	  small	  nuclear	  ribonucleoprotein	  200	  
kDa	  helicase	   SNRNP200	   2.55E+00	   3.13E-­‐02	  
Pinin	   PNN	   2.45E+00	   2.08E-­‐03	  
DNA	  topoisomerase	  1	   TOP1	   2.87E+00	   3.57E-­‐03	  
Nucleolar	  RNA	  helicase	  2	   DDX21	   2.75E+00	   1.76E-­‐02	  
FACT	  complex	  subunit	  SPT16	   SUPT16H	   2.86E+00	   4.44E-­‐02	  
40S	  ribosomal	  protein	  S26	   RPS26	   3.16E+00	   2.49E-­‐02	  
Thyroid	  hormone	  receptor-­‐associated	  
protein	  3	   THRAP3	   2.91E+00	   6.34E-­‐03	  





THO	  complex	  subunit	  4	   ALYREF	   2.10E+00	   9.28E-­‐03	  
Histone	  deacetylase	  complex	  subunit	  
SAP18	   SAP18	   2.76E+00	   3.11E-­‐02	  
Bcl-­‐2-­‐associated	  transcription	  factor	  1	   BCLAF1	   2.11E+00	   3.30E-­‐03	  
Serine/arginine-­‐rich	  splicing	  factor	  6	   SRSF6	   2.50E+00	   2.22E-­‐03	  
Major	  vault	  protein	   MVP	   4.68E+00	   8.60E-­‐05	  
Eukaryotic	  translation	  initiation	  factor	  2	  
subunit	  2	   EIF2S2	   3.53E+00	   3.78E-­‐02	  
Serine/arginine-­‐rich	  splicing	  factor	  1	   SRSF1	   4.18E+00	   8.48E-­‐03	  
Heterogeneous	  nuclear	  
ribonucleoproteins	  C1/C2	   HNRNPC	   3.01E+00	   3.92E-­‐02	  
Page 280
Calnexin	   CANX	   2.07E+00	   3.98E-­‐02	  
RNA-­‐binding	  motif	  protein,	  X	  
chromosome	   RBMX	   2.10E+00	   2.71E-­‐02	  
40S	  ribosomal	  protein	  S30	   FAU	   3.14E+00	   1.11E-­‐02	  
Pre-­‐mRNA-­‐processing-­‐splicing	  factor	  8	   PRPF8	   2.71E+00	   2.30E-­‐02	  
39S	  ribosomal	  protein	  L15,	  
mitochondrial	   MRPL15	   2.31E+00	   1.35E-­‐02	  
Enhancer	  of	  rudimentary	  homolog	   ERH	   3.05E+00	   1.87E-­‐03	  
ATPase	  inhibitor,	  mitochondrial	   ATPIF1	   2.49E+00	   4.52E-­‐02	  
U5	  small	  nuclear	  ribonucleoprotein	  40	  
kDa	  protein	   SNRNP40	   2.92E+00	   4.54E-­‐02	  
Serine/arginine-­‐rich	  splicing	  factor	  7	   SRSF7	   4.32E+00	   4.49E-­‐02	  
Cell	  division	  cycle	  5-­‐like	  protein	   CDC5L	   3.49E+00	   4.81E-­‐03	  
RNA-­‐binding	  protein	  8A	   RBM8A	   2.74E+00	   4.57E-­‐03	  
Transcription	  factor	  A,	  mitochondrial	   TFAM	   2.91E+00	   4.18E-­‐02	  
RNA-­‐binding	  protein	  with	  serine-­‐rich	  
domain	  1	   RNPS1	   3.13E+00	   9.87E-­‐03	  
ATP-­‐binding	  cassette	  sub-­‐family	  D	  
member	  3	   ABCD3	   2.66E+00	   1.42E-­‐02	  
U4/U6.U5	  tri-­‐snRNP-­‐associated	  protein	  
1	   SART1	   2.35E+00	   2.79E-­‐02	  
Transformer-­‐2	  protein	  homolog	  beta	   TRA2B	   2.97E+00	   1.85E-­‐02	  
General	  transcription	  factor	  3C	  
polypeptide	  4	   GTF3C4	   2.85E+00	   3.65E-­‐02	  
Eukaryotic	  translation	  initiation	  factor	  2	  
subunit	  1	   EIF2S1	   2.86E+00	   4.66E-­‐02	  
Proteasome	  activator	  complex	  subunit	  
3	   PSME3	   2.00E+00	   3.59E-­‐02	  
Pre-­‐mRNA-­‐processing	  factor	  19	   PRPF19	   2.24E+00	   7.09E-­‐03	  
Uncharacterized	  protein	  C12orf50	   C12orf50	   1.87E+01	   4.53E-­‐02	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40S	  ribosomal	  protein	  S27-­‐like	   RPS27L	   2.15E+00	   2.52E-­‐02	  





Cytochrome	  c	  oxidase	  protein	  20	  
homolog	   COX20	   2.88E+00	   3.51E-­‐02	  
Serine/arginine-­‐rich	  splicing	  factor	  2	   SRSF2	   2.97E+00	   4.04E-­‐02	  
Ubiquitin	  carboxyl-­‐terminal	  hydrolase	  
isozyme	  L5	   UCHL5	   2.15E+00	   3.88E-­‐02	  
Nucleolar	  GTP-­‐binding	  protein	  1	   GTPBP4	   2.01E+00	   4.17E-­‐03	  
AP-­‐3	  complex	  subunit	  delta-­‐1	   AP3D1	   2.75E+00	   4.32E-­‐02	  
Signal	  recognition	  particle	  14	  kDa	  
protein	   SRP14	   2.61E+00	   4.86E-­‐03	  
BAG	  family	  molecular	  chaperone	  
regulator	  3	   BAG3	   2.06E+00	   2.76E-­‐02	  
Probable	  ATP-­‐dependent	  RNA	  helicase	  
DDX23	   DDX23	   2.58E+00	   3.18E-­‐02	  
Histone	  acetyltransferase	  KAT8	   KAT8	   4.58E+00	   2.85E-­‐03	  
PC4	  and	  SFRS1-­‐interacting	  protein	   PSIP1	   3.35E+00	   4.94E-­‐02	  
Casein	  kinase	  II	  subunit	  alpha	   CSNK2A1	   3.17E+02	   4.68E-­‐04	  
Apoptotic	  chromatin	  condensation	  
inducer	  in	  the	  nucleus	   ACIN1	   2.55E+00	   9.10E-­‐04	  
Serine/arginine-­‐rich	  splicing	  factor	  10	   SRSF10	   3.55E+00	   2.69E-­‐02	  
Suppressor	  of	  tumorigenicity	  14	  
protein	   ST14	   2.15E+00	   2.25E-­‐02	  
High	  mobility	  group	  protein	  HMG-­‐
I/HMG-­‐Y	   HMGA1	   3.80E+00	   1.87E-­‐02	  
Squamous	  cell	  carcinoma	  antigen	  
recognized	  by	  T-­‐cells	  3	   SART3	   2.25E+00	   4.12E-­‐02	  
Casein	  kinase	  II	  subunit	  beta	   CSNK2B	   5.40E+00	   9.56E-­‐03	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Growth	  arrest	  and	  DNA	  damage-­‐
inducible	  proteins-­‐interacting	  protein	  1	   GADD45GIP1	   2.46E+00	   1.91E-­‐02	  
Heterochromatin	  protein	  1-­‐binding	  
protein	  3	   HP1BP3	   2.18E+00	   4.92E-­‐02	  
Serine/arginine-­‐rich	  splicing	  factor	  9	   SRSF9	   4.66E+00	   1.17E-­‐02	  
Cyclin-­‐T1	   CCNT1	   2.07E+00	   3.04E-­‐02	  
Sodium-­‐coupled	  neutral	  amino	  acid	  
transporter	  2	   SLC38A2	   2.77E+00	   2.65E-­‐02	  
U1	  small	  nuclear	  ribonucleoprotein	  70	  
kDa	   SNRNP70	   2.51E+00	   3.06E-­‐02	  
39S	  ribosomal	  protein	  L27,	  
mitochondrial	   MRPL27	   2.66E+00	   4.08E-­‐02	  
Pleiotropic	  regulator	  1	   PLRG1	   4.01E+00	   2.11E-­‐02	  
TATA-­‐binding	  protein-­‐associated	  factor	  
172	   BTAF1	   2.70E+00	   3.83E-­‐03	  
Multidrug	  resistance-­‐associated	  
protein	  1	   ABCC1	   2.40E+00	   4.47E-­‐02	  
NADH	  dehydrogenase	  [ubiquinone]	  
iron-­‐sulfur	  protein	  4,	  mitochondrial	   NDUFS4	   2.40E+00	   3.61E-­‐02	  
60S	  ribosomal	  protein	  L26-­‐like	  1	   RPL26L1	   2.39E+00	   1.76E-­‐02	  
Programmed	  cell	  death	  protein	  2-­‐like	   PDCD2L	   2.11E+00	   5.92E-­‐03	  
RNA-­‐binding	  protein	  25	   RBM25	   4.72E+00	   7.24E-­‐03	  
39S	  ribosomal	  protein	  L55,	  
mitochondrial	   MRPL55	   2.72E+00	   2.11E-­‐03	  
7SK	  snRNA	  methylphosphate	  capping	  
enzyme	   MEPCE	   3.04E+00	   1.68E-­‐02	  
LBH	  Domain	  containing	  1	   C11orf48	   3.11E+00	   1.58E-­‐03	  
39S	  ribosomal	  protein	  L48,	  
mitochondrial	   MRPL48	   3.11E+00	   4.03E-­‐02	  
Pre-­‐mRNA-­‐processing	  factor	  40	  
homolog	  A	   PRPF40A	   4.22E+00	   2.71E-­‐03	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Pre-­‐mRNA-­‐splicing	  factor	  SPF27	   BCAS2	   4.31E+00	   2.53E-­‐02	  
Reticulon-­‐4	   RTN4	   2.25E+00	   9.37E-­‐05	  
Lipoamide	  acyltransferase	  component	  
of	  branched-­‐chain	  alpha-­‐keto	  acid	  
dehydrogenase	  complex,	  mitochondrial	  
DBT	   4.40E+00	   3.38E-­‐02	  
Protein	  LLP	  homolog	   LLPH	   6.61E+00	   1.56E-­‐02	  
Protein	  DEK	   DEK	   7.92E+00	   4.17E-­‐02	  
Alpha-­‐globin	  transcription	  factor	  CP2	   TFCP2	   2.85E+00	   3.99E-­‐02	  
Putative	  methyltransferase	  NSUN4	   NSUN4	   4.05E+00	   2.58E-­‐02	  
Vacuolar	  protein	  sorting-­‐associated	  
protein	  28	  homolog	   VPS28	   2.45E+00	   2.27E-­‐02	  
Sideroflexin-­‐4	   SFXN4	   3.60E+00	   2.51E-­‐02	  
Suppressor	  of	  G2	  allele	  of	  SKP1	  
homolog	   SUGT1	   3.40E+00	   1.09E-­‐02	  
ATP-­‐dependent	  RNA	  helicase	  DDX18	   DDX18	   3.28E+00	   3.50E-­‐02	  
Zinc	  finger	  CCCH	  domain-­‐containing	  
protein	  18	   ZC3H18	   3.79E+00	   1.04E-­‐05	  
3-­‐beta-­‐hydroxysteroid-­‐
Delta(8),Delta(7)-­‐isomerase	   EBP	   4.56E+00	   2.96E-­‐02	  
Nucleolar	  protein	  14	   NOP14	   2.81E+00	   4.70E-­‐02	  
Heterogeneous	  nuclear	  
ribonucleoprotein	  U-­‐like	  protein	  2	   HNRNPUL2	   3.36E+00	   1.84E-­‐02	  
Nucleolar	  protein	  56	   NOP56	   2.32E+00	   2.83E-­‐02	  
Transformer-­‐2	  protein	  homolog	  alpha	   TRA2A	   5.08E+00	   1.33E-­‐03	  
Basic	  Transcription	  Factor	  3	   BTF3	   4.78E+00	   4.73E-­‐02	  
SRSF	  protein	  kinase	  1	   SRPK1	   3.63E+00	   2.42E-­‐02	  
Importin-­‐5	   IPO5	   2.45E+00	   4.77E-­‐02	  
Bloom	  syndrome	  protein	   BLM	   2.36E+00	   3.50E-­‐02	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Nucleoporin	  NDC1	   TMEM48	   2.09E+00	   3.94E-­‐02	  
Lysine-­‐specific	  histone	  demethylase	  1A	   KDM1A	   1.41E+01	   6.19E-­‐03	  
cAMP-­‐dependent	  protein	  kinase	  type	  
II-­‐alpha	  regulatory	  subunit	   PRKAR2A	   2.55E+00	   4.88E-­‐02	  
Thyroid	  Hormone	  Receptor	  Interactor	  
12	   TRIP12	   1.60E+01	   4.42E-­‐02	  
Pre-­‐mRNA-­‐splicing	  factor	  SYF2	   SYF2	   4.64E+00	   4.86E-­‐03	  
ESF1	  homolog	   ESF1	   4.27E+00	   3.44E-­‐02	  
Tripeptidyl-­‐peptidase	  1	   TPP1	   4.93E+00	   3.34E-­‐03	  
Eukaryotic	  translation	  initiation	  factor	  
1A,	  X-­‐chromosomal	   EIF1AX	   7.92E+00	   3.57E-­‐02	  
Protein	  SON	   SON	   2.59E+00	   1.26E-­‐03	  
Translation	  initiation	  factor	  eIF-­‐2B	  
subunit	  beta	   EIF2B2	   2.34E+00	   3.88E-­‐02	  
Coiled-­‐coil	  domain-­‐containing	  protein	  
12	   CCDC12	   7.23E+07	   1.53E-­‐02	  
Intron-­‐binding	  protein	  aquarius	   AQR	   7.33E+00	   9.20E-­‐03	  
Zinc	  finger	  and	  BTB	  domain-­‐containing	  
protein	  7A	   ZBTB7A	   8.76E+00	   1.88E-­‐02	  
Probable	  ATP-­‐dependent	  RNA	  helicase	  
DDX47	   DDX47	   3.80E+00	   4.25E-­‐02	  
Protein	  FAM92A1	   FAM92A1	   6.04E+00	   2.33E-­‐02	  
Exosome	  complex	  component	  RRP45	   EXOSC9	   2.01E+00	   2.53E-­‐02	  
Receptor-­‐type	  tyrosine-­‐protein	  
phosphatase	  gamma	   PTPRG	   7.08E+00	   2.88E-­‐02	  
Ferritin	  heavy	  chain;Ferritin	   FTH1	   9.37E+00	   4.63E-­‐03	  
Casein	  kinase	  II	  subunit	  alpha	   CSNK2A2	   7.64E+01	   2.46E-­‐04	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Thioredoxin-­‐related	  transmembrane	  
protein	  2	   TMX2	   3.49E+00	   2.92E-­‐02	  
Zinc	  finger	  protein	  691	   ZNF691	   2.37E+00	   4.44E-­‐02	  
Clathrin	  interactor	  1	   CLINT1	   2.00E+00	   1.44E-­‐02	  
Coatomer	  subunit	  gamma-­‐2	   COPG2	   4.42E+00	   2.11E-­‐02	  
Transcription	  initiation	  factor	  TFIID	  
subunit	  10	   TAF10	   2.60E+00	   2.59E-­‐02	  
mRNA	  turnover	  protein	  4	  homolog	   MRTO4	   6.67E+00	   2.69E-­‐02	  
Serine/threonine-­‐protein	  kinase	  PRP4	  
homolog	   PRPF4B	   7.81E+00	   3.47E-­‐02	  
G2/mitotic-­‐specific	  cyclin-­‐B1	   CCNB1	   2.53E+00	   2.12E-­‐03	  
Uncharacterized	  protein	  C18orf25	   C18orf25	   5.42E+00	   4.77E-­‐03	  
ATP-­‐dependent	  RNA	  helicase	  DDX50	   DDX50	   5.33E+00	   3.94E-­‐02	  
RNA	  methyltransferase-­‐like	  protein	  1	   RNMTL1	   5.24E+00	   2.63E-­‐02	  
UPF0449	  protein	  C19orf25	   C19orf25	   2.29E+00	   2.73E-­‐02	  





Microtubule-­‐associated	  protein	  RP/EB	  
family	  member	  2	   MAPRE2	   6.56E+00	   3.65E-­‐02	  
D-­‐beta-­‐hydroxybutyrate	  
dehydrogenase,	  mitochondrial	   BDH1	   2.47E+00	   1.27E-­‐02	  
Zinc	  finger	  CCHC	  domain-­‐containing	  
protein	  8	   ZCCHC8	   2.51E+00	   1.79E-­‐02	  
Periphilin-­‐1	   PPHLN1	   2.73E+00	   3.82E-­‐02	  
WD40	  repeat-­‐containing	  protein	  SMU1	   SMU1	   5.65E+00	   7.34E-­‐03	  
Serine/threonine-­‐protein	  phosphatase	  
4	  catalytic	  subunit	   PPP4C	   2.75E+00	   4.99E-­‐02	  
EF-­‐hand	  domain-­‐containing	  family	  
member	  A1	   EFHA1	   9.66E+06	   3.99E-­‐02	  
Ninein	   NIN	   5.27E+00	   4.03E-­‐02	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60S	  acidic	  ribosomal	  protein	  P1	   RPLP1	   7.15E+00	   8.87E-­‐03	  
Bcl-­‐2-­‐like	  protein	  1	   BCL2L1	   3.02E+01	   1.84E-­‐02	  
AP-­‐2	  complex	  subunit	  sigma	   AP2S1	   9.42E+00	   4.74E-­‐02	  
HLA	  class	  I	  histocompatibility	  antigen,	  
B-­‐37	  alpha	  chain	   HLA-­‐B	   1.73E+01	   1.16E-­‐02	  
Myelin	  basic	  protein	   MBP	   3.80E+00	   3.03E-­‐02	  
Arginine-­‐glutamic	  acid	  dipeptide	  
repeats	  protein	   RERE	   1.21E+08	   2.41E-­‐05	  
NF-­‐kappa-­‐B	  inhibitor-­‐interacting	  Ras-­‐
like	  protein	  1	   NKIRAS1	   5.88E+00	   4.47E-­‐02	  
Protein	  ELYS	   AHCTF1	   2.97E+00	   3.79E-­‐02	  
Unconventional	  prefoldin	  RPB5	  
interactor	  1	   URI1	   3.41E+00	   6.29E-­‐03	  
HEAT	  repeat-­‐containing	  protein	  7A	   HEATR7A	   4.70E+06	   4.68E-­‐02	  
Sorting	  nexin-­‐4	   SNX4	   9.50E+06	   3.42E-­‐02	  
Forkhead-­‐associated	  domain-­‐
containing	  protein	  1	   FHAD1	   4.55E+00	   1.00E-­‐02	  
MKI67	  FHA	  domain-­‐interacting	  
nucleolar	  phosphoprotein	   MKI67IP	   8.54E+00	   3.45E-­‐02	  
Apolipoprotein	  A2	   APOA2	   3.19E+00	   1.06E-­‐03	  
Nucleolar	  and	  spindle-­‐associated	  
protein	  1	   NUSAP1	   2.95E+00	   6.28E-­‐03	  
Lanosterol	  14-­‐alpha	  demethylase	   CYP51A1	   6.20E+06	   3.61E-­‐02	  
Insulin-­‐like	  growth	  factor-­‐binding	  
protein	  6	   IGFBP6	   1.21E+07	   3.59E-­‐02	  
Tubulin	  alpha-­‐1A	  chain	   TUBA1A	   3.44E+01	   4.36E-­‐02	  
Zinc	  finger	  and	  BTB	  domain-­‐containing	  
protein	  10	   ZBTB10	   9.76E+00	   4.82E-­‐02	  
Cell	  surface	  glycoprotein	  MUC18	   MCAM	   4.91E+00	   1.81E-­‐02	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Arfaptin-­‐2	   ARFIP2	   2.34E+00	   4.34E-­‐02	  
Activating	  signal	  cointegrator	  1	   TRIP4	   6.87E+00	   3.15E-­‐02	  
Band	  4.1-­‐like	  protein	  1	   EPB41L1	   6.69E+00	   1.75E-­‐03	  
WD	  repeat-­‐containing	  protein	  C2orf44	   C2orf44	   3.53E+00	   1.18E-­‐02	  
Splicing	  factor,	  arginine/serine-­‐rich	  19	   SCAF1	   4.67E+00	   2.62E-­‐03	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